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Abstract
Ischaemic preconditioning (PC) is the phenomenon whereby a short episode of
coronary occlusion followed by reperfusion protects the myocardium against a
subsequent period of prolonged (also called index or sustained) ischaemia. Even
though the exact mechanism of PC remains to be established, it implies that the heart
has an endogenous protective mechanism against ischaemia which, if identified, may
have important clinical implications. The importance of establishing the mechanism of
PC lies in the potential to convert this biological phenomenon into a therapeutic modality
to be used clinically. If mediated by certain components of a signal transduction
pathway, such a goal will be achievable.
Several triggers and signal transduction pathways have been implicated in the mechanism
of protection induced by PC: for example, receptor-dependent endogenous triggers (such
as adenosine and opioids) and receptor-independent endogenous triggers (such as free
radicals and calcium). However, the involvement of both the ~-adrenergic signalling
pathway as well as nitric oxide (NO) in PC has not been defined.
It has been suggested that all triggers are linked to a common final pathway, for
example, activation of protein kinase C (PKC) and/or the mitogen-activated kinases
(MAPKs), in particular p38 MAPK. However, the role of the latter is still controversial.
The aim of this study was to:
(A) characterize changes in the cyclic nucleotides, cAMP and cGMP, and p38 MAPK
occurring during the entire experimental procedure in an attempt to gain insights into
the possible mechanisms involved in ischaemie PC (Chapter 3);
(8) establish the significance of the changes observed in cAMP and cGMP by
pharmacological manipulation of their respective pathways (Chapters 4 and 5);
(C) establish the role of p38 MAPK in ischaemie PC: trigger or mediator involvement
(Chapter 6).
Isolated perfused working rat hearts were preconditioned by 3 x 5 min global ischaemia,
interspersed by 5 min reperfusion, followed by 25 min global ischaemia and 30 min
reperfusion. Functional recovery during reperfusion was used as end-point. Hearts
were freeze-clamped at different times during the PC protocol, sustained ischaemia, as
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well as during reperfusion. Tissue cyclic nucleotides (cAMP and cGMP), cyclic
nucleotide phosphodiesterase (cAMP- and cGMP-PDE) activities, adenylyl cyclase and
protein kinase A activities and p-adrenergic receptor characteristics were determined.
p38 MAPK activation was also assessed by Western blotting, using dual phospho-p38
MAPK (Thr180ITyr182) antibody as well as activating transcription factor 2 (ATF2)
activation. In addition, to evaluate the role of p38 MAPK in PC protection, the effect of
inhibition of p38 MAPK activation, by 8B203580, was determined in adult isolated rat
cardiomyocytes as well as in isolated perfused rat hearts.
Based on the results obtained, it is proposed that during a multi-cycle ischaemie PC
protocol triggers (presumably endogenous catecholamines and NO) are released which
induce cyclic changes in cyclic nucleotides, cAMP and cGMP. Both these cyclic
nucleotides transiently activate the downstream stress kinase, p38 MAPK, which may
trigger further downstream adaptive processes.
Furthermore, the sustained ischaemic period of PC hearts was characterized by
attenuated cAMP and elevated cGMP levels, as well as attenuated activation of p38
MAPK, which was associated with cardioprotection. In addition, pharmacological
attenuation of p38 MAPK activation during sustained ischaemia led to functional recovery.
It is concluded that the cardioprotection of PC is due to attenuation of ischaemia-induced
p38 MAPK activation. Pharmacological manipulation of this kinase should be considered
as a therapeutic modality in the future.
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vOpsomming
Isgemiese prekondisionering (PK) verwys na die verskynsel waardeur 'n kort,
verbygaande episode van isgemie gevolg deur herperfusie, die miokardium teen 'n
daaropvolgende langdurige periode van isgemie beskerm. Die presiese meganisme
van beskerming van PK moet nog opgeklaar word, maar dit impliseer dat die hart oor 'n
endogene beskermingsmeganisme beskik wat, indien geïdentifiseer, belangrike kliniese
implikasies mag hê. Die belang van opklaring van die meganisme van PK lê daarin dat
'n biologiese verskynsel in 'n terapeutiese modaliteit vir kliniese gebruik, omgeskakel
kan word. Sou dit deur bepaalde komponente van 'n seintransduksiepad gemedieër
word, is so 'n doel bereikbaar.
Verskeie stimuli en seintransduksiepaaie is in PK betrokke: byvoorbeeld, reseptor-
afhanklike endogene stimuli (soos adenosien en opioïde), asook reseptor-onafhanklike
endogene stimuli (soos vrye radikale en kalsium). Die betrokkenheid van die p-
adrenerge seintransduksiepad asook stikstofoksied (NO) in PK egter nog nie behoorlik
evalueer nie.
Dit is voorgestel dat alle stimuli op 'n finale algemene pad uitloop, soos byvoorbeeld die
aktivering van protein kinase C (PKC) en/of die mitogeen-geaktiveerde kinases
(MAPKs), spesifiek die p38 MAPKs. Laasgenoemde se rol in PK is steeds
kontroversieël.
Die doel van die studie was dus:
(A) karakterisering van die veranderinge in die sikliese nukleotiede, cAMP en cGMP,
en p38 MAPK wat tydens die hele eksperimentele prosedure plaasvind, in 'n
poging om meer insig te verkry aangaande moontlike meganismes betrokke in
isgemiese PK (Hoofstuk 3);
(8) bepaling van die belang van die waargenome veranderinge in cAMP en cGMP
deur hulonderskeie paaie farmakologies te manipuleer (Hoofstukke 4 en 5);
(C) bepaling van die rol van p38 MAPK in PK: betrokkenheid as stimulus of mediator
(Hoofstuk 6).
Geïsoleerde, geperfuseerde werkende rotharte is geprekondisioneer deur blootstelling
aan 3 x 5 min globale isgemie, afgewissel met 5 min herperfusie, gevolg deur 25 min
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globale isgemie en 30 min herperfusie. Funksionele herstel tydens herperfusie is as
eindpunt gebruik. Harte is op verskillende tye tydens die PK protokol, volgehoue
isgemie, asook herperfusie gevriesklamp. Weefsel sikliese nukleotiede (cAMP en
cGMP), die aktiwiteit van sikliese nukleotied fosfodiesterases (cAMP- en cGMP-PDE),
adeniel siklase en protein kinase A (PKA) asook die eienskappe van die p-adrenerge
reseptor is gemeet. p38 MAPK aktivering is met Westerse oordragtegnieke bepaal,
deur van dubbel gefosforileerde p38 MAPK (Thr180fTyr182) antiliggame asook
geaktiveerde transkripsie faktor 2 (ATF2) gebruik te maak. Die rol van p38 MAPK in PK
beskerming is evalueer deur die effek van inhibisie van p38 MAPK aktivering met SB
203580, in volwasse geïsoleerde rot kardiomiosiete asook in geïsoleerde geperfuseerde
rotharte, te bepaal.
Na aanleiding van die resultate, is voorgestel dat, tydens 'n multi-siklus isgemie PK
protokol, stimuli (moontlik endogene katekolamiene en NO) vrygestel word wat die
sikliese veranderinge in sikliese nukleotiede, cAMP en cGMP, veroorsaak. Beide
hierdie sikliese nukleotiede aktiveer die distale stres kinase, p38 MAPK, op 'n
betekenisvolle, maar verbygaande manier. Hierdie kinase mag verdere distale
aanpassingsprosesse stimuleer.
Die volgehoue isgemiese periode van PK harte is gekenmerk deur verminderde cAMP
en verhoogde cGMP vlakke, asook verminderde aktivering van p38 MAPK. Hierdie
veranderinge is met beskerming van die hart teen isgemie geassosieer.
Daarbenewens, farmakologiese vermindering van p38 MAPK aktivering tydens
volgehoue isgemie het tot verbeterde funksionele herstel gelei. Die gevolgtrekking is
gemaak dat die beskermende effek van PK die gevolg is van verminderde aktivering
van isgemies-geïnduseerde p38 MAPK. Farmakologiese manipulasie van hierdie
kinase moet in die toekoms as terapeutiese modaliteit oorweeg word.
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1CHAPTER 1
Literature Review
1.1 Ischaemiepreconditioning
1.1.1 Introduction
Ischaemie preconditioning (PC) describes the powerful myocardial protection against
ischaemie damage that follows a short episode of sub-lethal ischaemia. This was
recently considered at a NHBLI (National Heart, Lung and Blood Institute) workshop to
be the most potent form of myocardial protection against ischaemia and infarction yet
described (Kloner et aI., 1998). Since the first observation in dogs (Murry et aI., 1986),
the protective effect of PC has been demonstrated in rats, rabbits, pigs, as well as in
humans (Kloner and Yellon 1994). Because of PC's potential clinical use its
mechanism has been the subject of intense research during the last 15 years, with over
1500 papers published on the subject (Medline search of "ischemic preconditioning").
However, considerable controversy still exists regarding the mechanism whereby
protection against ischaemia is elicited.
This phenomenon was first described by Murry et al. (1986): canine myocardium
subjected to brief, transient episodes of coronary artery occlusion - too brief in
themselves to result in myocyte death - exhibited an increased resistance to infarction
caused by a subsequent sustained ischaemie insult. This original study described what
is now referred to as "classic" or "early" ischaemie PC which, although powerful, only
lasts 1 to 2 hours. It was subsequently discovered that the cardioprotection reappears
12 to 24 hours after the PC incident and although the benefits are less potent, they can
last up to 3 days (Kuzuya et aI., 1993, Marber et aI., 1993). This second phase of
protection is known as the "late" or "delayed" phase of ischaemie PC and is also
referred to as the "second window of protection" (SWOP). However, in this study the
focus will be on mechanisms involved in classic ischaemie PC.
Despite the obvious potential benefit of ischaemie PC, the risk of subjecting patients to
ischaemia to elicit this protection remains. Furthermore, hearts of hypertensive
(Moolman et aI., 1997) and diabetic rats (Kersten et aI., 2000) and pathological human
myocardium (Ghosh et aI., 2001) did not precondition successfully with a PC protocol
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2that elicited protection in normal myocardial tissue. Since subjecting the heart to
ischaemia, however short, it is clearly not ideal, the importance of establishing the
mechanism of PC lies in the potential to convert this biological phenomenon into a
therapeutic modality to be used clinically. If it is mediated by a ligand-receptor
interaction or signal transduction intermediate, such a goal will be achievable.
Furthermore, pharmacological manipulations could also be utilized to define the
mechanism of PC protection.
1.1.2 Factors affecting classic preconditioning
1.1.2.1 Duration of protection
There are certain limits to the benefits of PC. As mentioned before, the protection
afforded by brief episodes of ischaemia is transient and disappears after 1 to 2 hours of
reperfusion and although it reappears after 12 to 24 hours, the latter protection is less
potent. In addition, if the duration of prolonged (sustained) ischaemia exceeds 90 min
(in some models), then the benefits of PC are lost (Nao et aI., 1990).
1.1.2.2 Triggering
Obviously, the factor triggering protection is operative during the short periods of
ischaemia or reperfusion of ischaemie PC. The majority of evidence suggests that it is
the ischaemia and not the reperfusion that starts the PC cascade (Dekker 1998). For
example: Ischaemic PC by partial occlusion (Koning et aI., 1994) or a brief episode of
no-flow ischaemia (Schulz et al. 1995) without intermittent reperfusion, still provides
protection against subsequent sustained ischaemia. On the other hand, there is a
definite time frame for reperfusion between PC and sustained ischaemia: no protection
occurs if reperfusion is less than 30 s in duration (Alkhulaifi et aI., 1993) or if the interval
is prolonged beyond 1-2 h in most species (van Winkle et aI., 1991, Murry et aI., 1991,
Sack et al., 1993).
A PC regime of only 1 or 2 min of ischaemia with subsequent reperfusion prior to
sustained ischaemia has a protective effect in rats (Takeshima et aI., 1997), but not in
rabbits (van Winkle et aI., 1991), pigs (Schulz et al. 1998) and humans (Matsubara et
aI., 2000). A single 5 min episode of global ischaemia provided optimal functional
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3protection in isolated perfused rat hearts (Moolman et aI., 1995, Cave and Hearse
1992, Asimakis et al., 1992, Steenbergen et aI., 1993). Conversely, it has been
reported that multiple episodes of PC are more protective than a single episode in the
rat (Liu and Downey 1992, Moolman et aI., 1995) and rabbit heart (Sandhu et aI., 1997).
In a regional ischaemie model the latter protocol protected against arrhythmias only and
multiple episodes were necessary to limit infarct size (Liu and Downey 1992). However,
increasing the number of cycles used to induce PC does not result in a cumulative
increase in protection against necrosis (Walker and Yellon 1992, Jenkins et aI., 1995),
whereas it increased protection against arrhythmias (Lawson and Hearse 1994,
Seyfarth et aI., 1994). Furthermore, if the intensity of the PC stimulus exceeds a certain
threshold by extending or too frequently repeating the period of ischaemia, the
protective effect is lost (liiodromitis et aI., 1997).
Classicly, the stimulus for PC is a critical reduction of myocardial blood flow, and the
end-point is a reduction in myocardial necrosis (infarct size) (YelIon et aI., 1998).
However, PC is also induced by a reduction of coronary flow in buffer perfused (Cohen
et aI., 1995), or hypoxic buffer perfused (Cohen et aI., 1995) and blood perfused hearts
(Mei and Gross 1995). Furthermore, PC can also be induced in isolated cardiac muscle
preparations when ischaemia is simulated by a combination of hypoxia, substrate free
perfusion and pacing stress (Speechly et aI., 1995) and even in isolated cardiomyocytes
subjected to transient hypoxia and lack of glucose substrate (Armstrong et aI., 1994).
1.1.2.3 Endpoint
Many endpoints have been adopted to assess protection afforded by ischaemic PC,
including limitation of necrosis or infarct size (Liu and Downey 1992, Speechly-Dick et
al., 1994, Bugge and Ytrehus 1995a,b, Suematsu et aI., 2001, Yue et aI., 2001),
recovery of contractile function (stunning) (Cave 1995, Asimakis et aI., 1992, Moolman
et aI., 1995), reduction in arrhythmias (Hagar et aI., 1991, Shiki and Hearse 1987) and
reduction in cardiac enzyme release (Cave and Hearse 1992, Volovsek et aI., 1992). It
is unknown whether the protection afforded by PC against stunning and arrhythmias is
mediated by the same mechanism that mediates its protection against lethal cell injury
(Connaughton et aI., 1996, Przyklenk and Kloner 1995). For example, the efficacy of
ischaemie PC in reducing stunning (Ovize et aI., 1992) and arrhythmias (Ovize et aI.,
1995) has not been as consistent as its ability to reduce necrosis. In addition,
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4ischaemic PC in rabbits protects from cell death and necrosis, but does not improve
functional recovery (Asimakis et aI., 1996, Sandhu et aI., 1993). However, a lack of
functional recovery during short-periods of reperfusion cannot be used to deny PC's
morphological protection (anti-necrosis effect), because PC does not improve
myocardial function within the first hours of reperfusion (thus it does not attenuate
stunning) (Cohen et a/., 1999). In addition, indications are that improved recovery of
function is more difficult to achieve than a reduction in infarct size (Lochner et al.
unpublished data).
Thus, as long as the signal cascade of ischaemic PC is not clear, caution should be
exercised when extrapolating findings from recovery of contractile function and
protection against arrhythmias to reduction of infarct size. To a large extent, the use of
different end-points may be responsible for the many controversial results that
hampered the progress in the research on PC.
1.1.3 Possible signal transduction
preconditioning
mediated mechanisms of
1.1.3.1 Introduction
The signalling cascades that initiate the two distinct phases of PC protection may have
similar biochemical components. However, the protective effects of classic PC are
protein synthesis-independent, mediated primarily by phosphorylation of key proteins,
and therefore short-lived, whereas, the effects of late PC require new protein synthesis
and could be sustained for days (Nandagopal et ai., 2001).
Studying the mechanisms of early and late ischaemic PC has led to a signalling
paradigm that can be divided into three linear events: (i) triggers, i.e. factors released
during the PC stimulus that initiate the protective process; (ii) mediators, i.e. protein
kinases responsible for integrating and relaying the signal initiated by the triggers and
modulating the (iii) effectors, which could confer myocardial protection (reviewed by
Baines, et aI., 2001, Schulz et aI., 2001).
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51.1.3.2 Triggers
It is generally accepted that PC is a receptor-mediated process, initiated by numerous
possible triggers that could stimulate a variety of G protein-coupled receptors. For
example, adenosine acting via A1 and A3 adenosine receptors, opioids acting mainly via
81 opioid receptors, bradykinin via B2 receptors, acetylcholine via muscarinic receptors,
angiotensin via AT1 receptors, endothelin via ET1- receptors and noradrenaline acting
via U1- and ~-adrenergic receptors (for review see Dekker 1998, Yellon et aI., 1998,
Cohen et aI., 2000, Schulz et aI., 2001). The importance of different triggers varies
among different species; for example, in the rat opioid receptors have been suggested
to be the principal ones involved in PC (Schultz et aI., 1998b), and it is difficult to show a
role for adenosine (Li and Kloner 1993, Cave et aI., 1993) or bradykinin (Bugge and
Ytrehus 1996), while in rabbits and pigs opioids, adenosine and bradykinin may all be
importance.
A number of these ligands have been implicated as both triggers and mediators,
including adenosine (Mullane et al., 1995), acetylcholine (Yao et aI., 1993) and
bradykinin (Goto et aI., 1995). These substances could also generate nitric oxide (NO)
by activating the endothelially derived constitutive nitric oxide synthase enzyme (eNOS).
This has implicated NO as a potential trigger and/or mediator (Rakhit et aI., 1999).
Receptor-independent endogenous triggers of PC also exist. For example, free radicals
can also trigger PC since the administration of antioxidants during the brief triggering
ischaemia has been found to prevent both early and late PC (Sun et aI., 1996). An
alternative candidate for initiating PC is a pre-ischaemic mild increase of intracellular
Ca2+ concentration ([Ca2+]i): short episodes of ischaemia and reperfusion induce a loss
of Ca2+ from the sarcoplasmic reticulum and an accumulation of Ca2+ in the cytosol
(Kaplan et aI., 1992, Wu and Feher 1995). Furthermore, it was shown that a small
increase of [Ca2+]i acts as mediator of PC (Miyawaki et aI., 1996) via activation of
protein kinase C (PKC) (Miyawaki and Ashraf 1997a).
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61.1.3.3 Mediators
1.1.3.3.1 Protein kinase C (PKC)
It has been suggested that several triggers may be linked to a common final pathway by
sharing a key protein, for example protein kinase C (PKC) (for review see Nakano et aI.,
2000d, Cohen et aI., 2000). This has been demonstrated in rat (Cave and Apstein
1994, Speechly-Dick et aI., 1994, Mitchell et aI., 1995), rabbit (Ytrehus et aI., 1994,
Armstrong et al., 1994) and human studies (Ikonomidis et aI., 1997). However, a pivotal
role for PKC could not be corroborated by all workers in the field (for review see Brooks
and Hearse 1996, Simkhovich et aI., 1998), for example inhibition of PKC did not
prevent cardioprotection in rat (Kolocassides and Galinanes 1994), rabbit (Simkhovich
et al., 1996), pig (Vahlhaus et aI., 1996) and dog hearts (Przyklenk et aI., 1995).
One of the key features of PKC activation is translocation of the kinase from the cytosol
to membranes and cytoskeletal structures. Therefore, as long as PKC remains
translocated, the heart will be in a preconditioned state. However, data supporting the
translocation hypothesis are still controversial. For example, disruption of microtubules,
which inhibits intracellular translocation, blocked PC in rabbits (Liu et aI., 1994),
whereas a subsequent study in rabbit myocytes was unable to show translocation of
PKC following PC (Armstrong et aI., 1996). In addition, it is proposed that PKC activity
is not required during the period of PC, but may be essential only during the sustained
ischaemia (Yang et aI., 1997).
Another confounding factor in examining the effects of PKC is the presence of 11
isozymes (Ping et ai., 1997). However, not all isozymes of PKC are translocated by PC.
Ping et al. (1997) documented selective translocation of the PKC-f; and -11 isozymes
following brief ischaemia and reperfusion in the rabbit, while Mitchell et al. (1995)
reported movement of PKC-E and -ê in preconditioned rat hearts. Recently Vondriska
et al. (2001) used functional proteomics to confirm that PKCE is the isoform involved in
PC. Therefore measurement of total PKC translocation or activity simply does not
reflect the subtle alterations in the subcellular distribution of specific isozymes.
Furthermore, evidence indicates that translocation is dependent on PKC binding to a
family of proteins called receptors of activated C-kinase (RACKs) (Gray et ai., 1997).
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7The RACKs were considered to be highly isozyme-specific, i.e. for PKCE it was
thought to be RACK 2. This was confirmed by studying a peptide antagonist for RACK
2 (Johnson et a/., 1996), which blocked the ability of PC to protect both rat (Gray et a/.,
1997) and rabbit (Liu et a/., 1999) cardiomyocytes.
Despite earlier controversies, it would seem that PKC is important in the context of PC,
but new evidence indicate that it is certainly not the only kinase involved in the cascade
of events during PC.
1.1.3.3.2 Other kinases
Although it is likely that PKC may be part of the pathway leading to protection of PC, it is
still unclear what lies beyond PKC. Baines et al. (1998) showed that selective tyrosine
kinase antagonists, genistein and lavendustin A, abolished protection induced by PMA,
a direct activator of PKC, in rabbit hearts. Therefore tyrosine kinases appear to be
downstream of PKC. However, in other species, tyrosine kinases may also be present
in a second pathway that bypasses PKC. For example, in the pig (Vahlhaus et a/.,
1996) and rat (Fryer et a/., 1999) heart antagonists of PKC or tyrosine kinase alone
could not block protection from ischaemic PC. However if they were combined,
protection was completely abolished. This suggests that these kinases may work
through parallel pathways.
Potential downstream targets of PKC and tyrosine kinases are the mitogen-activated
protein kinases (MAPKs). Each subfamily of the MAPKs, namely extracellular signal-
regulated kinases (ERK 1/2), p46 and p54 c-Jun NH2-terminal kinases (JNK) and p38
MAPK, has been suggested to playa role in the cardioprotection achieved by ischaemic
PC (refer to section 1.3, reviewed by Ping and Murphy 2000, Michel et a/., 2001).
Therefore, these MAPKs may be possible contenders for the "final common pathway" of
PC, specifically the stress-activated kinase p38 MAPK (Maulik et a/., 1996, Weinbrenner
et a/., 1997).
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81.1.3.4 Effectors
1.1.3.4.1 Na+I H+exchanger
It is well-established that protons which are produced during ischaemia exit myocytes
via the Na+/ H+exchanger during ischaemia-reperfusion. The resulting Na+ loading can
increase ATP consumption by increasing Na+/ K+ -ATPase activity during the initial
phases of ischaemia. Subsequently, deleterious Ca2+ loading occurs as Na+, in turn,
leaves the cell via the Na+/ Ca2+ - exchanger (Piper et ai., 1996). The resulting rise in
[Ca2+]i could trigger Ca2+ -activated proteases and phospholipases that cause the
cellular damage (Tani 1990, Pierce et ai., 1995).
On the basis of this mechanism, Xiao and Allen (1999) have suggested that the Na+/ H+
exchanger might be an end-effector of PC. They showed that PC of rat hearts slowed
the rate of pHi recovery after ischaemia and blocked the Na+/ H+exchanger during early
reperfusion. This inhibition prevented Na+ entry and Ca2+ loading, which may be part of
the protective pathways in PC. However, Bugge and Ytrehus (1995b) indicated that a
reduced Na+/ H+ exchange might not be the only cause of protection, since the
beneficial effects of classic PC and Na+/ H+ exchange inhibition seem to be partially
additive. Furthermore, other data (for review see Avkiran 1999) do not support a role of
the Na+/ H+exchanger as the end-effector of PC, but rather suggest distinct pathways
and mechanisms.
1.1.3.4.2 Other potential end-effectors
The roles of the mitochondrial ATP sensitive potassium (KATP) channel (O'Rourke
2000) and downstream effectors of p38 MAPK, such as MAPKAPK2 and heat shock
proteins, particularly HSP27 (Sugden and Clerk, 1998) are currently being investigated
as end-effectors (Cohen et ai., 2000). Furthermore, in late PC, inducible nitric oxide
(iNOS) and antioxidants, such as mitochondrial superoxide dismutase (MnSOD), may
also act as effectors in cardioprotection (Baines et ai., 2001).
Therefore, with the increase in the knowledge of PC it became more apparent that there
are different means within the cell to attain protection and it may even be possible that
there is no "common pathway".
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91.1.4 Metabolic changes in classic preconditioning
1.1.4.1 Energy utilization
Murry et al. (1990) pointed out that the preconditioned myocardium (in dogs) is
characterized by a decrease in energy utilization (reduced ATP depletion and lactate
accumulation) that may be related to delayed cell death. Studies in rat hearts, however,
produced diverse results, with PC either reducing (Volovsek et aI., 1992, Vuorinen et aI.,
1995), increasing (Schaefer et aI., 1995, Kolocassides et el., 1996) or having no effect
(Cave and Hearse 1992, Chen et aI., 1995) on the rate of ATP consumption during
sustained ischaemia. The differences between these studies may relate to the PC
procedure.
Conversely, the relatively small influence of classic PC on the rate of energy depletion
during prolonged ischaemia is probably not sufficient to explain its cardioprotective
effect (Yellon et aI., 1998). Therefore, the energy-sparing effect of PC might only be
one of the possible mechanismswhereby cardioprotection is mediated.
1.1.4.2 Attenuation of acidosis
Several observations support an important role of reduced catabolite accumulation in
the protection of PC. In the isolated rat heart ischaemie PC attenuates acidosis
(Asimakis et aI., 1992, Finegan et aI., 1995). During brief PC episodes of ischaemia,
glycogen stores are depleted and lactate and protons accumulate. During the
reperfusion periods following these episodes, accumulated catabolites are rapidly
washed out (Kida et aI., 1991, Van Wylen 1994). The synthesis of glycogen proceeds
at a much slower rate, and glycogen stores remain substantially depleted over a period
of time, which coincides with the duration of classic ischaemie PC (Wolfe et aI., 1993).
When glycogen-depleted myocardium is exposed to prolonged ischaemia, lactate
accumulation is slowed (Kida et el., 1991). The consequent attenuation of proton
production is the main reason for the slower rate of progression of ischaemic acidosis in
preconditioned myocardium. This effect is much more prominent than that on energy
depletion, and the delay in pH reduction is more prolonged than the delay in ATP
depletion (Steenbergen et aI., 1993). However, reduced lactate accumulation per se
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does not explain the anti-infarct effect of classic PC. Glycogen-depleted
myocardium can still be preconditioned, and washout of catabolites during ischaemia
has no effect on infarct size (Sanz et al., 1995).
Thus, reduced proton and catabolite accumulation during prolonged ischaemia are
prominent effects of classic PC. However, it is not yet clear whether these metabolic
changes are mere markers of PC or whether they are necessary for protection, because
it is difficult to distinguish between cause and effect of certain observations.
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1.2 The role of cyclic nucleotides in classic preconditioning
1.2.1 Introduction
Despite the uncertainty regarding the exact mechanism whereby PC elicits protection, it
is generally accepted that it is triggered by stimulation of a variety of G protein-coupled
receptors (i.e. adenosine A1, U1 -adrenergic, muscarinic, bradykinin receptors) with
activation of protein kinase C as the common denominator in eliciting protection
(reviewed by Brooks and Hearse, 1996, Baxter 1997, Simkhovich et ai., 1998).
However, several other signal transduction pathways may also participate. For
example, Banerjee et al. (1993) showed that catecholamine release occurs within
minutes after the onset of myocardial ischaemia and this could trigger the p-adrenergic
signal transduction pathway (Strasser et aI., 1990), whereas bradykinin release early in
ischaemia has been accepted as a trigger for the release of nitric oxide (NO) (Parratt et
al., 1993). This suggests the possible involvement of these pathways in early PC.
However, both these pathways have received little or no attention regarding their
significance in the protection elicited by classic PC.
1.2.2 p-Adrenergic signalling pathway
monophosphate (cAMP) (Fig. 1.1)
and cyclic adenosine
1.2.2.1 Catecholamines
Catecholamines are released locally from the autonomic nerve endings in the
myocardium, increasing the interstitial concentration of mainly noradrenaline, where it
can bind and activate adrenergic receptors (Schërniq et ai., 1984). Noradrenaline is
measurable in the coronary effluent during reperfusion following brief myocardial
ischaemia (Schorniq et ai., 1984, Banerjee et ai., 1993) and could be a possible trigger
for PC.
Ahlquist (1948) proposed that adrenergic stimulation interacted with two types of
adrenergic receptors: u1-adrenergic and p-adrenergic. Convincing evidence has been
presented for ischaemic PC-mediated noradrenaline release and subsequent U1-
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Fig. 1.1 The (3-adrenergic signalling pathway. See text for details and abbreviations.
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adrenergic receptor stimulation (Bankwala et a/., 1994, Banerjee et al., 1993,
Tosaki et al., 1995, Thornton et a/., 1993, Banerjee et a/., 1993). However, previous
findings from our laboratory (Moolman et a/., 1996) as well as others (Asimakis and
Inners-McBride 1993, Bugge and Ytrehus 1995a) indicated that ischaemie PC was not
mediated through a1-adrenergic receptors in the isolated rat heart. Therefore, the focus
of this study will be on the involvement of the B-adrenergicsignalling pathway in PC.
1.2.2.2 B-Adrenergic receptors
The B-adrenergic receptor is a G-protein-coupled receptor, GPCR, with seven
transmembrane-spanning segments. Studies have revealed three subtypes of B-
adrenergic receptors in the heart, namely B-1, B-2 and B-3. The B-1 subtype usually
predominates (-85%) in the mammalian and rat heart. The ratio of B-1 and B-2 differs
in different regions of the human heart, where the percentage of B-1 is higher in the
ventricle than the atrium (Buxton et a/., 1987). Furthermore, Shen et al. (1996) showed
that B-3 adrenergic receptor stimulation was most profound in dogs, diminished but still
significant in rats and absent in primates. Evidence was also provided for the
expression of B-3 adrenergic receptors in human ventricles (Gauthier et aI., 1996).
1.2.2.3 Adenylyl cyclases (ACs) (Fig 1.2)
Binding of the ligands, such as noradrenaline (from the adrenergic nerve terminals in
the heart) and adrenaline (from the adrenal gland), to the B-adrenergic receptor
activates the GTP-binding regulatory proteins (or trimeric guanine nucleotide-binding
proteins or G-proteins) containing the as (or stimulatory) subunit. The a-subunit of the
Gs protein dissociates from the By-subunits and binds to the catalytic subunit of the
enzyme adenylyl cyclase generating the second messenger cyclic adenosine
monophosphate (cAMP) from ATP (Opie 1991,Alberts et a/., 1994).
Even though adenylyl cyclase isoforms are widely distributed, only types Vand VI have
been identified in ventricular heart tissue (Ishikawa and Homey 1997). Expression of
type VI is most abundant in the fetus, but declines with age. As all the other isoforms,
these two types are also stimulated by G as, but are not affected by calcium/calmodulin
as opposed to the other types (Ishikawa and Homey 1997).
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activation. See text for details and definitions of terms and abbreviations. (modified
from Alberts et al., 1994)
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A second G-protein, Gi, is responsible for inhibition of many isoforms of adenylyl
cyclase, including type Vand VI. For example, cholinergic stimulation of the muscarinic
receptor, by coupling to Gi rather to Gs, exerts inhibitory influences on the heart at least
in part by decreasing the rate of formation of cAMP (Opie 1998).
1.2.2.4 Cyclic adenosine phosphate (cAMP)
1.2.2.4.1 Introduction
Previously, it was shown that ventricular overdrive pacing (VOP) induced PC protection
in anaesthetized rabbits (Szilvassy et ai., 1994). This was associated with alterations in
cardiac cyclic nucleotide contents: a slight increase in cGMP and a profound elevation
in cAMP within 5 min of VOPo When VOP was preceded by a brief preconditioning
VOP, the cGMP increase was amplified, whereas the cAMP increase was significantly
attenuated. Therefore, it may be of great importance to investigate the role of these
cyclic nucleotides as triggers in the process of ischaemie PC.
1.2.2.4.2 Background
The 3', 5'-cyclic adenosine monophosphate (cAMP) was first discovered as an
intracellular mediator (second messenger) of hormone action, such as adrenaline, in
1959 by E. Sutherland (Nobel Prize, 1971). It has since been found to act as a second
messenger in all procaryotic and animal cells studied (Pastan, 1972). Another cyclic
nucleotide that has also been identified as a second messenger, was 3', 5'-cyclic
guanosine monophosphate (cGMP). However, cGMP is proposed to act in the same
manner as cAMP, but in reverse (see Fig. 1.3a, Bohinski 1983)
The cyclic nucleotides, cAMP and cGMP, are formed from the corresponding
triphosphonucleotides by the enzymes adenylyl cyclase and guanylyl cyclase,
respectively. The metabolic turnover of cyclic nucleotides is rapid and involves cyclic
phosphodiesterases (POEs), which catalyze the degradation of the cyclic diester on the
3' side, yielding the corresponding 5'-monophosphonucleotide (see Fig. 1.3b, Bohinski
1983).
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Fig.1.3 (a) Molecular structure of cyclic nucleotides, cAMP and cGMP. (b) The mechamism
of elevation or reduction of intracellular levels of cAMP and cGMP. See text for details.
(modified from Bohinski, 1983).
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1.2.2.4.3 Mechanism of action of cAMP
The ~-adrenergic effect on the heart is to increase the force and rate of contraction
(increased chronotropy and inotropy, respectively) and to increase the rate of relaxation
(Iusitropic effect). These effects are mainly mediated by cAMP through the activation of
a protein kinase, cAMP-dependent protein kinase (PKA) which phosphorylates, (i) the
L-type Ca2+ channels with the consequent increased entry of Ca2+ through the plasma
membrane and subsequent calcium-induced calcium release from the sarcoplasmic
reticulum (SR). This leads to the increase of [Ca2+]i (intracellular free calcium ion
concentration), causing an increase in force of contraction as Ca2+ interacts with
troponin C (Gibbons 1986, Morad et aI., 1987, Opie 1998); (ii) the ryanodine receptor
on the SR to release Ca2+ and increase [Ca2+]i (Valdivia et aI., 1995); (iii)
phospholamban to enhance Ca2+ uptake by the SR ATPase pump, resulting in
enhanced myocardial relaxation (Katz 1979); (iv) troponin-I to increase the rate of
crossbridge detachment and relaxation (Stull 1980, Robertson et aI., 1982); and (v) the
Na+/Ca2+ exchange protein to stimulate the rate of forward Na+/Ca2+ exchange which
would increase Ca2+ extrusion resulting in a decline in [Ca2+]i and a faster relaxation
(Perchenet et aI., 2000).
1.2.2.4.4 Regulation of cAMP
An interesting aspect of the catecholamine-induced inotropic response is that it occurs
transiently, even though the stimulus is maintained. Reasons for this phenomenon may
be: (i) When cAMP increases in the myocardial cell, the enhanced cytosolic calcium
concentration also activates calmodulin, which in turn enhances the activity of
phosphodiesterases (POEs), so that the rate of cAMP breakdown is increased. (ii) Also,
the intense stimulation of the p-adrenergic receptor leads to activation of p-ARK and
receptor downregulation that desensitizes the receptor to further stimulation (described
in 1.2.3.5.2) (Opie 1998).
1.2.2.4.4.1 Phosphodiesterases (POEs)
Four different cAMP hydrolyzing POEs have been shown to coexist in the heart muscle
and are characterized by their substrate specificity and dependence towards calcium
and calmodulin: (i) a POE regulated by calcium/calmodulin (POE1); (ii) a cGMP-
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stimulated POE (POE2); (iii) a cGMP-inhibited POE (POE3); and (iv) a low Km
cAMP-specific POE (POE4) (Shahid 1990, Beavo 1995, Podzuweit et el., 1995).
1.2.2.4.4.1.1 POE1 (calcium/calmodulin-stimulated cGMP POE)
This POE is present in nonmyocyte cells of whole rat ventricles (Bode et el., 1991).
POE1 is stimulated by calcium and calmodulin (Ca2+/CaIM), and preferentially
hydrolyses cGMP over cAMP (Bode et aI., 1991). However, the regulation of the overall
cyclic nucleotide concentration by POE1 isoform is expected to be complex because of
the competition for the active Ca2+/CaIM cofactor between this POE and other
Ca2+/CaIM -binding proteins, such as protein phosphatases and constitutive nitric oxide
synthases (NOSs) (Balligand 1999). Furthermore the activity of POE1 is regulated by
cross-talk between Ca2+ and cAMP signalling: POE1 can be phosphorylated by PKA,
resulting in a decrease in the enzyme's affinity for CalM, whereas the phosphorylation of
POE1 is blocked by Ca2+ and CalM (Sharma 1995).
1.2.2.4.4.1.2 POE2 (cGMP-stimulated POE)
POE2 hydrolyses both cAMP and cGMP, but the addition of low concentrations of
cGMP leads to enhanced cAMP breakdown (Bode et aI., 1991, Han et aI., 1998). It has
been purified in bovine adrenal and heart tissue (Martins et aI., 1982). POE2 contains
two fundamentally distinct domains; (i) a non-catalytic binding site having high
specificity for cGMP and when cGMP binds to this site, it increased the affinity of (ii) the
catalytic site by allosteric interaction. This POE is expressed in tissues in which the
effects of cGMP are opposite to those of cAMP (Hartzell et aI., 1986): cGMP has
negligible effects on basal L-type calcium current, but elevated intracellular cAMP via p-
adrenergic agonists initiates the cGMP stimulation of POE2 leading to cAMP hydrolysis
and a decrease in L-type calcium current. POE2 represented a minor component or the
total hydrolytic activity (Lugnier et aI., 1999).
1.2.2.4.4.1.3 POE3 (cGMP-inhibited POE)
This POE which selectively hydrolyses cAMP, was fractionated into two forms: one was
inhibited by cGMP (POE3) and the second was insensitive to cGMP (POE4, see
1.2.2.4.4.1.4) (Komas et aI., 1989). Both these POEs are insensitive to Ca2+/CaIM
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(Lugnier et ai., 1999). In the heart, such inhibition of POE3 by cGMP would initially
potentiate the increase in intracellular cAMP, thereby producing a positive inotropic
effect maybe through an increase in L-type calcium current. However the net result of
cGMP increases in the heart is difficult to predict, given the co-expression of both POE2
and POE3 isoforms in myocytes in rats (Bode et ai., 1991).
1.2.2.4.4.1.4 POE4 (cAMP-specific POE)
The POE4, recognized in human cardiac muscle, was insensitive to cGMP and like
POE3, also insensitive to calmodulin (Reeves et ai., 1987) and has a high affinity for
cAMP. POE4 was localized on the plasma membranes of rat cardiac and endothelial
cells, while POE3 was localized on the plasma membrane of cardiac cells only
(Okruhlicova et al., 1996). However, Lugnier et al. (1999) suggested that most of the
activity of these POEs was associated with the nuclear membrane.
Verde et al. (1999) demonstrated the POE3 and POE4 are dominant POE subtypes
involved in the regulation of basal L-type calcium current in rat ventricular myocytes,
while all four POEs determine the response of L-type calcium current to a stimulus
activating cAMP production, with the rank order of potency POE4> POE3> POE2>
POE1. Likewise, in the human myocardium POE4 might contribute significantly to the
regulation of intracellular cAMP when POE3 is already inhibited or when the
myocardium is under p-adrenergic receptor-mediated stimulation (Kajimoto et aI., 1997).
The factors involved to produce either a potentiation or an attenuation of the cAMP
effects in cardiac cells, include the relative differences in affinity of this cyclic nucleotide
between the isoforms of POE and the localization of each isoform together with effector
proteins for cAMP in the same subcellular compartment (Balligand 1999). For example;
Dodge et al. (2001) demonstrated that muscle-selective A-kinase anchoring protein
(mAKAP), maintains a cAMP signalling module, by including PKA and POE4 in heart
tissue. Furthermore, PKA activation stimulates mAKAP-associated POE4 activity,
whereas POE4 activity reduced the activity of the anchored PKA. This suggests that
the mAKAP signalling complex forms a negative feedback loop to restore basal cAMP
levels.
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1.2.2.4.4.2 Receptor desensitization (Fig. 1.4)
1.2.2.4.4.2.1 Loss of the receptor function
Exposure of GPCRs to an agonist often results in rapid attenuation of receptor
responsiveness, a process termed desensitization (Strasser 1989, Lefkowitz, 1990).
There are three types of p-adrenergic receptor desensitization. (i) Uncoupling is
initiated by prolonged p-agonist stimulation, which leads to activation of G-protein-
coupled receptor kinase (GRK) or the p-adrenergic receptor kinase (P-ARK) (Lefkowitz,
1993). Phosphorylation of the cytoplasmic domain of the p-receptor by p-ARK appears
to change the molecular configuration in such a way that the G-protein cannot interact
with the receptor, leading to functional uncoupling. Many GPCRs are phosphorylated
by second messenger-dependent kinases, such as PKA and PKC, on sites different
from GRKs, which also leads to a significant loss of the receptor function (Lefkowitz et
a/., 1990). (ii) The receptor may then be resensitized if it is dephosphorylated by a
phosphatase and is then again be able to link to Gs. This process is aided by the fact
that after the p-agonist stimulation is over, p-ARK ceases to be active (Opie, 1991). (iii)
Alternatively, the receptor can be internalized by either sequestration or downregulation.
In sequestration an internal vesicle forms that can be reincorporated into the cell
membrane. On the other hand, during downregulation the receptor numbers decrease
because there is degradation of the receptor, possibly by a lysosomal pathway.
Downregulation results from exposure to high concentrations of agonist (Ungerer et a/.,
1996,Opie, 1998).
1.2.2.4.4.2.2 Extracellular mitogen-activated protein kinase (ERK) signalling
Recent evidence suggests that GPCR desensitization and internalization are also
signalling events. Desensitized p-adrenergic receptors could function as scaffolds for
Src-dependent activation of ERK signalling pathways, while the p-arrestins function as
adapter proteins that link G-protein coupled receptors to tyrosine kinase-dependent
pathways (Luttrell et aI., 1999). In this case, binding of the p-adrenergic agonists to
their G-protein linked receptors results in the rapid phosphorylation of the agonist-
occupied receptor by the G protein-coupled receptor kinase (GRK) and the consequent
recruitment of a protein known as p-arrestin to the GRK-phosphorylated receptor. In
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turn, ~-arrestin functions as an adaptor protein, bringing Src to the agonist-occupied
receptor, and targeting both to clathrin-coated pits. Both Src binding and clathrin-
targeting are required for ~2-AR-mediatedERK activation.
1.2.2.5 ~-Adrenergic signalling and myocardial ischaemia
1.2.2.5.1 Catecholamines and ischaemia
As mentioned before, endogenous catecholamines are released during ischaemia
(1.2.2.1). Fleckenstein (1971) described how myocardial necrosis occurred in response
to high doses of catecholamine, with a greatly increased uptake of calcium by the
myocardium. Rona (1985) later confirmed that excess catecholamines could induce
extensive injury, very similar to that caused by infarction, namely myofibrillar lysis,
swollen mitochondria and disturbed cell morphology. This injury can be prevented by
the ~-adrenergic receptor blocker, propranolol or selected Ca2+ channel blockers
administered simultaneously with the ~-adrenergic receptor agonist, isoproterenol (Opie
et al., 1979). The catecholamine-induced injury appears to be the result of an
interaction between intracellular Ca2+ overload, high energy phosphate depletion and
"oxygen wastage" due to cAMP-mediated hydrolysis of triglyceride into free fatty acids
and glycerol (Kjekhus 1975, Opie et al., 1979). Furthermore, the harmful effects of
excess cAMP are also well-established (Opie 1991). Even in the absence of ischaemia,
elevations in cAMP have been shown to produce myocardial necrosis (Martorana 1971).
High levels of cAMP are also known (i) to increase sarcolemmal Ca2+entry (Tsien 1983)
which in turn results in intracellular Ca2+ overload and (ii) to increase the activation of
cardiac lipases (Opie 1982), effects known to aggravate ischaemie injury. Therefore an
attenuation of increases in cAMP during sustained ischaemia would be expected to
protect against necrosis. However,this is not always the case (1.2.2.5.3).
Adrenergic stimulation during ischaemia is also believed to be deleterious to the
myocardium, both on a structural and electrophysiological level, leading to cellular
damage and arrhythmias (Waldenstrom et al., 1978). However, the elimination of the
effect of catecholamines during ischaemia, such as the administration of ~-blockers
does not seem to limit infarct size, but only delay the development of infarction and
arrhythmias (Opie and Lubbe 1979, Hearse et al., 1986, Tsuchida et al., 1993).
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1.2.2.5.2 ~-Adrenergic receptor and adenylyl cyclase in ischaemia
Under normal physiological conditions, stimulation of the ~-receptors is followed by their
rapid inactivation and desensitization (Strasser 1989, Lefkowitz et a/., 1990). However,
early myocardial ischaemia is characterized by dual sensitization of the ~-adrenergic
system (Strasser et a/., 1990), namely independent upregulation of the ~-adrenergic
receptors and increased adenylyl cyclase activity, which could occur via three distinct
mechanisms: (i) An increase in number of functionally coupled ~-adrenergic receptor at
cell surface (Strasser et a/., 1988, Thandroyen et a/., 1990) due to the loss of high
energy phosphates like ATP (Strasser et a/., 1988) or due to receptor synthesis by rapid
upregulation of the mRNA levels of the receptor (Ihl-Vahl et a/., 1995). (ii) An
impairment of catecholamine-promoted uncoupling and internalization (Strasser et a/.,
1988), because the stimulatory Gs-protein remains coupled to the receptor, while the
coupling to the inhibitory Gi-protein is rapidly impaired (Strasser et a/., 1990). (iii) The
adenylyl cyclase is transiently sensitized during ischaemia: its activity increases rapidly
after the onset of ischaemia (5 - 15 min) followed by a gradual loss of activity during
sustained ischaemia (30 - 50 min) (Strasser et a/., 1990). The early sensitization of
adenylyl cyclase may be due to a rapidly reversible covalent modification (Strasser et
a/., 1990) or due to Gi-protein impairment and therefore removal of the inhibitory effect
on adenylyl cyclase (Strasser et a/., 1990) or due to activation by PKC independently of
u1-adrenergic receptors (Strasser et a/., 1992), while late inactivation of adenylyl
cyclase occurred independently of the ~-adrenergic receptor activation (Strasser et a/.,
1990). Therefore the persistent sensitization at the receptor level then meets an
unresponsive adenylyl cyclase.
1.2.2.5.3 cAMP and ischaemia
It is well known that ischaemia causes an increase in tissue levels of cAMP, the second
messenger of the ~-adrenergic system (Wollenberger et a/., 1969). Strasser et al.
(1990) reaffirmed that cAMP levels increased within 10 min after onset of ischaemia in
the rat myocardium, reaching maximum values after 20 min of severe ischaemia. This
may be linked to an increased tendency to ventricular arrhythmias at the onset of a
heart attack (Lubbe et a/., 1992). Stimulation of the sensitized ~-adrenergic receptor by
locally released endogenous catecholamines (as mentioned before) may contribute to
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this phenomenon, but results on this issue are inconclusive: both Rabinowitz et al.
(1975) and Krause et al. (1983) found that the increase in tissue cAMP after coronary
occlusion and aortic clamping, respectively, was prevented by blocking the p-adrenergic
receptor with a P-blocker, such as propranolol. Therefore their results support the
notion that the increase in cAMP was attributed to the sensitization or the increase in p-
adrenergic receptor density. In contrast, Muller et al. (1986) and Lubbe et al. (1981)
showed that p-adrenergic receptor blockade had no effect on the increase in tissue
cAMP levels of the ischaemiearea in pigs and rat hearts, respectively.
There may also be other reasons for the increase in tissue cAMP in the ischaemie
myocardium. One possibility is the formation of Iysophospholipids, such as
Iysophosphatidyl choline, during ischaemia that may activate adenylyl cyclase
(Ahumada et ai., 1979). Another possibility is the inactivation of myocardial
phosphodiesterases in the pig heart, which may be caused by acidosis during
ischaemia (Podzuweit et ai., 1994, 1996). However, the role of these factors in the
increase in cAMP in the ischaemiemyocardium has not yet been elucidated.
1.2.2.6 The role of adrenergic signalling in preconditioning
1.2.2.6.1 Catecholamines in preconditioning
As endogenous catecholamines are released during short episodes of ischaemia
(Schbmig et ai., 1984), it is possible that it may playa triggering role in ischaemie PC.
However, indications are that the release thereof only occurs after 10 min of ischaemia
(Schómiq et ai., 1984). On the other hand, Banerjee et al. (1993) showed that
catecholamines were released within 2 min of transient global ischaemia, although this
amounted to less than 3% of the total estimated quantity of rat heart noradrenaline.
Therefore, it is possible that either no or minute quantities of catecholamines are
released during the brief episodes of ischaemia associated with PC.
To investigate the role of catecholamines in ischaemie PC, Vander Heide et al. (1993)
depleted dog heart of endogenous catecholamines with reserpine. They found that the
infarct size in reserpinated dogs was slightly smaller than untreated animals, though not
significantly. Furthermore, ischaemie PC could limit infarct size in both treated and
untreated animals. Therefore they concluded that endogenous catecholamines might
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not be required to mediate the cardioprotective effect of PC. In addition, studies in
rat (Weselcouch et a/., 1995a, Moolman et al., 1996a) and rabbit (Ardell et al., 1994)
hearts could also not provide any evidence for the involvement of endogenous
catecholamines. In contrast, Banerjee et al. (1993) and Toombs et al. (1993) showed
that ischaemie PC in the rat and rabbit heart, respectively, was abolished by depletion
of endogenous catecholamines by prior reserpination.
Although Seyfarth et a/. (1996) did not observe catecholamine release during the cycles
of transient ischaemia in rat hearts, these ischaemie episodes reduced catecholamine
release during sustained ischaemia by protecting the neural tissue as it does myocardial
tissue.
1.2.2.6.2 u1-Adrenergic signalling in preconditioning
Convincing evidence has been presented for ischaemia-mediated noradrenaline release
and subsequent u1-adrenergic receptor stimulation and PKC activation (1.1.3.3.1):
administration of u1-agonists before sustained ischaemia elicit PC in rat (Banerjee et a/.,
1993, Tosaki et a/., 1995) or rabbit (Bankwala et a/., 1994, Tsuchida et a/., 1994) while
u1-adrenoceptor antagonists in rat (Banerjee et al., 1993) or rabbit (Thornton et a/.,
1993a) or PKC blockers in rat (Cave and Apstein 1994, Speechly-Dick et a/., 1994,
Mitchell et a/., 1995) or rabbit (Ytrehus et a/., 1994, Armstrong et al., 1994) have been
shown to abolish PC. Although investigators like Bugge and Ytrehus (1995a) indicated
that ischaemie PC in rat was not mediated through u1-adrenergic or adenosine
receptors, they found that it was still dependent on the activation of PKC. Furthermore,
Weinbrenner et a/. (1993) showed that a brief episode of ischaemia (2 - 5 min) caused
rapid translocation of PKC and although Strasser et al. (1992) found this to be U1-
independent, it is possibly involved in sensitization of the adenylyl cyclase system.
However, our laboratory could not find any evidence of either u1-adrenergic or PKC
activation in the mechanism of ischaemie PC in rat hearts (Moolman et a/., 1996).
Similar negative findings were reported by others: Asimakis and Inners-McBride (1993)
failed to demonstrate involvement of u1-adrenergic receptor stimulation in the
attenuated postischaemie contractile dysfunction associated with ischaemie PC.
Likewise, inhibition of PKC did not prevent cardioprotection in rat (Kolocassides and
Galinanes 1994), rabbit (Simkhovich et a/., 1996), pig (Vahlhaus et a/., 1996) and dog
hearts (Przyklenk et a/., 1995).
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Thus there is not yet clarity about the involvement of the u1-adrenergic receptor
signalling pathway in ischaemie PC. However, the differences in end-points or PC
protocols could be responsible for these discrepancies. For example, although both
Banerjee et al. (1993) and Asimakis and Inners-McBride (1993) evaluated the effect of
u1-agonists before sustained ischaemia in rats, their results were contradictory. This is
probably due to use of different end-points viz infarct size reduction vs. functional
recovery, respectively. Since these two end-points may be mediated by different
mechanisms, results from one model should not be extrapolated to the other.
Furthermore, Fryer et al. (1999) indicated that multiple cycles of PC could overcome the
abolishment of protection by PKC inhibitors in rats. The discrepancy between the
results obtained with PKC inhibitor in a one-cycle and a multi-cycle ischaemic-PC
protocol may thus be due to the fact that the latter provides more effective protection
than a one-cycle protocol and is less susceptible to blockade by inhibitors (Sandhu et
aI., 1997). It is now well-established that several receptor systems contribute to
triggering ischaemic-PC and one particular inhibitor often fails to inhibit protection
(Cohen et al., 2000).
Since catecholamines also have the capacity to stimulate the ~-adrenergic receptors
and its signal transduction pathway, it should also be considered as an additional trigger
of the PC process.
1.2.2.6.3 ~-Adrenergic signalling and preconditioning
Apart from one study by Asimakis et al. (1994), showing that transient ~-adrenergic
receptor stimulation by noradrenaline could mimic PC, the involvement of the ~-
adrenergic receptor as a trigger in classic PC has received little or no attention thus far.
Although, Fu et al. (1993) have shown that adenylyl cyclase activity of the
preconditioned segment was not different from those of the non-preconditioned
segment in pig myocardium, Strasser et al. (1992) convincingly demonstrated that acute
myocardial ischaemia induces a rapid increased activity of adenylyl cyclase after the
onset of ischaemia (5-15 min) and this is rapidly reversible on reperfusion in isolated rat
hearts. Preservation of adenylyl cyclase activity and improvement in the functional
activity of the stimulatory G-protein (Gs) have been shown to occur in preconditioned
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rabbit hearts (Iwase et al., 1993). On the other hand, it has been shown that the
activity of the inhibitory G-protein (Gi) was enhanced in PC (Niroomand et al., 1995), an
effect that would be expected to decrease cAMP. Previously, our laboratory (Moolman
et al., 1996) also indicated that prior PC significantly attenuated cAMP accumulation
during sustained ischaemia in isolated rat hearts. It is not known whether this is the
cause or effect of prior protection to ischaemic damage. Sandhu et al. (1996) reported
that PC did not affect the receptor responsiveness in the in vivo rabbit model, but
mediated attenuation in noradrenaline release resulting in a reduction in cAMP levels
during sustained ischaemia. However, they found that attenuation of the rise in cAMP
levels with PC during sustained ischaemia was not necessary for its protection against
necrosis, since raising cAMP via an activator of adenylyl cyclase, NKH477, did not block
the protection of a multi-cycle PC protocol. They subsequently showed that when PC
was induced with only a single cycle of transient ischaemia and reperfusion, raising
cAMP levels with NKH477 produces a block of PC (Sandhu et al., 1997). Therefore, a
multi-cycle ischaemic-PC protocol may provide a more effective protection than a one-
cycle protocol and is less susceptible to pharmacological manipulation (Sandhu et al.,
1997).
Thus, although the ~-adrenergic signal transduction system has been implicated in the
phenomenon of PC, results are controversial. Furthermore, both the role of the ~-
adrenergic receptor-adenylyl cyclase system and the changes in tissue cAMP levels
during the PC protocol were still undefined at the initiation of our studies. In addition,
changes in the downstream events of the ~-adrenergic-cAMP pathway, involved in PC,
are still unknown.
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1.2.3 Nitric oxide (NO)- cyclic Guanosine Monophosphate (cGMP)
pathway
1.2.3.1 Introduction
It has been proposed that nitric oxide (NO), a gas known to give rise to the formation of
cGMP, may playa role in ischaemic PC. Parratt and colleagues concluded that NO
was involved in pacing-induced PC against arrhythmias in dog heart (Parratt, 1994, Kis
et aI., 1999). The involvement of NO in the late phase of protection seen 24 hr after
ischaemie PC has been the focus of intense investigation. Bolli et al. (1998) recently
postulated a dual role for NO in this scenario: initially a trigger and subsequently as
mediator of protection. They proposed that triggering the development of late PC on
day one, involves generation of NO after a brief ischaemic stress (probably via
endothelial nitric oxide synthase, eNOS) (Bolli et ai., 1997) and subsequent activation of
PKC (Ping et ai., 1999c). The latter could in turn trigger a complex signalling cascade
that involves protein tyrosine kinases (Imagawa et ai., 1997). Furthermore, the
cardioprotective effects of late PC observed on day two might be due to upregulation of
inducible NOS (iNOS) (Takano et al., 1998a, Takano et al., 1998b). On the other hand,
the role of NO in early or classic PC is currently unclear, mainly because it was recently
shown that NO is not a trigger or mediator of classic PC against infarction in either
rabbits (Nakano et ai., 2000) or pigs (Post et ai., 2000).
1.2.3.2 Nitric oxide (Fig. 1.5)
Furchgott and Zawadzki (1980) made the fundamental discovery that acethylcholine,
the neurotransmitter of the cholinergic nervous system, dilated healthy blood vessels
but caused vasoconstriction when the endothelium was damaged, which led to the
discovery of an endothelial-derived relaxing factor (EDRF). Moncada and colleagues
later found EDRF to be nitric oxide (NO), an extremely short-lived free-radical (Palmer
et ai., 1987, Ignarro et ai., 1987). Since then it has become clear that NO also play an
important role in cardiovascular disease. Although initially characterized in the
vasculature, NO is also present in heart muscle (Schulz et aI., 1992), where it is
involved in regulation of cardiac function (Balligand 1999).
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Fig. 1.5 Regulation of contractility of arterial smooth muscle by nitric oxide (NO) and
cGMP. See text for details and definitions of terms and abbreviations (modified from
Moncada and Higgs 1993, Lowenstein et a/., 1994).
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Nitric oxide (NO) and citrulline production, via a live-electron oxidation of a
guanidino nitrogen from L-arginine, are catalyzed by NO synthase (NOS). The latter
consists of several isofarms, such as endothelial NOS (eNOS or NOS3), neuronal NOS
(nNOSor NOS1) and inducible NOS (iNOS or NOS2). Two of these (eNOS and nNOS)
are constitutively expressed and activated by Ca2+ and release small amounts of NO for
brief periods to signal adjacent cells. The other, iNOS, is transcriptionally regulated by
a variety of inflammatory cytokines, and releases large amounts of NO (Schmidt et al.,
1993, Lowenstein et a/., 1994). In addition, in cardiac myocytes the activation of the
extracellular mitogen-activated protein kinase 1 and 2 (ERK1/2) may be required for
induction of iNOS by cytokines (Singh et el., 1996 and see MAPKs ).
1.2.3.3 Metabolism of cGMP
Although cGMP was discovered more than thirty years ago, its role as a second
messenger has long been overshadowed by that of cAMP (Fig. 1.3). In the heart
muscle, cGMP could oppose the inotropic action of catecholamines after p-adrenergic
stimulation (Balligand and Cannon, 1997). Cyclic GMP has a well-established role as
vasodilatory messenger in vascular smooth muscle, in contrast to its still controversial
role in the myocardium.
1.2.3.3.1 Guanylyl cyclase (GC) (Fig. 1.5)
Synthesis of cGMP is catalyzed by two types of guanylyl cyclases: a soluble cytosolic
(sGC) and a particulate transmembrane form (pGC). The latter has a ligand-binding
domain on the outer surface of the plasma membrane for interaction with certain
peptide hormones, such as atrial natriuretic factor (ANF) (Vaandrager and De Jonge
1996). Binding of the ligand to this receptor promotes the catalytic activity of the
intracellular guanylyl cyclase cytosolic domain, leading to formation of cGMP from GTP.
Furthermore, soluble guanylyl cyclases (sGC) are activated several hundred-fold by
nitric oxide (NO). These enzymes are heterodimers and contain a bound heme
molecule that interacts with both subunits. Binding of NO to the heme leads to a
conformational change in the enzyme and stimulates its catalytic activity, leading to
conversion of GTP to cGMP (Schmidt et al., 1993, Vaandrager and De Jonge 1996).
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1.2.3.3.2 Phosphodiesterases (POEs)
POE1 (Ca2+/calmodulin-sensitive POE, described before) and POE5 (cGMP-specific
POE) contribute largely to the hydrolysis of cGMP, both in the presence and absence of
Ca2+/calmodulin, respectively. The cGMP-binding cGMP-specific phosphodiesterase
(POE5), which is very specific for cGMP hydrolysis, was first purified from rat lung
(Francis et aI., 1980). Selective inhibition of POE5 had no effect on cardiac function,
suggesting that this isoform is not important in the rat myocardium (Cohen et aI., 1996).
In fact, there was no detectable level of POE5 in the heart (Wallis et aI., 1999).
However, POE5A mRNA genes are produced in aortic smooth muscle cells, heart,
placenta, skeletal muscle and pancreas and to a much lesser extent in brain, liver and
lung of humans (Loughney et aI., 1998). The major POE activity in the human cardiac
ventricle was shown to be POE1.
In addition to its cGMP-selective catalytic site, POE5 contains two allosteric cGMP-
binding sites and at least one phosphorylation site (Ser92) on each subunit (Thomas et
aI., 1990). Both cGMP-dependent protein kinase (PKG) and cAMP-dependent protein
kinase (PKA) catalyse the phosphorylation of POE5, causing an increase in enzyme
activity and also increased affinity of cGMP for the allosteric cGMP-binding site.
Considerably higher concentrations of PKA than of PKG are required for activation.
Furthermore, phosphorylation of POE5 by PKG could be involved in a physiological
negative-feedback regulation of cGMP in bovine lungs (Corbin et aI., 2000).
1.2.3.4 Effect of NO-cGMP pathway
1.2.3.4.1 In vascular smooth muscle (Fig. 1.5)
The contractility of arterial smooth muscles is regulated by NO and cGMP. Receptor
activation by bradykinin or acetylcholine results in an influx of Ca2+ into endothelial cells
lining blood vessels. After Ca2+ binds to calmodulin, the resulting complex stimulates
the activity of eNOS. The NO that is synthesized diffuses from endothelial cells and
activates soluble guanylyl cyclase in nearby smooth muscle cells. The resulting rise in
cGMP mediates inhibition of voltage dependent L-type Ca2+ channels. This results in a
reduction of cytosolic calcium that leads to the relaxation of the muscle and vasodilation
(Moncada and Higgs 1993, Ishikawa et aI., 1993, Lowenstein et aI., 1994).
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Furthermore, smooth muscle relaxation can also be mediated by K+channels via both
cAMP and cGMP after agonist stimulation, such as p-adrenergic agents and ANF,
respectively. These activate the cAMP-dependent protein kinase (PKA) and cGMP-
dependent protein kinase (PKG), respectively, which in turn phosphorylate K+channels,
thus hyperpolarizing the cell membrane. This hyperpolarization inactivates the L-type
Ca2+ channels, resulting in decreased Ca2+ influx and subsequent relaxation (Walsh
1993, Somlyo and Somlyo 1994).
1.2.3.4.2 In myocardium (Fig. 1.6)
cGMP has several intracellular targets, including cGMP-gated ion channels (L-type Ca2+
channels), a cGMP-activated phosphodiesterase (PDE2), a cGMP-inhibited
phosphodiesterase (PDE3) and a cGMP-dependent protein kinase (PKG) (Butt et aI.,
1993, Schmidt et al., 1993,Vaandrager and De Jonge 1996).
Cyclic GMP may stimulate PKG to decrease heart rate and to have a negative inotropic
effect (Lohmann et aI., 1991). Such formation of cGMP could occur in response to
either cholinergic stimulation or activity of the NO pathway in the cardiac myocyte.
These mechanisms are not mutually exclusive. Cholinergic stimulation induces the
activity of the myocardial constitutive nitric oxide synthase (eNOS) to increase formation
of NO (Kelly et aI., 1996). However, whether the myocardial NO system plays a
physiological role in the myocardium is still controversial.
Balligand (1999) proposed a mechanism by which NO could regulate cardiac function
(see Fig. 1.6): As described before, p-adrenergic stimulation produces a positive
inotropic effect through Gus-coupled activation of adenylyl cyclase (AC), leading to
increases in intracellular cAMP. Subsequent activation of PKA leads to downstream
phosphorylation of target proteins, including those on the L-type Ca2+-channel. The
resultant increased influx of Ca2+ activates intracellular Ca2+-induced Ca2+ release and
enhances myofibrillar contraction. Inducible NOS (iNOS) gene transcription and protein
expression is induced in cardiac myocytes on exposure to cytokines or other
inflammatory mediators. Direct eNOS activation in cardiac myocytes occurs in
response to either muscarinic cholinergic or adrenergic receptor stimulation through
unidentified mechanisms. NO produced by either eNOS or iNOS activates the soluble
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Fig. 1.6 Second-messenger pathways for the action of nitric oxide (NO) in cardiac
myocytes. See text for details and definitions of terms and abbreviations (modified
from Balligand and Cannon, 1997).
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guanylyl cyclase to increase intracellular cGMP, which opposes the positive
inotropic effects of cAMP through (i) activation of the cGMP-stimulated POE (PDE2) to
enhance the breakdown of cAMP (on the contrary, cGMP may also potentiate the
effects of cAMP through inhibition of PDE3); (ii) activation of PKG may in turn decrease
the L-type Ca2+ current stimulated by PKA via phosphorylation of an intermediate
protein opposing the effect of PKA. PKG also promotes relaxation by decreasing
myofilament sensitivity to calcium. Besides eNOS activation, muscarinic cholinergic
receptor stimulation results in GBYi-mediatedinhibition of adenylyl cyclase (AC) and
activation of distinct K+channels.
In addition, NO may affect myocyte contraction through mechanisms independent of
cGMP elevations such as: (i) oxidation of contractile regulatory proteins, including the
cardiac Ca2+ release channel (ryanodine receptor) and L-type Ca2+ channel (Xu et al.,
1998); (ii) NO and its redox-related derivative (peroxynitrite) may also inactivate key
enzymes, including creatine kinase and cytochrome C oxidase, that regulate oxygen
consumption and ATP generation in heart muscle. (Torres et al., 1995).
1.2.3.5 NO-cGMP pathway and ischaemia-reperfusion
In cardiac myocytes, vascular endocardial endothelium and specific cardiac neurons,
NO is synthesized by a constitutively expressed and Ca2+-dependent NOS, such as
eNOS and nNOS. This NO plays an important role in the regulation of coronary
circulation and cardiac contractile function (Balligand et al., 1997).
Myocardial ischaemia led to increased activity of Ca2+-dependent eNOS (Depré et al.,
1997) and cGMP content (Depré et aI., 1994) in perfused rabbit hearts. Direct
measurement of myocardial NO indicated marked increases after 30 min of ischaemia
in Langendorff-perfused (Zweier et al., 1995) and working rat hearts (Csonka et al.,
1999). Others previously suggested ischaemia-induced increases in NOS on the basis
of indirect pharmacological evidence (Kitakaze et al., 1995, Node et al., 1996).
However, contradictory viewpoints exist about whether endogenous NO is detrimental
or protective in ischaemia-reperfusion and will be discussed in the following sections
(1.2.3.5.1 and 1.2.3.5.2).
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1.2.3.5.1 NO-cGMP pathway: deleterious?
NO may combine with superoxide (02-) to generate peroxynitrite (ONOO-) which
decomposes to yield hydroxyl radicals (OH-) and other reactive oxygen species (ROS)
(Beckman et al., 1990). The latter are known to play a major role in myocardial
ischaemia, and particularly reperfusion injury (McCord, 1985).
Results obtained by Schulz et al. (1995) and Woolfson et al. (1995) indicated that
inhibition of NOS protects against ischaemia-reperfusion injury. In addition, Wang and
Zweier (1996) reported that NOS inhibitors at concentrations that decreased NO during
ischaemia/ reperfusion reduce peroxynitrite generation as well as ischaemia/
reperfusion injury. It was suggested that the harmful effects of NO accumulation in the
ischaemie heart (Zweier et al., 1995, Csonka et al., 1999) was not due to NO itself but
rather to peroxynitrite, a reaction product of NO and superoxide (Beckman et a/., 1996,
reviewed by Rakhit et al., 1999). Addressing this controversy, Yasmin et al. (1997)
demonstrated that in rat hearts the NO-dependent ischaemia-reperfusion injury was
mediated by peroxynitrite generation. They showed that a NOS inhibitor (NG_
monomethyl-L-arginine, L-NAME) could abolish the latter and was cardioprotective.
However, a NO donor (S-nitroso-N-acetyl-penicillamine, SNAP) was also
cardioprotective in their model. This may be because NO in itself is an antioxidant that
interferes with peroxynitrite-mediated radical chain propagation reactions (Rubbo et al.,
1994). These ambiguous effects of NOwithin ischaemia-reperfusion were reinforced by
a recent study (Du Toit et al., 1998) in the isolated rat heart in which the NO donor
sodium nitroprusside (SNP) and the NOS inhibitor NG-nitro-L-arginine (LNA) both
reduced ischaemia-reperfusion injury. They proposed that the cardioprotective effect of
NO donors might be due to their ability to elevate cGMP levels. However, because low
concentrations of NOS inhibitors were used, it did not affect the cGMP levels and their
beneficial effects may be mediated via an additional mechanism independent of NOS
activity.
1.2.3.5.2 NO-cGMP pathway: protective?
Numerous studies have indicated that NO was directly protective during myocardial
ischaemia-reperfusion by administration of exogenous NO (Johnson et al. 1991,
Ferdinandy et al., 1995a, Nossuli et al., 1997, Yasmin et al. (1997), Du Toit et al.
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(1998). They could be protective via numerous mechanisms which will be
discussed in the following sections (reviewed by Rakhit et aI., 1999). However, the
exact mechanism by which these compounds act is unknown.
1.2.3.5.2.1 Calcium
There is strong evidence for a role of cytosolic Ca2+ overload in myocardial ischaemic-
reperfusion injury (Kusuoka et al., 1987, Marban et a/., 1989). Factors that contribute to
the elevation in cytosolic Ca2+ levels during ischaemia and reperfusion include
adrenergic stimulation leading to elevated cAMP levels (Wollenberger et a/., 1969) and
increased Ca2+ influx through sarcolemmal Ca2+ channels (Du Toit and Opie, 1992).
NO causes relaxation of vascular smooth muscle by increasing cGMP levels which in
turn activate cAMP phosphodiesterases (POEs), reducing cAMP and intracellular Ca2+
levels (Lohmann et a/., 1991). Exogenous administration of NO (Du Toit et a/., 1998) or
activation of myocardial NOS (Du Toit et a/., 1998, Oepré et a/., 1994, Oepré et al.,
1997) increases cGMP levels by increasing guanylyl cyclase activity. If, as in vascular
smooth muscle cells, elevations in myocardial cGMP lead to a decrease in cytosolic
Ca2+ levels, then NO-cGMP pathway stimulation may protect the ischaemic heart
against ischaemia-reperfusion induced Ca2+ overload.
It has indeed been shown that elevated tissue cGMP levels counter the cAMP induced
increase in the slow inward Ca2+ current and decreases cytosolic Ca2+ levels in frog
(Hartzell and Fischmeister, 1986) and rat myocytes (Sumii and Sperelakis, 1995) and
thereby inducing protection.
1.2.3.5.2.2 Phosphodiesterase (POE)
There is also pharmacological evidence that the guanylyl cyclase-cGMP-POE system
contributes to cardioprotection. For example, Ljusegren and Axelsson (1993) described
that an increase in myocardial cGMP by either SNP or ANP or zaprinast (an inhibitor of
cGMP-specific POE5), caused a reduction of lactate accumulation in isolated hypoxic
rat ventricular myocardium.
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1.2.3.5.2.3 Reactive oxygen species (ROS)
NO can act both as a pro-oxidant as well as an antioxidant depending on the relative
concentrations of individual ROS. As mentioned before, the pro-oxidant reactions of
NO will occur after reacting with superoxide (02-) to yield a potent secondary oxidant
peroxynitrite (ONOO-), while the antioxidant effects of NO are a consequence of direct
reaction with lipid radical species, such as alkoxyl (LO-) and peroxyl (LOO-) radicals,
resulting in termination of membrane lipid radical chain propagation reactions (Rubbo et
aI., 1994). Furthermore, ROS could also result in activation of PKC in the PC scenario,
such as protection elicited by late PC (Ping et aI., 1999c).
1.2.3.6 NO-cGMP pathway in classic preconditioning
1.2.3.6.1 NO and transient ischaemia (as in PC protocol)
Free radicals can also trigger PC protection, since the administration of antioxidants
during the brief triggering ischaemia has been found to prevent both early and late PC
(Sun et aI., 1996). Therefore, a detrimental component of NO (NO-derived radicals) can
paradoxically trigger subsequent protection.
Bradykinin is released early in ischaemia (parratt et aI., 1993) and has been postulated
as a trigger for the release of NO. Bradykinin is thought to act via B2 receptors to
activate nitric oxide synthase (NOS) in endothelial cells, leading to stimulation of soluble
guanylate cyclase in myocytes with a resultant increase in intracellular cGMP (Schini et
aI., 1990). Elevated cGMP may reduce calcium influx, stimulate cGMP
phosphodiesterase (POE) and therefore reduce cAMP levels, and decrease myocardial
oxygen demand via NO-mediated reduction in myocardial contractility (Brady et ai.,
1993). Pharmacological manipulation of this pathway could be utilized to define the role
for NO in PC protection.
1.2.3.6.2 Role of NO: trigger or mediator?
The role of NO as a trigger or mediator in the phenomenon of classic PC is however
much less defined and the few studies done thus far focused mainly on outcomes such
as reperfusion dysrhythmias. The results obtained were controversial: some studies
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reported that the anti-arrhythmic effects of PC were independent of NO (Lu et aI.,
1995, Siegfried et al., 1992), and that NOS-inhibition by L-NAME had no effect on PC-
induced reduction in infarct size (Woolfson et aI., 1995) or improvement in functional
recovery (Weselcouch et aI., 1995b); others showed that NO donors could mimic
(Bilinska et aI., 1996) or NOS-inhibitors abolish (Vegh et aI., 1992) the protective effects
of PC on arrhythmias. Further evidence for involvement of NO in PC was the recent
observation that cardiac NO biosynthesis was essential to trigger, but not to mediate PC
(Csonka et aI., 1999): when they added an inhibitor of NOS, NG-nitro-L-arginine (LNA),
during the PC protocol to reduce the basal NO synthesis, PC failed to protect against
ischaemia-reperfusion. Furthermore, when LNA was applied after the PC protocol, the
PC-induced protection was not affected. Thus far, the effect of NO donors on outcomes
such as infarct size or functional recovery during reperfusion has not been studied.
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1.3 Final common pathway of preconditioning: Mitogen Activated
Protein Kinase (MAPK)?
1.3.1 Introduction
Potential downstream targets of PKA, PKC and tyrosine kinases are the mitogen
activated protein kinases (MAPKs). Each of the three major subfamilies, namely ERK
(extracellular signal-regulated kinase) and the two stress-activated protein kinases
(SAPKs), p38 MAPK and JNK (c-Jun NH2-terminal kinases), has been suggested to
play a role in the cardioprotection achieved by PC (for review see Ping and Murphy
2000, Michel et aI., 2001, Schulz et aI., 2001). These three different signalling modules
will be discussed in detail, as well as the transcription factors involved, especially the
importance of the latter in the identification of a final effector of PC.
All three of the subfamilies of MAPKs are expressed in rodent, rabbit, as well as human
hearts (Cook et al., 1999). They are activated in response to a wide variety of stimuli,
including growth factors, G protein-coupled receptor agonists and environmental
stresses (Abe et aI., 2000). Their activation has been implicated in many cardiac
functions, such as cardiac hypertrophy (reviewed in Schaub et al., 1997), induction
(MacKay et aI., 1999, Wang et aI., 1998, Ma et aI., 1999) or inhibition of cell death
(apoptosis) (Zechner et aI., 1998) and ischaemie PC (Weinbrenner et aI., 1997). It is
suggested that ERK1/2 is part of a "survival" pathway whereas p38 MAPK and JNK
mediatea "death" pathway (Yue et a/., 2000, Abe et aI., 2000). In addition, the activities
of JNK and p38 were increased in heart failure secondary to ischaemie heart disease
(Cook et al., 1999).
1.3.2 Overview of MAPKs
The identification of a superfamily of related serine/threonine protein kinases, known as
mitogen-activated protein kinase (MAPK) (reviewed by Widmann et aI., 1999;
Bogoyevitch 2000; Kyriakis and Avruch 2001) are among the most widespread
mechanisms of eukaryotic cell regulation. All eukaryotic cells possess multiple MAPK
pathways, each recruited by distinct sets of stimuli, thereby allowing the cell to respond
to multiple divergent inputs. Mammalian MAPK pathways can be activated by a wide
variety of different stimuli acting through diverse receptor families, including (i)
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hormones and growth factors that act through cytokine receptors (i.e. growth
hormone) or receptor tyrosine kinases (i.e. insulin, epidermal growth factor (EGF),
platelet-derived growth factor (POGF), fibroblast growth factors), (ii) vasoactive
peptides acting through G protein-coupled seven-transmembrane spanning receptors
(i.e. angiotensin, endothelin), (iii) transforming growth factor (TGF)-p-related
polypeptide, acting through Ser-Thr kinase receptors, (iv) inflammatory cytokines of the
tumor necrosis factor (TNF) family and (v) environmental stresses such as osmotic
shock, ionizing radiation and ischaemie injury. MAPK pathways, in turn, coordinate
activation of gene transcription, protein synthesis, cell cycle machinery, cell death and
differentiation.
1.3.2.1 Major subfamilies of MAPKs
1.3.2.1.1 ERK
The initial molecule identified to mediate the mitogenic effects of growth factors which
stimulate receptor protein tyrosine kinases (RPTK), was a tyrosine-phosphorylated
protein of 42 kO (Cooper and Hunter 1983). Soon after, this molecule was identified as
a p42 mitogen-activated protein kinase (MAPK), which requires a dual phosphorylation
of both threonine and tyrosine for full activation (Ray and Sturgill 1988, Rossomando
1989). Molecular cloning of this molecule and a highly related protein, p44 MAPK,
revealed that they belong to a family of serine-threonine kinases related to a yeast
MAPK involved in the pheromone-induced mating response (Boulton et al., 1990,
Boulton et al., 1991). In mammalian cells, p44 MAPK and p42 MAPK, also known as
ERK1 and ERK2, respectively, are believed to be central components of proliferative
pathways. A wide variety of growth promoting or hypertrophic agents activate these
kinases in cardiac myocytes, fibroblasts, smooth muscle cells or endothelial cells
(Bogoyevitch 2000). Activation of ERK may also follow exposure to a variety of
extracellular stresses. Such activation of a potent growth factor-stimulated pathway by
stress may seem contradictory, but if stress-activated ERK is chemically inhibited, cell
death is accelerated (Wang et al., 1998). Therefore ERKs may contribute to
cardiovascular cell survival. Accordingly, recent findings suggest that ERK promote cell
survival by both inhibiting components of the cell death machinery (i.e. the proapoptotic
BcI-2 family protein, BAD) and increasing transcription of pro-survival genes (i.e. cAMP-
response element binding protein, CREB) (Bonni et el., 1999, Tan et al., 1999).
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1.3.2.1.2 JNK
There has been a recent focus on other MAPK subfamilies that are activated by a
diverse range of extracellular stresses such as irradiation, ultraviolet light, mechanical
stress (shear stress evoked by blood flow or stretch), hyperosmotie shock, heat shock,
hypoxia/reoxygenation, reactive oxygen species (ROS), proinflammatory cytokines
(such as interleukin, IL-1 and tumor necrosis factor, TNF-a) and to a lesser degree by
growth factors (Sugden and Clerk 1998, Bogoyevitch 2000).
A subfamily of MAPK, structurally related to ERKs, termed c-Jun NH2-terminal kinases
(JNKs) or stress-activated protein kinases (SAPKs), was discovered as a cycloheximide
(a protein synthesis inhibitor) activated 54 kDa protein kinase (Kyriakis and Avruch
1990). Molecular cloning revealed three genes that encode the 46- and 54-kDa
isoforms of JNK: SAPKa/JNK2, SAPKP/JNK3, SAPKy/JNK1 (Kyriakis et aI., 1994,
Derijard et al., 1994). These kinases selectively phosphorylate the NH2-terminal
transactivation domain of the transcription factor c-Jun (Hibi et al., 1993), which results
in gene expression of c-jun (Karin 1994). JNKs are important for cytokine biosynthesis
and are involved in cell transformation, stress responses and apoptosis (programmed
cell death) (Kyriakis and Avruch 1996, Dong et aI., 1998, Kuan et aI., 1999).
1.3.2.1.3 p38 MAPK
The p38 MAPK subgroup (also referred to as CSBP / Dp38 / HOG1 / Mxi2 / p40 / Phh1 /
RK / SAPK2 / Spc1 / Sty1 / XMpk2) was discovered as a lipopolysaccharide (LPS)-
induced tyrosine phosphoprotein and as the target of a drug developed to inhibit LPS-
induced tumor necrosis factor-a (TNF-a) biosynthesis (Han et aI., 1994, Lee et aI.,
1994). There are six isoforms of p38 MAPK: p38 a1/ a2 (also CSBP1 / SAPK2a), p38
P1/ P2 (also SAPK2b / p38-2), p38y (also SAPK3 / ERK6) and p380 (also SAPK4)
(Sugden and Clerk, 1998, Kyriakis and Avruch 2001). Like the JNKs, they are strongly
activated by environmental stresses and inflammatory cytokines and therefore also
referred to as stress-activated protein kinases. In almost all instances, the same stimuli
that recruit the JNKs also recruit the p38 MAPKs (Kyriakis and Avruch 1996). One
exception is ischaemia-reperfusion. JNKs are not activated during ischaemia, but rather
during reperfusion, whereas p38 MAPKs are activated during ischaemia and remain
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active during reperfusion (Pombo et al., 1994, Bogoyevitch et aI., 1996, Kyriakis
and Avruch 1996). The basis for this difference is unknown.
Activation of p38 MAPKs has been implicated in transcription, protein synthesis, cell
surface receptor expression and cytoskeletal structure, ultimately affecting cell survival
or leading to programmed cell death (apoptosis) (Obata et aI., 2000). In addition, p38
may also play a role in embryonic development (Mikkola et al., 1999) and
organogenesis (Ganiatsas et al., 1998). However, the significance of activation of p38
MAPKs and its downstream events in myocytes has not been fully characterized.
1.3.2.1.4 Other SAPKs
A less understood MAPK, Big MAPK (BMK1) or ERK5, was identified independently as
a 98 kDa protein kinase (Lee et al., 1995, Zhou et al., 1995). ERK5 was originally
cloned as a homolog of ERK1/2, but differs in its activation loop sequence and is
activated by a distinct upstream kinase, MEK5 (Zhou et aI., 1995). ERK5 is activated in
vascular smooth muscle cells or aortic endothelial cells exposed to oxidative stress,
osmotic shock or shear stress but not by angiotensin II or growth factors (Abe et aI.,
1996, Van et aI., 1999). Although the expression of ERK5 is high in the heart, the
manner and role of its activation in cardiac myocytes remains uncharacterized (Zhou et
al., 1995).
1.3.3 Upstream components of MAPKs
Although each MAPK subfamily member acts within a distinct signalling pathway, all
MAPKs are the final components of a basic assembly of a three-component protein
kinase cascade (Fig. 1.7). This basic assembly of MAPKs are themselves regulated by
a wide variety of stimuli (1.3.2). The first kinase of the assembly is a MAPK kinase
kinase (MKKK) (Fanger et aI., 1997) that could be activated either by (i)
phosphorylation by a MAPK kinase kinase kinase (MKKKK), or (ii) by small G-proteins
which are recruited when hormones or growth factors interacts with its receptor, or (iii)
oligomerization and subcellular relocalization. The MKKK are serine/threonine kinases
which, when activated, phosphorylate and activate the next kinase in the assembly, a
MAPK kinase (MKK) (Siow et aI., 1997). The MKK recognize and phosphorylate a Thr-
X-Tyr motif (X can be different amino acids among the MAPKs) in the activation loop of
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Fig. 1.7 Basic assembly of mitogen-activated protein kinase (MAPK) pathways is a three-
component cascade conserved from yeast to humans. Divergent stimuli (activators) feed
into core MAPK kinase kinase (MKKK), MAPK kinase (MKK) and MAPK pathways that are
sequentially activated by phosphorylation, which then recruit appropriate substrates and
responses (modified from Widmann et aI., 1999; Kyriakis and Avruch 2001).
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MAPK (Gartner et a/., 1992), defining MKK as a dual-specificity kinase. The
MAPKs are the final kinases in the three-kinase module and phosphorylate substrates
on serine and threonine residues. The vast majority of substrates for MAPKs are
transcription factors. However, MAPK have the ability to phosphorylate many other
substrates including other protein kinases, phospholipases and cytoskeleton-associated
proteins.
In mammalian systems the three major MAPKs, the ERKs, JNKs and p38 MAPK appear
to have distinct upstream kinases.
1.3.3.1 Upstream components of ERK: (Fig.1.8)
In the ERK1/2 cascade, the first of the three-component kinase assembly or MKKK is a
Raf isoform, Raf-1. Activation of Raf-1 usually requires Ras, although other
mechanisms, like PKC, have been proposed (Kolch et a/., 1993, Morrison et a/., 1997,
also see Fig 1.9). Once activated, Raf-1 then phosphorylates two residues, either
serine or threonine, to activate the protein kinases known as ERK kinases (MEK1 and
MEK2) or MKKs (Kyriakis et a/., 1992). These kinases are a family of dual-specificity
protein kinases that phosphorylate two residues, tyrosine and threonine, to selectively
activate their MAPK targets (Payne et a/., 1991). MEK1/2 phosphorylate and activate
only ERK1/2 and no other MAPK family member (Crews et a/., 1992, Wu et a/., 1993).
There are two additional MKKKs, A-Raf and B-Raf, whose pattern of expression is more
restricted than that of Raf-1 (Storm et aI., 1990). The B-Raf appears to be the major
MEK (MKK) activator in brain (Catling et a/., 1994), while A-Raf activates MEK in
cardiac myocytes after stimulation with hypertrophic agonists (Bogoyevitch et a/.,
1995b).
1.3.3.2 Upstream components of JNK and p38 MAPK: (Fig 1.8)
Members of the MKKK (MAPKKK, MEKK) superfamily responsible for activating JNK
and p38 MAPK pathways that have been identified, include MEKK-1, MEKK-2, MEKK-3,
MEKK-4 (MTK), MUK (MAPK upstream kinase), MLK (mixed lineage kinase), Tpl-2
(tumor progression locus-2), TAK-1 (TGF-p activated kinase 1), ASK-1 (apoptosis
signal-regulation kinase) and TAO (thousand and one amino acid protein kinase)
(reviewed in Obata et a/., 2000, Gutkind 2000 and Widmann et a/., 1999). These
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MKKKs are regulated by Rac and Cdc42, two small guanosine 5'-phosphate (GTP)-
binding proteins of the Rho family, in a manner similar to that of Ras acting on Raf
(Minden et ai., 1995). At least a portion of this JNKlp38 MAPK activation by small GTP-
binding proteins involves activation of a serine/threonine kinase called PAK (p21-
activated kinases) (Bagrodia et ai., 1995). The relative contribution of each MKKK to
either JNK or p38 MAPK pathways has not yet been clearly defined. MEKK-1, MEKK-2,
MEKK-3, MUK, MLK and Tpl-2 seemed to preferentially activate JNK, rather than p38
(Fanger et ai., 1997, Obata et al., 2000, Gutkind 2000), through two MKKs, MKK4
(Sek1, JNKK1) (Sanchez et al., 1994) and MKK7 (Sek2) (Tournier et aI., 1997). On the
other hand, MEKK-4, TAK-1, ASK-1 and TAO appear to be more effective activators of
p38 MAPK (Obata et ai., 2000), through MKK6 and MKK3 (Moriguchi et al., 1996).
MKK6 appears to phosphorylate all p38 MAPK isoforms, whereas MKK3
phosphorylates only p38a, y and 8 (Enslen et al., 1998).
Cross-talk between the JNK and p38 MAPK pathways has also been observed, since
MEKK-1 can activate p38 MAPK through MKK-4 in NIH 3T3 cells (Guan et ai., 1998),
and similarly, MEKK-2 or MEKK-3 can couple to p38 MAPK pathway via MKK6 (Deacon
and Blank, 1999).
1.3.4 Activation of MAPKs via G protein-coupled receptors (GPCR)
1.3.4.1 Receptor protein tyrosine kinases (RPTK) and ERK pathway (Fig. 1.9)
Different receptor types are able to activate the ERK 1/2 pathway (reviewed in Widmann
et al. 1999 and Gutkind 2000). Originally ERKs were activated in response to activation
of RPTK by growth factors (1.3.2.1.1, Cooper and Hunter 1983). Upon stimulation of
RPTKs with growth factors their intrinsic domains are activated, leading to
phosphorylation of specific substrates including the receptor itself. Tyrosine
phosphorylation of the receptor allows the binding of adapter proteins, like Shc, to the
receptor. The association of Shc permits phosphorylation thereof by the receptor itself
or by intracellular tyrosine kinases such as Src. This phosphorylation allows the binding
of another adaptor protein, Grb2, which also results in the recruitment of SOS. The
latter stimulates the exchange of GOP bound to Ras for GTP (Downward 1996) and
initiates the protein kinase cascade that results in phosphorylation and activation of
ERK1/2 (as mentioned in 1.3.3.1).
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Fig. 1.9 Multiple pathways linking G protien-coupled receptors to the MAPKs (i.e. ERK1/2).
See text for details and definitions of terms and abbreviations. Arrows, positive stimulation;
blocked lines, inhibition. (modified from Gutkind, 2000)
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1.3.4.2 G protein-coupled receptors (GPCRs) and ERK pathway (Fig. 1.9)
It has become increasingly apparent that like the RPTKs, GPCRs are involved in the
regulation of cell growth and differentiation (reviewed in Post and Brown 1996). The
activation of ERKs in response to agonists acting on seven transmembrane-spanning
receptors linked to heterotrimeric G proteins, the so-called G protein-coupled receptors
(GPCRs), is also well documented (reviewed in Sugden and Clerk 1997). In the case of
Gi-coupled m2 muscarinic and a2-adrenergic receptors (Koch et al., 1994, Crespo et al.,
1994) and Gs-coupled p-adrenergic receptors (Crespo et aI., 1995, Faure et aI., 1994),
the activation of ERKs is mediated primarily by GPy subunits. On the other hand, Gq-
coupled m1 muscarinic acetylcholine and a1-adrenergic receptors induce ERK
activation mainly through Ga subunits (Koch et aI., 1994, Hawes et aI., 1995).
However, the nature of the biochemical pathways linking GPCRs to ERKs remains the
subject of intense investigation (Zheng 2000).
1.3.4.2.1 Gpy-protein (Fig. 1.9)
One major pathway of GPCR-mediated activation of MAPKs is dependent on "trans-
activation" of a panel of receptor tyrosine kinases. Specifically, stimulation of GPCRs
leads to the release of free GPy subunits, which in turn, could activate the Src kinases
that have been found to mediate the phosphorylation of Shc on tyrosine residues,
resulting in activation of ERK1/2 (Hordijk et aI., 1994, Luttrell et aI., 1996). In addition,
alternate biochemical routes might also cooperate with those described above to
connect GPCR to ERKs. For example, Ras-GRF (Ras-guanine-nucleotide releasing
factor) is a distinct Ras- guanine-nucleotide exchange factor that is activated in
response to GPCR stimulation or upon coexpression of Gpy by a mechanism involving
Ca2+ and thereby linking GPCR and GPy to Ras and ERKs (Mattingly and Macara,
1996).
Stellenbosch University http://scholar.sun.ac.za
40
1.3.4.2.2 Ga-protein (Fig. 1.9)
1.3.4.2.2.1 Phospholipase C
The fact that GPy subunits or Gaq coupled receptors can stimulate phospholipase C
(PLC) suggest that the subsequent stimulation of protein kinase C (PKC) may contribute
to MAPK activation by GPCRs (Gutkind 2000). Although PKCs can activate Raf by
direct phosphorylation (Kolch et aI., 1993) this alone does not result in an ability of Raf
to phosphorylate MEK. Thus, PKC might act directly on Raf to facilitate full activation of
Raf upon binding to Ras (Burgering and Bos, 1995).
1.3.4.2.2.2 PKA
Daaka et al. (1997) proposed a model for P2-ARmediated ERK activation in which PKA-
mediated phosphorylation of the receptor enables it to couple to Gai-proteins: Upon
agonist binding the receptor activation of Gas stimulates adenylyl cyclase activity and
the resulting rise in cAMP activates PKA, which could phosphorylate the receptor. This
phosphorylation of the P2-AR by PKA switches receptor coupling from the adenylyl
cyclase stimulatory G-protein Gs to Gi-proteins. GTP-bound Gai dissociates from the
GPy subunit and free Gpy mediates activation of the ERKs.
Activation of G protein as subunits may also inhibit ERKs via a PKA-dependent or -
independent pathway. For example: (i) inhibition of ERK1/2 is mediated by the
negative regulation of Raf-1 by PKA, due to direct phosphorylation of serine 621
(Mischak et aI., 1996) or activation of the Ras-like GTPase, Rap-1 (itself a PKA
substrate) can block ERK activation by competing with Ras for binding to Raf (Kawasaki
et aI., 1998); (ii) cAMP can directly activate Rap-1, in a PKA-independent manner, via a
guanine-nucleotide exchange factor named Epac (de Rooij et aI., 1998). On the other
hand, Vossler et al. (1997) proposed that PKA activation of Rap-1 could stimulate ERKs
through the activation of another Raf isoform, B-Raf. However, B-Raf has a more
restricted distribution than the ubiquitously expressed Raf-1.
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1.3.4.2.2.3 Receptor desensitization (GRKs and Arrestins) (Fig. 1.4)
Recent evidence suggests that GPCR desensitization and internalization are also
signalling events. Exposure of GPCRs to an agonist often results in rapid attenuation of
receptor responsiveness, a process termed desensitization (as mentioned before,
Lefkowitz, 1993). Desensitized ~-adrenergic receptors could function as scaffolds for
Src-dependent activation of ERK signalling pathways, while the ~-arrestins function as
adapter proteins that link G-protein coupled receptors to tyrosine kinase-dependent
pathways (Luttrell et aI., 1999). In this case, binding of the ~-adrenergic agonists to
their G-protein linked receptors results in the rapid phosphorylation of the agonist-
occupied receptor by the G protein-coupled receptor kinase (GRK) and the subsequent
recruitment of a protein known as ~-arrestin to the GRK-phosphorylated receptor. In
turn, ~-arrestin functions as an adaptor protein, bringing Src to the agonist-occupied
receptor, and targeting both to clathrin-coated pits. Both Src binding and clathrin-
targeting are required for ~2-AR-mediatedERK activation.
1.3.4.3 G protein-coupled receptors (GPCRs) and JNK pathway (Fig. 1.10)
In contrast to the wealth of knowledge available regarding GPCR-mediated ERK1/2
activation, the role of GPCRs in regulating JNK and p38 MAPK activity is still under
investigation. For example, the molecular mechanisms by which extracellular signals
are transmitted from the membrane receptors to most of the upstream kinases in the
JNK and p38 signalling modules are not fully understood.
It was observed that GPCRs, but not tyrosine kinase receptors, potently activate JNK
(Coso et aI., 1995). Signalling from GPCRs to the JNK might be regulated by a distinct
set of upstream signalling molecules. For example: Rac1 and Cdc42, two small
GTPases of the Rho family, were found to initiate an independent kinase cascade
regulating JNK activity (Minden et ai., 1995). Regulation of guanine-nucleotide
exchange factors (GEFs) may link ~y to Rac1 and Cdc42. For example: Ras-GRF1,
which upon ~y binding can act as a Ras GEF and can induce guanine-nucleotide
exchange on Rac1 (Kiyono et ai., 1999), while Tiam1, a Rac-specific GEF is
phosphorylated on threonine residues in a Gqa - PKC - dependent manner (Fleming et
al., 1997).
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Fig. 1.10 Molecules linking G protein-coupled receptors to JNK and p38 MAPKs.
See text for details and definitions of terms and abbreviations. Arrows, positive stimulation.
(modified from Gutkind, 2000)
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Constitutively active forms of G proteins, Ga12 and Ga13, with less well defined
signalling pathways also activate the SAPK pathways (Prasad et ai., 1995). Both these
G-protein subunits can activate the JNK through small GTPases, Rac1 or Cdc42, while
inhibiting ERK pathway in a Ras-and Raf-independent fashion (Collins et ai., 1996,
Voyno-Yasenetskaya et ai., 1996). Only the Ga13 subunit has been shown to be
involved in the activation of p38 MAPKs (Wilk-Blaszczak et ai., 1998).
1.3.4.4 G protein-coupled receptors (GPCRs) and p38 MAPK pathway
(Fig.1.10)
In HEK 293 (human embryonal kidney 293) cells, p38 MAPK can be activated through
GPCRs, such as Gq/11-coupled m1 and the Gj-coupled m2 muscarinic acetylcholine
receptors and Gs-coupled p-adrenergic receptors. Overexpression of GPy and Gaq, but
not Gas and Gai, can stimulate p38 MAPK, suggesting that the activation of p38 MAPK
by the p-adrenergic and m2 receptors occurs mainly by GPy, but not by Gas and Gai,
whereas the activation via m1 muscarinic receptors is mediated by both GPy and Gaq
(Yamauchi et ai., 1997). Furthermore, Lazou et al. (1998) indicated that in perfused rat
hearts, a1-adrenergic receptor agonists, such as phenylephrine, also activate p38
MAPK via Gaq. Thus, depending on the GPCR, p38 MAPK activation can be mediated
by the GPy-subunit or the Ga-subunit of heterotrimeric G proteins. However, Communal
et al. (2000) reported that in adult rat ventricular myocytes both P1- and P2-adrenergic
receptor subtypes stimulate p38 MAPK in a pertussis toxin sensitive manner, therefore
via Gj proteins. Likewise, stimulation of Gj via the activation of m2 muscarinic receptors
by treatment with carbachol, also activate p38 MAPK. On the other hand, Zheng et al.
(2000) showed that in adult mouse cardiac myocytes, p2-adrenergic receptor activation
of p38 MAPK occurs via a cAMP dependent protein kinase (PKA) pathway, rather than
by Gj or the GPy subunit. Similarly, in rat epididymal fat cells, a cell permeable cAMP
analogue increased the p38 MAPK activity to a similar extent to isoproterenol,
suggesting that the effect of the p-adrenergic agonist is mediated via cAMP and PKA
(Mouie et ai., 1998).
Furthermore, it has recently been reported that PKA activation causes a increase in p38
MAPK activity through inactivation of protein tyrosine phosphatases in rat fibroblasts,
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HEK 293 and COS cells (Saxena et aI., 1999, Blanco-Aparicio et aI., 1999). Both
protein tyrosine phosphatases, HePTP and PTP-SL bind to the MAPKs, p38a and
ERK1/2, resulting in inactivation of the MAPKs by dephosphorylating the critical
phosphorylated tyrosine residue in their activation loop. The PKA-mediated release of
the MAPKs from the phosphatases is sufficient to activate the kinases.
Despite the above uncertainties regarding the regulation of p38 MAPK by different G
protein subfamilies, p-adrenergic stimulation could activate p38 MAPK. Therefore p-
adrenergic stimulation could be a useful tool to evaluate the contribution of this stress
kinase to cardioprotection in ischaemie or p-adrenergic PC.
1.3.5 Downstream substrates of MAPK (Fig. 1.8)
1.3.5.1 Protein kinases
MAPKs phosphorylate both transcription factors and other protein kinases (Kyriakis and
Avruch, 2001). The latter substrates allow signal diversification and amplification
downstream of the MAPKs.
One of the selective protein kinase targets of ERK is MAPKAPK-1/p90Rsk (MAPK-
activated protein kinase-1/p90 ribosomal S6 kinase, Erkison 1991). Essential functions
of p90Rsk (Frodin and Gammeltoft, 1999) include (i) regulation of gene expression via
phosphorylation of transcription factors, including c-Fos (Seger and Krebs, 1995) and
cyclic AMP response element-binding protein, CREB (Xing et aI., 1996); (ii) regulation of
protein synthesis by phosphorylation of polyribosomal proteins and glycogen synthase
kinase-3 (GSK3); the latter has also been shown to negatively regulate c-Jun
(Widmann et aI., 1999); (iii) stimulation of Na+/H+exchanger by phosphorylating Na+/H+
exchanger isoform-1 (NHE-1) kinase (Takahashi et ai., 1999); (iv) phosphorylation and
inactivation of BAD (a proapoptotic Bcl-2 family protein) which suppressed apoptotic cell
death (Bonni et ai., 1999, Tan et aI., 1999).
Stress-activated MAPKs, in particular p38a and p38p MAPKs (but not by p38y or p388)
selectively recruit protein kinase substrates, namely MAPKAPK-2 and-3 (mitogen-
activated protein kinase-activated protein kinase-2 and -3), as well as PRAK (p38-
regulated and activated kinase) (Freshney et ai., 1994, Rouse et aI., 1994). These
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protein kinases are unrelated to MAPKAPK-1/Rsks. The phosphorylated and
activated MAPKAPK-2, a SerlThr kinase, can phosphorylate and activate small 27-kDa
heat shock protein, HSP27 (Rouse et a/., 1994). This activation coincides with the
dissociation of HSP27 into monomers and dimers, and with the redistribution of HSP27
to the actin cytoskeleton (Huot et a/., 1997).
Other protein kinase substrates, like MNKs (MAPK-interacting kinases) and MSKs
(mitogen- and stress-activated protein kinases), are activated by both p38 MAPK and
ERKs and consequently intergrate both stress and mitogen signalling pathways. The
MNKs phosphorylates the mRNA 5' cap-binding protein, eIF-4E (eukaryotic initiation
factor-4E), which is a key participant in the control of gene expression at the translation
level that is important for cell growth and proliferation (Sonenberg and Gingras, 1998).
The MSKs are potent stress- and mitogen activated CREB (see transcription factors)
kinases (Deak 1998). These kinases may also phosphorylate nucleosomal proteins
such as histone H3 and HMG-14 (high mobility group-14) (Thomson et a/., 1999).
These proteins are involved in chromatin remodelling that enables the transcription
machinery to gain access to genes.
1.3.5.2 Transcription factors
1.3.5.2.1 Introduction
Transcription factors form a major group of MAPK substrates, although some should be
considered as indirect targets of the MAPK pathways. These factors regulate gene
expression and modulate long-term changes in the cell (Bogoyevitch 2000).
Activation of MAPKs, such as ERKs and JNKs, takes place in the cytoplasm and the
activated enzyme moves to the nucleus. This translocation is essential to enable the
kinase to phosphorylate transcription factors (Obata et al., 2000). Although, p38 MAPK
was reported to be present in both the nucleus and the cytoplasm, it also translocates
from the cytoplasm to the nucleus in response to stress stimuli (Raingeaud et a/., 1996,
Maulik et a/., 1998). In contrast, a complex of p38 MAPK bound to one of its effector
molecules, MAPKAPK-2, appears to be exported from the nucleus to the cytoplasm
following p38 MAPK activation (Ben-Levy et a/., 1998), which permits them to
phosphorylate substrates in the cytoplasm.
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1.3.5.2.2 Major transcription factors
The MAPK pathway phosphorylates and enhances the activity of some of the major
transcription factors, including Elk-1 (Ets-related ternary complex factor), Sap-1 (serum
response factor accessory protein), ATF-1/2 (activating transcription factor), c-Jun,
CREB (cyclic AMP response element-binding protein), CHOP/GADD153 (CREB
homologous protein/growth arrest and DNA damage), Max, MEF-2A12C (myocyte
enhancer factor) and HSF-1 (heat shock factor) (Obata et aI., 2000). Elk-1 can be
activated as substrate for all the MAPKs, while others such as ATF-1/2 are suitable for
only p38 MAPK and JNK. Other substrates are suitable for only one MAPK subfamily,
such as c-Jun for JNK; and Sap1a, CHOP, Max and MEF2A1C for p38 MAPK
(Bogoyevitch 2000, Kyriakis and Avruch 2001). CREB may be considered as an
indirect target of the ERK and p38 MAPK pathways, as it is a substrate for kinases
downstream of these MAPKs.
The transcription factors which have been well-characterized and which play significant
roles within cells of the cardiovascular system, include Elk-1, c-Jun, ATF-2, MEF-2 and
CREB (Bogoyevitch, 2000).
1.3.5.2.2.1 Elk-1
Elk-1 and Sap1a, are ternary complex factors (TNFs), which together with serum-
response factor (SRF) controls transcription from the serum-response element (SRE)
and MEF-2 transcription factors (Marais et aI., 1993). These factors mediate the
expression of many immediate-early genes, including e-tos and Egr-1 that regulate
muscle-specific and immune cell gene expression (Han et aI., 1997). ERK, as well as
JNK but not p38 MAPK, can phosphorylate Elk-1, while p38 MAPK can efficiently
phosphorylate Sap1a (Janknecht and Hunter, 1997). By these processes, MAPKs
activated by both stress and mitogens can come together to contribute to e-tos
induction. However, skeletal a-actin, cardiac a-actin and ANF (atrial natriuretic factor)
promoters possess SREs that do not have Elk-binding sequences and expression may
be dependent on other transcription factors, such as ATFs (Hines et aI., 1999, Thuerauf
et al., 1998).
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1.3.5.2.2.2 c-Jun
One of the major substrates of JNKs is c-Jun (a product of one of the immediate-early
genes, c-jun), which is also a member of the bZip (basic leucine zipper, that enables
homo- and heterodimerization) family of transcription factors (Force et aI., 1996). c-Jun
functions as a heterodimer with c-Fos or ATF-2 (a member of the CREB family). When
complexed with c-Fos, the dimer is targeted to AP-1 (activator protein-1) containing
promoters of a number of genes of importance in the heart, such as skeletal muscle a-
actin (Bishopric et a/., 1992). However, when complexed with the ATF-2, the dimer
prefers CRE (cAMP response element) sequences and c-jun promoters containing AP-1
variants, which controls the induction of c-jun (Force et a/., 1996). In addition, c-Jun
plays an important role in regulation of cytochrome c expression during electrical pacing
of myocytes. In these hypertrophied myocytes, enhanced c-Jun transcriptional activity
allows for increases in mitochondria number and cytochrome oxidase activity, which are
essential to satisfy the increased energy demand (Xia et a/., 1998).
1.3.5.2.2.3 ATF-2
ATF-2, unlike the related CREB, is not activated by increased cAMP, but by stimuli that
activate SAPKs. Both JNK and p38 MAPKs regulate ATF-2 and its mechanism of
regulation of transcriptional activating activity appears to be similar to that of c-Jun
(Gupta et a/., 1995). Phosphorylated ATF-2 can form dimers with ATF-3, CREB, c-Jun
or NF-kB. This suggests a potential for widespread roles in promoter activation
(Bogoyevitch 2000). Furthermore, the ATF family is implicated in the hypertrophic gene
programme. For example, in cardiac myocytes p38 MAPK phosphorylated ATF-6,
which resulted in ANF gene binding to the serum response factor, independent of Elk-1 ,
and participated in ANF induction (Thuerauf et a/., 1998).
1.3.5.2.2.4 MEF-2
The MEF-2 transcription factors can bind to DNA sequences in promoters of muscle-
specific genes, such as the a-cardiac myosin heavy chain promoter (Lee et a/., 1997).
Consequently, an essential role for MEF-2C in cardiac development has been
demonstrated (Lin et a/., 1997). Furthermore p38 MAPK phosphorylation of MEF-2C
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(Han et aI., 1997) leads to the increase in c-jun transcription, thus linking p38 MAPK
and JNK pathways.
1.3.5.2.2.5 CREB
CREB is also a bZIP transcription factor that trans-activates pro-survival genes
containing CRE (Kyriakis and Avruch 2001). As mentioned before, PKA (protein kinase
A), which is activated by agonist elevation of cAMP, represents the major kinase to
phosphorylate CREB (Habener 1990). Furthermore, both growth- and stress-regulated
pathways may also be responsible for CREB phosphorylation. On the one hand,
p90Rsk2, the downstream kinase of ERK, phosphorylate CREB in the nucleus, allowing
c-Fos expression (Xing et aI., 1996). Furthermore, in cardiomyocytes MEK-1 mediated
activation of CREB, leads to the induction of expression of the antiapoptotic factor Bcl-2
(Mehrhof et aI., 2001). On the other hand, two downstream kinases of p38 MAPK,
namely MAPKAPK-2 and MSK-1, may also mediate activation of CREB (Tan et aI.,
1996, Deak et al., 1998). The phosphorylation of CREB is implicated in cardiac
disease, since inactivation of CREB, by overexpression of a negative CREB protein,
results in cardiac dilation, fibrosis and chronic venous congestion (Fentzke et aI., 1998).
1.3.6 Inactivation of MAPKs by phosphatases
Protein phosphatases have been suggested to play a central role in regulation of
signalling pathways mediated by the MAPKs, resulting in inactivation and down-
regulation of these pathways (reviewed in English et aI., 1999, Bogoyevitch 2000).
However, compared to the wealth of knowledge on MAPKs, relatively little is known
about these phosphatases.
Protein phosphatases include three families based upon their substrate specificity.
These are the serine/threonine protein phosphatases (Cohen, 1989), the tyrosine
protein phosphatases (Fischer et el., 1991) and the dual-specificity tyrosine protein
phosphatases (Franklin and Kraft 1997). MAPKs contain both phosphothreonine and
phosphotyrosine and are therefore potential substrates for all classes of phosphatases.
One group of phosphatases, the MAPK phosphatases (MKPs), have dual-specificity for
both threonine and tyrosine residues of the MAPK family, leading to dephosphorylation
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and inactivation (Zheng and Guan 1993). Nine members of this group have been
reported, including MKP-1 (CL-100, VH1), MKP-2 (hVH2, TYP-1), MKP-3 (Pyst1, rVH6),
MKP-4 (Pyst3), MKP-5, PAC1, hVH2 (B-23), M3/6 (hVH5) and Pyst1 (Obata et aI.,
2000). All the MKPs, with the exception of Pyst1, are immediate-early genes that are
induced by various mitogens, growth factors and stresses. MKP-1, the first isolated
MKP is a dual specificity phosphatase that dephosphorylates MAPKs (Sun et aI., 1993).
This MKP-1 has been shown to inhibit JNK and p38 MAPKs more potently than ERKs
(Franklin et al., 1998). In addition, Chu et al. (1996) showed that MKP-1, MKP-2 and
PAC1 have unique substrate specificity and reduced activity in vivo toward the ERK2.
Similarly, M3/6 and MKP-5 were also found to inactivate both JNK and p38 MAPK, but
not ERK, whereas MKP-3 and MKP-4 preferably dephosphorylate ERK over JNK and
p38 MAPK (Muda et aI., 1996, Tanoue et aI., 1999). Other phosphatases, namely
protein phosphatase 2A and 1 (PP2A and PP1) are also important in inactivating
MAPKs (Alessi et aI., 1995, Sontag et aI., 1993). For example, the use of okadaic acid,
a cell-permeable inhibitor of PP2A, caused activation of both JNKs, in ventricular
myocytes (Fischer et aI., 1998), and ERKs in ventricular myocytes, fibroblasts and H9c2
myoblasts (Andersson et al., 1998).
According to Bogoyevitch (2000) it remains possible that phosphatase inhibition during
ischaemia will facilitate higher levels and/or prolonged phosphorylation of proteins that
provide protection. Furthermore, it has been shown that protein phosphatase inhibitors
could mimic the protective effects of PC in rabbit cardiomyocytes (Armstrong and
Ganote 1992, Armstrong et aI., 1996). In addition, pre-incubation of the latter cells with
calyculin A, a protein phosphatase PP1/2A inhibitor, induced high levels of
phosphorylation in p38 MAPK during a prolonged period of ischaemia, which resulted in
protection (Armstrong et aI., 1998). In contrast, Mackay and Mochly-Rosen (2000) used
a tyrosine phosphatase inhibitor, vanadate, to prevent p38 MAPK inactivation,
extending the strength and length of p38 MAPK activation during ischaemia, which
resulted a higher susceptibility to cell death. Therefore they concluded that a tyrosine
phosphatase is inactivated during ischaemia, resulting in prolonged activation of p38
MAPK which causes cell death.
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1.3.7 Biological function of p38 MAPKactivation
1.3.7.1 Introduction
All three major subfamilies of MAPKs, namely ERK, JNK and p38 MAPK can be
activated by short episodes of ischaemia-reperfusion (as occurs during the ischaemie
PC protocol) (Ping et aI., 1999a, Ping et aI., 1999b), as well as by sustained ischaemia-
reperfusion (Bogoyevitch et al., 1996, Ma et aI., 1999). In particular, activation of p38
MAPK is under investigation as a candidate kinase in protection elicited by ischaemie
PC. However, the importance of p38 MAPK activation for cardioprotection remains
controversial. Furthermore, the relationship between p38 MAPK activation and the
underlying cellular mechanisms of cardioprotection by ischaemie PC is not yet clear.
Therefore, the remainder of the chapter will focus on the role of p38 MAPK activation.
Various GCPR-mediated stimuli are involved in induction of ischaemie PC (as described
before). It has been reported that PC can be mimicked pharmacologically by transient
~-adrenergic receptor stimulation in isolated rat hearts (Asimakis et aI., 1994, Miyawaki
and Ashraf 1997b, Yabe et aI., 1998). Since ~-adrenergic receptor stimulation also
stimulates p38 MAPK activation in rat (Communal et aI., 2000) and mouse cardiac
myocytes (Zheng et aI., 2000), it could be a useful tool to evaluate the contribution of
this stress kinase to cardioprotection in ischaemieor ~-adrenergic PC.
1.3.7.2 Role of MAPKs in cell death or survival
Emerging evidence suggest that in models of myocardial ischaemia-reperfusion, the
MAPKs, including ERK, p38 MAPK and JNK, may be important determinants of cell
death or survival, but their respective roles in this regard and their interaction with one
another are not well understood (Bogoyevitch et aI., 1996, Vue et aI., 2000,
Gysembergh et aI., 2001).
Although it is predicted that the extent and duration of activation of the MAPKswill affect
their final cellular responses, the ultimate role of the SAPKs (JNK and p38 MAPK)
remains to be established. For example: (i) SAPKs may contribute to signal
transduction pathways that culminate in cell death following stress, while (li) on the
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other hand, these SAPKs may also lead to cell survival by preventing wide-spread
cell death, limit damage or mediate adaptation (Bogoyevitch 2000).
In response to ischaemia-reperfusion in the heart, the most severely affected myocytes
will die, either by necrosis or controlled apoptosis. The pathways regulated by both p38
MAPK and JNK may contribute to a significant extent to apoptosis (Abe et aI., 2000).
However, the role of p38 MAPK in myocyte apoptosis is complicated since this kinase
can also mediate cell survival, particularly in ischaemie PC. Therefore the role of p38
MAPK has been investigated in ischaemia-reperfusion, as well as in PC and will be
discussed separately.
1.3.7.2.1 p38MAPKand Cell Death in Ischaemia-Reperfusion
1.3.7.2.1.1 Introduction
Growing evidence indicates that apoptosis or programmed cell death plays a role in
myocardial reperfusion injury (Gottlieb et al., 1994). Originally Xia et al. (1995)
examined the role for MAPKs in regulating apoptotic cell death after withdrawal of
growth factors from neuronal cells. They demonstrated that activation of JNK and p38
MAPK and concurrent inhibition of ERK are critical in promoting apoptosis. The JNKs
and p38 MAPKs have also been implicated in apoptosis in other cell types (Ichijo et aI.,
1997, Chauhan et al., 1997), but studies in the heart are in their early stages.
In cultured cardiac myocytes (Aikawa et aI., 1997, Krown et aI., 1996) activation of JNK
and p38 MAPK, for example by proinflammatory cytokines and reactive oxygen species
(ROS) (Clerk et aI., 1997, Aikawa et aI., 1997), induces apoptosis. However, the role of
p38 MAPK activation in myocardial injury caused by ischaemia-reperfusion, an extreme
stress to the heart, is unclear.
Bogoyevitch et al. (1996) were the first to demonstrate that myocardial ischaemia-
reperfusion activates p38 MAPK and JNK. They found that only p38 MAPK was
activated during ischaemia with no activation of JNK, but the latter was activated only
during reperfusion following ischaemia. Furthermore, ERK was not activated by either
ischaemia or ischaemia-reperfusion. Yin et al. (1997) correlated these events with
tissue damage: a significant increase in DNA fragmentation (a marker of apoptosis)
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was evident during ischaemia-reperfusion concomitant with the activation of JNK
and p38 MAPK. However, the specific assessment of the role of SAPKs in this scenario
requires the use of specific inhibitors or overexpression of MAPKs.
1.3.7.2.1.2 Inhibitors of p38MAPKand ischaemia-reperfusion
Using chemical inhibitors has led to the conclusion that activation of the p38 MAPKs
promote cardiac myocyte death during extended periods of ischaemia (Mackay and
Mochly-Rosen 1999, Saurin et ai., 2000, Barancik et al., 2000). In a cultured neonatal
rat cardiac myocyte model, inhibition of p38 MAPK protects against ischaemie injury as
indicated by decreased LDH release (marker for cell damage) (Mackay and Mochly-
Rosen 1999, Saurin et al., 2000). In addition, Barancik et al. (2000) reported that a
specific inhibitor of p38 MAPK, SB203580, protected pig myocardium against ischaemie
injury in an in vivo model by reducing infarct size.
Several studies indicated that p38 MAPK plays a pivotal role in promoting myocardial
apoptosis (Ma et ai., 1999, Mackay and Mochly-Rosen 1999, Vue et a/., 2000). Ma et
al. (1999) demonstrated that in isolated perfused rabbit hearts, ischaemia alone caused
a moderate but transient (peaked at 15 min, declined at 30 min and maintained low
levels thereafter) increase in p38 MAPK activity. Reperfusion further activated p38
MAPK after 10 min and remained elevated throughout reperfusion (20 min).
Administering SB203580 before ischaemia and during reperfusion completely inhibited
p38 activation and exerted significant cardioprotective effects, characterized by
decreased myocardial apoptosis and improved post-ischaemie cardiac function, as well
as attenuated myocardial necrotic injury. In contrast, administering SB203580 10 min
after reperfusion (a time point when maximal MAPK activation had already been
achieved) failed to convey significant cardioprotection. Mackay and Mochly-Rosen
(1999) indicated that in neonatal rat cardiac myocytes, two distinct phases of p38
activation were observed during ischaemia: the first phase began within 10 min and
lasted for less than 1 h, and the second began after 2 h and lasted throughout the
ischaemie period. They demonstrated that SB203580 also protected cardiac myocytes
against ischaemia by reducing activation of caspase-3 (a key event in apoptosis).
However, the protective effect was seen even when the inhibitor was present during
only the second, sustained phase of p38 activation. Subsequent studies by Vue et al.
(2000), exposing rat neonatal cardiomyocytes to ischaemia showed a rapid and
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transient activation of p38 and JNK. On reoxygenation, further activation of SAPKs
was noted. With pretreatment of cells with S8203580 apoptotic cells were reduced,
suggesting that p38 activation mediates apoptosis in rat cardiomyocytes subjected to
ischaemia-reoxygenation. In addition, Vue et a/. (2000) also showed that in isolated rat
hearts S8203580 improved cardiac contractile function of ischaemie hearts.
Inhibition of p38 MAPK activation was therefore correlated with cardioprotection against
ischaemia-reperfusion in cardiac myocytes as well as isolated hearts.
1.3.7.2.1.3 Overexpression of p38 MAPK
MKK6 appears to phosphorylate all p38 MAPK isoforms, whereas MKK3
phosphorylates only p38a, y and 8 (Enslen et aI., 1998). Zechner et al. (1998) reported
that overexpression of MKK6, an upstream activator of p38 MAPK, resulted in
protection of cardiac myocytes from apoptosis induced by either anisomycin or MEKK1,
an upstream activator of JNK pathway. In addition, expression of MKK6 elicited a
hypertrophic response, which was enhanced by co-infection of p38p (Wang et aI.,
1998). Therefore a distinct isoform of p38 MAPK, p38p, may participate in mediating
cell survival. In contrast, overexpression of MKK3 in mouse cardiomyocytes led to
programmed cell death (apoptosis), which was increased by co-infection of p38a (Wang
et a/., 1998). Therefore, differential activation of p38 MAPKs isoforms may exert
opposing effects: p38a is implicated in cell death, while p38p may mediate myocardial
survival.
To determine whether p38 MAPK activation was isoform selective, rat neonatal
cardiomyocytes were infected with adenoviruses encoding wild-type p38a or p38p
(Saurin et aI., 2000). They showed that transfected p38a and p38p were differentially
activated during sustained ischaemia, with p38a remaining activated but p38p
deactivated. Furthermore, cells expressing a dominant negative p38a, which prevented
ischaemia-induced p38 MAPK activation, were resistant to sustained ischaemie injury.
Therefore, activation of p38a MAPK isoform during ischaemia is detrimental.
In addition, Hreniuk et al. (2001) demonstrated that treatment of rat cardiac myocytes
with antisense oligonucleotides that specifically targeted either JNK1 or JNK2 and
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significantly reduced both mRNA and protein expression of the target isoforms,
resulted in almost complete attenuation of reperfusion-apoptosis. These observations
suggest that also JNK activation contribute directly to apoptotic cell death.
1.3.7.2.2 p38 MAPK and Cell Survival in Preconditioning
1.3.7.2.2.1 Introduction
In contrast to the previous mentioned evidence, that increased p38 MAPK activation
during ischaemia-reperfusion mediate cell death, some studies could not demonstrate
this association (Weinbrenner et ai., 1997, Maulik et ai., 1998d, Armstrong et ai., 1999,
Omura et ai., 1999, Nakano et ai., 2000). Omura et ai., 1999 even indicated that p38
MAPK decreased during sustained coronary occlusion in an in vivo rat model. In other
well-defined cell systems, i.e. fibroblasts (Roulston et ai., 1998) and Hela cells (Assefa
et ai., 1999), activation of JNK and p38 MAPKs enhances cell survival. It has therefore
been suggested that an increase in p38 MAPK activation may also play a role in cell
survival leading to cardioprotection (as in the phenomenon of PC, Weinbrenner et ai.,
1997).
1.3.7.2.2.2 p38 MAPK and Preconditioning
It is well established that stress stimuli can elicit a survival signal, as occurs in PC,
which is characterized by attenuated apoptosis during ischaemia-reperfusion (Maulik et
ai., 1998c). The role of the p38 MAPK signalling pathway in the protection mediated by
PC has been extensively investigated (Weinbrenner et al., 1997, Maulik et ai., 1998d,
Armstrong et al., 1999, Nakano et ai., 2000, Nagarkatti et ai., 1998, Saurin et ai., 1999,
Schneider et ai., 1999, 8arancik et ai., 2000). These studies have sought to determine
(i) whether prior PC induces the activation of p38 MAPKs during sustained ischaemia
and (ii) whether inhibition of p38 MAPKs abolishes the cardioprotective effect.
However, these observations are inconsistent, and the role of p38 MAPK in classic PC
at this stage seems to be controversial.
On the one hand, it has been shown that PC is associated with an increased
phosphorylation of p38 MAPK during sustained ischaemia (Weinbrenner et ai., 1997,
Maulik et ai., 1998d, Armstrong et ai., 1999, Nakano et ai., 2000a). Weinbrenner et al.
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(1997) indicated that isolated rabbit hearts preconditioned, with 5 min ischaemia
and 10 min reperfusion, enhanced the phosphorylation of p38 MAPK after 10 and 20
min of ischaemia. Maulik et al. (1998d) subjected isolated rat hearts to a 4-cycle
ischaemia-reperfusion PC protocol, which resulted in an increase in p38 MAPK
phosphorylation that moved to the nucleus during the subsequent sustained ischaemic
period and translocated to the cytoplasm after 10 min reperfusion. This PC-induced
increase in p38 MAPK was also associated with enhanced MAPKAPK2 activity, the
downstream substrate of p38 MAPK (Maulik et al., 1998d), which in turn could result in
the phosphorylation of HSP27 (Rouse et aI., 1994). The latter has been implicated in
regulating cytoplasmic actin (lu et al., 1997). Similarly, Armstrong et al. (1999) showed
that PC increased the dual phosphorylation of p38 MAPK as well as HSP27
phosphorylation in isolated adult hypoxic rabbit cardiomyocytes. In addition, Nakano et
al. (2000a) also confirmed that the p38 MAPKIMAPKAPK2 pathway is activated during
ischaemia only if the heart is in a preconditioned state.
On the other hand, Nagarkatti and Sha'afi (1998) found that exposure of the rat
myoblast cell line H9C2 to PC led to a reduction in ischaemia-induced p38 MAPK
activation and protection against a second lethal stress. In addition, several studies
have reported that activation of p38 MAPK during a multi-cycle ischaemie PC protocol is
transient and does not correlate with the PC effect (Ping et al., 1999a, Behrends et aI.,
2000), thereby questioning the significance of p38 MAPK activation in PC.
Furthermore, Saurin et al. (2000) showed that prior PC prevented the activation of p38a
MAPK isoform during the subsequent sustained ischaemia in neonatal rat myocytes.
Therefore, inhibition of the p38a MAPK activation during ischaemia reduces injury and
may contribute to PC-induced cardioprotection.
Therefore, there are two opposing theories for the role of p38 MAPK in PC. PC-induced
cardioprotection is either associated with (i) an increased activation of p38 MAPK or (ii)
an attenuation of p38 MAPK activation during sustained ischaemia.
1.3.7.2.2.3 Pharmacological activation of p38 MAPK
In the cardiovascular system, evidence also supports a pro-survival role for p38 MAPK
activation: Pharmacological activation of p38 MAPK by administration of anisomycin
before the onset of sustained ischaemia, elicited cardioprotection in isolated rabbit
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cardiomyocytes (Weinbrenner et aI., 1997), protected rat neonatal cardiac
myocytes (Mackay and Mochly-Rosen, 1999), perfused rat hearts (Nakano et aI.,
2000a) and pig hearts (Barancik et al., 1999). However, anisomycin, an inhibitor of
protein synthesis, is also a powerful stimulant of JNK (Barancik et al., 1999, Schneider
et aI., 2001) and is therefore unsuitable for use in studies aimed at elucidating the role
of p38 MAPK per se.
1.3.7.2.2.4 Pharmacological inhibition of p38 MAPK in preconditioning
Besides determining the activation status of p38 MAPK during ischaemie PC,
pharmacological inhibition of p38 MAPK was also used to elucidate whether p38 MAPK
activation was the cause or effect of protection. However, data obtained using the
specific p38 MAPK inhibitors (SB 203580 or SB 202190) also produced controversial
results (see Table 1.1). Careful evaluation of data showed that the timing of SB 203580
administration to preconditioned hearts may account for the controversial findings. For
example, Maulik et al. (1998d) and Nagarkatti et al. (1998) noted that pretreatment of
rat hearts and a rat myoblast cell line, respectively, with SB 203580 before the
ischaemie PC protocol completely abolished protection. Furthermore, a recent study in
dogs showed that SB 203580 blocked cardioprotection only when given prior to the PC
protocol, but not when given prior to sustained ischaemia (Sanada et aI., 2001). This
was also confirmed by Sato et al. (2000) in working rat hearts. In contrast, according to
a preliminary report by Schneider et al. (1999) SB 202190 pretreatment during a multi-
cycle PC protocol could not abolish protection in isolated perfused rat hearts. In
addition, Barancik et al. (2000) also confirmed that infusion of SB 203580 before and
during the PC protocol did not influence the infarct size reduction mediated by PC in an
in vivo pig model. On the other hand, Mocanu et al. (2000) recently showed that
induction of SB 203580 during the PC protocol did not abolish protection, but
administration after the PC protocol, prior to sustained ischaemia only, completely
blocked protection. Furthermore, Nakano et al. (2000a, 2000c) also indicated that
inhibition of p38 MAPK prior to sustained ischaemia only, completely abolished PC-
induced protection. Therefore, exact timing of inhibitor administration may help clarify
whether p38 MAPK acts as a trigger during the PC process or whether this kinase acts
as a mediator of protection during the sustained ischaemia.
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Summary of studies on pharmacological inhibition of p3S MAPK in preconditioning
SB 203580 abolish PC induced protection:
Authors Species Model Protocol SB Endpoint
concentration
Maulik et al rat Isolated PC: 4x(5minl+10minR) 51lM J. LVDP
1998d perfused !IR: 15minl+120minR t Infarct size
heart SB: before PC
Nagarkatti and rat Myoblasts PC: 5minl+60minR 151lM J.Cell survival
Sha'afi 1998 (H9C2) I: 45minl
SB: before PC
Sato et al rat Isolated PC: 4x(5minl+5minR) 51lM t Infarct size
2000 perfused !IR: 30minl+120mnR
heart SB: before PC+10min washout
Nakano et al rabbit Isolated PC: 5minl+10minR 10llM and t Infarct size
2000a and perfused !IR: 30minRI+120minR 211M
2000c heart SB: PC+20minSB starting 5min
before RI
Mocanu et al rat Isolated PC: 2x(5minl+10minR) 10llM t Infarct size
2000 perfused !IR: 35minRI+120minR
heart SB: PC+SB+!lR
Sanada et al dogs In vivo PC: 4x(5minl+5minR) 111M t Infarct size
2001 !IR: 90minCO+6hR
SB: before PC
SB 203580 could not abolish PC induced protection:
Authors Species Model Protocol SB Endpoint
concentration
Schneider et rat Isolated PC: 4x(5minl+5minR) 10llM J. Necrosis
a/1999 perfused IIR: 20minl+30minR t LVDP
heart
SB: before and during PC
Barancik et al pigs In vivo PC: 2x(10minCO+10minR) unknown J. Infarct size
2000 IIR: 60minCO+60minR
SB: before and during PC
Mocanu et al rat Isolated PC: 2x(5minl+10minR) 10llM ,J.. Infarct size
2000 perfused IIR: 35minRI+120minR
heart
SB: during PC
Sanada et al dogs In vivo PC: 4x(5minl+5minR) 111M J. Infarct size
2001 !IR: 90minCO+6hR
SB: PC+SB+!lR
PC = preconditioning
I = global ischaemia
R = reperfusion
RI = regional ischaemia
CO = coronary occlusion
LVDP = left ventricular developed pressure
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A further cause for concern is the drugs used as inhibitors to elucidate the role of
p38-MAPK. The pyridinyl imidazole inhibitors have been widely used, particularly
8B203580 and the related 8B202190, however their efficacy and selectively are still
unclear. Although they have a potent effect on the activity of p38 a and p38 P MAPKs,
their efficacy for the p38 y and p38 6 isoforms is low (Lee et a/., 1999). Although
inhibition of p38 MAPK has been demonstrated at < 1 ).tM, these inhibitors are normally
used at the concentrations (2:: 10 ).tM) that could also inhibit JNKs (IC50 = 5 ).tM) (Clerk
et aI., 1998b, Vue et al., 2000) and phosphatidylinositol-3-kinase (PI3K) / protein kinase
B (PKB) (IC50 = 3-5 ).tM) (Lali et aI., 2000). Both the JNKs and PI3Ks have been shown
to be recruited by ischaemic PC (Ping et a/., 1999a, Tong et a/., 1999). Therefore,
these data suggest that extreme caution should be taken when interpreting data where
8B203580 has been used at concentrations above 1-2 ).tM. However, comparison of
the concentrations used in the different protocols (Table 1.1) showed that although a
broad range was used, it did not affect the outcome: For example, both 10 ).tM and 2
).tM 8B203580 abolished PC induced protection in the same protocol (Nakano et al.
2000a and 2000c).
1.3.8 Nitric oxide (NO) and p38 MAPK
1.3.8.1 Introduction
Although several observations suggested that nitric oxide (NO) might act as a trigger for
PC, conflicting results were published (as mentioned before). There are numerous
mechanisms by which the NO/cGMP system and its downstream effectors could elicit
protection (reviewed by Rakhit, et a/., 1999). However, its role in classic PC is less well
defined.
1.3.8.2 p38 MAPK: up- and downstream of NO
p38 MAPK may be involved in the generation of NO at two points. First, the p38
pathway can enhance NO production by increasing the intracellular concentration of the
substrate for NO synthetase via stimulation of arginine transporter activity (Caivano
1998). Second, p38 MAPK activity is required for increased gene expression of the
inducible form of NO synthetase (iNOS, NOS2) (Guan et a/., 1997). p38 MAPK may
also be involved in the transduction of NO signalling. Activation of p38 MAPK in human
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neutraphils following lipopolysaccharide (LPS) stimulation is attenuated by inhibitors
of NOS and by NO scavengers whereas treatment with NO releasing agents (donors)
increased MKK3, 6 activity and p38 MAPK phosphorylation (Browning ef aI., 1999).
Similarly, the NO-induced apoptosis in a neutrophil-like cell line (HL-60) requires p38
MAPK activation (Jun ef al., 1999).
1.3.8.3 p38 MAPK and NO in preconditioning
The role of the stress kinase, p38 MAPK and that of the mitochondrial KATP channel in
the mechanism of ischaemie PC is currently being investigated. Activation of the
mitochondrial KATP channel by NO has indeed been demonstrated (MacKay and
Mochly-Rosen, 1999; Sasaki ef al., 2000), but to our knowledge the relationship
between NO and p38 MAPK in PC has not been investigated previously. There is also
no data concerning the downstream effects of cGMP in the context of PC.
A recent study (Kim ef aI., 2000) investigated the role of sodium nitroprusside (SNP), a
commonly used vasodilator that acts as a NO donor, in the regulation of the MAPKs in
isolated adult rat cardiomyocytes. SNP maximally activated ERK1, ERK2, p38 MAPK
and MAPKAPK2 within 5 - 10 min. They showed that activation of MAPKAPK2 by SNP
was blocked by the soluble guanylyl cyclase inhibitor, 1H-[1 ,2,4]oxadiazolol[4,3-
alquinoxatin-t-one (000) and the p38 MAPK inhibitor SB203580. The activation of
ERK1 was insensitive to aDa but completely blocked by the MEK1 inhibitor P098059.
The membrane-permeable homologue of cGMP, 8-Br-cGMP, also activated p38 MAPK,
but not ERK1 or ERK2. Their results indicated that p38 MAPK and MAPKAPK2 are
activated by NO in cGMP-dependent-pathways, while ERK1 activation by NO is
independent of cGMP levels.
1.3.9 Other MAPKs and preconditioning
One should also consider the role that ERK plays in the response to stress. The well-
defined role of ERKs in modulating growth responses indicates that this subfamily could
mediate cell survival. In support of this, cells overexpressing an active MEK (upstream
of ERK) are more likely to survive than cells expressing dominant-negative MEKs
(Guyton ef aI., 1996). Although Bogoyevitch ef al. (1996) showed that neither global
ischaemia nor ischaemie reperfusion did activate the ERKs in perfused rat hearts, Seko
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et al. (1996) demonstrated that, both hypoxia and hypoxia/reoxygenation caused
rapid activation of Raf-1, followed by ERK activation in cardiac myocytes. In addition,
coronary reperfusion increased ERKs in an in vivo rat model (Omura et aI., 1999).
Aikawa et al. (1997) reported that oxidative stress activates ERK and suggested that it
may be important for protecting cardiac myocytes from apoptotic cell death.
Furthermore, in the presence of PD98059 (a MEK1/MEK2/ERK inhibitor), ischaemia-
triggered myocyte apoptosis was significantly enhanced, confirming that the ERK
pathway is important for survival of cells (Yue et aI., 2000).
Furthermore, ERK (Ping et aI., 1999b) and JNK (Ping et aI., 1999a) remained activated
throughout a multi-cycle PC protocol, which was associated with activation of PKCE in
conscious rabbits. These data implicate PKCE as the specific isoform responsible for
PKC-induced MAPK activation and suggest that both ERK and JNK contribute to PKCE-
mediated protection against ischaemia (Ping et aI., 1999a).
1.3.10 Conclusion
The above indicated that no consensus has been reached regarding the significance of
particularly p38 MAPK in PC. Thus, in view of the controversy regarding the time and
role of p38 MAPK activation in ischaemia-reperfusion and ischaemic PC, careful
evaluation and manipulation of the activation of this kinase is required, with meticulous
attention to protocols and endpoints.
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1.4 Motivation and Aims
1.4.1 General
Classic ischaemic PC implies that the heart has an endogenous protective mechanism
against ischaemia. However the exact mechanism of this protection remains to be
established, which if identified, may have important clinical implications. It is now
generally accepted that several ligand-receptor interactions and signalling pathways are
involved as triggers and mediators/effectors, respectively (as discussed in Chapter 1).
Endogenous triggers of PC may include substances released during the transient
ischaemia and reperfusion (PC protocol), namely adenosine, opioids, bradykinin,
acetylcholine, angiotensin and endothelin, as well as free radicals, nitric oxide (NO) and
calcium. The release of endogenous catecholamines, i.e. noradrenaline, during the PC
protocol with subsequent activation of the a-adrenergic system has been implicated as
one of the important triggers in the mechanism of PC (Banerjee et ai., 1993, Bankwala
et ai., 1994). However, there is also evidence to the contrary from others (Asimakis and
Inners-McBride 1993, Bugge and Ytrehus 1995), as well as from our laboratory
(Moolman et ai., 1996). Another pathway which may also be involved in PC via the
release of endogenous catecholamines, is the p-adrenergic signal transduction
pathway. Although Strasser et ai., (1990) confirmed that activation of this pathway
occurs within minutes after the onset of myocardial ischaemia, the contribution of p-
adrenergic signalling to the phenomenon of PC has received relatively little attention
thus far. Other receptor-independent endogenous triggers, namely free radicals, nitric
oxide (NO) and calcium may also be involved in PC (reviewed by Schulz et ai., 2001).
The involvement of NO as an initial trigger and subsequently as mediator, in the late
phase of PC is well-established (Bolli et ai., 1998). However, although nitric oxide
synthase (NOS) activity increased within 5 min of global ischaemia (Depré et aI., 1997),
the role of NO in classic PC has not been defined.
It has been suggested that all triggers may be linked to a common final pathway. One
such pathway may be via activation of protein kinase C (PKC) (Ytrehus et ai., 1994,
Brooks and Hearse 1996, Baxter 1997). Lately, the mitogen-activated kinases (MAPKs)
have received attention as possible role players. Particularly the p38 MAPK has been
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investigated by a number of workers (Weinbrenner et ai., 1997), but its role is still
controversial.
1.4.2 Hypothesis
Knowledge of events occurring during the PC protocol is a prerequisite for elucidating
the significance of the different riggers released during repetitive short episodes of
ischaemia and reperfusion. At the time when this study was initiated, most previous
studies focussed on events during sustained ischaemia only, while ignoring events
during the PC protocol, as well as reperfusion after ischaemia.
(i) We propose that careful characterization of events during the entire experimental
procedure of PC is required to elucidate the significance and interaction of these
complex mechanisms.
(ii) Based on previous studies we hypothesize a role for catecholamines, in particular p-
adrenergic signalling, and nitric oxide in PC. Accordingly, abolishment or attenuation of
these events during either the PC protocol phase or during sustained ischaemia,
causing inhibition of protection during reperfusion, may indicate a role as trigger or
mediator, respectively. Conversely, pharmacological manipulation of these events
during either the PC protocol or during sustained ischaemia, causing protection during
reperfusion, may confirm a role as trigger or mediator, respectively.
(iii) We further hypothesize that, due to the sensitivity of p38 MAPK to stress, a multi-
cycle ischaemie PC protocol per se should also elicit marked activation of this enzyme,
which in turn, could be an important downstream event of both the p-adrenergic
signalling and NO-cGMP pathways.
1.4.3 Specific aims:
1.4.3.1 Evaluation of events in ischaemie preconditioning: (Chapter 3)
To elucidate the role of endogenous catecholamines and nitric oxide release as triggers,
evaluating changes in tissue levels of cyclic nucleotides (cAMP and cGMP), cyclic
nucleotide phosphodiesterases (cAMP-POE and cGMP-POE), as well as p38 MAPK
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activation during the PC protocol, sustained ischaemia as well as during reperfusion
in the isolated perfused working rat heart, using functional recovery during reperfusion
as end-point.
1.4.3.2 Manipulation of cyclic nucleotides: (Chapter 4 and 5)
The next aim was to establish the significance of the changes observed. Therefore use
will be made of pharmacological interventions, such as selective blockers or activators
of either the p-adrenergic (Chapter 4) or the NO-cGMP (Chapter 5) pathway, which
would abolish or mimic the ischaemia-induced changes in cyclic nucleotides and p38
MAPK activation during the PC protocol, respectively.
1.4.3.3 Role of p38 MAPK activation: trigger or mediator? (Chapter 6)
Timing of protein kinase activation appears to be critical for cardioprotection achieved
by ischaemie PC. Therefore our final aim was to evaluate the role of p38 MAPK as
trigger or mediator in ischaemie PC as well as in p-adrenergic-induced PC by using a
p38 MAPK inhibitor, S8203580.
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CHAPTER 2
2. Materials and Methods
2.1 Animals
Male Wistar rats weighing between 250 and 350g were used. Before experimentation,
rats were allowed free access to food and water. This investigation was approved by
the Ethics committee of the University of Stellenbosch (Faculty of Medical Sciences)
and conforms with the Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH publication No. 85-23, revised 1985).
2.2 Perfusion Technique
The well-characterized isolated working rat heart was used as experimental model as
described previously (Edoute, et ai., 1988). Rats were anaesthetized by injecting
sodium pentobarbitol (30 mg/rat) intraperitoneally. The hearts were rapidly excised and
arrested in ice-cold Krebs-Henseleit bicarbonate buffer, pH 7.4, containing (in mM):
NaCI 119, NaHC0325, KCI 4.75, KH2P04 1.2, MgS040.6, NaS040.6, CaCl2 1.25, and
glucose 10. After removal, the hearts were perfused uniformly via the aorta cannula, by
the Langendorff technique (Langendorff, 1895). This was done in a retrograde, non-
recirculating manner at 100 cm H20 (not electrically stimulated) with Krebs-Henseleit
buffer oxygenated with 95% O2 / 5% C02 at 37°C. The left atrium was cannulated to
allow atrial perfusion (atrial pressure 15 cm H20) according to the working heart model
of Neely (Neely et ai., 1967) as modified by Opie and coworkers (1971).
Normothermic zero-flow global ischaemia was utilized for both ischaemie
preconditioning as well as for induction of sustained ischaemia. Global ischaemia was
induced by simultaneous clamping of both the aortic and left atrial supply tubes. Hearts
were surrounded by a small tightly stoppered water-jacketed chamber to prevent cooling.
Temperature was maintained at 36.5°C during global ischaemia and monitored
continuously by a temperature probe inserted into the pulmonary artery.
Stellenbosch University http://scholar.sun.ac.za
63
Reperfusion was initiated by unclamping the tube leading to the aortic cannula,
allowing retrograde perfusion. Functional recovery was assessed by measuring the
mechanical activity before (during 15 min of working heart mode) and after global
ischaemia (at the end of the reperfusion period), so that each heart served as its own
control. Mechanical activity was determined by manually measuring the aorta output
(Qa) and coronary flow (Qe), with their sum being the cardiac output (CO) in ml/min.
Aorta pressure was obtained through a side arm of the aortic cannula, which was
connected to a pressure transducer (Viggo Spectromed) and was recorded as a
function of time by a computer. Peak systolic pressure (PSP) and heart rate (HR) were
obtained from these recordings. The external power produced by the left ventricle as
measured by total work performance (Wtot) was calculated according to the following
formula (Kannengieser et a/., 1979):Wtot= 0.002222 x PSP x CO.
2.3 Standardperfusion protocol: (Fig.2.1)
In all hearts (at least 6 per series), a stabilization period of 15 min retrograde perfusion
was followed by 15 min in the working heart mode. Non-preconditioned hearts were
subsequently perfused retrogradely for a further 30 min, whereas the hearts to be
preconditioned(PC)were subjected to three episodesof 5 min global ischaemia (PC1-, 2-,
3-), interspersedby 5 min retrograde perfusion (PC1+, 2+,3+) (total duration 30 min). All
hearts were then subjected to 25 minutes of total global ischaemia followed by 30 min
reperfusion (10 min retrograde and 20 min working heart) for evaluation of functional
recovery.
2.4 Biochemical analysis
2.4.1 Tissue high energy phosphate (HEP),cAMPand cGMPanalysis
Heartswere freeze-clamped at various times during the perfusion protocol (see detail in
following chapters) with precooled Wollenberger tongs and immediately plunged into
and stored in liquid nitrogen.
For tissue HEP and cAMP analyses, 100-200 mg tissue was extracted with 1.2 ml 6%
perchloric acid. Extracts were neutralized and filtrated through a 0.45J.lm(Millipore)
filter. Analysis of HEP (adenosine triphosphate, ATP and creatine phosphate, CrP) was
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Non-preconditioned hearts:
STABILIZATION RETROGRADE (R) SUSTAINED ISCHAEMIA REPERFUSION... ...... ...... ...... ...
RETROGRADE WORKING HEART RETROGRADE WORKING HEART
Preconditioned hearts:
PRECONDITIONING ......
PC1- PC1+ PC2- PC2+ PC3- PC3+
I------------~~----------~--~--~----~--~--~----~--~--~----~------~--------~~----~~------~
0 15 30 35 40 45 50 55 60 65 70 75 85 95 105 115
TIME (MINUTES)
Fig 2.1 Standard perfusion protocol for non-preconditioned and preconditioned hearts. PC1-, PC2- and PC3- indicate hearts
exposed to 5 min of global ischaemia; PC1+, PC2+ and PC3+ indicate hearts reperfused for 5 min after global ischaemia.
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done by the reversed phase high pressure liquid chromatography (HPLC)
technique, developed by Victor and coworkers (1987). Samples were separated by
HPLC (LUNA 511C18(2) , 250 x 4.6 mm, Phenomenex) with on-line UV detection (210
nm) and quantitated with appropriate standards (Sigma). The mobile phase (flow rate
2.0 ml/min) consisted of a buffer, pH 4.0, containing (in mM): KH2P04 257,
tetrabutylammoniumphosphate 1.18 and HPLC graded methanol 12.5% (v/v).
Tissue cAMP content was determined using Amersham's cAMP [3H] assay system.
This assay is based on the competition between unlabelled cAMP and a fixed quantity
of eH] cAMP for binding to a protein with high affinity and specificity for cAMP. A
standard curve ranging form 0.125-16 picomol cAMP was included in each assay.
Tissue cGMP (-100 mg tissue) was extracted with 1.2 ml 5% trichloracetic acid. The
extracts were washed 4 times with 3.0 ml ether before analysis with Amersham's cGMP
C251] assay system. This assay is based on the competition between unlabelled cGMP
and a fixed quantity of [1251] cGMP for a limited number of binding sites on a cGMP-
specific antibody. The concentration of unlabelled cGMP in the samples was
determined by interpolation from a standard curve (2-128 fmol cGMP).
2.4.2 Tissue cAMP-dependent PKA activity
Tissue cAMP-dependent PKA activity was determined with an assay from Gibco.
Frozen tissue was homogenized in an extraction buffer (5 mmol/L EOTA, 50 mmol/L
Tris, pH 7.5) and centrifuged for 10 min at 600g, and the supernatant was diluted to -5
Ilg protein/10 III extract. Four assay conditions were used for each sample (with and
without inhibitor as well as with and without cAMP). Results were expressed as pmol
activated PKA . min-I. mg protein". The protein content of samples was determined by
either the Lowry et aI., (1951), or the Kaplan and Pedersen (1985) technique.
2.4.3 Tissue cAMP- and cGMP- phosphodiesterase (POE) activity
Phosphodiesterase (POE) activity assays were performed on freeze-dried material, which
was homogenized in water (50 Ill/mg dry weight). Since the homogenate was
concentrated, it contained endogenous cyclic nucleotides as well as Mg2+ in a
concentration close to that found in vivo.
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The POE activity of the homogenate was determined using a radiotracer dilution
method. The reaction was initiated by adding 100 ul of homogenate to 20 ul incubation
mixture containing c[8-3H]AMP (SA 962 GBq/mmol) and c[8-3H]GMP (SA 363
GBq/mmol) (ca 200 000 cpm). After 10 min incubation (temperature 25°C) the reaction
was terminated by addition of 20 jll 60% perchloric acid. After centrifugation (2 min, 12
DOOg)the supernatant was separated by reversed phase HPLC (Purospher RP 18, 5
microspher, Merck) with on-line radiochemical detection of labelled nucleotides. The
mobile phase consisted of (A) 100 mM ammoniumphosphate pH 5.5 and (B) Buffer A
plus 6% acetonitrile. A linear gradient was used from 100% A to 100% B in 20 min (flow
rate 0.5 ml/min). POE activity was calculated as the percentage of cleavage products to
total radioactivity (which was equivalent to the radioactive cyclic nucleotide initially
present in the reaction mixture). This was done by Dr. Thomas Podzuweit (Centre for
Experimental Cardiology, Max-Plank Institute, Bad Nauheim, Germany).
2.4.4 Characterization of p-adrenergic response
2.4.4.1 Membrane preparation
To determine the characteristics of the p-adrenergic receptor population, a sarcolemmal
enriched membrane fraction was prepared by a modification of the method described by
Strasser et al., (1992). Tissue was homogenized in 20 ml buffer A (50mM Tris, 5mM
EOTA, 2mM EGTA, 1mM dithiotreitol (OTT), pH 7.2 at 4° C) with a polytron PT 10
homogenizer for 3 x 10 sec at maximum speed. This homogenate was centrifuged for
10 min at 755 x g at 4° C. The resultant supernatant was centrifuged for 15 min at 45
000 x g at 4° C. The pellet obtained was washed twice with 5 ml buffer A and once with
5 ml buffer B (75mM Tris, 12.5mM MgCb, 1.5mM EOTA, pH 7.4 with HCI at 4° C) and
each time centrifuged for 15 min at 45 000 x g. The final pellet was suspended in buffer
B to give a concentration of 10 mg protein/ml. Depending on the amount of protein, the
protein content of each membrane preparation was determined by either the Lowry et
al., (1951), or the Kaplan and Pedersen (1985) technique.
2.4.4.2 p-Adrenergic receptor assay
The characteristics of the p-adrenergic receptor population were determined using the
radiolabelled p-antagonist [1251]iodocyanopindolol as specific ligand as described by
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Strasser et al., (1990). The number of ~-receptors was determined in saturation
experiments using increasing concentrations of ligand (0.01-0.5 nM) in an assay volume
of 250 Ill, containing 10-20 Ilg membrane protein/tube. Non-specific binding was
determined by the nondisplaceable binding in the presence of the unlabeled ~-
antagonist, alprenolol (10-6M).All determinations were done in triplicate. After 1 hour of
incubation at 25° C, the reaction was terminated by addition of 0.6ml 25% polyethylene
glycol (MW 8000) and 50111(containing 1251lg)gamma-globulin. After centrifugation for
30 min at 3 000 rpm, the pellets were washed once with buffer B and counted for
radioactivity. Kd and Bmaxvalues of the receptor population were calculated, using the
Enzfitter computer programme (Robin J Leatherbarrow, published by Elsevier-Biosoft).
2.4.4.3 Adenylyl cyclase activity
Adenylyl cyclase activity was determined as described by Salomon et al., (1974). The
incubation medium contained 75mM Tris-HCI, pH 7.5, 12.5mM MgCI2, 1mM EDTA,
0.1mM GTP, 0.001mM DIT, 0.1mM cAMP, 1mM isobutylmethylxanthine, 20mM
phosphocreatine, 2 units creatine kinase and 0.5mM [a_32P]ATP (- 200 000 cpm). For
stimulation, forskolin (10-6M) was added. The reaction was started by the addition of -
100 Ilg membrane protein per tube, incubated for 10min at 37° C and stopped by
addition of 500 III ice-cold NaHC03 (120mM) and 500lli Zinc acetate (125mM). The
radiolabelled cAMP was eluted from aluminium oxide columns prepared as described
by Jakobs et al. (1976) (recovery 80-90%) and the eluates counted in 10ml Instagel for
radio-activity.
2.4.5 Western blotting for p38 Mitogen Activated Protein Kinases (MAPK)
2.4.5.1 Preparation of Iysates
Cytosolic p38 MAPK was determined by homogenizing freeze-clamped hearts with a
lysis buffer containing (in mM): Tris 20; p-nitrophenylphosphate 20; EGTA 1; NaF 50;
sodium orthovanadate 0.1; phenylmethyl sulphonyl fluoride (PMSF) 1; dithiotreitol
(OTT) 1; aprotinin 10 Ilg/ml; leupeptin 10 Ilg/ml. These Iysates were diluted in
Laemmli sample buffer, boiled for 5 min and 1Dug protein was separated by
electrophoresis on a 12% polyacrylamide gel, using the standard Bio-RAD Mini-
PROTEAN II system. The lysate protein content was determined using the Bradford
Stellenbosch University http://scholar.sun.ac.za
67
technique (Bradford 1976). The separated proteins were transferred to a PVDF
membrane (Irnmobilonl'r-P, from Millipore). These membranes were stained with
Ponceau S red (reversible stain) to visualize the proteins. To assess the quality and
quantity of the transfer, these membranes were laser-scanned and densitometrically
analysed (UN-SeAN-IT, Silkscience). Non-specific binding sites on the membranes
were blocked with 5% fat-free milk in Tris-buffered saline, 0.1% Tween-20 (TBST).
2.4.5.2 p38 MAPK dual phosphorylation
The activated p38 MAPK was visualized with an appropriate primary phospho-antibody
(phospho-p38 MAPK (Thr180fTyr182) Anitbody, New England Biolabs). Membranes
were washed with large volumes of TBST (5 x 5min) and the immobilized primary
antibody was conjugated with a diluted horseradish peroxidase-labelled secondary
antibody (purchased from Amersham Life Science). After thorough washing with TBST,
membranes were covered with Eel TM detection reagents and quickly exposed to an
autoradiography film (Hyperfilm Eel, RPN 2103) to detect light emission through a non-
radioactive method (Eel TM Western blotting from Amersham Pharmacia Biotech). Films
were densitometrically analysed and activated p38 MAPK values were corrected for
minor differences in protein loading, if required.
2.4.5.3 p38 MAPK activity
For analysis of p38 MAPK activity using an assay kit, tissue Iysates were prepared
(using the same buffer as described above) containing 200 Ilg total protein/200 III cell
lysate. A monoclonal phospho-specific antibody to p38 MAPK (Thr180fTyr182) was
used to selectively immunoprecipitate the p38 MAPK from the lysate. The resulting
immunoprecipitate was then incubated with ATF2 fusion protein in the presence of 200
IlM ATP. Phosphorylation of ATF2 at Thr71 was measured by Western blotting using a
phospho-ATF2 (Thr71) antibody. Films were densitometrically analysed as described
above.
2.5 Drugs
The drugs that were used in this study include: a direct activator of adenylyl cyclase,
forskolin was dissolved in dimethyl sulfoxide (DMSO) to a stock solution of 10-3 molll
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and diluted to final concentrations of 10-8, 10-7 or 10-6 molll (0.04% OMSO); ~I-
adrenergic receptor agonist, isoproterenol (10-8, 10-7 or 10-6 molll); ~z-adrenergic
receptor agonist, zinterol (10-7, 10-6or 10-5 molll), nonselective ~l/ ~z-adrenergic blocker
alprenolol (10-5 or 7.5 x 10-5 mol/I); u1-adrenergic receptor antagonist, prazosin (0.3
).lM), selective adeniosine A1 receptor antagonist, CPT or 8-cyclopentyltheophyline (10-5
and 2 x 10-5 mol/I) from Research Biochemicals Incorporated; Ca2+ channel blocker,
verapamil (0.5, 1 and 2 !J.M).
NO-donors, s-nitroso-penicillamine (SNAP) dissolved in OMSO and diluted in buffer to
10 or 50 ).lM (0.04% OMSO) and sodiuminitroprusside or SNP (100 ).lM); a selective
inhibitor of guanylyl cyclase, ooa or 1H-[1 ,2,4]oxadiazolol[4,3-a]quinoxalin-1-one
purchased from TOCRIS was either dissolved in OMSO or ethanol and diluted in buffer
to final concentrations of 10 or 20 ).lM (0.04% OMSO, 2% ethanol); L-arginine (10mM);
NOS inhibitors, L-NAME or NG-nitro-L-arginine methyl ester (50).lM) and NroNitro-L-
Arginine or L-NNA (50).lM); Intramed adrenaline (10-6M) was used for ~-adrenergic
stimulation; highly selective p38 MAPK inhibitor, SB 203580 (1 or 10).lM) from
CALBIOCHEM. Routine chemicals were obtained from Merck, Cape Town.
2.6 Statistics
Results are given as mean ± standard error of the mean (SEM). Multiple comparisons
were analyzed by one-way analyses of variance (ANOVA) followed by the Bonferroni
correction as post hoc test. In the case of p38 MAPK activity determinations, data
scattered due to differences in overall blot densities, which might introduce type-II
statistical errors, therefore unpaired t-test was used. A p < 0.05 was considered
significant.
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CHAPTER 3
Evaluation of events in Ischaemie Preconditioning
3.1 Introduction
Despite intensive efforts, elucidation of the exact mechanism(s) of ischaemic
preconditioning (PC) has still not been accomplished. Involvement of several signal
transduction pathways has been implicated. For example, stimulation of a variety of G
protein-coupled receptors (i.e. adenosine A1, U1 -adrenergic, muscarinic, bradykinin
receptors) results in activation of protein kinase C, the latter being suggested as the
common denominator in eliciting protection (Downey et al., 1996, Lawson et al., 1993).
However, involvement of other signal transduction pathways has been proposed,
including the ~-adrenergic signal transduction pathway (Asimakis et al., 1994, Sandhu
et al., 1996) and mitogen activated kinases (MAPKs) (Brooks et al., 1996).
3.1.1 ~-Adrenergic signal transduction pathway
Activation of the ~-adrenergic signal transduction pathway occurs within minutes after
the onset of myocardial ischaemia (Strasser et aI., 1990), therefore suggesting the
possible involvement of this pathway in PC. Furthermore, our laboratory (Moolman et
al., 1996) and others (Sandhu et al., 1996) indicated that prior PC significantly
attenuated cAMP accumulation during sustained ischaemia in isolated rat and rabbit
hearts. This observation may be due to, (a) upstream effects, i.e. reduced
noradrenaline release or desensitization of the ~-receptor (Sandhu et al., 1996),
changes in function of stimulatory- (Gs) or inhibitory- (Gi) G-proteins or adenylyl cyclase
activity (Niroomand et al., 1995, Iwase et al., 1993) and/or (b) downstream
mechanisms, such as less inhibited phosphodiesterase (POE) activity. The activity of
the POEs is also influenced by cGMP and other reputed mediators of PC (such as nitric
oxide or bradykinin) (parrat et al., 1995), that in turn increase tissue cGMP levels. The
changes in downstream factors involved in cAMP metabolism/ breakdown in PC are
presently unknown.
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3.1.2 Mitogen activated kinases (MAPKs)
Emerging evidence suggests that, in models of myocardial ischaemia-reperfusion,
mitogen activated protein kinases (MAPKs) - including p38 MAPK, extracellular signal-
regulated kinases (ERK1 and ERK2), c-Jun N-terminal kinases (JNK1 and JNK2) and
big MAPK-1 - may be important determinants of myocyte viability (Abe et ai., 2000).
Although all members of the MAPK family have been investigated in the setting of PC-
induced cardioprotection, the greatest interest was shown in p38 MAPK (which appears
to be the more sensitive kinase to stress signals) (Bogoyevitch et ai., 1996, Clerk et aI.,
1998, Gysembergh et ai., 2001). Therefore, it has been studied intensively as a
possible mediator in the transduction of the stress signal (i.e. ischaemie PC) into the
generation of a protective protein or activation of another downstream protective kinase.
However, whether the ischaemia-induced activation of p38 MAPK is beneficial or
deleterious is still controversial.
Most previous studies focussed on events during sustained ischaemia only, while
ignoring events during the PC protocol, as well as during reperfusion after ischaemia.
We therefore hypothesized that, in view of the sensitivity of p38 MAPK to stress, the
multicycle ischaemie PC protocol per se should also elicit marked activation of this
enzyme, which in turn, could affect subsequent events during sustained ischaemia and
reperfusion.
3.1.3 The aim:
The aim of this study was therefore to evaluate myocardial levels of cAMP, cGMP and
high energy phosphates (HEPs), as well as the activity of the POEs and p38 MAPKs
during (i) the PC (PC) protocol, (ii) sustained ischaemia and (iii) during subsequent
reperfusion.
After having demonstrated cyclic increases in tissue cAMP during a multicycle PC
protocol, we further hypothesized that these changes were caused by the release of
endogenous catecholamines, resulting in downregulation of the p-adrenergic signal
transduction pathway, contributing to attenuation of cAMP during sustained ischaemia
and functional improvement during reperfusion. Therefore we also evaluated whether:
Stellenbosch University http://scholar.sun.ac.za
71
pretreatment with reserpine would abolish the changes in cAMP during the PC
protocol and
- downregulation of the p-adrenergic signal transduction pathway during sustained
ischaemia occurred by evaluation of the (i) p-adrenergic receptor characteristics, (ii)
PKA activity and (iii) p-adrenergic responsiveness of preconditioned myocardial
tissue.
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3.2 Experimental Protocols and Results
3.2.1 Evaluation of events during the ischaemie PC protocol
(preceding sustained ischaemia)
3.2.1.1 Experimental protocol
Non-preconditioned or control hearts:
Hearts were stabilized by perfusing retrogradely for a period of 15 min, followed by 15
min in the working mode. Non-preconditioned hearts were subsequently perfused
retrogradely for a further 30 min. Hearts were freeze-clamped at 30 and 60 min total
perfusion time (Fig. 3.1).
Preconditioned hearts:
Hearts were stabilized for a period of 30 min (15 min retrograde, 15 min working mode)
and then preconditioned by subjecting the hearts to three episodes of 5 min global
ischaemia designated as PC1-, 2-, 3-, alternated by 5 min of retrograde perfusion
designated as PC1+, 2+, 3+. Hearts were freeze-clamped at the beginning and end of
each period of 5 min ischaemia, as well as at the end of the third reperfusion phase
(Fig. 3.1). At least six hearts were freeze-clamped at each time point.
3.2.1.2 Results
3.2.1.2.1 Evaluation of changes in tissue cyclic nucleotides (cAMP and cGMP)
Control values for cyclic nucleotides were found to be similar after 30 and 60 min
perfusion. Values were therefore pooled.
Hearts exposed to three episodes of 5 min global ischaemia (PC1-, 2-, 3-), showed
significant alternating increases in myocardial content of cAMP when compared to the
control. During each reperfusion episode (PC1+, PC2+, PC3+) the cAMP levels
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Non-preconditioned hearts:
RETROGRADE WORKING HEART RETROGRADE
~ .~~~t
Preconditioned hearts:
... PRECONDITIONING ...
RETROGRADE WORKING HEART PC1- PC1+ PC2- PC2+ PC3- PC3+
o 15 30
TIME (MINUTES)
60
Fig 3.1 Evaluation of the changes occurring during the preconditioning protocol. Experimental protocol. PC1-, PC2-
and PC3- indicate hearts exposed to 5 min of global ischaemia; PC1+, PC2+ and PC3+ indicate hearts reperfused
for 5 min after global ischaemia. Arrows indicate time of freeze-clamping. Controls were freeze-clamped after 30 min
and 60 min perfusion. Six hearts were studied at each time interval for each experimental series.
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Fig 3.2 Cyclic changes in tissue cAMP and cGMP during the preconditioning protocol. Abbreviations as in
Fig 3.1.
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Table 3.1
Effects of 3 x 5 min preconditioning on tissue cGMP and cAMP levels and the
cAMP/cGMP ratio before onset of sustained ischaemia.
cGMP cAMP cAMP/cGMP
Control (n = 11) 8.42 ± 0.35 317.0 ± 9.27 37.65
Preconditioning
(n = 2: 9/series)
PC1- 12.18±0.71 * 402.8 ± 13.23 * 33.07
12.71 ± 1.37 307.0 ± 13.51 & 24.15
20.22 ± 0.91 * 368.7 ± 13.84 * 18.23
13.12 ± 1.65 -s 283.0 ± 10.34 & 21.57
16.79±1.12* 370.2 ± 9.74 * 22.05
12.54 ± 0.69 -s 277.1 ±9.16& 22.10
PC1+
PC2-
PC2+
PC3-
PC3+
Values are means ± SE in pmoles/g wet weight. Control hearts were perfused for 60 min (15 min
retrograde, 15 min working heart, 30 min retrograde perfusion) (similar values were obtained at 30
min of control perfusion conditions).
Individual cAMP/cGMP ratios not calculated in control and preconditioned series as values were
obtained from different hearts.
&P < 0.05 PC- vs PC+
* P < 0.05 vs control (untreated)
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recovered to those of control hearts. Furthermore, in each of the three episodes,
tissue cAMP levels were significantly higher at the end of ischaemia (PC1-, 2-, 3-), than
after reperfusion (PC1+, 2+, 3+) (Fig. 3.2 and Table 3.1).
Tissue cGMP levels at the end of each ischaemic episode (PC1-, PC2-, PC3-) showed
the same tendency as the cAMP levels, viz. a significant increase. With the exception
of the first reperfusion episode (PC1+), reperfusion caused a significant reduction in
tissue cGMP, although not to baseline values (Fig. 3.2). Therefore tissue cGMP at the
end of the PC protocol was significantly higher than control.
Since tissue cAMP and cGMP levels were determined in two separate series of
experiments, cAMP/cGMP ratios could not be calculated for each individual heart and
the values given in Table 3.1 were derived from the means of each series. Since the
percentages increase in cGMP at PC1-, PC2- and PC3- (45, 140 and 99%,
respectively) exceeded those of cAMP (27, 16 and 17%, respectively), the cAMP/cGMP
ratios at these time points were reduced, when compared to controls.
3.2.1.2.2 Evaluation of changes in tissue phosphodiesterase (POE) activity
The marked fluctuations in myocardial cAMP and cGMP levels during ischaemic-
reperfusion cycles were reflected by opposite changes in both cAMP- and cGMP-
hydrolysing POE activities. At PC1-, both phosphodiesterases showed a significant
reduction in their activities, followed by a return to baseline values during PC1+. Similar
observations were made at the second and third PC episodes, however, inhibition of
POEswas less than during PC1- (Fig. 3.3).
3.2.1.2.3 Evaluation of changes in tissue high energy phosphates (HEPs)
During the ischaemie PC protocol, the tissue creatine phosphate (CP) values were
significantly higher at each reperfusion episode (PC1+, PC2+, PC3+) than those of the
controls, while each 5 min ischaemic episode (PC1-, PC2-, PC3-) lowered these values
significantly. Although tissue ATP showed similar fluctuations, the changes were not
significant and did not differ from controls. Tissue ADP and AMP showed opposite
fluctuations which were also not significant from controls (Fig. 3.4).
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3.2.1.2.4 Characterization of changes in p-adrenergic signalling pathway
during the PCprotocol
3.2.1.2.4.1 Role of release of endogenous catecholamines in causing increases
in cAMP
Depletion of endogenous catecholamines was attained by intraperitoneal administration of
reserpine (7 mg/kg) 24 h before experimentation (dose according to Toombs, et aI., 1993).
Hearts from reserpinized and untreated animals were first perfused retrogradely (15
min), then for 15 min in the working mode (mimicking the exact technique used
previously, Moolman, et aI., 1995). Non-preconditioned (Non-PC) hearts were
subsequently perfused retrogradely for 30 min, whereas preconditioned (PC) hearts
were subjected to three episodes of 5 min global ischaemia, alternated by 5 min
retrograde reperfusion. Hearts were freeze-clamped after 30 min. total perfusion time
(controls) as well as at the end of each 5 min period of global ischaemia (PC1-, PC2-,
and PC3-) (Fig. 3.1).
Results indicate that hearts of non-reserpinized rats subjected to PC exhibited similar
increases in tissue cAMP as shown in Fig. 3.2, whereas depletion of catecholamines by
prior reserpination abolished these increases at every time-point studied (p > 0.05 vs.
reserpinated controls at each time point) (Fig. 3.5).
3.2.1.2.4.2 Evaluation of changes in p-adrenergic signalling pathway
Non-PC hearts were perfused (as described in 3.2.1.1) and freeze-clamped after 30 and
60 min total perfusion time. The changes in the p-adrenergic signalling pathway were
evaluated at the beginning and end of the PC protocol. Thus, PC hearts were freeze-
clamped after 30 min total perfusion time (before onset of PC), at PC1- and PC3- and at
the end of PC1+ and PC3+ for determination of p-adrenergic receptor characteristics,
adenylyl cyclase and PKA activities (In view of the inordinate large number of rats
required for protocols like these, it was decided not to study hearts at PC2- and PC2+).
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~-receptor population:
Results from Fig. 3.6 A and B indicate that PC caused a gradual increase in receptor
density (Bmax),and Kd (i.e. decrease in affinity), which became significant at PC3-. At
the end of PC (PC3+), Bmaxwas increased by 39% and affinity decreased by 35.5%.
Adenylyl cyclase activity:
Although the forskolin-stimulated adenylyl cyclase activity (Fig. 3.7A) was increased
significantly at PC1- and PC3-, it was reduced at PC3+ (i.e. the activity at onset of
sustained ischaemia did not differ from those of controls).
PKA activity:
cAMP-dependent PKA activity (Fig. 3.7B) changed in the same way as tissue cAMP
levels, being significantly elevated at the beginning (PC1-) and the end (PC3-) of the PC
ischaemic episodes, while returning to control levels upon reperfusion (PC1+, PC3+).
PKA activity at the end of PC3+ was significantly lower than at PC3-.
3.2.1.2.4.3 Evaluation of ~-adrenergic receptor responsiveness
To determine whether the ~-adrenergic signalling pathway was being desensitized
during repeated transient ischaemie insults (for example, during a multi-cycle PC
protocol), ~-adrenergic responsiveness was evaluated by measuring changes in tissue
cAMP content after administration of ~-adrenergic agonists for a period of 2 min.
Non-PC and PC hearts were perfused as described in 3.2.1.1. At 58 minutes perfusion
time, either forskolin (10-6 mol/I) or isoproterenol (10-8, 10-7 or 10-6 mol/I) was added to
the perfusate and the hearts freeze-clamped after 2 minutes for cAMP determination
(see Fig. 3.8 for protocol). Control non-PC and PC samples were taken from hearts
freeze-clamped after 60 minutes perfusion without administration of drugs.
Form the results (Fig. 3.9) it can be seen that isoproterenol (10-8, 10-7 or 10-6 mol/I)
caused a significant dose-dependent increase in cAMP content of non-PC hearts
compared to untreated control hearts, whereas cAMP of all PC groups remained
unchanged, indicating desensitization of the p-adrenergic response. Forskolin (10-6
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Fig 3.8 l3-adrenergic pathway responsiveness after the ischaemie preconditioning protocol: Experimental protocol. Abbreviations
as in Fig 3.1. At 58 min of perfusion time of non-PC and PC hearts, either isoproterenol 10-8, 10-7, 10-6 M or forskolin 10-6 M was
added to the perfusate and hearts were freeze-clamped (as indicated by arrows) after 2 min for cAMP determination. Control hearts
were freeze-clamped after 60 min of perfusion without administration of drugs. n = 6 hearts per series.
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Fig 3.9 f3-adrenergic pathway responsiveness after the ischaemie preconditioning protocol: cAMP generation in response to
different agonists: Comparison of ~-adrenergic response of non-PC and PC rat hearts to stimulation with isoproterenol 10-8, 10-7, 10-6 M or
forskolin 10-6 M for 2 min. One series of hearts was pretreated with pertussis toxin 48h before experimentation Isoproterenol caused a
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pertussis toxin- treated PC hearts, indicates that the attenuation in ~-adrenergic response was not due to increased Gi protein activity.
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mol/I) elicited a similar two-fold increase in tissue cAMP in both non-PC and PC
hearts, indicating that prior ischaemie PC induced a change at p-adrenergic receptor
level.
To evaluate the role of the inhibitory G-protein (Gj protein), similar experiments were
performed on rats pre-treated with pertussis toxin in saline (25 !-lg/kg) (Lawson, et a/.,
1993) or saline only, 24 hours before experimentation. After 58 min total perfusion time
isoproterenol (10-7 mol/I) was added to the perfusate and the hearts freeze-clamped
after 2 min. The cAMP generation in response to isoproterenol 10-7 mol/I by hearts from
pertussis toxin treated rats did not differ from hearts of untreated animals (Fig. 3.9),
indicating that the diminished response to p-adrenergic stimulation by PC hearts was
not due to increased Gj protein activity.
In addition to these experiments, the p-adrenergic receptor responsiveness of the
ischaemie PC myocardium was also evaluated by measuring work performance after
administration of the p-adrenergic agonist, isoproterenol, in a dose dependent manner.
Non-PC and PC hearts were perfused as described in 3.2.1.1. At 65 min perfusion time,
isoproterenol 10-8M was added to the perfusate for 5 min, increasing the dose to 10-7M
and 10-6 M at 5 min intervals. Work performance (aortic output and total work) were
measured every 2 min after the first addition of isoproterenol. The initial 30 min
perfusion time served as controls for non-PC and PC hearts (see Fig. 3.10 for protocol).
The results (Fig. 3.11 A, B) demonstrate that isoproterenol (10-8, 10-7 or 10-6 mol/I)
caused a transient, but significant increase in aortic output and work performance 2 min
after drug administration. The response to 10-7 M isoproterenol elicited in the PC hearts
was significantly lower compared to non-PC hearts, whereas the PC hearts were
desensitised to 10-6 M isoproterenol.
3.2.1.2.5 Evaluation of p3SMAPK activation during the PC protocol
Experimental protocol
Dual phosphorylation of p38 MAPK (residues Thr 180 / Tyr 182 are phosphorylated)
was assayed at PC1-, PC2-, PC3-, as well as at PC1+, PC2+ and PC3+ (4 - 6
hearts/series). In all series studied the activation of p38 MAPK, as indicated by its dual
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Fig 3.10 p-adrenergic receptor responsiveness to isopoterenol after the ischaemie preconditioning protocol: Experimental protocol.
Abbreviations as in Fig 3.1. Arrows indicate time of isoproterenol administration in a concentration range from 10-8 to 10-6 M.
Mechanical function was measured every 2 min after the first addition of isoproterenol. n = 6 hearts per series.
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phosphorylation, was reflected by its kinase activity as detected by phosphorylation
of the substrate ATF-2. The latter was determined at selected intervals (3
hearts/series) .
Results
Exposure of the heart to 5 min global ischaemia (PC1-) caused a significant dual
phosphorylation of p38 MAPK (Fig. 3.12A) as well as activation of ATF-2 (Fig. 3.128),
when compared to controls (obtained from hearts perfused for 30 min). This significant
activation was also seen at the end of the second PC episode (PC2-), but activation at
the end of the third episode (PC3-) was no longer significant. Reperfusion after the first
PC episode (PC1+) caused a significant decline in p38 MAPK activation, compared to
PC1-. Therefore, although dual phosphorylation and activation of p38 MAPK were
observed during all three PC episodes, the activation was maximal during PC1-,
becoming progressively less during PC2- and PC3-.
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Fig 3.12 The ischaemie preconditioning protocol: A. Analysis of p38 MAPK dual
phosphorylation state (n = 4-6 hearts/series). B. Comparison with its kinase activity
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hearts/series). Representative blots are given. p38 MAPK is transiently
phosphorylated and activated during the ischaemie preconditioning protocol.
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3.2.2 Evaluation of events during Sustained Ischaemia:
3.2.2.1 Experimental protocol:
Non-preconditioned or control hearts:
To evaluate the changes in tissue nucleotides during sustained global ischaemia, non-
preconditioned hearts were stabilized for 60 min (15 min retrograde, 15 min working
mode, 30 min retrograde), followed by 25 min sustained global ischaemia. Non-PC
hearts were freeze-clamped before onset of sustained ischaemia (at 60 min total
perfusion time), as well as at 10 min and 25 min during sustained ischaemia (Fig.
3.13A).
Preconditioned hearts:
Hearts were stabilized for a period of 30 min (15 min retrograde, 15 min working mode),
followed by a PC protocol of 3 x 5 min global ischaemia and a subsequent period of 25
min global ischaemia. Similar to non-PC hearts, PC hearts were also freeze-clamped
before onset of sustained ischaemia (at 60 min total perfusion time), as well as at 10
min and 25 min during sustained ischaemia. Four to six hearts were freeze-clamped at
each time point (Fig. 3.13A).
3.2.2.2 Results
3.2.2.2.1 Changes in tissue cyclic nucleotides
Tissue cAMP at the onset of sustained ischaemia (zero-time) was similar in both non-
PC and PC groups, and increased significantly at all durations of ischaemia (10 and 25
min of ischaemie time) in both groups compared to zero-time. However, cAMP levels
were significantly lower in PC hearts compared to non-PC hearts at both 10 and 25 min
ischaemia (Fig. 3.138).
In contrast, cGMP levels of PC hearts were significantly higher than those of non-PC
hearts at the onset of sustained ischaemia and remained higher in the PC hearts
throughout sustained ischaemia compared to non-PC hearts (Fig. 3.13C).
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Fig3.13 Tissue cAMP and cGMP levels during sustained global ischaemia. Two way analyisis of variance of cAMP showed
significant interaction between time and group. Tissue cAMP was significantly lower in PC hearts at both 10 and 25 min
ischaemia, while tissue cGMP of PC hearts was significantly higher than non-PC hearts throughout sustained ischaemia.
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Table 3.2
The cAMP/cGMP ratios in non-preconditioned (non-PC) and preconditioned (PC)
hearts during sustained ischaemia.
cAMP/cGMP ratios
Sustained Ischaemia Non-PC PC
Zero-time 69.6 ± 6.48 51.7 ± 1.4*#
10 min 72.6 ± 8.38 59.7 ± 5.4*#
25 min 134.2 ± 14.6 78.9 ± 5.2*
Values are means ± SE of individual cAMP/cGMP ratios (tissue cAMP and cGMP levels in Fig.
3.13). n = 6 hearts per series.
* p < 0.05 vs non-PC
8 p < 0.05 vs 25min non-PC
# p < 0.05 vs 25min PC
Stellenbosch University http://scholar.sun.ac.za
79
In both groups the cAMP/cGMP ratios increased markedly with prolongation of the
ischaemic time (Table 3.2). At all time intervals studied (also zero-time values obtained
immediately before onset of sustained ischaemia), this ratio was lower in PC hearts.
3.2.2.2.2 Changes in tissue POE activity
In both PC and non-PC hearts, cAMP- and cGMP-PDE activities declined over the
ischaemic time period of 10 - 25 min. This inhibition was maximal after 15 min. With
increasing periods of global ischaemia, both POE activities were significantly less inhibited
in PC than in non-PC hearts (Figs. 3.14 A, B & C).
3.2.2.2.3 Changes in tissue HEPs
Before the onset of sustained ischaemia, the total adenine nucleotides (TAdN, which
includes ATP, ADP and AMP) levels differed significantly between the different groups.
This was attributable to differences in ATP and ADP which were both lower in the PC
group than those of the non-PC control group. Tissue CP values also differed
significantly, with the PC group having higher CP levels than that of the non-PC control
group (Fig. 3.15). At the end of 25 min sustained global ischaemia the TAdN levels as
well as the CP contents of non-PC and PC hearts were similar (Fig. 3.15).
Consequently, more TAdN was utilized in non-PC than PC hearts, whereas more CP was
utilized in PC hearts.
3.2.2.2.4 Evaluation of p38 MAPK activation during sustained ischaemia
Experimental protocol
During sustained ischaemia, non-PC and PC hearts were freeze-clamped at 5, 10, 15
and 25 min (Fig. 3.14A). Dual phosphorylation of p38 MAPK (residues Thr 180 / Tyr
182 are phosphorylated) was assayed at all the above mentioned time intervals (4 - 6
hearts/series). In all series studied the activation of p38 MAPK, as indicated by its dual
phosphorylation, was reflected by its kinase activity as detected by phosphorylation of
the substrate ATF-2. The latter was determined at selected intervals (3 hearts/series).
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Results
Dual phosphorylation and activation of p38 MAPK was monitored at 5, 10, 15 and 25
min during sustained ischaemia of non-PC and PC hearts. Sustained global ischaemia
caused significant activation of p38 MAPK within 5 min in non-PC hearts, reaching
maximal values after 15 min compared to control perfused hearts (Fig. 3.16A).
Although p38 MAPK phosphorylation in PC hearts was also significantly elevated
compared to controls, it was significantly less at 15 and 25 min of ischaemia when
compared to non-PC hearts (Fig. 3.16A). p38 MAPK activity (as reflected by ATF-2
phosphorylation, Fig. 3.168) also reflected similar results as dual phosphorylation,
indicating a significant activation of p38 MAPK at 25 min ischaemia in non-PC
compared to PC hearts.
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Fig 3.16 Sustained ischaemia: A. Analysis of p38 MAPK dual phosphorylation state
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3.2.3 Evaluation of events during Reperfusion Phase (after
sustained ischaemia)
3.2.3.1 Experimental Protocol
Non-preconditioned hearts:
Hearts were stabilized for 60 min (15 min retrograde, 15 min working mode, 30 min
retrograde), followed by 25 min sustained global ischaemia. Hearts were subsequently
reperfused for 30 min, which consisted of 10 min retrograde perfusion and 20 min
working heart perfusion (Fig. 3.17). Functional recovery during reperfusion was used as
endpoint to evaluate the extent of protection against ischaemie damage. Therefore the
myocardial mechanical function, which included the coronary flow, aortic output, cardiac
output, peak systolic pressure, heart rate and total work performance, was monitored
during reperfusion (at 20 min and 30 min reperfusion time). These measurements were
compared with the mechanical activity before sustained ischaemia (15 min of working
heart mode during stabilization) - each heart served as its own control.
Preconditioned hearts:
Hearts were stabilized for a period of 30 min (15 min retrograde, 15 min working mode).
Preconditioned hearts were then subjected to 3 x 5 min global ischaemia, followed by a
subsequent period of 25 min global ischaemia and 30 min reperfusion. Like non-PC
hearts, the functional recovery of PC hearts was monitored at 20 min and 30 min
reperfusion time. Four to six hearts were monitored at each time point (Fig. 3.17).
3.2.3.2 Results
3.2.3.2.1 Effect of ischaemie PCon functional recovery
At the end of the initial stabilization phase (15 min retrograde and 15 min working heart
perfusion), the myocardial function of both PC and non-PC groups was comparable
(Fig. 3.18). In both experimental groups, exposure of the heart to 25 min sustained
global ischaemia, caused a significant decline in all parameters (apart from coronary
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Fig 3.17 Evaluation of events after sustained ischaemia during the reperfusion phase: Experimental protocol. Abbreviations
as indicated in Fig 3.1. Arrows indicate time points of measurement of mechanical function, at the end of stabilization and during
reperfusion (6 hearts / time point).
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Fig 3.18 Effect of ischaemie preconditioning on functional recovery after 25 min sustained ischaemia. At the end of stabilization,
the function of both PC and non-PC hearts were comparable. Apart from the coronary flow rate, PC caused a significant
improvement in all parameters of function measured during reperfusion compared to non-PC.
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Fig 3.19 High energy phosphate (HEP) levels after 30 min reperfusion. In PC hearts the tissue creatine phosphate (CP), but
not tissue ATP levels, were significantly increased compared to that in non-PC hearts.
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flow rate) of function measured during reperfusion as compared to pre-ischaemie
function. However, comparison of the functional performance during reperfusion
revealed significant differences between the groups. For example, PC with 3 episodes
of 5 min ischaemia prior to sustained ischaemia, caused a significant improvement in
the aortic output (20.5 ± 2.0 ml/min) of hearts during reperfusion after sustained
ischaemia, that was significantly higher than the values obtained in non-PC hearts (2.4
± 1.2 ml/min) (Fig. 3.18). This significant improvement in function by PC hearts
compared to non-PC hearts was also confirmed by the cardiac output, peak systolic
pressure, heart rate and total work performance.
3.2.3.2.2 High energy phosphates
Measuring high energy phosphate levels after 30 min of reperfusion, indicated that
tissue creatine phosphates (CP) of PC hearts were significantly higher than that of non-
PC hearts (Fig. 3.19). On the other hand, tissue ATP levels did not differ significantly
between these two groups.
3.2.3.2.3 p38 MAPK activation during reperfusion
Experimental protocol
During reperfusion samples were taken at 10 min intervals (10, 20 and 30 min)
(Fig. 3.20). Dual phosphorylation of p38 MAPK (residues Thr 180 / Tyr 182 are
phosphorylated) was assayed at all the above mentioned time intervals (4 to 6
hearts/series). In all series studied the activation of p38 MAPK, as indicated by its dual
phosphorylation, was reflected by its kinase activity as detected by phosphorylation of
the substrate ATF-2. The latter was determined at selected intervals (3 hearts/series).
Results
Both non-PC and PC hearts showed a similar and significant activation of p38 MAPK
within 10 min of reperfusion (Fig. 3.21A). However, in the non-PC hearts this activation
was maintained for 30 min, whereas it significantly declined in the PC series. The p38
MAPK activity as reflected by ATF-2 phosphorylation, was significantly lower in PC
hearts compared to non-PC hearts at both 20 and 30 min reperfusion time (Fig. 3.21B).
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Fig 3.20 Sampling for p38 MAPK in non-preconditioned and preconditioned hearts: Experimental protocol. Abbreviations as
indicated in Fig 3.1. Arrows indicate time of freeze-clamping at 10, 20 and 30 min reperfusion. (n = 4 to 6 hearts in each series).
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Fig 3.21 Reperfusion: A. Analysis of p38 MAPK dual phosphorylation state (n = 4-6
hearts/series). B. Comparison with in vitro phosphorylation of ATF-2, to determine p38
MAPK activity (n = 3 hearts/series). Representative blots are given. p38 MAPK
activation is attenuated during reperfusion in preconditioned hearts.
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3.2 Discussion of ischaemie preconditioning (PC)
3.3.1 Validity of experimental model in this study
3.3.1.1 Working heart vs. retrograde perfusion
The phenomenon of ischaemie PC has been reported in the hearts of all species of
animals studied thus far (reviewed by Kloner and Yellon 1994). In practical terms, the
rat heart is by far, the best characterized and also the most frequently used for more
complex perfusion preparations such as working and blood perfused hearts (reviewed
by Sutherland and Hearse 2000). Two modes of perfusion have been used in studies
on PC: (i) the retrogradely perfused heart (according to the technique of Langendorff
1895) fitted with an intraventricular balloon which allows monitoring of left ventricular
developed pressure (LVDP), heart rate and the onset of contracture (in the case of
sustained ischaemia). In most cases regional ischaemia was induced by left coronary
artery ligation and infarct size has mostly been used as end point (Yellen et al., 1992,
Strasser et aI., 1989, Downey et aI., 1996); (ii) the working perfused rat heart (as
originally described by Neely et aI., 1967), where the left atrium is cannulated to allow
left atrium and ventricle perfusion. This model uses functional recovery as endpoint, as
indicated by coronary flow rate, aortic output, developed pressure and heart rate. In this
model, hearts were subjected to total global ischaemia, rather than regional ischaemia.
This technique has been used by a number of workers (Moolman et aI., 1995, Cave and
Hearse 1992, Volovsek et aI., 1992, Asimakis et al., 1992, Steenbergen et aI., 1993,
Tosaki et aI., 1995, Ferdinandy et aI., 1995b, Sandhu et aI., 1996).
This working perfused rat heart model is regarded to be more physiological than the
retrograde perfused heart since it allows evaluation of the cardiac pump function at a
fixed preload (15 - 20 cm H20) and afterload (100 cm H20), while the retrograde
perfusion model is actually an empty beating heart which provides measurement of left
ventricular systolic and diastolic pressures only (for review see Sutherland and Hearse
2000).
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3.3.1.2 Endpoints
In the original study by Murry et al. (1986), which first described the phenomenon of PC,
the endpoint was reduced infarct size. Since then the majority of workers in the field of
PC used the infarct size as endpoint, which is now regarded as the "gold standard" by
many (Liu and Downey 1992, Speechly-Dick et aI., 1994, Bugge and Ytrehus 1995a,b,
Suematsu et a/., 2001, Vue et a/., 2001). However, other endpoints have been used for
example: protection against post-ischaemie left ventricular dysfunction (stunning) (Cave
1995, Asimakis et a/., 1992) and arrhythmias (Shiki and Hearse 1987, Hagar et al.,
1991, Wang et al., 2001) in the isolated rat heart. However, the efficacy of ischaemie
PC in reducing stunning (Ovize et al., 1992) and arrhythmias (Ovize et al., 1995) has
not been as consistent as its ability to reduce necrosis. In addition, in some models a
reduction in infarct size is not always associated with improved function. For example,
ischaemie PC in rabbits protects from cell death and necrosis, but does not improve
functional recovery (Asimakis et al., 1996, Sandhu et al., 1993). Therefore, a lack of
functional recovery during short-periods of reperfusion does not deny PC's
morphological protection (anti-necrosis effect) in animals such as pigs and rabbits
(reviewed by Cohen et a/., 1999).
Furthermore, it is unknown whether the protection afforded by PC against stunning and
arrhythmias is mediated by the same mechanism that mediates its protection against
lethal cell injury (Connaughton et al., 1996, Przyklenk and Kloner 1995). Thus, as long
as the signalling cascade of ischaemic PC is not clear, great caution should be used
when extrapolating findings from recovery of contractile function and protection against
arrhythmias to reduction of infarct size. PC-induced protection against contractile
dysfunction is likely to represent a combination of protection against cell death and
stunning (Cave 2000).
3.3.1.3 Reasons for choice
Although infarct size reduction is regarded as the "gold standard" as endpoint in PC
(Hatter Institute, 1998), many workers, including ourselves, prefer to use contractile
recovery during reperfusion as endpoint, since assessment of infarct size can be
complicated by the choice of staining and the degree of collateral flow (Farber et al.,
1993, Takahashi et aI., 2000, Cave, 2000). Therefore, myocardial function may
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perhaps be the more physiological indicator of the beneficial effects of PC. In fact,
indications are that improved recovery of function is more difficult to achieve than a
reduction in infarct size (Lochner et al. submitted for publication).
In view of the above, it was decided to use the working rat heart as model throughout
this study. Preference was given to global ischaemia, rather than regional ischaemia, to
induce both the PC stimulus and sustained ischaemia. Careful characterization of this
model (Moolman et ai., 1995) showed that improved contractile recovery of the working
heart is always associated with morphological improvement (i.e. reduction in necrosis).
Another advantage is that this model lends itself to measurement of both mechanical
function and biochemical changes in the same heart and these measurements can be
made in the absence of the confounding effects of other organs (reviewed by
Sutherland and Hearse 2000). The globally ischaemie heart also has the advantage
that it yields more tissue than regional ischaemia for biochemical analysis.
Since previous studies indicated that multiple (rather than a single) cycles induced the
strongest protection against arrhythmias and infarct size (Liu et ai., 1992, Yellon et ai.,
1992, Seyfarth et ai., 1996, Sandhu et ai., 1997), a protocol consisting of three episodes
of transient ischaemia and reperfusion was utilized to elicit PC in this study and
evaluated by using parameters such as changes in energy metabolism (changes in high
energy phosphates, HEPs).
Additionally, subjecting the heart to ischaemia, however short, it is clearly not ideal,
hence examining the possibility that the protection provided by ischaemic PC could be
mimicked pharmacologically, is important. Therefore, the fact that the isolated working
heart model is able to rapidly wash out drugs, as well as allowing controlled dose-
response studies of drugs with speed, reproducibility and precise control over
concentration, makes it well suited for pharmacological manipulations.
3.3.1.4 High energy phosphates (HEPs)
After 25 min of global ischaemia in the rat heart, varying degrees of stunning, apoptosis
and necrosis may contribute to the reduced mechanical performance during
reperfusion. We have previously shown that PC reduces the ischaemia induced
structural damage in this model (Moolman et ai., 1995).
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3.3.1.4.1 Changes in HEPs during the PC protocol
Similar to our study, Bradamante et al. (1995) demonstrated that myocardial creatine
phosphate (CP) levels decreased during each ischaemie period of a multi-cycle PC
protocol, and recovered during reperfusion. However, in our study a significant
overshoot in CP levels occurred during the reperfusion phases of the PC protocol (Fig
3.4) causing it to be high at the onset of sustained ischaemia (Fig. 3.15). Both Asimakis
et al. (1992) and Volovsek et al. (1992) reported similar observations and proposed that
this could have played a major role in ATP replenishment, thus conserving energy.
3.3.1.4.2 Changes in HEPs at end of sustained ischaemia
At end of sustained ischaemia no difference in HEPs between PC and non-PC hearts
was observed in this study (Figs. 3.15). However calculating the rate of HEP utilization
of the ischaemic myocardium according to the equation of Murry et al. (1990), indicated
that during 25 min ischaemia the adenine nucleotide utilization of non-PC (0.31 urneles
HEP/g wet weight/minute) was higher than that of PC hearts (0.26 urneles HEP/g wet
weight/minute), whereas CP made a substantial contribution to the energy utilization of
PC (0.23 urneles HEP 19wet weight/minute) compared to non-PC hearts (0.19 urneles
HEP 19wet weight/minute) (data from Moolman et al. 1996). Therefore the reduction in
energy utilization observed during 25 min sustained ischaemia, was consistent with the
known metabolic behaviour of PC hearts (Murry et ai., 1990), and functional data (Fig.
3.18) confirmed that this PC protocol protected preconditioned hearts effectively.
Furthermore, the finding that the mitochondrial oxidative phosphorylation of PC hearts
upon 30 min reperfusion, as indicated by CP generation (Fig. 3.19), was superior to that
of non-PC hearts may be indicative of more pronounced protection. Likewise, Volovsek
et al. (1992) speculated that preservation of mitochondrial function and oxidative energy
production is involved in PC protection.
Thus, we have demonstrated that utilizing a protocol consisting of three episodes of
transient ischaemia and reperfusion to elicit PC conserved energy and resulted in a
reduction in energy utilization during 25 min sustained global ischaemia and
improvement of post-ischaemie functional recovery. These observations confirmed that
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our perfusion protocol was effective in eliciting PC and could therefore be used to
study the phenomenon.
3.3.2 Changes during the ischaemie PCprotocol and subsequent sustained
ischaemia
In this study the results have shown that cyclic increases in tissue cAMP and cGMP
levels (Fig. 3.2) and opposite changes in cAMP- and cGMP-PDE activities (Fig. 3.3), as
well as high energy phosphates (i.e. creatine phosphate) (Fig. 3.4) occurred during a
multi-cycle PC protocol. When exposing the preconditioned myocardium to a
subsequent sustained global ischaemia, the rise in cGMP and cAMP was significantly
higher and lower, respectively, than in the non-PC hearts (Fig. 3.13, Moolman et a/.,
1996). This was associated with functional recovery significantly superior to that of non-
PC hearts (Fig. 3.18). A major issue therefore was to establish whether these changes
per se elicit protection against subsequent ischaemic damage of whether they are mere
epiphenomena or mere reflection of protection initiated by another mechanism.
3.3.2.1 Cyclic increases in cAMP and cGMPduring PC?
Although increases in tissue cAMP and cGMP during long periods of myocardial
ischaemia have been described previously (Krause et a/., 1978, Podzuweit T et aI.,
1995d), the present study is the first to describe the profiles of both these second
messengers during repeated short episodes of ischaemia and reperfusion as occurs
during the PC protocol (Fig. 3.2). Previously, it was shown that another model of PC,
namely ventricular overdrive pacing (VOP), induces PC protection in anaesthetized
rabbits (Szilvassy et aI., 1994). This was associated with alterations in cardiac cyclic
nucleotide contents: a slight increase in cGMP and a profound elevation in cAMP within
5 min of VOPo When this VOP was preceded by a preconditioning VOP, the cGMP
increasewas amplified, whereas the cAMP increase was significantly attenuated.
3.3.2.1.1 Tissue cAMP
A rapid rise in tissue cAMP during 5 min global ischaemia may be due to several
factors, for example, (i) release of endogenous catecholamines (Banerjee et a/., 1993),
(ii) dual sensitization of the p-adrenergic system (Strasser et a/., 1990), or (iii) inhibition
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of POEs (Podzuweit T et al., 1996), or (iv) increase in inhibitory G-protein (Gi)
(Niroomand et ai., 1995). The observation that the cyclic increases in cAMP during the
PC protocol could be abolished by prior reserpination, suggested that these increases
were due to the release of endogenous catecholamines (Fig. 3.5). Furthermore, the
cyclic increases in cAMP during the PC protocol were also accompanied by similar
changes in PKA activity (Fig. 3.7B), increased adenylyl cyclase activity (Fig. 3.7B) and
reduction in POE activity (Fig. 3.3).
3.3.2.1.1.1 Releaseof endogenous catecholamines
According to our data the release of endogenous catecholamines is mainly responsible for
the cyclic increases in tissue cAMP during PC, because prior reserpination abolished
cAMP generation at PC1-, PC2- and PC3- (Fig. 3.5). The findings that release of
noradrenaline occurred within 2 min of ischaemia in the rat heart (Banerjee et ai., 1993)
and that a substantial reduction in synaptic noradrenaline store content occurred during
brief (~ 10 min) ischaemia, while the release of noradrenaline stopped instantly upon
reperfusion (Podzuweit et ai., 1995a), support our findings. A role for catecholamines and
<X1-adrenergic receptors has also been suggested in the reduction of infarct size in
preconditioned rat (Banerjee et aI., 1993) and rabbit hearts (Toombs et aI., 1993, Thornton
et ai., 1993, Bankwala et ai., 1994).
3.3.2.1.1.2 Sensitization
Another mechanism that may be involved in the cyclic increases in cAMP, which occur
within minutes after the onset of ischaemia, is the dual sensitization of the p-adrenergic
system (Strasser et ai., 1990): Firstly adenylyl cyclase activation was attributed to PKC
activation and intracellular acidosis during acute myocardial ischaemia (Simonis et a/.,
1998). Secondly upregulation of the p-adrenergic receptor has been shown to be due to
loss of ATP in ischaemia: the internalization of p-adrenergic receptors is ATP dependent,
and the increased receptor density during ischaemia has been shown to be the
consequence of increased externalization (Strasser et a/., 1992). Thus, the increases in
p-receptor Bmaxvalues at PC1-, although not significant, and the marked increase in
adenylyl cyclase activity at this time-point in our study is in agreement with the concept of
dual sensitization of the p-adrenergic system (Fig. 3.6). Strasser et al. (1990) observed
upregulation of the p-receptor population to occur after exposure to 15 min ischaemia,
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which may explain why the changes in Bmaxobtained in the present study only
became significant towards the end of the PC protocol. However, its effects could be
counteracted by the reduced affinity (a 52% increase in Kd) at PC3- (Fig. 3.6).
Therefore the rise in cAMP at PC3- was probably largely due to the continued increase
in adenylyl cyclase activity and reduced POE activity at this stage.
3.3.2.1.1.3 Phosphodiesterase (POE)
Another role player in the observed fluctuations in cAMP is the marked reduction in the
activities of both cAMP- and cGMP- POEs during PC1-, PC2- and PC3- (Figs 3.2, 3.3),
which is supported by the finding that brief (~ 10 min) ischaemia caused a substantial
inhibition in total POE activity, that was readily reversed by reperfusion (Podzuweit et aI.,
1995b). Podzuweit et al. (1996) suggested that acidosis is a major determinant of POE
inhibition in ischaemia, which would explain why POE inhibition is readily reversed by
reperfusion as hydrogen ions are washed out.
It should be pointed out that POE as measured in this study indicates the total cAMP
and cGMP hydrolyzing capacity of the isoenzymes present in heart muscle. The rat
myocardium is reported to contain at least four POE isoenzymes (Shahid et aI., 1990) of
which POE1 (calcium-calmodulin stimulated) and POE2 (cGMP stimulated) hydrolyze
cGMP, while POE3 (cGMP inhibited) and POE4 (cAMP specific) hydrolyze cAMP only.
By offering cAMP or cGMP as substrate or isoenzyme-selective inhibitors, one can
estimate which isoforms may be involved.
3.3.2.1.1.4 Gi protein
Although ~-adrenergic receptors do not transduce their signals via Gi proteins, Gi affects
the balance between stimulatory and inhibitory effects on adenylyl cyclase and may thus
contribute to the decreased response to ~-adrenergic agonists (Hajjar et ai., 1998).
Niroomand et al. (1995) have reported that in canine myocardium, Gi proteins were
sensitized during reperfusion following a single 5 min period of transient ischaemia and
that this sensitization was maintained during a subsequent period of ischaemia. In our
study, pertussis toxin pretreatment failed to increase cAMP in preconditioned hearts,
excluding a role for the Gi protein (Fig. 3.9). In addition, studies showed that PC against
either infarction or arrhythmias in the rat, does not appear to involve a pertussis toxin
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sensitive G protein (Liu et aI., 1993, Lawson et aI., 1993, Yabe et a/., 1995).
However, pertussis toxin has been shown to abolish the cardioprotective effect of
ischaemiePC in rat (Piacentiniet aI., 1993, Schultz et aI., 1998), rabbit (Thornton et aI.,
1993) and dog (Miura et a/., 1997) hearts.
3.3.2.1.2 Tissue cGMP
Tissue cGMP levels showed similar cyclic changes during PC2-/+ and PC3-/+ as the
cAMP levels (Fig. 3.2). The significant inhibition of cGMP-PDE during PC2- and PC3-
(Fig. 3.3) are possibly responsible for the rise in cGMP, whereas the rise in POE activity
during reperfusion may account for the reduction in cGMP during the reperfusion
episodes. Depré and coworkers (1997) have shown that activation of NOS (suggested
to be the soluble fraction of the eNOS isoenzyme) occurs within 5 min of ischaemia and
returns to normal levels during reperfusion. This was recently confirmed by a study on
conscious rabbits, in which brief myocardial ischaemia caused an immediate activation
of cNOS (most likely eNOS) (Xaun et al., 2000). Therefore the activation of NOS during
the ischaemic episodes of PC and normalization during reperfusion, may also be
responsible for the fluctuations in cGMP levels. The mechanism of the ischaemia-
induced activation of NOS is not known, but could occur secondary to an increased
[Ca2+]j (Kelly et al., 1996).
The reason for the relatively minor change in tissue cGMP levels observed at PC1-, in
the presence of marked inhibition of cGMP-PDE activity remains to be established.
This rather modest change in cGMP, amongst others, may contribute to the observation
that one episode of PC was less effective than three episodes in eliciting protection in
the isolated perfused rat heart (Liu et al., 1992, Downey and Cohen 1996, Sandhu et
aI., 1997, reviewed by Cohen et aI., 2000).
3.3.2.1.3 cAMP and cGMP
Simultaneous generation of these two cyclic nucleotides could lead to considerable
crosstalk. For example, it has been shown that NO (and thus cGMP) attenuates
p-receptor mediated responses (Ebihara et aI., 1996), while in vitro (Balligand et aI.,
1993) and in vivo studies (Keany et aI., 1996, Hare et a/., 1995) demonstrated that NOS
inhibition and reduced cGMP levels could enhance the positive inotropic response to
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~-adrenergic stimulation (by i.e. isoproterenol). Therefore, the contribution of
these cyclic changes in cAMP and cGMP, alone and in combination, to the protection
conferred by PC remains to be established.
3.3.2.2 p38 MAPK activation during the PC protocol
Our observation that a robust increase in p38 MAPK activation occurred within 5 min of
ischaemia (Fig. 3.12), is consistent with several studies obtained by immuno-blotting, in-
gel kinase and biochemical assays in rat (Bogoyevitch et aI., 1996, Shimizu et a/., 1998,
Maulik et a/., 1998d), rabbit (Ma et a/., 1999, Ping et a/., 1999a, Gysembergh et a/.,
2001), pig hearts (Baranick et a/., 2000) and in isolated cardiomyocytes (Mackay and
Mochly-Rosen 1999, Vue et a/., 2000). Apart from ourselves, only one group made an
attempt to evaluate changes in p38 MAPK activation during the PC protocol (Ping et a/.,
1999a).
We found that the activation of p38 MAPK (as evidenced by both dual phosphorylation
and kinase activity) during the repetitive cycles of ischaemia-reperfusion (PC protocol)
is transient, since the significant activation observed during the first two episodes (PC1-
and PC2-), disappeared during PC3-. These data concur with the study by Ping et al.
(1999a), who observed that a single 4-min period of ischaemia induced a robust
activation of the p38 MAPK cascade, which was attenuated after 5 min reperfusion and
disappeared after six cycles of 4-min ischaemia-reperfusion. These cyclic elevations in
p38 MAPK activity are most likely due to the release of the many substances which
could act as trigger in the PC process, for example, U1- and ~-adrenergic receptor
stimulation due to release of endogenous catecholamines (Schërniq et a/., 1991),
activation of nitric oxide synthase and generation of nitric oxide (NO) (Depré et a/.,
1997), adenosine (Haq et a/., 1998) and generation of oxygen free radicals (Das et a/.,
1999). The rapid decline in activity during the reperfusion periods probably occurs as a
result of washout of these substances. Activation of phosphatases may also contribute,
but the pattern of activation was not assessed in this study.
Furthermore, p44/p42 MAPK (ERK) (Ping et a/., 1999b) and c-Jun NH2-terminal kinase
(JNK) (Ping et a/., 1999a), remained activated throughout a multi-cycle PC protocol, the
latter via a PKC£ dependent signalling pathway (Ping et a/., 1999a). In view of the
transient nature of p38 MAPK activation during a multi-cycle PC protocol while the
Stellenbosch University http://scholar.sun.ac.za
92
activation of PKCE persisted, it was suggested that activation of p38 MAPK was not
coupled to that of PKCE (Ping et aI., 1999a). In addition, over-expression of PKCE in
cardiac myocytes failed to increase p38 MAPK activity (Ping et a/., 1999a). However,
the transient activation of p38 MAPK during the PC protocol does not exclude its acting
as a trigger: it may rapidly phosphorylate downstream substrates, setting in motion the
cardioprotective response.
3.3.3 Changes during sustained ischaemia
3.3.3.1 cAMP and cGMP
Even in the absence of ischaemia, elevations in cAMP have been shown to produce
myocardial necrosis (Martorana 1971). High levels of cAMP are also known (i) to increase
sarcolemmal calcium entry (Tsien 1983) which in turn results in intracellular calcium
overload and (ii) to increase the activation of cardiac lipases (Opie 1982), effects known to
aggravate ischaemie injury. Therefore an attenuation of increases in cAMP during
sustained ischaemia may be necessary to protect against necrosis.
As observed before (Sandhu et aI., 1996 and Moolman et aI., 1996), PC leads to
significant reduction in tissue cAMP during sustained ischaemia. Tissue cGMP, on the
other hand, was significantly higher in PC hearts (Fig. 3.13). Similar findings in the in vivo
rabbit heart also showed that cGMP is significantly higher during long ischaemia (30 min
regional ischaemia) if previously exposed to 5 min ischaemia and 10 min reperfusion
(Iliodromitis et aI., 1996), while no difference was found between baseline and values
obtained at the end of sustained ischaemia in the ineffectively PC (with 1 min ischaemia)
and control groups. It is not yet known whether these changes are merely the
consequence or reflection of the PC-induced protection or whether they are protective by
them.
It is possible that cAMP acts in synergism with cGMP during sustained ischaemia: these
two cyclic nucleotides have opposing effects on the cardiac slow Ca2+ channel (cAMP
stimulating and cGMP inhibiting) (Sperelakis 1994). The lowering of tissue cAMP and
elevation in cGMP may reduce Ca2+ influx during ischaemia as well as during reperfusion.
Elevation of endogenous cGMP has long been known to lower intracellular Ca2+ (Lincoln
1989). As discussed before, NO (and thus cGMP) is an important endogenous inhibitory
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regulator of the actions of adrenergic agonists and may thus playa role in the
attenuated p-adrenergic response during sustained ischaemia.
Whether the decrease in cAMP is the cause or merely a reflection of the protection
induced by PC remains to be established. Attempts to manipulate cAMP during the PC
protocol by administration of forskolin immediately before sustained ischaemia (Moolman
et aI., 1996) failed to demonstrate a clear effect between tissue cAMP and protection. In
view of the observations and the known effects of ischaemia on the p-adrenergic signalling
pathway (Strasser et aI., 1990), it was decided not to further examine the role of cAMP
and thus also the effects of PC on adenylyl cyclase (AC) and protein kinase A (PKA)
activation in sustained ischaemia. In addition, unpublished studies from our laboratory
showed that PKA activation was significantly depressed throughout sustained ischaemia
in PC hearts (Lochner et al. unpublished data).
3.3.3.2 Attenuation of the p-adrenergic response to sustained ischaemia
Although the decreased cAMP accumulation in PC hearts during sustained ischaemia is
likely to be due to a reduced response, there is no proof as yet that the preconditioned
myocardium is indeed less responsive to p-adrenergic stimulation. This attenuated
response may be due to (i) less inhibited breakdown by cAMP- and cGMP-POE (as shown
in Fig. 3.14B, C) (ii) desensitization of the p-adrenergic receptor (unlikely according to
Sandhu et aI., 1996) or (iii) diminished release of catecholamines (Seyfarth et ai., 1996,
Takasaki et aI., 1998).
3.3.3.2.1 POE activity
Despite the increased cGMP-PDE activity in PC hearts during sustained ischaemia, the
cGMP levels remained somewhat elevated and therefore it appears that its generation
overrides its breakdown. The latter was confirmed by Depré et al. (1994), who showed
that activation of NOS is maintained throughout sustained ischaemia. The increased
cGMP levels in PC hearts may also contribute to activation of the cGMP-stimulated POE
(Hardman et aI., 1971). However, the rise in cGMP also causes inhibition of POE3 with
little effect on total cAMP degrading capacity (Beavo et ai., 1995).
Stellenbosch University http://scholar.sun.ac.za
94
As discussed before, inhibition of POE during ischaemia may be caused, in part, by
acidosis (Podzuweit et aI., 1996). This corroborates the work by Wollenberger et al.
(1968), who proposed that ischaemia-induced increase in cAMP was due to an
inactivation of POE activity caused by a lowering in pH. Since ischaemie PC
significantly attenuates the decrease in pH induced by sustained ischaemia (Asimakis et
el.. 1992; Steenbergen et aI., 1993, Miura et aI., 1997), the POE activity of such hearts
may be increased compared to that of non-PC hearts; as was the case in the present
study (Fig. 3.14B, C). Podzuweit et al. (1995b) have reported that, in pig hearts, PC
attenuates the inhibition of myocardial POE activity during subsequent ischaemie
episodes, thereby limiting the accumulation of cAMP. Reduced accumulation of cAMP
may conceivably be protective because of the reduction in energy demand and calcium
influx.
Although attenuated inhibition of POE activity during sustained ischaemia may be of
particular importance in conferring protection, this possibility has received relatively little
attention and should be determined by use of appropriate blockers. Sanada et al. (2001 b)
recently showed that transient pre-treatment with POE3 inhibitors could indeed limit infarct
size in open chest dogs.
3.3.3.2.2 Desensitization
It is possible that the episodes of transient ischaemia in PC hearts results in the liberation
of norepinephrine, as well as other mediators, which then act to desensitize the p-
adrenergic pathway and prevent the rise in cAMP during subsequent sustained ischaemia.
We focused on the p-adrenergic pathway, because the p-adrenergic receptor can
desensitize fairly rapidly (Roth et aI., 1991), a requirement for a role in ischaemie PC. It
is well-established that the process of desensitization can be mediated (i) by changes in
the functional state of the receptor induced by phosphorylation (Hein et aI., 1997, January
et aI., 1997) and (ii) by changes in the number of receptors present on the cell surface
(Hein et aI., 1997).
In our study, at the end of the PC protocol (PC3+) before the onset of sustained
ischaemia, the following situation prevails: a significant (39%) increase in p-adrenergic
receptor density (Bmax)and a reduction in the affinity of the p-adrenergic receptor for its
ligand (% increase in Kd: 45%), concomitant with normalization of adenylyl cyclase and
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POE activities (Fig. 3.6). Since the decrease in ~-adrenergic receptor affinity was
accompanied by an almost similar increase in density, it was not clear to us whether these
two effects of similar magnitude would cancel each other. Our data show that, using
cAMP generation in response to ~-adrenergic receptor stimulation with isoproterenol as
parameter, that the preconditioned myocardium is indeed less responsive, and that the ~-
adrenergic receptor itself must be implicated: isoproterenol elicited a marked increase in
cAMP in non-PC hearts, but not in PC hearts, while forskolin caused similar increases in
cAMP in both groups (Fig. 3.9). It is therefore possible that the reduced affinity of the
receptor for its ligand overrides the effect of the increase in Bmax, resulting in a
desensitized but not internalized receptor.
On the other hand, Sandhu et al. (1996) could not demonstrate reduced ~-adrenergic
receptor sensitivity in a rabbit model after a PC protocol, because stimulation of the ~-
adrenergic receptor with isoproterenol produced similar increases in cAMP in non-
ischaemic hearts and in hearts subjected to three cycles of transient ischaemia-
reperfusion. Further evidence against ~-adrenergic receptor desensitization in ischaemic
PC comes from work by Iwase et al. (1993), who observed that coronary occlusion
induced a rapid and progressive reduction in the Bmax, stimulatory G protein (Gs) and
adenylyl cyclase activities after 60 min of ischaemia in rabbit hearts. Their data also
indicated that PC did not affect the reduction in Bmax, although it prevented the early
reductions in Gs and adenylyl cyclase activities after 10 and 20 min, but not 60 min of
sustained ischaemia. Therefore, PC delays the ischaemia-induced reductions in ~-
adrenergic signal transduction. Thus, both Sandhu et al. (1996) and Iwase et al. (1993)
suggest that the ~-adrenergic signal transduction pathway are not desensitized by PC.
This is contradictory to our findings and may be due to the differences in the species
employed (both used rabbits).
Should cyclic increases in cAMP or PKA activity during PC protocol be important,
how do they confer desensitization or protection?
One possibility is that cAMP may act as a messenger or signal to elicit protection against
subsequent ischaemie damage. The signal is, however, readily abolished during PC
reperfusion, but we have convincingly demonstrated the downstream effector, PKA, is
indeed activated under these circumstances. As mentioned before, desensitization can
also be mediated by changes in the functional state of the receptor induced by
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phosphorylation (Hein et aI., 1997). The significant elevation in PKA activity,
especially during the third PC episode, could be particularly important in the
desensitization process. There are two consensus sites for PKA phosphorylation in the p-
adrenergic receptor, one in the third intracellular loop and one in the carboxy-terminus
(Clark et al., 1989). Evidence points to the former as being functionally the most important
phosphorylation site. Likewise, the receptor could be phosphorylated by another class of
protein kinases, the G protein coupled receptor kinases or p-adrenergic receptor kinases
(P-ARK) (Hausdorff et aI., 1990, Premont et aI., 1993). These kinases, which require the
inhibitory protein p-arrestin (Lohse et aI., 1990, Attramadal et aI., 1992), mediate a very
rapid desensitizing process during ischaemia (Ungerer et aI., 1996), however their role in
PC is unknown.
In addition, Ma and Huang (2002) demonstrated that Gas -and Gai-, but neither Gaq -,
Ga12 - nor GPy -, coupled p-adrenergic receptors directly stimulate the kinase activity of a
c-Src family tyrosine kinase, independent of cAMP and PKA. The c-Src tyrosine kinase
also binds the p-adrenergic receptor via phospho-Tyr-350, phosphorylates p-ARK 2,
and mediates agonist-induced receptor desensitization (Fan et aI., 2001). The
desensitized p-adrenergic receptors could also function as scaffolds for Src-dependent
activation of ERK signalling pathways, while the p-arrestins function as adapter proteins
that link G-protein coupled receptors to tyrosine kinase-dependent pathways (Luttrell et
al., 1999).
3.3.3.2.3 Endogenous catecholamines
Endogenous catecholamine release may playa role in ischaemie PC either as a trigger or
as a target within the process of PC. As mentioned before, some authors suggest a role
of catecholamines. and particularly the a1-adrenergic receptors in the reduction of infarct
size by PC (Toombs et aI., 1993, Thornton et aI., 1993, Banerjee et al., 1993, Bankwala et
al., 1994).
Schëmig (1990) has shown that in non-PC rat hearts, periods of myocardial ischaemia
of more than 10 min duration can increase norepinephrine release (called nonexocytotic
release), which does not depend on local sympathetic activation, but rather on local
metabolic factors to cause a reverse in the uptake-carrier to produce an efflux of
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norepinephrine from the cytoplasm of the nerve terminals to the extracellular
space. On the other hand, PC may lead to the preservation of myocardial autonomic
nerve terminals (Miyazaki et ai., 1989), reduction in activity of the sympathetic nervous
system (Takasaki et ai., 1998) and reduced release of endogenous catecholamines
during sustained ischaemia (Seyfarth et ai., 1996, Sandhu et ai., 1996), - if so, it will add
to the protective effect of the down-regulated p-adrenergic response and, consequently,
reduced cAMP accumulation, as observed in our study. Conversely, Lawson et al. (1996)
indicated that PC had no significant effect upon tissue catecholamine content in isolated
rat hearts perfused with whole blood.
According to Seyfarth et al. (1996), a single 5 min ischaemic episode was sufficient to
reduce norepinephrine release during sustained ischaemia. However the most
pronounced effect of transient ischaemia was achieved with two to three ischaemia-
reperfusion cycles. This suppression could not be further enhanced by an additional
cycle of transient ischaemia. These findings further support the efficiency of our 3-cycle
ischaemie PC model, as well as the previous studies in which multiple cycles induced
the strongest protection against arrhythmias and infarct size (Liu et ai., 1992, Yellon et
al., 1992).
3.3.3.3 p38 MAPK activation during sustained ischaemia and reperfusion
The time-dependent activation of the stress kinase during sustained ischaemia is
probably due to the same factors as described above for the PC protocol as well as the
osmotic imbalances characteristic of ischaemia (Jennings et ai., 1991). Some workers
failed to demonstrate activation of p38 MAPK by 30 min global ischaemia in isolated
rabbits (Weinbrenner et aI., 1997) and 30-120 min coronary ligation in in vivo rats
(Omura et ai., 1999). On the other hand, most others reported a significant activation
regardless of the experimental model, but their results are conflicting regarding the
duration, with some reporting only transient activation (Yin et ai., 1997, Shimizu et ai.,
1998, Ma et aI., 1999, Yue et ai., 2000), while others reported a sustained activation
(Bogoyevitch et ai., 1996, Maulik et ai., 1996). Our results are in agreement with the
latter reports in which ischaemia caused sustained activation of p38 MAPK (Fig. 3.16).
Furthermore, the biphasic response to ischaemia observed in neonatal cardiomyocytes
(the first phase began within 10 min and lasted less than 1 h, and the second began
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after 2 h and lasted throughout the ischaemie period) (MacKay et al., 1999), was
not seen in our model where the duration of sustained ischaemia is shorter (25 min).
Although the p38 MAPK showed dual phosphorylation and increased activity, by
phosphorylation of its substrate ATF-2, at all time intervals during sustained ischaemia
of non-preconditioned and preconditioned hearts, the activation of the kinase was
significantly less between 10 and 25 min in the preconditioned hearts. Using
phosphorylation of ATF-2 and HSP27 as indicators of p38 MAPK activation, Nagarkatti
and Sha'afi (1998) also showed significantly less activation during ischaemia of
preconditioned rat heart myoblast cells (H9C2). These results as well as those obtained
in the present study, are in direct contradiction to those observed by others
(Weinbrenner et al., 1997, Maulik et al., 1998d, Nakano et al., 2000): not only could
these workers not demonstrate increased p38 MAPK activation during ischaemia in
non-preconditioned hearts, but they also reported a significant increase in kinase
activity in preconditioned hearts, suggesting that increased p38 MAPK activation may
be a key step in cardioprotection. These completely controversial results may be due to
differences in (i) species (rats vs rabbits) or (ii) experimental preparation
(cardiomyocytes vs perfused heart) or (iii) ischaemia (regional vs global) or (iv) PC
regimen (one vs multi-cycles) or (v) method of tissue collection (repeated biopsy vs
sampling of whole heart at one time point) or (vi) isoenzyme distribution (p38a vs p38p
MAPK). Obviously it is of paramount importance to elucidate these discrepancies.
Another potentially important difference may be the use of antibodies against tyrosine-
182 of p38 MAPK only (Weinbrenner et al., 1997, Maulik et al., 1998d) as opposed to
the dual-phosphorylated p38 MAPK as well as p38 MAPK activity (the ability of the
enzyme to phosphorylate and activate its downstream substrate, ATF-2) used in the
present study. This discrepancy may be explained by the fact that activation of p38
MAPK requires dual phosphorylation of both tyrosine-182 and threonine-180 (Armstrong
et al., 1999, Kumar et al., 1999), thus these data may not adequately reflect the
activation status of the enzyme. This was verified by Gysembergh et al. (2001), who
quantified p38 MAPK activity (the ability of the enzyme to phosphorylate and activate its
downstream substrate, MAPKAPK2) and observed modest attenuation thereof at 5 min
into coronary occlusion in PC rabbit hearts. They speculated that the difference in
outcome - increased phosphorylation/activation of p38 MAPK, but unchanged or
attenuated activity of the enzyme in their study - might imply a defect or uncoupling in
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the p38 MAPK signalling pathway in the rabbit heart. However, Ping et aI, (1999a)
demonstrated that the p38 MAPK pathway is intact in the in vivo rabbit heart and our
results in rat heart also confirmed this.
However, Omura et al. (1999) for example assessed the activity levels of p38 MAPK, by
phosphorylation of ATF-2 and also could not find any increase during continuous
coronary ligation (30-120 min) of an in vivo rat model, rather a decrease was observed.
The reason for these discrepancies is not clear. In addition, a recent study by Pain et
al. (2000) showed that, like PC, diazoxide-induced reduction in infarct size was also
characterized by increased p38 MAPK activation during sustained ischaemia.
Although reperfusion of both ischaemie preconditioned and non-preconditioned hearts
caused a significant activation of p38 MAPK within 10 min, this effect was transient in
the former, with p38 MAPK activation returning to normal after 20 - 30 min of
reperfusion (Fig. 3.21). The sustained activation of p38 MAPK during reperfusion in the
non-preconditioned hearts was concurrent with findings in isolated perfused rabbit
hearts (Ma et el., 1999). The burst of activation seen during the early phase of
reperfusion may have been due to generation of free radicals at this stage (Das et eï.,
1999, Ferrari et et., 1994).
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3.4 SUMMARY
3.4.1 Effect of ischaemiePCon cyclic nucleotides:
The results obtained in the present study demonstrated significant changes in the cyclic
nucleotides both during the trigger ischaemia of the PC protocol and during the
subsequent sustained ischaemia.
In particular, the PC protocol was characterized by cyclic increases in tissue cAMP and
cGMP that might be caused by the concomitant changes in cAMP- and cGMP- POE
activities. Furthermore, the changes in the p-adrenergic pathway was associated by
marked fluctuations in adenylyl cyclase and protein kinase A (PKA), accompanied by a
decrease in receptor affinity (Kd) and responsiveness despite a gradual upregulation of
the p-adrenergic receptor population (Bmax). In addition to the above, the rise in tissue
cAMP during the PC protocol was shown to be dependent on the release of endogenous
catecholamines. However, since catcholamines were not assessed during PC, it does not
allow speculation whether POE or catcholamines is the primary mechanism.
Sustained ischaemia of preconditioned hearts was characterized by an attenuated p-
adrenergic response and elevated tissue cGMP, associated with less POE inhibition and
reduced energy utilization. Whether these events mediate the protection conferred by
prior PC, or whether they are merely epiphenomena associated with myocardial protection
against ischaemia, remains to be established. Nevertheless we suggest that both of these
cyclic nucleotides may be involved in triggering the protection conferred by PC. Possible
proof of involvement will be given in chapters 4 and 5.
3.4.2 Effect of ischaemiePCon p38MAPKactivation:
Although only one study attempted to evaluate changes in p38 MAPK during the
repetitive ischaemia-reperfusion (PC) protocol (Ping et ai., 1999a), our study is the first
attempt to evaluate changes in p38 MAPK activation throughout the entire experimental
protocol of a preconditioned heart and to correlate these changes with functional
recovery during reperfusion. Our results show activation of p38 MAPK during all three
stages of the experimental protocol, while attenuation of p38 MAPK activity during both
ischaemia and reperfusion is associated with cardioprotection. Indeed, a very recent
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study suggested that while activation of p38 MAPK (via cAMP- PKA activation)
during the PC protocol (stimulus) was required for early PC in dogs, the subsequent
inhibition of p38 MAPK during the sustained ischaemia was also necessary (Sanada et
ai., 2001 b).
The pattern of changes observed in p38 MAPK activation follows the same pattern as
observed in the cAMP levels - activation during the PC protocol and continued, but
attenuated activation during sustained ischaemia. The cause and significance of these
observations remain to be established.
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CHAPTER4
Manipulation of cyclic adenosine monophosphate (cAMP)
4.1 Introduction
The previous chapter showed that myocardial protection, induced by ischaemie PC, is
associated with attenuation of cAMP generation during the sustained ischaemie period.
Therefore, manipulation of cAMP levels per se during sustained ischaemia by either ~-
adrenergic blockade or ~-adrenergic stimulation should also elicit or abolish protection,
respectively. Our laboratory has previously shown that attenuation of ~-adrenergic
effects during ischaemia by prior treatment with propranolol (Edoute et al., 1981) or
reserpination (Moolman et aI., 1996) elicited functional protection similar to that of PC.
In contrast, increasing cAMP levels during sustained ischaemia by administration of
either a ~-adrenergic agonist, isoproterenol (Podzuweit et aI., 1996) or adenylyl cyclase
activator, forskolin (Sandhu et aI., 1994, Moolman et aI., 1996) after PC but before the
onset of sustained ischaemia, causing high cAMP levels throughout this period, failed to
abolish PC. These experiments may illustrate the protective effect of PC against drug-
induced cAMP increases, rather than elucidating the role of cAMP in the protective
effect of PC.
Should cAMP be involved in PC, it is more likely to act as a trigger during the PC
protocol, prior to sustained ischaemia. Consequently, the observation that transient ~-
adrenergic stimulation can precondition the isolated rat heart (Asimakis et aI., 1994;
Miyawaki et aI., 1997b) suggests that these changes in cAMP content, at least, may be
important. Asimakis et al. (1994) suggested that the increased workload produced by ~-
stimulation might cause a degree of demand ischaemia that, in turn, produced PC,
probably via attenuation of Ca2+ overload during reperfusion.
According to the results from the previous chapter (Chapter 3), we have shown that a
multiple-episode PC protocol is characterized by cyclic increases in cAMP, coinciding
with opposite changes in phosphodiesterase (POE) activity, indicating that this particular
pathway is changed during both PC and sustained ischaemia.
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In this chapter we address the question whether the cyclic increases in cAMP (and thus
PKA activation) occurring during PC are involved in eliciting protection against
ischaemia. Two possibilities should be considered - cAMP/PKA may playa role in ~-
adrenergic desensitization, and/or may phosphorylate an unknown downstream target.
We investigated both possibilities.
4.1.1 Aims
The aim therefore was to evaluate whether pharmacological interventions (i.e. ~-
adrenergic blockade or stimulation) would;
(i) abolish or mimic the ischaemia-induced cyclic increases in cAMP during the PC
protocol, respectively;
(ii) lead to or cause ~- adrenergic receptor desensitization and thus reduced cAMP
generation during sustained ischaemia;
(iii) prevent or elicit myocardial protection during ischaemia and reperfusion,
respectively.
To elucidate the possibility of phosphorylation of a downstream target, we chose to
investigate the role of p38 MAPK in ~-adrenergic induced protection by;
(i) characterization of the effects of ~-adrenergic receptor stimulation (time, dose-
dependency) on p38 MAPK activation and
(ii) comparison of changes in p38 MAPK activation of ~-adrenergic- and ischaemie-
preconditioned hearts during sustained ischaemia as well as reperfusion.
(iii) evaluation of the effects of ~-adrenergic blockade during the PC protocol on p38
MAPK activation during sustained ischaemia and reperfusion
(iv) determination of the effects of inhibition of ~-adrenergic-induced p38 MAPK
activation on myocyte viability during hypoxia.
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4.2 Experimental Protocols and Results
4.2.1 Effect of ~-adrenergic receptor manipulation during the PC
protocol
4.2.1.1 p-adrenergic receptor blockade during the PC protocol
4.2.1.1.1 Choice of p-adrenergic receptor blocker
A prerequisite for assessing the effects of p-adrenergic receptor blockade during PC,
was complete washout of the blocker before onset of sustained ischaemia as well as
attenuation of cAMP generation during the PC protocol.
In the first series of experiments the p-adrenergic receptor blocker, propranolol, was
evaluated for this purpose. Hearts were stabilized by perfusing retrogradely for a period
of 10 min, followed by 10 min in the working mode. Control hearts were subsequently
perfused retrogradely for a further 25 min, before administration of adrenaline (10-6 M).
In another series, propranolol (10-7 M) was administered at 20 min total perfusion time
for 15 min and washed out for 10 min, followed by administration of adrenaline (Fig.
4.1A). Control hearts respond significantly to 2 min of adrenaline (% increase in cardiac
output from controls: 31 ± 3.1) (Fig. 4.1 B). Propranolol treatment significantly reduced
the cardiac output compared to controls. However, these treated hearts could not
respond to adrenaline (10-6 M) stimulation after the 10 min washout period (Fig. 4.1 B),
indicating that propranolol, a lipid-soluble antagonist, cannot be washed out under these
conditions. It was thus decided to use the non-selective PIl P2-adrenergic blocker,
alprenolel.
After the hearts were stabilized for 20 min (controls), alprenolol was administered every
2 min in a dose-dependent manner until the cardiac output was suppressed sufficiently.
Drug administration was ceased and immediately followed by a 12 min period of
adrenaline (10-6 M) administration (Fig. 4.2A). Results from fig. 4.2B indicate that 7.5 x
10-5 M alprenolol adequately suppressed the cardiac output (85.9 ± 1.5 % decrease in
cardiac output from control). Furthermore, its effect could be reversed after 10 min
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Fig 4.1 Cardiac output of hearts treated with p-adrenergic blocker, propranolol (10-7M). A. Experimental protocol. Arrows indicate time
of measurement of mechanical function. B. Propranolol treated hearts could not respond to 2 min adrenaline (Adr. 10-6M) after 10 min
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cessation of alprenolol, as indicated by the response to adrenaline (10-6M) [% decrease
in cardiac output from control after alprenolol withdrawal: 2 min adrenaline (without
alprenolol) 41.9 ± 2.0 vs. 10 min adrenaline (without alprenolol) 23.7 ± 3.0; n=4].
Therefore indicating that alprenolol could be washed out within 10 min after being
administered at its most effective concentration.
To establish whether 7.5 x 10-5 M alprenolol could attenuate cAMP generation during
the PC protocol, hearts were preconditionedwith 3 x 5 min ischaemia in the absence or
presenceof alprenolel. In the latter series, alprenolol was administered 5 min before the
onset of PC1- and during PC1+ and PC2+ (Fig. 4.3). In a separate series, hearts were
stabilized for 25 min followed by alprenolol administration for 3 episodes of 5 min
alternated by 5 min periods of perfusion with buffer (protocol not shown), which
indicated that alprenolol per se had not effect on control hearts (Fig. 4.4). However,
transient administration of alprenolol (7.5 x 10-5M) during the PC protocol prevented the
characteristic increases in cAMP (as shown in Fig. 3.2), while neither at PC1- nor at
PC3- were the changes in cAMP content different from their corresponding controls
(Fig.4.4).
4.2.1.2 Repeated p-adrenergic stimulation: effect of cAMP
For meaningful simulation of PC-induced fluctuations in tissue cAMP, dose-response
curves with forskolin and isoproterenol were required. A preliminary experiment was
performed where hearts were perfused for 30 min (15 min retrograde, 15 min working
mode) before administration of either forskolin (10-8, 10-7 and 10-6 M) or isoproterenol
(10-8 or 10-7 M) (Fig. 4.5A). After 5 min of drug administration hearts were freeze-
clamped for subsequent cAMP analyses. Results showed that both drugs caused dose-
dependent increases in tissue cAMP (Fig. 4.58). We therefore decided to use forskolin
at 10-6M and isoproterenol at 10-7M concentrations.
In a subsequent study, tissue cAMP and high energy phosphate levels were monitored
during repeated administration (3 x 5min) of either forskolin (10-6 M) or isoproterenol
(10-7 M). In this study hearts were freeze-clamped at the end of the first and third
administration of the drug as well as after 5 min reperfusion with normal buffer (for
protocol see Fig. 4.6A). At both administration times, forskolin caused a significant
increase in tissue cAMP, while reperfusion caused a decline, although not to control
Stellenbosch University http://scholar.sun.ac.za
Preconditioned hearts:
PRECONDITIONING
WORKING HEART PC1- PC1+ PC2- PC2+ PC3- PC3+
il\:: sc '" 4( "" .... ss:: '" 1£ .... '" Cl 1£ c: 1£ 11£ "" tt: "" 1£ ... '" "" ij( IC '1'1
RETROGRADF
Preconditioned plus Alprenolol hearts:
PRECONDITIONING
PC1- PC1+ PC2- PC2+ PC3- PC3+
... Alp Alp Alp IJlt
Alprenolol (Alp)
t t t
o 15 25 65
TIME (MINUTES)
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Table 4.1
Metabolic changes during administration of forskolin or isoproterenol
ATP CP
Controls 3.45 ± 0.18 4.25 ± 0.37
Forskolin:
10-6 molll: (n=5)
1 x 5 min
1 x 5 min + 5 min reperfusion
3 x 5 min
3 x 5 min + 5 min reperfusion
3.64 ± 0.14
3.26 ± 0.41
3.02 ± 0.31
3.40 ± 0.11
4.84 ± 0.28
4.32 ± 0.37
3.74 ± 0.67
3.94 ± 0.19
Isoproterenol:
10-7 molll: (n=5)
1 x 5 min
1 x 5 min + 5 min reperfusion
3 x 5 min
3 x 5 min + 5 min reperfusion
5.74 ± 0.30 4.36 ± 0.78
4.37 ± 0.59 4.07 ± 0.68
Hearts were freeze-clamped at the end of each intervention (n=5 for each series) (Fig. 4.6). High
energy phosphates (ATP and creatine phosphate, CP) are expressed as f-lmoles/g wet weight.
Controls were perfused for 30 min before freeze-clamping.
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levels (Fig. 4.68). Isoproterenol when administered for 5 min only caused a significant
elevation in tissue cAMP, which returned to control levels when reperfused with normal
buffer. However, repeated administration of isoproterenol for 3 x 5 min, caused
complete desensitization of the p-adrenergic receptor, as reflected by the very low
cAMP values after the third administration (Fig. 4.68). To establish whether p-
adrenergic stimulation induces a condition of demand ischaemia, high energy
phosphate (HEP) levels were also measured. The HEP levels, such as tissue ATP and
creatine phosphate (CP) levels, were not significantly affected by any of the above
interventions (Table 4.1).
4.2.1.3 Repeated p-adrenergic stimulation: effect on p-adrenergic receptor
responsiveness
The following experiments were performed, to assess whether pharmacological
stimulation of the p-adrenergic signalling pathway also reduced the p-adrenergic
response comparable to PC hearts. Tissue cAMP levels were measured after
additional p-adrenergic receptor stimulation, by administration of isoproterenol (10-7 M)
for a period of 2 min after p-adrenergic stimulation with isoproterenol (10-8 or 10-7 M for
1 x 5 min) or forskolin (10-7 or 10-6 M for 1 x 5 min or 3 x 5 min) (Fig. 4.7). With each
drug, administration of isoproterenol for 2 min was preceded by a 5 min washout period.
As observed previously (Fig. 3.9), the ischaemic PC protocol (3 x 5 min global
ischaemia) significantly desensitizes the heart to further p-adrenergic receptor
stimulation, when compared to that of non-PC hearts (Fig. 4.8). Hearts stimulated with
isoproterenol (10-8 M) for 5 min only, was still sensitive to additional p-adrenergic
stimulation, as evidenced by the significant increase in tissue cAMP (similar to that of
non-PC hearts) (Fig. 4.8). However at 10-7 M for 1 x 5 min or 3 x 5 min, isoproterenol
caused a significant desensitization of the B-adrenerqtc response, with no increase in
tissue cAMP. Forskolin, when administered for 1 x 5 min only, at 10-6 M did not cause
desensitization (Fig. 4.9). Similar results were obtained with forskolin at 10-7 M, whether
administered for 1 x 5 min or for 3 x 5 min. However, forskolin (10-6 M, 3 x 5 min) also
caused a partial, but significant desensitization of the p-adrenergic response, as
reflected by significantly reduced tissue cAMP compared to non-PC levels (Fig. 4.9).
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Fig 4.7 p-adrenergic receptor responsiveness after repeated p-adrenergic stimulation: Experimental protocol. Abbreviations as in
fig 4.3. p-adrenergic stimulation with isoproterenol (10-8 or 10-7 M, 1 x 5 min) or forskolin (10-7 or 10-6 M, 1 x 5 min or 3 x 5 min) was
followed by additional p-adrenergic receptor stimulation with isoproterenol (10-7 M) for 2 min. Arrows indicate time of freeze-clamping
for cAMP determination. n = 6 hearts per series.
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Fig 4.8 p-adrenergic receptor responsiveness after repeated p-adrenergic stimulation with isoproterenol. Ischaemie PC hearts (3 x 5 min),
as well as hearts treated with isoproterenol (10-7 M for 1 x 5 min or 3 x 5 min) were desensitized to further p-adrenergic receptor stimulation,
with no increase in cAMP levels. However, hearts stimulated with isoproterenol (10-8 M) for 5 min only was still sensitive to additional
p-adrenergic stimulation.
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4.2.1.4 Evaluation of p38 MAPK activation
4.2.1.4.1 Effects of ~-adrenergic receptor stimulation on p38 MAPK activation
To establish the role of p38 MAPK in ~-adrenergic induced protection, it was necessary
to (i) characterize the effects of ~-adrenergic receptor stimulation (time, dose-
dependency) on p38 MAPK activation and (ii) study the effects of U1- or ~-adrenergic
blockade, as well as L-type Ca2+ channel or Ar-adenostne receptor blockade on
ischaemia- or isoproterenol-induced activation of p38 MAPK.
4.2.1.4.1.1 Effects of time and dosage of different ~-adrenergic stimulants
Experimental protocol
After 30 min of stabilization (15 min retrograde, 15 min working heart), hearts were
perfused with isoproterenol (10-6, 10-7, 10-8 M) for 2, 3, 5, 10, 15 or 20 min before
freeze-clamping (Fig. 4.10A). Zinterol (10-7, 10-6, 10-5 M), a ~2-adrenergic receptor
agonist, or forskolin (10-8, 10-7, 10-6 M), an activator of adenylyl cyclase, was
administered for 5 min only before freeze-clamping (Fig. 4.11A). At least 4 hearts were
studied in each series. Dual phosphorylation of p38 MAPK was assayed at the above
time intervals, while ATF-2 phosphorylation was studied at selected times.
Results
As indicated by its dual phosphorylation, isoproterenol activated p38 MAPK in a dose-
and time-dependent manner (Fig. 4.1OB, C). During the first 2 min after administration
of isoproterenol, its effects are dose-dependent, with 10-8M having a significantly
smaller effect than 10-7 and 10-6 M. However, after 10 min p38 MAPK appears to be
maximally activated, regardless of the concentration used. In the case of 10-6 M
isoproterenol the activation is maintained for at least 20 min, while in the case of 10-8
and 10-7 M the activation is transient and wanes after 15 min (Fig. 4.1 OB, C).
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Fig 4.10 Characterization of effects of p-adrenergic stimulation on p38 MAPK activation.
Effect of isoproterenol (10-8, 10-7, 10-6 M) and time (0 - 20 min). P1-adrenergic activation of
p38 MAPK is dose- and time dependent. The blots given are representative of each series.
Four hearts were studied at each time point.
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Fig 4.11 Characterization of effects of ~-adrenergic stimulation on p38 MAPK activation.
Comparison of effects of isoproterenol (10-8, 10-7, 10-6 M), forskolin (10-8, 10-7, 10-6 M)
and zinterol (10-7, 10-6, 10-5 M) administration for 5 min. The blots given are representative
of each series. n = 4 hearts/series.
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Fig 4.12 Isoproterenol dose-response: comparison of dual phosphorylation and kinase
activity (ATF-2 phosphorylation) of p38 MAPK. Effect of isoproterenol (10-8, 10-7, 10-6M)
at time 20 min. The blots are representative of each experiment. n = 4 hearts/series.
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Forskolin,which directly activates adenylyl cyclase, also activated p38 MAPK in a dose-
dependent manner within 5 minutes. Zinterol, a P2-adrenergicreceptor agonist, when
administered for 5 min had a maximal effect on p38 MAPK at 10-5 M, although
significantly less than isoproterenol (10-7M), (Fig. 4.118, C).
Activation of p38 MAPK as indicated by its kinase activity (activation of ATF-2), was
studied in the case of isoproterenol only: the pattern of activation was similar to that
observed using dual phosphorylation as indicator (Fig. 4.12).
4.2.1.4.1.2 Manipulation of p38 MAPK activation induced by 5 min ischaemia
(PC1-) or isoproterenol
Experimental protocol
After a stabilization period of 25 min, alprenolol (7.5 x 10-5 M) or an u1-adrenergic
receptor blocker, prazosin (3 x 10-7M) or a combination of both was administered 5 min
before the onset of global ischaemia. Hearts were freeze-clamped after 5 min global
ischaemia (PC1-). Appropriate controls were generated by perfusing hearts for 5
minuteswith alprenolol or prazosin or a combination of both drugs (Fig. 4.13A).
In the case of the isoproterenol-treated hearts, alprenolol (7.5 x 10-5 M) or a selective
Aj-adenosme receptor blocker, 8-cyclopentyltheophylline (CPT, 10-5M) or aL-type Ca2+
channel blocker, verapamil (5 x 10-7 M) was administered for 10 min after the 25 min
stabilization period. During the last 5 min of administration of either of these blockers,
isoproterenol (10-7M) was infused simultaneously. As before, appropriate controls were
generated by 5 min infusion of each of these drugs (Fig. 4.14A).
Results
Ischaemia-induced (PC1-) activation of p38 MAPK as indicated by its dual
phosphorylation (Fig. 4.138) could be partially, but significantly inhibited by blockade of
the p-adrenergic receptor (alprenolol, 7.5 x 10-5 M), u1-Adrenergic receptor blockade
(prazosin, 3 x 10-7M) as well as a combination of the drugs. This partial inhibition could
be attributed to a drug effect, as the drugs themselves significantly increased p38
MAPK phosphorylation when compared to 30 min control perfused hearts (Fig. 4.138).
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Furthermore, the p38 MAPK activity (ATF-2 phosphorylation) was also significantly
inhibited by alprenolol when administered to a 5 min global ischaemie heart (Fig. 4.15).
Similarly, isoproterenol-induced (10-7 M) phosphorylation of p38 MAPK could be
blocked completely by alprenolol (7.5 x 10-5 M) as well as by verapamil (5 x 10-7 M),
while Ai-adenosine receptor blockade by CPT (10-5 M) had no effect (Fig. 4.148).
These results prove that the p-adrenergic receptor as well as Ca2+, but not adenosine
was involved in p-adrenergic induced phosphorylation of p38 MAPK. The drugs, when
administered in the absence of isoproterenol, had no significant effect on p38 MAPK
activation when compared to control perfused hearts (Fig. 4.148).
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Fig 4.13 Manipulation of brief ischaemic-induced p38 MAPK activation. Effects of
alprenolol (Alp., 7.5 x 10-5M), prazosin (Pz., 3 x 10-7 M) or a combination of the drugs
when administered alone or 5 min before onset of 5 min global ischaemia (PC 1-). A
representative blot is given for each experiment. n == 4 hearts/series.
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Effect of p-adrenergic receptor manipulation during PC
protocol on cyclic nucleotides during sustained ischaemia
4.2.2.1 ~-adrenergic receptor blockade during the PC protocol
As described before, PC reduced the ~-adrenergic response to subsequent sustained
ischaemia, compared to non-PC. To establish whether ~-adrenergic blockade could
reverse this effect, PC hearts were pretreated with alprenolol (7.5 x
10-5 M) during the PC protocol before sustained ischaemia. Alprenolol was
administered 5 min before the onset of PC1-, during PC1+, PC2+ and washed out for
10 min following PC3- prior to 25 min sustained ischaemia (Fig. 4.16).
Alprenolol administered during the PC protocol resulted in a significant increase in
tissue cAMP at the end of 25 min ischaemia, almost to the same extent as non-PC
hearts, compared to untreated PC hearts. This increased cAMP level in PC hearts
caused by ~-adrenergic blockade was also significant compared to PC hearts,
suggesting a partial involvement of the ~-adrenergic receptor (Fig. 4.17).
4.2.2.2 Repeated ~-adrenergic receptor stimulation prior to sustained
ischaemia
To assess whether repeated stimulation of the ~-adrenergic receptor prior to ischaemia
also reduce the ~-adrenergic response to subsequent sustained ischaemia in a manner
similar to PC hearts (see 3.2.2.2.1), tissue cAMP levels were compared after 25 min of
global ischaemia in non-PC, PC, forskolin- and isoproterenol-pretreated hearts (Fig.
4.16).
One episode of isoproterenol (10-7M, 1 x 5 min) stimulation, caused a similar significant
reduction in tissue cAMP levels after 25 min of sustained ischaemia as observed in PC
hearts, however 10-8M isoproterenol (1 x 5 min) did not affect tissue cAMP levels during
this period (Fig. 4.18). Repeated forskolin (10-6 M, 3 x 5 min) pre-treatment caused a
significant reduction in tissue cAMP levels at the end of sustained ischaemia and values
similar to those of PC hearts were obtained (Fig. 4.19). Although one episode of
forskolin (10-6 M, 1 x 5 min) reduced tissue cAMP levels, the values obtained were not
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n = 4 hearts/series.
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significantly different from those of non-PC hearts. Forskolin at 10-7 M, when
administered for either 1 x 5 min or 3 x 5 min, had no effect on tissue cAMP levels at the
end of sustained ischaemia (Fig. 4.19).
Therefore, ischaemie PC, isoproterenol (10-7 M, 1 x 5 min) and forskolin (10-6 M, 3 x 5
min) resulted in significant desensitization of the p-adrenergic response at the onset of
sustained ischaemia (Fig. 4.8,4.9), and a significant reduction in cAMP accumulation at
the end of 25 min sustained ischaemia (Fig. 4.18, 4.19).
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Evaluation of events after sustained ischaemia during
reperfusion: Role of ~-adrenergic signalling pathway in
eliciting protection against ischaemiedamage
To investigate the role of the p-adrenergic signalling pathway in eliciting protection
against ischaemie damage, it was essential to determine whether the cyclic increases in
tissue cAMP levels during the PC protocol acts as a trigger in eliciting protection. For
this purpose isolated working rat hearts were subjected to (i) p-adrenergic blockade with
alprenolol during the PC protocol or (ii) stimulation with either forskolin or isoproterenol
before onset of sustained ischaemia. Functional recovery during reperfusion was used
as endpoint to evaluate the extent of protection against ischaemie damage.
4.2.3.1 Effect of p-adrenergic receptor blockade during PC protocol on
functional recovery
4.2.3.1.1 Experimental protocol
Control hearts and alprenolol
Control hearts were perfused for 115 min (Fig. 4.20A). In a separate series alprenolol (7.5
x 10-5 M) was administered at 25 min total perfusion time for 3 episodes of 5 min
interspersed by 5 min periods of perfusion with normal buffer, followed by perfusion in the
retrograde (at 75 min for 10 min) and working (10 min) mode. Furthermore, evaluation of
the recovery potential of the control hearts was done by adding adrenaline (10-6 M) after
the 10 min working mode at 105 min total perfusion time. Subsequently, mechanical
function was monitored for a further 10 min (Fig. 4.20A) at 115 min total perfusion time.
Non-Preconditioned hearts and alprenolol:
Non-Preconditioned hearts were perfused as above, in the absence or presence of
alprenolol (Fig. 4.20B). After the last administration of the drug, the hearts were perfused
with buffer for 10 min followed by 25 min sustained global ischaemia and 20 min
reperfusion (10 min retrograde, 10 min working heart). Evaluation of the recovery
potential of the non-preconditioned hearts was also done by adding adrenaline (10-6 M)
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Fig 4.16 p-adrenergic response to 25 min sustained global ischaemia: Experimental protocol. Abbreviations as in fig 4.3. p-adrenergic
receptor blocker, alprenolol (7.5 x 10-5 M), was administered 5 min before the the onset of PC1- and during PC1+ and PC2+. Following PC3-,
the drug was washed out for 10 min before the onset of 25 min global ischaemia. p-adrenergic stimulation with isoproterenol (10-8 or 10-7 M,
1 x 5 min) or forskolin (10-7 or 10-6 M, 1 x 5 min or 3 x 5 min) replaced the ischaemie PC before 25 min global ischaemia. Arrows indicate
time of freeze-clamping for cAMP determination. n = 6 hearts per series.
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after the 20 min reperfusion phase at 105 min total perfusion time. Subsequently,
mechanical function was monitored for 10 min (Fig. 4.20B) at 115 min total perfusion
time.
Preconditioned hearts and alprenolol:
Preconditioned hearts were preconditioned with 3 x 5 min ischaemia in the absence or
presenceof alprenolol (Fig. 4.20C). Alprenolol was administered 5 min before the onset
of PC1- and during PC1+ and PC2+. Following PC3-, the drug was washed out for 10
min before the onset of 25 min sustained global ischaemia and 20 min reperfusion.
Evaluation of the recovery potential of the preconditioned hearts was done as described
above.
4.2.3.1.2 Results
Effect of alprenolol administration on functional recovery:
We observed that alprenolol had no effect on control hearts not subjected to ischaemia
(Fig. 4.21). Neither did transient administration of alprenolol prior to the onset of
sustained ischaemia in non-PC hearts have any effect on functional recovery, for both
untreated and alprenolol treated hearts failed to produce a significant aortic output (Fig.
4.21A) or total work (Fig. 4.21B) during reperfusion. Alprenolol, when given prior to and
during the PC protocol, significantly reduced functional recovery during reperfusion: in
alprenolol treated PC hearts both the aortic output (Fig. 4.21A) and the total work
performance (Fig. 4.21B), as well as the coronary flow, cardiac output and peak systolic
pressure (Table 4.2) were significantly lower than those of untreated PC hearts, but
significantly better than those of non-PC hearts. The latter indicates that alprenolol
could only partially abolish the protective effect of PC.
Effect of adrenaline on recovery potential of hearts treated with alprenolol:
Although the aortic output and total work performance both alprenolol treated and
untreated PC groups could be increased by adrenaline administration, the values
remained lower in the alprenolol treated hearts (Fig. 4.21A, B). This was not due to a
drug effect of alprenolol, as the response to adrenaline of control hearts (not subjected
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Fig 4.17 ~-adrenergic response to 25 min sustained global ischaemia. Tissue cAMP accumulation was reduced in PC hearts compared to
non-PC hearts. ~-adrenergic receptor blocker, alprenolol (7.5 x 10-5M), administration to PC hearts before sustained ischaemia, partially
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Fig 4.18 p-adrenergic response to 25 min sustained global ischaemia. Isoproterenol pretreatment, for 1 x 5 min only at 10-8M did not cause
a reduction in cAMP at the end of sustained ischaemia. On the other hand, one episode of 10-7M isoproterenol pretreatment reduced
cAMP accumulation at the end of 25 min sustained ischaemia in a manner similar to ischaemie PC hearts.
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to ischaemia) treated with alprenolol, was similar to that of untreated control hearts (Fig.
4.21A, B).
4.2.3.2 Effect of repeated agonist-induced increases in cAMP prior to
sustained ischaemia on functional recovery
4.2.3.2.1 Experimental protocol
Hearts were stabilized by perfusing retrogradely for 15 min, followed by 15 min of
working heart. In separate groups tissue cAMPwas then elevated experimentally by:
(i) 3 x 5 min global ischaemia, alternated by 5 min reperfusion (PC hearts) (Fig.
4.22B);
(ii) 1 x 5 min isoproterenol (10-8 or 10-7 M) followed by 5 min reperfusion
(administration of isoproterenol was preceded by 20 min retrograde perfusion
after initial stabilization) (Fig. 4.22C);
(iii) 3 x 5 min isoproterenol (10-7 M), interspersed by 5 min reperfusion (Fig. 4.220);
(iv) 1 x 5 min forskolin (10-7, 10-6 M) followed by 5 min reperfusion (administration of
forskolin was preceded by 20 min retrograde perfusion after initial stabilization)
(Fig. 4.22C);
(v) 3 x 5 min forskolin (10-8, 10-7, 10-6 M), interspersed by 5 min reperfusion (Fig.
4.220).
Non-PC hearts, which served as appropriate controls, were perfused retrogradely for 30
min after the initial stabilization period (Fig. 4.22A).
All hearts were then subjected to 25 min global ischaemia, followed by 30 min
reperfusion (10 min retrograde, 20 min working heart) for evaluation of functional
recovery (Fig. 4.22).
4.2.3.2.2 Results
Effect of isoproterenol on functional recovery
At both concentrations (10-8 and 10-7 M) studied, isoproterenol administered for 5 min
only, caused a significant improvement in functional recovery during reperfusion. In
these hearts aortic output (Fig. 4.23A), total work performance (Fig. 4.23B), as well as
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Fig 4.19 ~-adrenergic response to 25 min sustained global ischaemia. Forskolin pretreatment, for 1 x 5 min only at 10-7M or 10-6M, or for
3 x 5 min at 10-7M, did not cause a reduction in cAMP at the end of 25 min sustained ischaemia. However, repeated administration of forskolin
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Fig 4.20 Functional recovery during reperfusion after p-adrenergic receptor blockade with alprenolol (7.5 x 10-5 M): Experimental protocol.
Abbreviations as in fig 4.3. Control, non-PC and PC hearts were treated with alprenolol (Alp.) prior to 25 min of sustained global ischaemia.
Adrenaline (Adr.) 10-6 M was administered at the end of reperfusion (post-sustained ischaemia) of each experiment for a period of 10 min.
Arrows indicate time of determination of mechanical function. n = 5 hearts per series.
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Fig 4.21 Functional recovery after p-adrenergic receptor blockade with alprenolol (7.5 x 10-5 M). In control hearts, alprenolol had no effect on
aortic ouput nor on total work performance at 105 min perfusion time (- Adrenaline), these hearts respond to the same extent to Adrenaline 10-6M
(+ Adrenaline, after 115 min). In non-PC hearts, both untreated and alprenolol treated hearts prior to sustained ischaemia, failed to recover significantly
during reperfusion. Furthermore, adrenaline could not reverse these effects. In PC hearts, pretreatment with alprenolol during the PC protocol reduced
both aortic output and total work performance during reperfusion (- Adrenaline). Although aortic output and total work performance in both alprenolol
treated and untreated PC groups could be increased by adrenaline (+ Adrenaline), the values remained lower in the alprenolol treated hearts.
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Table 4.2
Effect of Adrenaline (10-6 M) on mechanical performance during reperfusion of
hearts pretreated with Alprenolol.
Coronary flow Cardiac output Peak systolic Heart Rate
(ml/min) (ml/min) Pressure (beats/min)
(mm Hg)
Control:
Before Arrest 15.1±1.9 63.0 ± 0.9 110 ± 2.1 288±15.7
Control:
Without Alprenolol :
Adrenaline 13.8 ± 0.6 42.9 ± 3.2 101 ± 3.0 280 ± 21.0
+ Adrenaline 16.9 ± 1.0# 56.8 ± 5.3# 115±6.4# 337 ± 6.6#
With Alprenolol :
Adrenaline 13.1 ± 1.1 47.0 ± 4.7 99.8 ± 3.0 283 ± 17.8
+ Adrenaline 19.5 ± 1.1# 65.5 ± 4.9# 117 ± 1.5# 317 ± 6.6#
Non-Preconditioned:
Without Alprenolol :
Adrenaline 3.0 ± 2.9 7.5 ± 7.0 21.5 ± 20.0 72.0 ± 70
+ Adrenaline 4.3 ± 4.0 9.3 ± 9.0 21.9 ± 19.9 106 ± 99
With Alprenolol :
Adrenaline 0.0 0.0 0.0 0.0
+ Adrenaline 5.9 ± 2.1 6.6 ± 2.4 41.6 ± 6.6# 166 ± 11.8#
Preconditioned:
Without Alprenolol :
Adrenaline 14.1 ± 0.9$ 36.5 ± 3.3$ 97.3 ± 2.2$ 247 ± 14.2$
+ Adrenaline 17.7 ± 0.9#$ 53.1 ± 4.6#$ 104 ± 1.8#$ 361 ± 11.0#$
With Alprenolol :
Adrenaline 11.0 ± 1.5*$ 15.8 ± 1.5*$ 79.8 ± 3.8*$ 254 ± 16$
+ Adrenaline 12.6 ± 0.4*$ 29.0 ± 3.7*#$ 96.0 ± 2.0#$ 322 ± 9.0#$
Results expressed as the mean values ± SE obtained after 20 min of reperfusion. Hearts
were preconditioned or treated with the Alprenolol as shown in Fig. 4.20.
Adrenaline was administered after 20 min of reperfusion and mechanical performance
monitored after 10 min.
* p < 0.05 vs without Alprenolol (7.5 x 10-5 M)
# P < 0.05 vs - Adrenaline (10-6 M)
$ p < 0.05 vs non-PC
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Fig 4.22 Functional recovery after repeated pharmacological increases in cAMP as a tigger for eliciting preconditioning: Experimental
protocol. Abbreviations as in fig 4.3. ~-adrenergic stimulation for 1 x 5 min or 3 x 5 min with isoproterenol (10-8 or 10-7 M) or forskolin
(10-8 , 10-7 or 10-6 M) replaced the ischaemie PC before 25 min global ischaemia followed by 30 min reperfusion. Arrows indicate time of
determination of mechanical function. n = 6 to 8 hearts per series.
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Fig 4.23 Functional recovery after repeated increases in cAMP with isoproterenol. Both concentrations of isoproterenol (10-8 and 10-7M)
administered for 5 min only caused improved aortic output and total work performance during reperfusion, similar to PC hearts. However,
repeated (3 x 5 min) isoproterenol (10-7 M) administration caused complete mechanical failure.
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Table 4.3
Effect of p-adrenergic stimulation with isoproterenol or forskolin on mechanical
function during 30 min of reperfusion.
Coronaryflow Cardiac output Peak systolic Heart Rate
(ml/min) (ml/min) Pressure (beats/min)
(mm Hg)
Non-Preconditioned: 10.5 ± 1.0 10.5± 1.0 36.2 ± 13.4 122 ± 47.4
Preconditioned: 13.0 ± 0.6 32.7 ± 2.8* 88.6 ± 2.9* 235 ± 8.7*
1 x 5 min Isoproterenol:
10-7 M 10.1 ± 0.9 29.7 ± 1.5* 94.2 ± 4.3* 202 ± 17.2*
10-8 M 10.6 ± 0.5 27.9 ± 2.5* 91.5 ± 1.4* 216 ± 9.8*
3 x 5 min Isoproterenol:
10-7 M 4.3 ± 1.8* 8.8 ± 4.4 55.4 ± 14.3 160 ± 34.7
1 x 5 min Forskolin:
10-6M 10.6 ± 0.4 22.1 ± 3.0* 87.6 ± 1.4* 208 ± 12.7*
10-7 M 5.4 ± 2.0* 7.4 ± 3.4 47.2 ± 17.5 107 ± 39.5
3 x 5 min Forskolin:
10-6 M 11.3±0.9 19.9± 1.9* 77.0 ± 1.0* 225 ± 14.1 *
10-7 M 9.8 ± 0.4 14.0 ± 4.3 70.8 ± 11.9 190 ± 12.6
10-8 M 5.3±1.1* 7.1 ± 1.9 63.0± 11.2 208 ± 29.9
Results expressed as the mean values ± SE obtained during 30 min reperfusion after 25
min sustained ischaemia. Hearts were stimulated with p-adrenergic stimulants before
sustained ischaemia as shown in Fig. 4.22.
* p < 0.05 vs non-PC
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cardiac output, peak systolic pressure and heart rate (Table 4.3) improved significantly
compared to non-PC hearts and a similar protection as in PC hearts was observed. On
the other hand, isoproterenol (10-7 M) administration for 3 x 5 min, which resulted in no
increases in cAMP after the first administration (Fig. 4.6), causing complete mechanical
failure upon reperfusion (Fig. 4.23A, 8 and Table 4.3).
Effect of forskolin on functional recovery
Forskolin (10-8 and 10-7 M) administered either once or three times failed to improve
functional recovery compared to non-PC hearts (Fig. 4.24A, 8 and Table 4.3). However,
similar treatment with 10-6 M forskolin, resulted in cyclic increases in cAMP (Fig. 4.6)
before sustained ischaemia, followed by a significant improved functional recovery
during reperfusion. Although forskolin (10-6 M) significantly increased aortic output (Fig.
4.24A), total work performance (Fig. 4.248), cardiac output, peak systolic pressure and
heart rate (Table 4.3) compared to non-PC hearts, the protection was less than that of
PC hearts (Fig. 4.24A, 8 and Table 4.3).
4.2.3.3 p38 MAPK activation during sustained ischaemia and reperfusion of
p-adrenergic receptor manipulated hearts
To establish the role of p38 MAPK in p-adrenergic induced protection, it was necessary
to compare changes in p38 MAPK activation of p-adrenergic- and ischaemie-
preconditioned hearts during sustained ischaemia and reperfusion.
4.2.3.3.1 Experimental protocol
In this series, non-preconditioned and isoproterenol-treated hearts were freeze-clamped
at 5, 10, 15 and 25 min global ischaemia and at 10, 20 and 30 min of reperfusion (Fig.
4.25). Ischaemie and alprenolol-treated preconditioned hearts were freeze-clamped at
the end of 25 min global ischaemia, as well as 10, 20 and 30 min of reperfusion (Fig.
4.25). At least four hearts were studied at each time point. Dual phosphorylation of p38
MAPK was assayed at the above time intervals, while ATF-2 phosphorylation was
studied at selected times.
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Fig 4.25 Effect of f3-adrenergic manipulation (during the PC protocol) on p38 MAPK activation during sustained ischaemia and reperfusion:
Experimental protocol. Manipulations before 25 min global ischaemia and 30 min reperfusion include either f3-adrenergic stimulation with
isoproterenol (10-7 M, 1 x 5 min) replacing ischaemie PC or f3-adrenergic blockade with alprenolol (7.5 x 10-5 M) during the PC protocol.
Abbreviations as in fig 4.3. Arrows indicate time of freeze-clamping for determination of dual phosphorylation of p38 MAPK, while ATF-2
phosphorylation was studied at selected times. n = 4 to 6 hearts per series.
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4.2.3.3.2 Results
Dual phosphorylation of p38 MAPK by transient administration of isoproterenol (1 x 5
min, 10-7 M) before the onset of sustained ischaemia, was associated with a significant
reduction (although still higher than controls) in the activation of this stress kinase at all
time intervals studied (5, 10, 15 and 25 min) during sustained ischaemia, when
compared to the significant increases observed in untreated, non-PC hearts (Fig.
4.26A). These significant differences were due to the treatment and not to time (as
determined by two way ANOVA).
Furthermore, during reperfusion of non-PC hearts, p38 MAPK remained significantly
elevated during the entire period, while that of the isoproterenol-treated hearts
decreased over time, becoming significantly lower at 20 and 30 min of reperfusion when
compared with 10 min. Therefore at 20 and 30 min reperfusion of isoproterenol-treated
hearts p38 MAPK activation was also significantly attenuated compared to non-PC
hearts (Fig. 4.268).
Results obtained with isoproterenol-treated hearts were similar to those subjected to a 3
x 5 min ischaemic PC protocol: p38 MAPK activation was significantly attenuated at all
times of global ischaemia studied (described in Fig. 3.16, only 25 min shown in Fig.
4.28), while its activation declined over time during reperfusion (Fig. 4.27). On the other
hand, inhibition of p38 MAPK activation by alprenolol (7.5 x 10-5 M) during the
ischaemic PC protocol, led to a significant elevation in p38 MAPK activation at the end
of 25 min global ischaemia, which remained elevated and unchanged throughout
reperfusion, when compared to values obtained in preconditioned hearts (Fig. 4.27).
Activation of p38 MAPK as indicated by its kinase activity (ATF-2 phosphorylation) was
evaluated at selected time intervals (25 min ischaemia and 20 min reperfusion) and
compared with its dual phosphorylation. Similar results were obtained: attenuated
activation (ATF-2) and dual phosphorylation (p38 MAPK) in isoproterenol-treated
hearts, when compared to non-preconditioned hearts (Fig. 4.28A). On the other hand,
alprenolol administration during the ischaemie PC protocol reversed its effects on
attenuation of p38 MAPK activation (Fig. 4.288).
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Fig 4.27 Effect of ~-adrenergic blockade with alprenolol (7.5 x 10-5M), administered
during the ischaemie PC protocol) on p38 MAPK phosphorylation after 25 min sustained
ischaemia and during reperfusion: comparison with ischaemie PC. A representative
blot is given for each series. (n = 4 hearts/series). Two-way analysis of variance of p38
MAPK activation showed significant interaction between time and treatment; Alprenolol
administered during the ischaemie PC protocol, reversed its effects on attenuation of p38
MAPK activation.
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Fig 4.28 Comparison of dual phosphorylation and kinase activity of p38 MAPK in non-
PC, isoproterenol-PC (A), ischaemie-PC and alprenolol-treated hearts (8) after 25 min
sustained ischaemia and 20 min reperfusion. A representative blot is given for each
series. (n = 4 hearts/series).
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4.3 Discussion
Previously we have shown that cyclic increases in tissue cAMP occurred during a multi-
cycle PC protocol (in chapter 3), which was accompanied by reduced cAMP generation
by the preconditioned myocardiumwhen subsequently exposed to sustained ischaemia
(Moolman et el., 1996). A role for p-adrenergic receptor stimulation and activation of
the p-adrenergic signalling pathway as a trigger in PC has previously been suggested
by Asimakis et al. (1994), who showed that 5 min of noradrenaline or isoprenaline
administration followed by 5 min washout before 30 min global ischaemia mimicked the
protection of PC and this could be prevented by p-adrenergic blockade. In this
particular study no correlation was made between changes in tissue cAMP levels and
functional recovery. It was suggested that the increased workload produced by these
drugs might have resulted in a degree of demand ischaemia that was sufficient to
produce ischaemie PC. A major issue therefore was to establish whether the changes,
observed in the present study, per se elicit protection against subsequent ischaemie
damage or whether they are mere epiphenomena or the result of PC protection initiated
by another mechanism.
4.3.1 Prevention of cAMP generation during the PC protocol
One approach would be to establish whether abolishment of the cAMP fluctuations by
p-adrenergic blockade during the PC protocol could prevent the beneficial effects of PC.
To accomplish this, the drug to be used should be administered before the first PC
episode (PC1-) and washed out before the onset of sustained ischaemia. The latter is
particularly important since the presence of p-adrenergic blockers before and during the
onset of sustained ischaemia could protect the rat heart against ischaemie damage
(Edoute et et., 1981) and elicit protection in a manner similar to PC (Moolman et al.,
1996). Propranolol was found to be unsuitable to test our hypothesis, due to its
lipophilic properties: it could not be washed out within 10 minutes and such hearts
showed a much-depressed response to adrenaline stimulation (Fig. 4.1).
Although some workers failed to demonstrate a lowering in tissue cAMP in ischaemia by
p-receptor blockade (Muller et al., 1986), we found that the non-specific P1/ P2 blocker,
alprenolol, at a concentration of 7.5 x 10-5 M was suitable for our purpose: it
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significantly attenuated the cyclic increases in cAMP during the PC protocol (Fig. 4.4)
and could be washed out within 10 minutes, as was shown by the response of the
control perfused hearts to adrenaline stimulation (Fig. 4.2). p-adrenergic receptor
blockade during the PC protocol caused a significant reduction in functional recovery
during reperfusion (Fig. 4.21) and although adrenaline could improve their performance,
the values obtained were still significantly lower than those of the untreated PC hearts.
These results emphasize the significance of activation of the p-adrenergic signal
transduction pathway during the PC protocol in eliciting protection during sustained
ischaemia.
4.3.2 Simulation of ischaemia-induced cAMP increases
The reverse approach would be to establish whether repeated stimulation of cAMP
generation before the onset of sustained ischaemia could elicit protection. Our data
(Fig. 4.5), as well as work by Krause and Szekeres (1995), indicate a strong correlation
between dose-dependent p-adrenergic increase in contractility and relaxation on one
hand and the concomitant increase of myocardial cAMP levels on the other hand.
These increases in cAMP were not due to demand ischaemia caused by administration
of either forskolin or isoproterenol, because the tissue high energy phosphates levels
(ATP and CP in Table 4.1) were not decreased by this intervention.
Furthermore, our study shows that, depending on the protocol and concentration,
activation of the p-adrenergic signalling pathway by either isoproterenol (Fig. 4.23), or
forskolin (Fig. 4.24) significantly improves functional recovery during reperfusion after
25 min global ischaemia, when compared to non-PC hearts.
A definite correlation between elevation in tissue cAMP levels prior to sustained
ischaemia and subsequent protection, was not observed. Although isoproterenol (10-8
M), capable of generating cAMP levels comparable to those observed during a PC
protocol (428 ± 26 vs. 403 ± 13 pmoles/g wet weight respectively), elicited protection
similar to that induced by PC (Fig. 4.23), further elevation of cAMP levels to 1036 ± 55
pmoles/g wet weight by 10-7 M isoproterenol (Fig. 4.5), prior to the onset of sustained
ischaemia, did not further enhance recovery (Fig. 4.23).
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On the other hand, forskolin, a direct activator of adenylyl cyclase, elicited protection in
a dose-dependent manner: at 10-6M the drug was most effective, regardless of the
frequency of administration, while at 10-7 M the work performance did not increase
significantly (Fig. 4.24). However, prior to sustained ischaemia forskolin (10-7 M)
induced elevation of cAMP to levels comparable to those induced by PC1- (539 ± 26 vs.
403 ± 13 pmoles/g wet weight, respectively) that had little effect on functional recovery
and only at a concentration of 10-6 M and cAMP levels of higher than 1000 pmoles/g
wet weight did forskolin elicit protection, although significantly less than in PC hearts
(Fig.4.24).
Of interest is the observation that elevation in tissue cAMP to comparable levels by
isoproterenol (10-7 M) and forskolin (10-6M) (Fig. 4.5), did not lead to a similar degree of
protection against ischaemie damage: aortic output of 19.6 ± 2.4 ml/min vs. 11.5 ± 1.4
ml/min, respectively (Figs. 4.23A and 4.24A). Additionally, a single isoproterenol
administration proved to be significantly more protective than repeated administration of
forskolin: aortic output of 10-8M: 17.3 ± 2.3 vs.1.85 ± 1.0 ml/min and of 10-7 M: 19.6 ±
2.4 vs. 4.17 ± 4.0 ml/min, respectively (Figs. 4.23A and 4.24A). A possible explanation
for this phenomenon may be the fact that forskolin increases cAMP in a
compartmentalized manner, so that AMP levels per se are not necessarily indicative of
its effectiveness (Worthington et aI., 1992). Furthermore cAMP levels during repeated
forskolin stimulation did not return to control levels, while only one episode of
isoproterenol increased cAMP levels followed by desensitization of the response to
further stimulation (Fig. 4.6). A further difference between the drugs is the fact that in
contrast to forskolin, repeated stimulation with isoproterenol led to complete mechanical
failure during reperfusion after sustained ischaemia (Fig. 4.23). This may be due to
Ca2+ overloading, which is a well-established cause of damage (Opie 1991).
We therefore decided to use the 1 x 5 min (10-7 M) isoproterenol protocol to mimic the 3
x 5 min ischaemie PC protection (Fig. 4.23), because the 3 x 5 min isoproterenol could
not mimic the cyclic changes in cAMP (Fig. 4.6) and resulted in complete mechanical
failure (Fig. 4.23).
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4.3.3 Mechanism of protection: cAMP related?
It remains to be established how transient stimulation of the p-adrenergic signalling
pathway and cAMP generation lead to protection against ischaemie damage. Although
cAMP is washed out during each reperfusion phase, activation of the downstream PKA
occurs (as described in chapter 3), which in turn, may have further longer lasting
downstream effects. The results obtained in this study suggest that PC-induced
protection may result from down-regulation by the PC protocol of the p-adrenergic
receptor responsiveness to subsequent ischaemia.
The mechanism of protection elicited by p-adrenergic agonists is complex. With
ischaemie preconditioned or isoproterenol (10-7 M, 1 x 5 min) or forskolin (10-6 M, 3 x 5
min) treated hearts, the following pattern emerged: (i) a significant desensitization of
the p-adrenergic receptor, as evidenced by the significant reduction in cAMP generation
upon 2 min of isoproterenol administration (Figs. 4.8 and 4.9) and (ii) a significant
reduction in cAMP content after 25 min sustained ischaemia (Figs. 4.18 and 4.19).
Desensitization of hearts exposed to a short episode of ischaemia (Ungerer et aI., 1996)
or isoproterenol (Mayor et aI., 1998) could probably be attributed to activation of both
the p-adrenergic receptor kinase and PKA, whereas in the case of forskolin probably
PKA only was involved. However, the mechanism of desensitization in PC hearts
remains to be elucidated.
The above suggestion was also substantiated by the observation that in the case of
forskolin (10-7 M; 1 x 5 min and 3 x 5 min) where no significant improvement in aortic
output or work performance during reperfusion occurred (Fig. 4.24), no p-adrenergic
receptor desensitization (Fig. 4.9) nor reduced cAMP during sustained ischaemia was
observed (Fig. 4.19).
However, isoproterenol (10-8 M) or forskolin (10-6 M) when administered for 1 x 5 min
did cause functional protection during reperfusion (Figs. 4.23 and 4.24), which was not
associated with desensitization of the p-receptor (Figs. 4.8 and 4.9) or a reduction in
cAMP levels at the end of sustained ischaemia (Figs. 4.18 and 4.19). It is possible that
one 5 min episode was too short (in the case of forskolin) or the concentration of the
agonist was too low (in the case of 10-8 M isoproterenol) to elicit desensitization of the
receptor and that the protection observed in these hearts may be due to the
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characteristic increases in heart rate produced by both these agonists. It has recently
been shown that increases in heart rate by rapid pacing can protect isolated working
hearts against ischaemia, via production of nitric oxide (Ferdinandy et al., 1996,
Ferdinandy et al., 1997). This possibility is supported by previous findings that transient
stimulation with ~-adrenergic agonists, which increased the heart rate, could mimic
ischaemie PC (Asimakis et aI., 1994). These investigators suggested that the increased
workload produced by these drugs might have resulted in a degree of demand
ischaemia that was sufficient to produce ischaemie PC. Moreover, repeated ~-
adrenergic stress (induced by 5 intravenous administrations of isoproterenol, repeated
at 10 min intervals in conscious rabbits) has also been shown to increase cardiac
workload and induce a long-term cardiac adaptation manifested by a significant
reduction of harmful ischaemie changes due to cardiac stress 24 and 48 h after PC
(Kovanecz et al., 1996).
It is thus possible that intermittent increases in heart rate, which was observed in all the
protocols using isoproterenol or forskolin in our study, could contribute to the results
obtained. It is unlikely though that the increased workload produced by either forskolin
or isoproterenol caused a degree of demand ischaemia sufficient to produce ischaemie
PC, since the tissue high energy phosphates were unchanged during repeated
administration of high concentrations of these drugs (Table 4.1). In addition, even
increases in heart rate by rapid pacing was associated with the release of
catecholamines and activation of the adenylyl cyclase/cAMP pathway (Krause and
Szekeres 1995, Parratt and Szekeres 1996).
Therefore, in view of these discrepancies, we suggest the following possible
mechanisms: (i) the activation of PKA observed in all agonist treated hearts (results not
shown) may act via desensitization of the ~-adrenergic receptor and/or phosphorylation
of a protective protein, (ii) agonist-induced increases in heart rate may protect against
ischaemia via NO production. It is possible that both factors playa role in the protection
observed.
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4.3.4 PKA and PKC
The results obtained provide proof that the protection elicited by ischaemie PC, may be
partially dependent on activation of the ~-adrenergic signalling pathway, implicating a
role for PKA in downstream events.
Our observation that blockade by alprenolol could only partially, although effectively,
abolish the protective effect of ischaemie PC, comes as no surprise in the view of the
convincing evidence for involvement of other G-protein coupled receptors, acting via
PKC activation (for review see Baxter 1997). In particular administration of a1-agonists
before sustained ischaemia elicit PC (Bankwala et aI., 1994, Banerjee et aI., 1993,
Tosaki et aI., 1995) while a1-adrenoceptor antagonists (Thornton et aI., 1993, Banerjee
et aI., 1993) and PKC blockers (Ytrehus et aI., 1994, Armstrong et aI., 1994) have been
shown to abolish PC. Although investigators like Bugge and Ytrehus (1995a) indicated
that ischaemie PC was not mediated through a-adrenergic or adenosine receptors, it
was still dependent on the activation of PKC in isolated rat hearts. In addition, Yabe et
al. (1998) observed that pharmacological PC induced by ~-adrenergic stimulation (2 min
of isoproterenol) is also mediated by activation of PKC in isolated rat hearts.
In spite of the fact that PKC activation has long been advocated as the main signal
transduction pathway in PC, our laboratory could not find any evidence of either a1-
adrenergic or PKC activation in the mechanism of ischaemic PC using the working
perfused heart as model (Moolman et aI., 1996). Similar negative findings were
reported by others (Kolocassides et aI., 1994, Asimakis et aI., 1993, Haessler et aI.,
1996) and PKC as a major role player has been questioned (Brooks et aI., 1996,
Simkhovich et aI., 1998).
Subsequent studies from our laboratory (Lochner et aI., submitted for publication)
showed that the mode of perfusion, the PC protocol and the endpoint used (infarct size
vs. functional recovery) may affect the outcome of PC and may be potential reasons for
several of the current controversies. For example, the significance of the PC protocol
has recently been emphasized by Sandhu et al. (1997), who demonstrated that a 3-
cycle PC protocol provided more effective protection than one cycle and was less
susceptible to specific inhibitors. However, the significance of ~-adrenergic stimulation
as a trigger of protection is underscored by the fact that ~-adrenergic blockade could
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abolish a 3-cycle induced protection (Fig. 4.21). Therefore failure of ai-adrenergic or
PKC blockade to abolish protection in our particular model (isolated perfused rat heart)
may be due to the use of a multi-cycle protocol and functional recovery as endpoint
(Moolman et a/., 1996). In addition, most studies confirming the involvement of either
ai-adrenergic system or PKC made use of infarct size, which may be a more tractable
end-point (Lochner et a/., submitted for publication).
4.3.5 Further downstream events of ~-adrenergic stimulation and
p38 MAPK activation
The results obtained in this study confirm that transient ~-adrenergic stimulation (with
10-7 M isoproterenol) of the isolated rat heart mimics the cardioprotective effect of our
three-cycle ischaemic PC protocol (Fig. 4.23). During both ~-adrenergic stimulation and
ischaemic PC protocols generation of cAMP (Figs. 4.6 and Fig. 3.2, respectively) and
transient activation of p38 MAPK occur (Figs. 3.12 and 4.11, respectively), which were
associated with lowering of tissue cAMP (Figs. 4.19 and 3.13, respectively) and
attenuation of p38 MAPK activity during sustained ischaemia and reperfusion (Figs.
3.16, 3.21 and 4.26A, B) as well as improvement in functional recovery (Fig. 4.23).
These observations suggest that activation of p38 MAPK during the PC protocol may
act as trigger, while attenuation of its activation during sustained ischaemia and
reperfusion is associated with cardioprotection. The significance of activation of the ~-
adrenergic signalling pathway during ischaemie PC is emphasized by the observation
that alprenolol-induced blockade of the receptor and thus attenuation of cAMP
elevations (Fig. 4.4) and inhibition of p38 MAPK activation (Fig. 4.13) during the PC
protocol only, results in increased tissue cAMP (Fig. 4.17) and activation of p38 MAPK
(Fig. 4.27) during both sustained ischaemia and reperfusion with concurrent mechanical
failure (Fig. 4.21), similar to the pattern observed in non-PC hearts.
As discussed in the previous chapter, it is still unsure whether p38 MAPK activation is
indeed associated with cardioprotection. Increased activation of p38 MAPK signalling
during sustained ischaemia in preconditioned hearts (Weinbrenner et el., 1997,
Armstrong et a/., 1999, Nakano et a/., 2000a) has been shown to be associated with
cardioprotection, on the other hand activation of this kinase during sustained
ischaemia/reperfusion has, in several studies, been associated with myocyte
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necrosis/apoptosis (Bogoyevitch et al., 1996, Ma et al., 1999, Mackay et al., 1999,
Baranick et al., 2000).
In view of the current controversy regarding the significance of p38 MAPK activation in
ischaemie damage (Ping et al., 2000), we therefore suggested that the PC-mimetic
properties of isoproterenol, as well as the fact that it activates p38 MAPK, could be a
useful experimental tool in evaluating the significance of this kinase in cardioprotection.
Furthermore, in contrast to the wealth of knowledge as to G protein-coupled receptor
(GPCR) -mediated ERK1/2 activation, the role of GPCRs in regulating p38 MAPK
activity and its physiological relevance in heart muscle remains unclear. Therefore our
study could further elucidate the relationship between the p-adrenergic receptor and
p38 MAPK activation in myocardial protection.
4.3.5.1 Characteristics of p-adrenergic-mediated stimulation of p38 MAPK
In order to use p-adrenergic stimulation of the isolated perfused rat heart as a tool in
evaluating the role of p38 MAPK in cardioprotection, it was necessary to gain more
information regarding its effects on the activity of the kinase.
We studied P1-adrenergicstimulation of the isolated rat heart with isoproterenol and
could also show a rapid onset (within 2 min), dose-dependent activation of p38 MAPK
that is maintained for at least 15 min (Fig. 4.10). A similar maximal response after 15
min was also reported for stimulation of both the P1-and P2-adrenergicreceptor in adult
mouse and rat cardiomyocytes (Zheng et al., 2000, Communal et al., 2000). Using
adult mouse cardiomyocytes expressing the p2-adrenergic receptor, isoproterenol
elicited a maximal response at ~ 1 J.lM(Zheng et al., 2000), similar to the results
obtained in this study (Fig. 4.10). A recent study regarding the activation of p38 MAPK
by G protein-coupled receptors, reported that isoproterenol also activates p38 MAPK in
a time and dose-dependent manner in HEK293 cells (Yamauchi et al., 1997).
Interestingly, Zinterol, a P2-adrenergicreceptor agonist, was much less effective in the
isolated rat heart and even concentrations 100 x higher (10-5 M) than those used for
isoproterenol could not elicit the same stimulation of p38 MAPK (Fig. 4.11). Despite
these differences in susceptibility to p-stimulation (which may due to differences in
species and experimental models), both P1-and p2-adrenergic receptor subtypes can
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couple to the activation of p38 MAPK (Zheng et aI., 2000, Communal et aI., 2000).
Furthermore, it is possible that the apparent ability of both P1- and P2-adrenergic
receptor subtypes to activate p38 MAPK may reflect differential activation of p38 MAPK
isoforms, which may exert opposing effects on apoptosis in cardiac myocytes (Wang et
al., 1998). However, our observations indicate that the marked activation of p38 MAPK,
induced by either global ischaemia or isoproterenol, is mediated by the P1-, rather than
the P2-, adrenergic receptor.
Direct stimulation of adenylyl cyclase by forskolin (10-6 M), is almost as effective as P1-
adrenergic stimulation by isoproterenol (10-7 M) in increasing tissue cAMP (Fig. 4.6) and
activating p38 MAPK (Fig. 4.11). Furthermore, abolishment of cAMP increases by the
p-adrenergic blocker alprenolol (Fig. 4.4) abolishes p38 MAPK activation (Figs. 4.13
and 4.14). Therefore activation of p38 MAPK by stimulation of the p-adrenergic
signalling pathway is not receptor, but cAMP dependent. In addition, Zheng et al.
(2000) showed that P2-receptor activation of p38 MAPK occurs via a cAMP-PKA
dependent pathway, rather than by Gi or the GPy subunit. However, Communal et al.
(2000) reported that both P1- and P2-adrenergic receptor subtypes stimulate p38 MAPK
in a pertussis toxin sensitive manner, therefore via Gi protein. However, these aspects
were not addressed in the present study.
4.3.5.2 Manipulation of ischaemia- or isoproterenol-induced p3S MAPK
activation
The contribution of endogenous catecholamines to the phenomenon of ischaemie PC is
well established and we therefore evaluated their contribution to the ischaemia-induced
activation of p38 MAPK by administration of the appropriate blockers 5 min before the
onset of 5 min of ischaemia (PC 1- as indicated in Fig. 4.13). Ischaemia-induced
activation of p38 MAPK, as occurs during an ischaemic-PC protocol, can be reduced
significantly by both U1and P-blockade: when compensating for the effects of prazosin
and alprenolol per se on p38 MAPK activation, it seems as if each blocker effectively
abolishes ischaemia-induced activation of p38 MAPK. Although the contribution of
other triggers cannot be ruled out, these results suggest that endogenous
catecholamines playa significant role in p38 MAPK activation during an ischaemie PC
protocol. Furthermore, although no role for the u1-adrenergic receptor stimulation (and
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PKC) could be demonstrated in ischaemic-PC of the isolated perfused working rat heart
model (our particular model of ischaemic PC) (Moolman et aI., 1996), it is possible that
the marked activation of p38 MAPK which occurs within 5 min of ischaemia, may also
be attributed to PKC activation.
As expected, p-adrenergic receptor induced (isoproterenol 10-7 M) activation of p38
MAPK can be abolished completely by alprenolol (Fig. 4.14), whereas the Ca2+
antagonist verapamil was almost as effective, demonstrating a role for influx of
extracellular Ca2+ in activating the kinase, as was also demonstrated in neonatal
cardiomyocytes (Zhu et aI., 1999), PC 12 cells (Conrad et aI., 2000), mouse
osteoblastic MC 3T3 - EI-cells (Yamaguchi et aI., 2000) and mesangial cells (Sodhi et
al., 2000). This observation suggests that the triggering of PC by elevation of
intracellular [Ca2+]i, as demonstrated by Miyawaki and Ashraf (1997a, 1997b) may
involve p38 MAPK activation.
Although the adenosine Ai-receptor is suggested to play an important role in triggering
PC (Cohen et aI., 2000), it does not appear to be involved in isoproterenol-induced
activation of p38 MAPK, ruling out adenosine as trigger in cardioprotection in this
particular scenario (Fig. 4.14). This is in contrast to the results obtained by
Weinbrenner and coworkers (1997), who showed that addition of 8-(p-sulfophenyl)-
theophylline (8-SPT) blocked ischaemie PC-induced activation of p38 MAPK as well as
the protective effects of PC in rabbits. However, our results are not surprising in view of
the fact that adenosine plays little (Headrick 1996), if any (Liu and Downey 1992, Bugge
and Ytrehus 1995a, Cave 2000), role in PC in rats.
4.4 SUMMARY
4.4.1 Effect of p-adrenergic stimulation
Our results emphasize the significance of p-adrenergic stimulation as a trigger during
the PC protocol: abolishment of the increases in cAMP during the PC protocol
attenuated functional recovery during reperfusion. The reverse approach was to
establish whether repeated generation of cAMP before the onset of sustained
ischaemia could elicit protection. Although such a relationship could be established, it
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depended on the mode of administration and concentration of the p-adrenergic receptor
agonists.
In view of the results obtained in the present study, we propose that, in addition to
stimulation of G-protein coupled receptors such as the ai-adrenergic, muscarinic,
angiotensin II or opioid receptors (Banerjee et aI., 1993, Baxter et aI., 1997, Miki et al.,
1998), or PKC activation (Brooks et aI., 1996), ischaemia-induced activation of the p-
adrenergic signalling pathway is an important trigger or contributory factor in eliciting
PC.
It also appears as if the tissue cAMP levels at the end of sustained ischaemia may be
merely a reflection of the protection conferred by the initial trigger mechanism. This is
suggested by our previous findings (Moolman et aI., 1996), where preconditioned rat
hearts were stimulated with forskolin before the onset of sustained ischaemia causing
cAMP levels of PC hearts to increase to the same level after 25 min global ischaemia as
observed in non-PC hearts. However, the protective effect of PC on functional recovery
was not abolished by this intervention. This was also suggested by Sandhu et aI.,
(1994 and 1996), who observed that infusion of adenylyl cyclase activators, like
forskolin and NKH477, throughout the three cycles of transient ischaemia in PC hearts
also did not block the protection of PC against necrosis in rabbits, even though it
significantly increased cAMP levels. The possibility also exists that forskolin increased
cAMP in a compartmentalized manner (Worthington and Opie 1992), thus not allowing
assessment of the effects of increased cAMP levels on the protection conferred by PC.
Finally, whether desensitization of the p-adrenergic receptor is the only way by which
the ischaemie myocardium is protected by activation of the p-adrenergic signalling
pathway or whether this is linked to the suggested subsequent phosphorylation of a
membrane bound effector (Brooks et aI., 1996, Baxter et aI., 1997) still needs to be
resolved.
4.4.2 Downstream events of p-adrenergic stimulation: role of p38 MAPK
activation
Furthermore, during p-adrenergic stimulation transient activation of p38 MAPK
occurred, which was associated with attenuation of p38 MAPK activity during sustained
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ischaemia and reperfusion as well as improvement in functional recovery. These
observations suggest that activation of p38 MAPK during the PC protocol may act as
trigger downstream of cAMP, while attenuation of its activation during sustained
ischaemia and reperfusion is associated with cardioprotection. Therefore the
importance of this will be investigated later in chapter 4.
The significance of activation of the p-adrenergic signalling pathway during ischaemie
PC is emphasized by the observation that alprenolol-induced blockade of the receptor
during the PC protocol only, resulted in abolishment of the increases in tissue cAMP
and inhibition of p38 MAPK activation. p-Adrenergic receptor blockade with alprenolol
resulted in increased activation of p38 MAPK during both sustained ischaemia and
reperfusion with concurrent mechanical failure, similar to the pattern observed in non-
PC hearts.
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CHAPTER 5
Manipulation of cyclic guanosine monophosphate (cGMP)
5.1 Introduction
We hypothesized previously that characterization of events during the PC protocol
would yield more insight into the triggers and signalling pathways involved in the
protective effect of classic PC. Subsequently, we showed that a 3 x 5 min PC protocol
caused cyclic elevations in the cyclic nucleotides, cAMP and cGMP. The latter
observation as well as the fact that nitric oxide (NO) synthase (NOS) activity is
increased within 5 min of global ischaemia (Depré et aI., 1997) suggested the possibility
that NO may also be a trigger in PC. In addition, it has been shown that rapid pacing
can protect isolated working hearts against ischaemia, via production of nitric oxide, NO
(Ferdinandy et ai., 1996, Ferdinandy et ai., 1997).
As mentioned previously, ischaemie preconditioning (PC) occurs in two phases: an
early phase (classic PC), which develops immediately and lasts approximately 2 - 3 h
after the ischaemic stimulus and a delayed phase (late PC or second window of
protection), which appears 12 - 24 h later and lasts for 3 - 4 days (Kuzuya et ai., 1993,
Marber et ai., 1993). Involvement of NO in the late phase of PC has been the focus of
intense investigation. Bolli et al. (1998) recently postulated a dual role for NO in this
scenario: initially a trigger and subsequently as mediator of protection. They proposed
that triggering the development of late PC on day one, involves generation of NO after a
brief ischaemic stress (probably via eNOS) (Bolli et aI., 1997) and subsequent activation
of PKC (Ping et aI., 1999). The latter could in turn trigger a complex signalling cascade
that involves protein tyrosine kinases (Imagawa et aI., 1997), the transcription factor
nuclear factor-KB (Xuan et aI., 1999), and most likely other as yet unknown
components. Furthermore, increasing evidence indicates that the cardioprotective
effects of late PC observed on day two are due to upregulation of inducible NOS
(Takano et aI., 1998a). Further convincing evidence of a role for NO in late PC is that
NOdonors mimic and NOS inhibitors abolish late protection (Takano et aI., 1998b).
The role of NO as a trigger or mediator in the phenomenon of classic PC is however not
yet clear, because of the controversial results from the few studies done thus far. The
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discrepancies are generally attributed to species differences, different PC stimuli and
different study end points, i.e., myocardial function, arrhythmias or infarct size (parrat
1994, Baxter et aI., 1996). Some studies reported that the anti-arrhythmic effects of PC
were independent of NO (Lu et aI., 1995, Sun et ai., 1997), and that NOS-inhibition by
L-NAME had no effect on PC-induced reduction in infarct size (Woolfson et ai., 1995) or
improvement in functional recovery (Weselcouch et aI., 1995); however, others showed
that NO donors could mimic (Bilinska et ai., 1996) or NOS-inhibitors could abolish (Vegh
et ai., 1992) the protective effect of PC on arrhythmias. Further evidence for
involvement of NO in classic PC was the recent observation that cardiac NO
biosynthesis was essential to trigger, but not to mediate PC (Csonka et ai., 1999). Thus
far, the effect of NO donors on outcomes such as infarct size or functional recovery
during reperfusion, has not been studied.
Although there is ample evidence for generation of NO and peroxynitrite during
ischaemia-reperfusion (Csonka et ai., 1999,Wang et ai., 1996,Weselcouch et ai., 1995,
Yasmin et ai., 1997), no increase in tissue NO could be demonstrated during the PC
protocol itself (Csonka et ai., 1999). However, in view of observations that NOS
activation (Depré et aI., 1999) and increases in cGMP (from chapter 3) occur within 5
min of global ischaemia, it seems very likely that NO is generated during an ischaemic
PC protocol and may act as trigger.
5.1.1 The aim:
We therefore investigated whether the cyclic increases in tissue cGMP, elicited by
multiple short episodes of ischaemia/reperfusion (as occurs during a multi-cycle PC
protocol), indicated involvement of NO, and thus cGMP, as a trigger of classic PC in the
isolated working rat heart model.
Our concept is that events occurring during the PC protocol serve to activate (i.e.
trigger) the protective mechanism of PC. Biochemical events that take place during the
subsequent phase of sustained ischaemia reflect the protection that was elicited by prior
PC. Accordingly, abolishment or attenuation of biochemical events during either the PC
phase or during the sustained ischaemia, causing inhibition of protection during
reperfusion as reflected by mechanical recovery, may indicate a role as trigger or
mediator, respectively.
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The aim of this study was therefore to evaluate the role of NO and cGMP in classic PC
by the following interventions:
(i) evaluation of the role of NO and thus cGMP during the PC protocol (as trigger):
by abolishing the cyclic changes in cGMP via inhibition of the NO-cGMP pathway
before and during the PC protocol only.
(ii) confirmation on the trigger effect of NO: by mimicking cyclic changes in cGMP
via transient administration of exogenous NO donors.
(iii) evaluation of the role of NO production during sustained ischaemia (as mediator):
by inhibiting the NO-cGMP pathway after the PC protocol, before the onset of
sustained ischaemia only.
Functional recovery during reperfusion of the globally ischaemie heart and tissue cyclic
nucleotides at the end of sustained ischaemia will be used as indicators of protection.
In addition, the functional reserve of non-preconditioned, preconditioned and hearts
pretreated with NO donors will be evaluated by administration of adrenaline during
reperfusion.
Finally, in view of the putative role of p38 MAPK in ischaemie- and p-adrenergic PC, the
downstream effects of NO and cGMP generation during the PC protocol and sustained
ischaemia were evaluated by determination of p38 MAPK activation.
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5.2 Experimental Protocols and Results
5.2.1 Manipulation of the NO-cGMP pathway during PC protocol before
sustained ischaemia
5.2.1.1 Inhibition of cyclic increases in cGMP during ischaemie PC protocol
To investigate the role of the NO-cGMP pathway during ischaemie PC protocol, (i)
cGMP generation was inhibited by a guanylyl cyclase (GC) inhibitor, 000 and (ii) NO
formation was suppressed by a nitric oxide synthase (NOS) inhibitor, L-NAME. The
concentration of the inhibitors used, was such that it prevented the rise in cGMP during
PC.
5.2.1.1.1 Experimental protocol
000 or 1H-[1,2,4]oxadiazolol[4,3-a]quinoxalin-1-one, a selective inhibitor of guanylyl
cyclase, was administered 5 min preceding the first 5 min episode of ischaemie PC
(PC1-) as well as during each 5 min reperfusion episode (PC1+, PC2+ and PC3+).
Hearts were freeze-clamped at PC1-, PC1+, PC3- and PC3+ as indicated in Fig. 5.1.
Appropriate controls and preconditioned hearts were perfused as described before
(3.2.1.1). Hearts were freeze-clamped at 30 and 60 min total perfusion time for controls
and at PC1-, PC1+, PC3- and PC3+ for PC hearts, as indicated in Fig. 5.1.
5.2.1.1.2 Results
The effect of inhibition of cGMP generation during the ischaemie PC protocol was
studied with 000, which was administered 5 min before the onset of PC1- as well as
during each reperfusion phase (Table 5.1). Since 000 was dissolved in OMSO, a
control series was included where OMSO (0.04%) plus 000 (20 j.lM)was administered
retrogradely for 3 x 5 min after the usual stabilization period of 30 min. The combination
of aDa and OMSa significantly increased tissue cGMP levels (Untreated controls: 8.42
± 0.35 vs. OOO+OMSO controls: 11.22 ± 0.43 picomoles/g wet weight) while lowering
cAMP levels (Untreated controls: 317 ± 9.3 vs. OOO+OMSO controls: 241.5 ± 10.1
picomoles/g wet weight). The OOO+OMSO controls were used for comparing the
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Fig 5.1 Inhibition of cyclic increases in cGMP during the ischaemic preconditioning protocol: Experimental protocol.
Abbreviations as in Fig 3.1. The guanylyl cyclase (GC) inhibitor, 000 (20~M), was administered 4 x 5 min during the
preconditioning protocol. Arrows indicated time points of freeze-clamping for cGMP and cAMP determinations. (n = 6
hearts/series) .
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Fig 5.2 Manipulations of cGMP and cAMP levels during the ischaemie preconditioning protocol with 000 (20 11M)+ OMSO (0.04%).
Untreated or 000 + OMSO treated controls were taken as 100%, and were used to compare the effects of ischaemie PC on tissue cyclic
nucleotides in the absence or presence of 000, respectively. 000 + OMSO prevented the significant rise in cGMP, while not affecting the
cyclic rises in cAMP, during the PC protocol.
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Table 5.1
Effects of CDQ, an inhibitor of guanylyl cyclase on tissue cyclic nucleotide levels
and ratio during a 3 x 5 min preconditioning protocol.
cGMP cAMP cAMP/cGMP
Untreated controls 8.42 ± 0.35 317.0 ± 9.27 37.65
(n = 11/series)
Preconditioning: (n = ~ 9/series)
PC1- 12.18±0.71 * 402.8 ± 13.23 * 33.07
PC1+ 12.71 ± 1.37 307.0 ± 13.51 8 24.15
PC3- 16.79±1.12* 370.2 ± 9.74 * 22.05
PC3+ 12.54 ± 0.69 *8 277.1 ±9.168 22.10
ODa + DMSO: (n = 6/series)
Controls 11.22 ± 0.43 * 241.5 ± 10.1 * 24.60 ± 2.56
PC1- 11.51 ± 0.58 * 362.4 ± 39.7 ** 30.90 ± 3.91
PC1+ 11.60 ± 0.75 * 261.2 ± 16.28 23.91 ± 2.18
PC3- 17.92±1.00* 330.0 ± 15.08 ** 15.50 ± 1.71
PC3+ 12.34±0.51 * 259.7 ± 16.208 20.59 ± 1.19
Values are means ± SE in pmoles/g wet weight. Untreated control hearts were perfused for 60 min
(15 min retrograde, 15 min working heart, 30 min retrograde perfusion). CDa + DMSO controls:
ODa (20 f.lM) + DMSO (0.04%) were administered for 3 x 5 min, as described above.
op < 0.05 PC- vs PC+
* p < 0.05 vs control (untreated)
** p < 0.05 vs controls, perfused with aDa and DMSO
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effects of preconditioning on cyclic nucleotides in the presence of ooa. ooa
prevented the significant rise in cGMP occurring during the PC protocol at PC1- and
PC3- (as observed in untreated hearts), whereas tissue cAMP increased in a similar
manner as observed before (Fig. 5.2)
The nitric oxide synthase inhibitor, L-NAME (N(G)-nitro-L-arginine methyl ester), was
also administered as described for ooa, but these hearts were freeze-clamped at the
end of PC3- only. L-NAME (50 IlM) also caused a reduction in cGMP, when measured
at PC3- (11.32 ± 0.85 (n=6) vs. 16.79 ± 1.12 (n=9) picomoles/g wet weight, p < 0.05).
5.2.1.2 Repeated increases in cGMP by nitric oxide (NO) donors before
sustained ischaemia
The cyclic increases in tissue cGMP during a three-episode ischaemic PC protocol was
mimicked by 3 x 5 min administration of the NO donors s-nitroso-penicillamine (SNAP),
sodiumnitroprusside (SNP) or L-arginine in the absence of ischaemia.
5.2.1.2.1 Experimental protocol
All hearts were stabilized for 30 min (15 min retrograde, 15 min working) as described
before. The NO-donors SNAP, SNP or L-arginine or the solvent OMSO were then
administered transiently for 3 x 5 min episodes, alternated by 5 min reperfusion with
normal buffer. In these studies cGMP and cAMP were analyzed after freeze-clamping
the hearts (at least six hearts at each time point) at the end of the first and third
episodes of administration (1 x 5 min and 3 x 5 min) and also after 5 min of reperfusion
(1 x 5 min + reperfusion and 3 x 5 min + reperfusion, as indicated in Fig. 5.3).
Appropriate controls and preconditioned hearts were perfused as described before
(3.2.1.1). Hearts were freeze-clamped at 30 and 60 min total perfusion time for controls
and at PC1-, PC1+, PC3- and PC3+ for PC hearts, as indicated in Fig. 5.3.
5.2.1.2.2 Results
Pilot studies were done to ensure that the concentration of donors used yielded cGMP
levels equal to or exceeding those observed during the ischaemic PC protocol. The
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Fig 5.3 Repetitive increases in cGMP by NO donors: Experimental protocol. Abbreviations as in Fig 3.1. The cyclic increases
in cGMP during a three-episode ischaemie preconditioning protocol was mimicked by 3 x 5 min administration of the NO donors,
SNAP (10 IlM or 50 IlM) or SNP (100 IlM) in the absence of ischaemia. Arrows indicated time points of freeze-clamping for
cGMP and cAMP determinations. (n = 6 hearts/series).
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Fig 5.4 Repetitive increases in cGMP by NO donors. Cyclic increases in cGMP occurred after 1 x 5 min and 3 x 5 min episodes of both
the NO donors, SNAP (10!lM or 50 !lM) or SNP (100 J..lM)in the absence of ischaemia. Upon reperfusion (Rep.) with normal buffer, these
values returned to control levels. The effect of SNAP on cGMP levels was dose-dependent and much more effective than SNP.
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Fig 5.5 Effect of repetitive administration of NO donors on cAMP levels. Cyclic increases in cAMP occurred during an ischaemie PC protocol,
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Table 5.2
Effects of administration of NO donors (SNAP or SNP) on tissue cyclic nucleotides
before onset of sustained ischaemia.
cGMP
Control (n = 11) 8.42 ± 0.35
SNAP (10 IlM)
(n = > 7/series)
1 x 5 min 38.77 ± 7.56 *
1 x 5 min + Rep. 10.11 ± 0.26 8
3 x 5 min 34.94 ± 4.87 *
3 x 5 min + Rep. 9.30 ± 0.28 8
SNAP (50 IlM)
(n = 5/series)
1 x 5 min 52.44 ± 7.13 *
1 x 5 min + Rep. 12.97 ± 0.80 8
3 x 5 min 44.19 ± 7.74 *
3 x 5 min + Rep. 11.82 ± 3.05 8
SNP (100 gM)
(n = > 8/series)
1 x 5 min 18.96 ± 3.67 *
1 x 5 min + Rep 6.38 ± 0.378
3 x 5 min 13.05 ± 0.75 *
3 x 5 min + Rep. 8.22 ± 0.47 8
L-Arginine (10 mM)
(n = 5/series)
1 x 5 min 8.14 ± 0.35
3 x 5 min 7.37 ± 0.58
cAMP cAMP/cGMP
317.0 ± 9.27 37.65
360.5 ± 20.2 11.78± 2.02
403.8 ± 23.7 * 43.63 ± 1.72
364.7 ± 11.8 11.81±2.23
359.3 ± 24.3 41.47 ± 4.03
339.7 ± 7.33 4.72 ± 0.99
346.2 ± 10.43 28.30 ± 0.92
379.4 ± 37.87 8.29 ± 1.15
318.5 ± 21.89 20.23 ± 2.72
270.7 ± 31.85 14.82 ± 2.10
340.9 ± 37.11 53.47 ± 8.2
270.7 ± 7.32 18.46 ± 0.79
270.9 ± 11.77 30.00 ± 2.87
Results expressed as pmoles/g wet weight. Control hearts were perfused for 60 min (15 min
retrograde, 15 min working heart, 30 min retrograde perfusion) (similar values were obtained at 30
min of control perfusion conditions).
8 P < 0.05 1 x 5 min vs 1 x 5 min + Rep or 3 x 5 min vs 3 x 5 min + Rep
* p < 0.05 vs control (untreated)
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cyclic increases in tissue cGMP during a three-episode ischaemic PC protocol could be
mimicked by 3 x 5 min administration of the NO donors, SNAP and SNP (in the absence
of ischaemia) (Fig. 5.4). The effect of SNAP on tissue cGMP levels is dose-dependent:
1 x 5 min administration of SNAP at 10 ).tM increased cGMP levels to 38.77 ± 7.56,
compared to 52.44 ± 7.13 pmoles/g wet weight with 50 ).tMSNAP. Fig. 5.4 shows that
cyclic increases in cGMP occur after 1 x 5 min and 3 x 5 min episodes of both 10 and
50 ).tM SNAP administration. Upon reperfusion with normal buffer, these values
returned to control levels. SNP appeared to be a less effective NO donor, since at 100
).tMcGMP levels were lower than those induced by 10 ).tMSNAP (Fig. 5.4). However, it
also caused significant increases in cGMP at both 1 x 5 min and 3 x 5 min of
administration. L-arginine (L-Arg) had no effect on tissue cGMP values, because 1 x 5
min and 3 x 5 min administration of L-Arg (10 mM) resulted in 8.14 ± 0.35 and 7.37 ±
0.58 pmoles/g wet weight, respectively, which were not significantly different when
compared to the control value of 8.42 ± 0.35 pmoles/g wet weight.
In order to study the effects of NO (or cGMP) in isolation, it was required that no
concomitant changes in cAMP occur upon administration of SNAP or SNP. Although it
appears that SNAP (10 and 50 ).tM) increases tissue cAMP levels, the changes were
not significant compared to the control levels (except for SNAP 10 ).tM, 1 x 5 min +
reperfusion) (Fig. 5.5).
Due to the marked increases in tissue cGMP upon administration of NO donors, SNAP
(10 and 50 ).tM) or SNP (100 ).tM) (Fig. 5.4), the cAMP/cGMP ratios were severely
depressed during 1 x 5 min and 3 x 5 min, compared to reperfusion with normal buffer
during 1 x 5 min + Rep. and 3 x 5 min + Rep. (Table 5.2).
5.2.1.3 p-adrenergic receptor responsiveness after repeated NO stimulation
Should NO donors contribute to increases in cAMP, then repeated NO donor treatment
would result in desensitization of the p-adrenergic receptor as observed after repeated
increases in cAMP by ischaemic-PC or isoproterenol-PC (Fig. 4.8). Therefore the
following experiments were performed to assess whether repeated stimulation of with
the NO donor, SNP, might reduce the p-adrenergic response at the end of the simulated
PC protocol before sustained ischaemia.
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Fig 5.6 f3-adrenergic receptor responsiveness after repeated NO stimulation. Experimental protocol. Abbreviations as in Fig 3.1. The cyclic
increases in cGMP during a three-episode ischaemie preconditioning protocol was mimicked by 3 x 5 min administration of the NO donor,
SNP (100 11M)in the absence of ischaemia. At 58 min of perfusion time of non-PC, PC hearts and SNP treated hearts, isoproterenol (10-7 M)
was added to the perfusate and hearts were freeze-clamped (as indicated by arrows) after 2 min for cAMP determination.
(n = 6 hearts/series).
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Fig 5.7 f)-adrenergic receptor responsiveness after repeated NO stimulation. Repeated administration of NO donor, SNP (3 x 5 min, 100 f.lM),
does not desensitize hearts to additional f)-adrenergic stimulation, for the cAMP content was not significantly different from non-PC hearts.
On the other hand, repeated ischaemie preconditioning (3 x 5 min global ischaemia) significantly desensitizes the heart to further f)-adrenergic
stimulation (as observed before).
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5.2.1.3.1 Experimental protocol
Tissue cAMP levels were measured after additional p-adrenergic receptor stimulation,
by administration of isoproterenol (10-7 mol/I) for a period of 2 min after repeated
administration of 100 j.1MSNP (Fig. 5.6).
5.2.1.3.2 Results
As observed previously (3.2.1.2.4.3 and Fig. 3.9), the ischaemie PC protocol (3 x 5 min
global ischaemia) significantly desensitizes the heart to further p-adrenergic receptor
stimulation, when compared to that of non-PC hearts. Hearts administered with SNP
(100 j.1M)for 3 x 5 min was still sensitive to additional p-adrenergic stimulation, for the
cAMP content was not significantly different from that of non-PC hearts (Fig. 5.7).
5.2.1.4 Manipulation of p3S MAPK activation by inhibition or stimulation of
NO-cGMP pathway during the PC protocol
To assess whether repeated elevation of tissue cGMP during the PC protocol, had an
effect on p38 MAPK activation, it was necessary to characterize the effects of
manipulation of the NO-cGMP pathway on p38 MAPK activation during this protocol.
5.2.1.4.1 Experimental protocol
Following the stabilization period of 25 min, inhibitors of the NO-cGMP pathway 000
(20 j.1M),a guanylyl cyclase inhibitor or L-NAME (50 j.1M)a nitric oxide synthase
inhibitor, was introduced 5 min preceding 5 min global ischaemia (PC1-) (Fig. 5.8A).
Furthermore, after 25 min of stabilization, hearts were also subjected to either 5 min
global ischaemia or 5 min treatment with NO donors, SNP and SNAP (Fig. 5.9A).
5.2.1.4.2 Results
The ischaemia-induced (PC1-) activation of p38 MAPK, as indicated by its dual
phosphorylation, was significantly inhibited by L-NAME (Fig. 5.8B). On the other hand,
introducing 000 prior to 5 min global ischaemia (PC1-), led to a slight, but not
significant decrease of the ischaemia-induced activation of p3B MAPK (Fig. 5.BC, last
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Fig 5.8 Manipulation of ischaemia-induced p38 MAPK activation by inhibition of NO-
cGMP pathway. A. L-NAME (50 j..tM)or 20 j..tM000 in DMSO (0.04%) was
administered 5 min prior to 5 min global ischaemia (PC1-). B. L-NAME inhibited the
ischaemia-induced p38 MAPK activation, C. however 000 could not (last lane:
DMSO+ODQ+PC1-). A representative blot is given for each experiment n = 4-6
hearts/series.
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p38 MAPK. A representative blot is given for each experiment. n = 4-6 hearts/series.
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lane, DMSa + aDa + PC1-). Because aDa was dissolved in DMSa, a control series
with DMSa (0.04%) alone or DMSa + PC1- or DMSa + aDa was also included.
Although DMSa alone had no significant effect on p38 MAPK activation, it did however
partially suppress the PC-induced p38 MAPK activation. Furthermore, DMSa + aDa
increased p38 MAPK activation to a much lesser extent than PC1- (Fig. 5.8C).
Both Na donors, SNP and SNAP, increased the phosphorylation p38 MAPK
significantly compared to controls, however not to the same extent as that induced by 5
min ischaemia (PC1-) (Fig. 5.9B).
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5.2.2 Evaluation of events during sustained ischaemia
5.2.2.1 Effect of prior manipulation of the NO-cGMP pathway on cyclic
nucleotides during sustained ischaemia
To evaluate the effect of prior inhibition or stimulation of the Na-cGMP pathway on
sustained ischaemia, it was necessary to determine the changes in cyclic nucleotides at
the end of 25 min sustained ischaemia.
5.2.2.1.1 Experimental protocol
Six series of hearts (Non-PC, PC, or pre-treated with coc (20 JlM), SNAP (50 JlM) or
SNP (100 JlM), as described above (5.2.1.1.1 and 5.2.1.2.1), were subjected to 25 min
global sustained ischaemia and then freeze-clamped (6 hearts/series) (Fig. 5.10). The
cAMP and cGMP responses to 25 min sustained ischaemia were determined as
described in the methods (chapter 2). Cyclic nucleotides at this stage of the protocol
were not assessed in L-arginine and L-NAME treated hearts.
5.2.2.1.2 Results
5.2.2.1.2.1 GC inhibition
At the end of 25 min sustained ischaemia, the ischaemic PC protocol causes a
significant increase in tissue cGMP when compared to non-PC hearts (Fig. 5.11A and
Table 5.3). ooo (20JlM) significantly increased tissue cGMP compared to untreated
controls (Fig. 5.11A and Table 5.3). Consequently, when aDa + DMSa was
introduced to PC hearts, no significant change in tissue cGMP occurred compared to
control hearts treated with aDa + DMSa. Therefore, introducing aDa + DMSa to PC
hearts diminished the significant percentage rise in cGMP occurring in untreated PC
hearts after 25 min ischaemia from 42% (untreated control vs. untreated PC) to 15%
(control + aDa + DMSa vs. PC + aDa + DMSa).
As indicated before (3.2.2.2.1), cAMP values at the end of 25 min sustained ischaemia
were significantly increased in both non-PC and PC hearts compared to controls.
However, PC significantly reduced cAMP when compared to non-PC hearts (Fig. 5.11 B
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Fig 5.10 Tissue cyclic nucleotide responses to 25 min sustained global ischaemia after prior manipulation of the NO-cGMP pathway.
Experimental protocol. Abbreviations as in Fig 3.1. Prior to 25 min sustained global ischaemia, the inhibitor of guanylyl cyclase, 000
(4 x 5 min, 20 j...lM),was administered before and during the ischaemie PC protocol, while the three-episode ischaemic preconditioning
protocol was mimicked by 3 x 5 min administrations of the NO donors, SNAP (50 j...lM)or SNP (100 j...lM)in the absence of ischaemia.
Arrows indicate time of freeze-clamping for cGMP and cAMP determination. (n = 6 hearts per series).
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Fig 5.11 Tissue cGMP and cAMP levels after 25 min sustained ischaemia: effect of manipulation with aDO (20 !J.M). Treating control hearts
with 000 + OMSO (administered for 3 x 5min interspersed with drug-free buffer, after equilibration for 30 min) increased cGMP, while lowering cAMP
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Table 5.3
Tissue cyclic nucleotides and cAMP/cGMP ratio at the end of 25 min sustained
ischaemia
cGMP cAMP cAMP/cGMP
Controls 8.42 ± 0.38 317.0 ± 9.27 * 37.65
Controls (OMSO + 000) 11.22 ± 0.43 * 241.5 ± 10.10 * 24.60 ± 2.56
After 25 min sustained ischaemia:
Non-PC 8.20 ± 0.58 612.7 ± 25.80 58.62 ± 6.37
PC 11.92 ± 0.62 * 417.5 ± 34.00 * 36.41 ± 3.19*
PC+OOO (20 11M,in OMSO) 12.87 ± 0.42 * 476.4 ± 35.59 8 37.02 ± 3.21*8
SNAP (10 11M) 13.27 ± 0.76 * 554.3 ± 31.05 41.8 ± 1.58*
SNAP (50 11M) 11.86 ± 1.12 *
SNP (100 11M) 14.45 ± 0.76 *
563.6 ± 25.44 22.24 ± 3.66*
460.6 ± 27.42 * 31.93 ± 2.66*
Values are means ± SE in pmoles/g wet weight; n = >6 hearts /series. Controls were perfused for
60 min (15 min retrograde, 15 min working heart, 30 min retrograde). Controls + OMSO + 000:
OMSO (0.04%) + 000 (20 11M)were administered for 3 x 5 min interspersed with a drug-free
buffer after equilibration for 30 min. PC+OOO, SNAP and SNP were administered as shown in
Fig.5.12.
* p < 0.05 vs non-PC
8 p < 0.05 vs controls + OMSO + 000
# P < 0.05 vs PC
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and Table 5.3). ODa dissolved in DMSO had no significant effect on the cAMP levels
in either control or PC hearts compared to their untreated levels, respectively (Fig.
5.11 B and Table 5.3). However, introducing ODa + DMSO to PC hearts increased the
significant percentage rise in cAMP occurring in untreated PC hearts after 25 min
ischaemia from 32% (untreated control vs. untreated PC) to 97% (control + ODa +
DMSO vs. PC + ODa + DMSO). Of interest is the similarity between the percentage
increase in cAMP content of non-PC (93%) and ODa + OMSO treated PC (97%)
hearts, when compared with their respective controls (Fig. 5.11 B).
Comparison of cGMP and cAMP values at the end of 25 min sustained ischaemia,
showed that an ischaemie PC protocol caused a significant reduction in cAMP/cGMP
ratio, when compared to non-PC hearts (Table 5.3). Although ODa dissolved in DMSO
significantly reduced cAMP/cGMP ratio in PC hearts compared to non-PC (Table 5.3), it
was significantly increased compared to control hearts treated with ODa + DMSO.
5.2.2.1.2.2 NO donors
At the end of sustained ischaemia the NO donors SNAP (50 )lM) and SNP (100 )lM)
also caused significant increases in cGMP when compared to non-PC hearts (Fig.
5.12A). However, although both the donors significantly reduced the cAMP/cGMP ratio,
SNAP had no effect on tissue cAMP levels, while SNP significantly lowered tissue
cAMP compared to non-PC hearts (Fig. 5.12B and Table 5.3).
5.2.2.2 Effect of NO-cGMP pathway manipulations on p38 MAPK activation
at the end of sustained ischaemia
To assess whether p38 MAPK activation was involved in the protection induced by the
cyclic elevation of cGMP during the PC protocol, it was necessary to compare changes
in p38 MAPK activation during sustained ischaemia of NO or cGMP manipulated- and
ischaemie- preconditioned hearts.
5.2.2.2.1 Experimental protocol
As described before, non-PC, ischaemic PC (with and without ODa or L-NAME) and
NO donor (SNAP or SNP)-treated hearts were freeze-clamped at the end of 25 min
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global ischaemia (as Fig. 5.10). At least 4 hearts in each series were assayed for dual
phosphorylation of p38 MAPK.
5.2.2.2.2 Results
At the end of sustained ischaemia the significant increase in p38 MAPK activation in
non-PC hearts, was unaffected by prior L-NAME-treatment (Fig. 5.13A). In contrast,
inhibition of p38 MAPK activation during the PC protocol by L-NAME before sustained
ischaemia (Fig. 5.88), was associated with a significant increase in p38 MAPK
activation when compared to untreated PC hearts at the end of sustained ischaemia
(Fig. 5.13A). Conversely, as ODa + OMSO or DMSO alone caused decreases in p38
MAPK activation during the PC protocol (Fig. 5.8C), p38 MAPK of ODa-treated PC
hearts remained attenuated at the end of sustained ischaemia similar to untreated PC
hearts (Fig. 5.138).
Furthermore, dual phosphorylation of p38 MAPK by NO donors (SNAP and SNP) before
the onset of sustained ischaemia (Fig. 5.9) was associated with a significant attenuation
in p38 MAPK activation at the end of sustained ischaemia (Fig. 5.14) when compared to
untreated non-PC hearts. These results were comparable to activation levels of p38
MAPK in ischaemie PC hearts.
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Fig 5.13 Effect of NO-GMP pathway inhibition on p38 MAPK activation at the end of 25
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5.2.3 Evaluation of events after sustained ischaemia during reperfusion:
Role of NO-cGMP pathway in eliciting protection
To establish whether NO release and thus the increases in tissue cGMP levels during
the PC protocol acts as a trigger and/or a mediator in eliciting protection, isolated
working rat hearts were subjected to (i) inhibition of guanylyl cyclase (GC) or nitric oxide
synthase (NOS) with aDa or L-NAME, respectively, during the PC protocol or (ii)
pharmacological elevation of tissue cGMP levels by NO donors, SNAP or SNP, before
onset of sustained ischaemia. Functional recovery during reperfusion was used as
endpoint to evaluate the extent of protection against ischaemie damage.
5.2.3.1 Effect of inhibition of guanylyl cyclase (GC) or nitric oxide synthase
(NOS) during PC protocol on functional recovery
5.2.3.1.1 Experimental protocol
To establish whether NO acts as a trigger and/or mediator in ischaemie PC, the
following protocols were used:
(i) Trigger and Mediator:
In the PC hearts, either coo (20 ~M) or L-NAME (50 ~M) or L-NNA (50 ~M) was
administered during the PC protocol, 5 min before and after PC1- and during
reperfusion after PC2- and PC3-. In non-PC hearts, each of these drugs was
administered for 4 x 5 min, interspersed by 5 min perfusion with normal buffer before
onset of sustained ischaemia. All hearts were subsequently subjected to 25 min global
ischaemia followed by 30 min reperfusion (10 min retrograde, 20 min working heart)
(Fig. 5.15i).
(ii) Mediator:
Hearts were preconditioned as described above and aDa (20 ~M) or L-NAME (50 ~M)
administered for 5 or 15 min during reperfusion after the PC protocol (PC3+), before the
onset of sustained ischaemia. In non-PC hearts, drugs were given for 5 or 15 min
before the onset of sustained ischaemia (Fig. 5.15ii).
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Fig 5.15 Effect of inhibition of the L-arginine-NO-cGMP pathway on functional recovery during reperfusion: Experimental protocol. (i) Trigger
and mediator: Inhibitors (ODQ, 20 f..I.Mor L-NAME, 50 f..I.M)were administered for 4x5 min until onset of sustained ischaemia, (ii) Mediator: Inhibitors
were administered for 5 or 15 min until onset of sustained ischaemia, (iii) Trigger: Inhibitors were administered for 3x5 min and washed out for 10 min
before onset of sustained ischaemia. Hearts were reperfused for 20 min after sustained ischaemia, then adrenaline (10-6 M) was added to the working
heart. Arrows indicate time points of measurement of mechanical function during reperfusion (6 hearts / time point).
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(iii) Trigger:
In PC hearts, either 000 (20 ~M) or L-NAME (50 ~M) was administered during the PC
protocol, 5 min before the onset of PC1- and during reperfusion after PC1- and PC2-.
After PC3- hearts were perfused for 10 min with drug-free buffer only (to wash out the
inhibitors), before onset of sustained ischaemia. In non-PC hearts the inhibitors were
administered for 3 x 5 min alternated with perfusion with buffer and followed by a
washout period before sustained ischaemia (Fig. 5.15iii).
Functional recovery was measured after 20 min reperfusion (105 min or 110 min total
perfusion time) of each experimental group, as indicated in Fig. 5.15. Table 5.4, Figs.
5.16 and 5.17 summarize the effects of the inhibitors 000, L-NAME and L-NA on the
mechanical recovery during reperfusion.
The contractile reserve or recovery potential of hearts subjected to treatment with GC or
NOS inhibitors was assessed by adding adrenaline (10-6 M) during the reperfusion
phase for 10 min and monitoring changes in function occurred at 115 or 120 min total
perfusion time (Fig. 5.15). The results were expressed as the percentage increase
induced by adrenaline when compared to the values obtained during reperfusion before
stimulation (Table 5.5).
5.2.3.1.2 Results
5.2.3.1.2.1 Vehicle
Since DMSO was used as a solvent for 000 (L-NAME and L-NA being water soluble),
a series of non-PC and PC hearts was studied in which DMSO alone was administered
either 4 x 5 min or 15 min before onset of sustained ischaemia (Fig. 5.15). DMSO when
administered for 4 x 5 min caused a significant reduction in coronary flow rate and
cardiac output of non-PC hearts, while 15 min of administration had no significant effect
(Table 5.4). However, DMSO (regardless of the protocol of administration) had no
effect on any parameter of functional recovery in PC hearts.
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Fig 5.16 Effect of 000 (20 J.lM,dissolved in OMSO) pretreatment on functional recovery during reperfusion of non-PC and PC hearts. 000
reduced the aortic output as well as the work performance of PC hearts when given during the PC protocol for either 4 x 5 min or 3 x 5min, but washed out
for 10 min before the onset of sustained ischaemia, however 000 had no effect on functional recovery when given 5 min before the onset of sustained
ischaemia. These results suggest a role for NO as a trigger.
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before the onset of sustained ischaemia, however L-NAME had no effect on functional recovery when given 5 min before the onset of sustained ischaemia.
These results also suggest a role for NO as a trigger.
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Table 5.4
Effect of ischaemie preconditioning, ODQ, L-NAME and L-NA on functional recovery
during reperfusion after 25 min sustained ischaemia.
Coronary flow Cardiac output Peak systolic Heart Rate
(ml/min) (ml/min) pressure (beats/min)
(mmHg)
Before arrest (7) 14.1 ± 0.4 56.1±1.5 104 ± 3 271 ± 15
During Reperfusion:
Non-Preconditioned:
Untreated (6) 11.2± 1.5 13.6 ± 2.08 68 ± 3.78 213 ± 208
Vehicle:
4x5 min OMSO (6) 4.0 ± 1.9t 4.5±1.9t 34 ± 14 115 ± 39
15 min oMSO (3) 9.7 ± 0.4 13.1 ± 1.4 79 ± 1.4 192 ± 10
Trigger + mediator (4x5 min):
20 11MOoQ + oMSO (7) 5.4±1.7 5.4 ± 1.7 32±9 t 120 ± 31
50 11ML-NAME (6) 8.8 ± 2.4 10.5 ± 2.6 69 ± 13 183 ± 37
50 11ML-NA (4) 8.6 ± 1.2 9.7±1.8 68± 9 271 ± 13 t
Mediator:
5 min OoQ + DMSO (9) 10.5 ± 1.6 18.1±3.7 80± 7 207 ± 10
15 min ODQ + DMSO (4) 3.1 ± 1.6 t 3.1 ± 1.6 t 26.3±13 94 ±49
5 min L-NAME (7) 5.8 ± 0.9 t 10.6 ± 3.2 59 ± 12 175 ± 8
15 min L-NAME (4) 7.2 ± 0.4 16.0 ± 1.6 90 ± 1.0 211± 2.4
Trigger:
3 x 5 min OoQ + oMSO (7) 8.6 ± 0.5 9.2 ± 1.0 70±5 197 ± 17
3 x 5 min L-NAME (6) 9.6 ± 0.8 16.6 ± 2.5 82 ± 3 240 ± 16
Table 5.4 I...
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Coronary flow Cardiac output Peak systolic Heart Rate
(ml/min) (ml/min) pressure (beats/min)
(mmHg)
Before arrest (7) 14.1 ±0.4 56.1 ± 1.5 104 ±3 271 ± 15
During Reperfusion:
Preconditioned:
Untreated (7) 13.7 ± 0.3 34.2 ± 2.2t 90 ± 2.5t 218 ± 7
Vehicle:
4x5 min DMSO (7) 12.4±1.1 27.7 ± 2.5t 83 ± 2.0 242 ± s+
15 min DMSO (4) 11.6 ± 0.6 29.1 ± 3.5t 85 ± 1.5 208±1.4
Trigger + mediator (4x5min):
20!-lM ODO +DMSO (4) 10.3 ± 0.9 19.2 ± 0.6 to 86±4 211 ± 14
50 !-1ML-NAME (8) 9.3 ± 1.0 16.6 ± 3.6 to 77±6 229 ± 21
50).1M L-NA (6) 7.1 ± 0.5 14.85 ± 2.1 to 89±3 202 ± 25
Mediator:
5 min ODO +DMSO (6) 11.8± 0.7 29.0 ± 3.0t 92 ±3t 209 ± 17
15 min ODO +DMSO (4) 11.0± 1.1 21.2 ± 0.1t 83 ± 1.1 188 ± 22
5 min L-NAME (6) 10.8 ± 0.8 28.1 ± 1.6t 90±4t 207 ± 19
15min L-NAME (4) 8.2 ± 1.4 24.2 ± 5.9t 83± 9 184 ± 22
Trigger:
3x5 min ODO +DMSO (9) 10.0±1.0 18.6±2.5 to 86±2 219 ± 15
3x5 min L-NAME (7) 9.0 ± 0.7 16.8 ± 2.8 to 83 ± 3 240 ± 19
Results expressed as the mean values ± SE obtained after 20 min of reperfusion. Numbers in
parentheses indicate number of hearts.
In all series, the parameters of function measured during reperfusion differed significantly (p <
0.05) vs before arrest (control values)
t p < 0.05 vs non-PC
Ó p < 0.05 vs PC
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5.2.3.1.2.2 Inhibitors to non-PC hearts
000, regardless of its mode of administration, significantly affected functional recovery
of non-PC hearts. For example, administration of 000 for 5 min before onset of
sustained ischaemia yielded values significantly higher than when administered for 3 x 5
or 4 x 5 min (Fig. 5.16). On the other hand, L-NAME administration had no effect on
functional recovery during reperfusion of non-PC hearts, regardless of the protocol used
(Fig. 5.17 and Table 5.4).
5.2.3.1.2.3 Inhibitors to PC hearts
(i) Trigger and Mediator:
Inhibitors administered before and during the PC protocol up to the onset of sustained
ischaemia (4 x 5 min) will allow evaluation of the roles of NO and cGMP as trigger as
well as mediator of protection.
Inhibition by 000 + DMSO (4 x 5 min) caused partial inhibition of the protection
induced by PC: in these hearts aortic output (Fig. 5.16A) and total work performance
(Fig. 5.16B) during reperfusion averaged 10.98 ± 1.6 ml/min and 4.12 ± 0.3 mW
respectively compared to 20.5 ± 2.1 ml/min and 6.9 ± 0.5 mW respectively in PC hearts.
Inhibition of NOS activity by L-NAME or L-NA in a similar protocol also caused partial
inhibition of the protection conferred by PC (Fig. 5.17A, B and Table 5.4).
(ii) Mediator:
Administration of 000 (in DMSO) or L-NAME after the PC protocol, either for 5 min or
15 min before the onset of sustained ischaemia, had no effect and post-ischaemie
function (aortic output: Figs 5.16A and 5.17A and total work: Figs 5.16B and 5.17B) was
similar to that of PC hearts, suggesting that NO does not act as a mediator.
(iii) Trigger:
Both 000 (in DMSO) and L-NAME, when given during the PC protocol, but washed out
for 10 min before the onset of sustained ischaemia (Fig. 5.15iii), caused a significant
reduction in aortic output (Figs 5.16A and 5.17A) and total work performance (Figs
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5.168 and 5.178), as well as cardiac output (Table 5.4), when compared with untreated
PC hearts. These results suggest a role for NO as a trigger.
5.2.3.1.2.4 Effect of Adrenaline on recovery potential of hearts treated with GC
or NOS inhibitors
The percentage increases in all parameters induced by adrenaline were similar in
untreated PC and non-PC hearts. Similarly, neither of the protocols with ODa (3 x 5
min or 5 min; in DMSO) or L-NAME caused a significant difference in recovery potential
when compared with untreated PC and non-PC hearts. However, significantly higher
increases in coronary flow rates, cardiac output and total work performance were
observed in both PC and non-PC hearts treated with 3 x 5 min L-NAME. On the other
hand, administration of ODa for 15 min before the onset of sustained ischaemia,
significantly impaired recovery potential in non-PC hearts (Table 5.5). Furthermore, 3 x
5 min ooa caused a significant reduction in recovery potential of PC hearts.
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Table 5.5
Effect of Adrenaline (10-6 M) on mechanical performance during reperfusion of
hearts after treatment with inhibitors.
% increase Coronary flow Cardiac output Peak systolic Heart rate Total Work
pressure performance
Non-Preconditioned:
Untreated (6) 31.0± 8.1 62.1 ± 28.5 13.7± 4.0 52.8 ± 21.2 97± 35
Vehicle:
15min DMSO (3) 39.3± 7.6 104.7± 18.4 11.4± 0.4 57.9± 19.1 128.6± 18.4
Mediator:
5 min 000* (9) 41.8 ± 5.2 65.6 ± 6.3 16.7± 5.4 45.4 ± 6.5 94.3 ± 8.8
15min 000* (4) 6.34 ± 14.1t 6.34 ± 14.1t -21.1 ± s.z+ 1.91± 19.9t -14.9± 17.5t
5 min L-NAME (7) 60.2 ± 11.9 72.9 ± 18.4 34.5± 10.9 46.1 ± 5.8 137.2± 33.0
15min L-NAME(6) 53.3 ± 10.4 42.3 ± 13.5 6.3 ± 1.6 40.0 ± 3.2 52.6 ± 16.1
Trigger:
3 x 5 min 000* (7) 24.0 ± 3.0 26.8 ± 5.2 5.3 ± 2.7 56.0 ± 16.3 33.7 ± 7.5
3 x 5 min L-NAME (6) 66.3± 7.8t 149± 22.3t 20.3 ± 3.0 35.7 ± 9.1 205 ± 37.6t
Preconditioned:
Untreated (9) 41.7 ± 5.5 42.3 ± 5.2 7.1 ± 2.5 46.5 ± 3.0 54.4 ± 7.6
Vehicle:
15min DMSO (4) 42.3 ± 5.9 56.2 ± 7.7 9.6 ± 2.1 51.4± 6.7 72.8± 11.1
Mediator:
5 min000* (6) 56.1 ± 4.7
15min000* (4) 43.3 ± 4.4
5 min L-NAME(6) 58.2 ± 7.9
15minL-NAME(6) 37.5± 9.1
38.0± 6.2
63.5 ± 12.8
78.6 ± 10.4
34.0± 12.1
5.8 ± 0.9
9.4 ± 1.8
9.6 ± 2.1
3.9 ± 2.0
55.1 ± 8.1 46.8 ± 6.9
41.2± 7.2 81.0± 16.9
51.3 ± 13.2 98.2 ± 13.3
32.1 ± 9.1 40.3 ± 15.1
Trigger:
3 x 5 min 000* (9) 24.5 ± 5.9
3 x 5 min L-NAME (5) 65.2 ± 8.50
14.7± 8.20
116.0± 13.80
1.3 ± 1.9
17.1± 1.50
35.1 ± 9.1 16.9± 9.50
33.6± 5.4 156.1± 17.60
Values expressed as the percentage increase from results obtained after 20 min of reperfusion. Adrenaline
was administered after 20 min of reperfusion and mechanical performance monitored after 10 min. Hearts
were preconditioned or treated with the NO inhibitors as shown in Fig 5.17. Numbers in parentheses indicate
number of hearts. (*ODQ dissolved in DMSO).
t p < 0.05 vs non-PC
o p < 0.05 vs PC
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5.2.3.2 Effect of NO donors on functional recovery
5.2.3.2.1 Experimental protocol
After a stabilization period of 30 min, hearts were subjected to either 30 min retrograde
perfusion (non-PC) or 3 x 5 min global ischaemia (PC) or 3 x 5 min SNAP (10 or 50 flM)
or 3 x 5 min SNP (100 flM) or 3 x 5 min L-arginine (10 mM) prior to 25 min sustained
global ischaemia, followed by 30 min reperfusion (10 min retrograde, 20 min working
heart) (Fig. 5.18). Administration of donors was interspersed by normal buffer
perfusion. Functional performance was evaluated in all series before the onset of
sustained ischaemia (30 min total perfusion time) and during reperfusion (105 min total
perfusion time (Fig. 5.18).
In order to assess and compare the contractile reserve of hearts subjected to treatment
with NO donors, adrenaline (10-6 M) was administered during the reperfusion phase and
the changes in function monitored. Non-PC, PC, SNAP or SNP treated hearts were
perfused as described above until 20 min of reperfusion (105 min total perfusion time).
After registration of mechanical performance at this time-point, adrenaline (10-6 M) was
added to the working heart and the mechanical activity monitored after 10 min (Fig.
5.18).
5.2.3.2.2 Results
5.2.3.2.2.1 NO donors
In all series studied, exposure of the heart to 25 min sustained global ischaemia caused
a significant decline in all parameters of function measured during reperfusion
compared to values obtained before arrest. However, comparison of the functional
performance during reperfusion revealed significant differences between the groups
(Table 5.6).
Intermittent administration (3 x 5 min) of NO donors SNAP (50 flM) or SNP (100 J.lM),
prior to 25 min sustained ischaemia, significantly improved functional recovery during
reperfusion, when compared to non-PC hearts. The protection afforded by these
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Fig 5.18 Effect of prior stimulation of the L-arginine-NO-cGMP pathway on functional recovery during reperfusion. Experimental protocol.
Abbreviations as in Fig 3.1. Prior to 25 min sustained global ischaemia, the three-episode ischaemie preconditioning protocol was mimicked
by 3 x 5 min administrations of the NO donors, SNAP (50 )lM) or SNP (100 )lM), or L-arginine (10 mM) in the absence of ischaemia. Hearts
were reperfused for 20 min after sustained ischaemia, then adrenaline (10-6 M) was added to the working heart. Arrows indicate time points
of measurement of mechanical function during reperfusion (6 hearts I time point).
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Fig 5.19 Effect of prior stimulation of the L-arginine-NO-cGMP pathway on functional recovery during reperfusion. Intermittent administration
(3 x 5 min) of NO donors (SNAP, 50 JlM or SNP, 100 JlM), in the absence of ischaemia, improved aortic output as well as work performance
during reperfusion when compared to non-PC hearts. However, L-arginine (3 x 5 min, 10 mM) did not improve functional recovery.
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Table 5.6
Effect of ischaemie preconditioning and NO donors on functional recovery after
25 min sustained ischaemia
Coronary flow
(ml/min)
Cardiac output
(ml/min)
Peak systolic
pressure
(mmHg)
Heart rate
(beats/min)
Before arrest
(9)
12.4±0.6 54.6 ± 2.0 101 ± 2 278 ± 9
During reperfusion
L-Arginine (10 mM)
(5)
11.2 ± 1.5 13.6 ± 2.0* 68 ± 3.7* 213 ± 20*
13.7 ± 0.3 34.2 ± 2.2*t 90 ± 2.5t 218 ± 7
12.8 ± 0.53 30.8 ± 3.7*t 93 ± 0.5t 273 ± 11
8.5 ± 0.4 29.0 ± 2.6*t 89 ± 1t 248 ± 15
8.3 ± 0.5 25.3 ± 0.2*t 92 ± 0.7t 229± 8
9.4 ±0.8 30.5 ± 1.3*t 94±2t 227±5
9.4 ± 0.5 14.8 ± 0.8*5 82 ± 1* 255 ± 13
Non-PC
(6)
PC
(9)
SNAP (10 ~M)
(2)
SNAP (50 ~M)
(9)
SNAP (100 ~M)
(2)
SNP (100 ~M)
(10)
Results expressed as the mean values ± SE obtained after 20 min of reperfusion. Numbers in
parentheses indicate number of hearts.
In all series, the parameters of function measured during reperfusion differed significantly (p <
0.05) vs before arrest (control values)
* p < 0.05 vs before arrest (control values)
t p < 0.05 vs non-PC
8 p < 0.05 vs PC
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interventions was similar to that elicited by prior PC: aortic output (Fig. 5.19A), total
work performance (Fig. 5.198), cardiac output, peak systolic pressure and heart rate
(Table 5.6) were similar in these groups. Different concentrations of SNAP induced
similar protection: in hearts treated with 10, 50 and 100 JlM SNAP the aortic output
averaged 18.0 ± 4.2,20.5 ± 2.5 and 17.0 ± 0.7 ml/min, respectively. L-arginine (10 mM;
3 x 5 min), on the other hand, did not improve functional recovery during reperfusion
and values similar to those of non-PC hearts were obtained (Fig. 5.19A, 8 and Table
5.6).
5.2.3.2.2.2 Effect of Adrenaline on recovery potential of hearts treated with NO
donors
The results in Table 5.7 were expressed as the percentage increase induced by
adrenaline when compared to the values obtained during reperfusion of non-PC, PC,
SNAP and SNP hearts before stimulation (Fig. 5.19A, 8 and Table 5.6). The
percentage increases in all parameters induced by adrenaline were similar in PC and
non-PC hearts. However, SNAP (50 JlM) treated hearts showed significantly higher
increases in coronary flow rates, cardiac output, peak systolic pressure and total work
performance, when compared with non-PC, as well as PC hearts. Similarly, SNP (100
flM) treatment also caused significantly higher increases in cardiac output and total
work performance (Table 5.7). These results indicate that hearts, in which protection
was elicited by treatment with NO donors, have a superior recovery potential to those in
whom ischaemia was used to induce protection.
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Table 5.7
Effect of Adrenaline (10-6 M) on mechanical performance during reperfusion of
hearts on NO donors.
% increase Coronary flow Cardiac output Peak systolic Heart rate Total Work
pressure performance
Non-Preconditioned 31.0±8.1 62.1 ± 28.5 13.7 ± 4.0 52.8 ± 21.2 97 ± 35
Preconditioned 41.7 ± 5.5 42.3 ± 5.2 7.1 ± 2.5 46.5 ± 3.0 54.4 ± 9.3
SNAP (50 f.tM) 62.9 ± 7.5t 122.1 ± 18.0t8 17.0 ± 0.58 50.2 ± 2.9 167.6 ± 22.78
SNP (100 f.tM) 44.0 ± 4.6 114.8± 13.3t8 16.6± 1.3 53.1 ± 6.5 154.8± 16.88
Results expressed as the percentage increase from values obtained after 20 min of
reperfusion. Adrenaline was administered after 20 min of reperfusion and mechanical
performance monitored after 5 and 10 min. Hearts were preconditioned or treated with the
NO donors as shown in Fig 5.20.
t p < 0.05 vs non-preconditioned
8 p < 0.05 vs Preconditioned
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5.3 Discussion
The observation that a multi-cycle PC protocol elicits cyclic increases in both cGMP and
cAMP (Fig. 3.2) suggests the possibility of a role for both as triggers in the phenomenon
of ischaemie PC. To establish the relevance of the significant increases in cGMP per
se, appropriate pharmacological agents were employed in the present study that
allowed evaluation of such changes in the absence of concomitant changes in cAMP
(Figs. 5.2 and 5.5). The results obtained suggest that NO and subsequent cGMP
generation also act as a trigger in the phenomenon of classic PC - prevention of
ischaemie PC-induced cyclic elevations in cGMP (by inhibition of either guanylyl cyclase
or NOS activation) attenuated protection (Table 5.4, 5.5, Figs 5.16 and 5.17), while the
non-endothelium dependent NO donors SNAP and SNP, both elicited protection against
ischaemie damage (Table 5.6,5.7, Fig. 5.19).
5.3.1 Abolishment of protection by prevention of cyclic increases in cGMP
during PC
5.3.1.1 Inhibitors and vehicles
The significance of the elevation of tissue cGMP during the PC protocol was
investigated using L-NAME or L-NA, inhibitors of NOS, as well as aDa, an inhibitor of
soluble guanylyl cyclase. The latter has no effect on either NOS activity or NO
generation (Hobbs et aI., 1997). Vehicle related studies were not required in the case of
L-NAME or L-NA, since both are water soluble. According to the recommendations of
the manufacturer (Toeris Cookson, Ltd), aDa was dissolved in 0.04% DMSO. While
DMSO alone had no effect on tissue cGMP levels, the combination of DMSO and aDa
caused an unexpected increase in basal cGMP levels. An explanation for this finding is
not readily available.
In addition to the above, DMSO per se, when administered for 4 x 5 min before onset of
sustained ischaemia caused a significant decline in functional recovery of the non-PC
heart. Also in combination with aDa, when administered for 4 x 5 min or for 15 min
before the onset of sustained ischaemia, functional recovery (as evidenced by coronary
flow, cardiac output and work performance) was significantly less than that of non-PC
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hearts. These detrimental effects may be time-dependent, since they were not seen
when ODO and DMSOwere administered for 5 min only (Table 5.4) and may indicate a
direct toxic effect of ODO+DMSO on the heart. This was also substantiated by the
observation that the positive inotropic and chronotropic effects of adrenaline were
absent in non-PC hearts pretreated with 15 min ODO+DMSO (Table 5.5). However,
these harmful effects were not seen in the PC hearts and regardless of the protocol
used, similar values were obtained with ODO+DMSO, L-NAME and L-NA. Whether the
protection induced by ischaemie PC, also protects against the possible harmful effects
of ODO+DMSO, remains to be established.
The question thus arose whether any significance could be attached to observations
made with ODO+DMSO. After careful evaluation of the data, it was decided that, while
recognizing its putative toxic effects on the non-PC heart, ODO could be used as
inhibitor in our studies, since (i) it had no detrimental effects on the PC heart and (ii) its
effects were similar to those of L-NAME and L-NA.
5.3.1.2 PC and inhibitors
By using appropriate protocols (Fig. 5.15), it was shown convincingly that endogenous
NO acts as a trigger only in the phenomenon of PC: both L-NAME and ODO, if present
before and throughout the PC procedure, but washed out before sustained ischaemia,
significantly attenuated functional protection during reperfusion of preconditioned
hearts, while having no inhibitory effects when added only after the PC protocol, before
onset of sustained ischaemia (Figs 5.16 and 5.17). Similar conclusions were made by
Csonka et al. (1999) in isolated working rat hearts; when NG-nitro-L-arginine(LNA, 4.6
11M)was applied before the PC protocol, it abolished protection, while it failed to block
the protective effects of PC when administered after the PC protocol, therefore
confirming that NO synthesis by the heart is necessary to trigger classic PC. Although
the results of Vegh et al. (1992) support the involvement of NO in PC, they did not
distinguish whether NO act as mediator or trigger when they demonstrated that NG_
nitro-L-arginine methyl ester (L-NAME, 10mg/kg) abolished the antiarrhythmic effect of
PC in a coronary occlusion model in anesthetized dogs. Furthermore, recent results
confirmed that endogenous NO is not a mediator of ischaemic PC, since L-NAME
(3mM), when administered for 5 min after ischaemic PC (1 x 2 min) before 20 min
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global ischaemia in Langendorff perfused rat hearts (Suematsu et a/., 2001), did not
abolish the protective effect of PC.
Involvement of NO and cGMP as a trigger in cardioprotection has also been
demonstrated in ventricular overdrive pacing (VOP) PC of a conscious rabbit model
(Szilvassy et aI., 1994) and isolated working rat hearts (Ferdinandy et a/., 1996). In
addition, Csonka and coworkers (1999) showed that intact basal NO synthesis was
required to trigger PC, but that NO itself does not mediate protection, in both VOP-
induced and no-flow ischaemia-induced PC of working rat hearts. Therefore, with
reference to the role of NO, it appears that there is no difference between the
mechanism of PC induced by VOP and no-flow ischaemia.
In contrast to our results, Lu et al. (1995), Sun et al. (1997), Weselcouch et al. (1995)
and Nakano et al. (2000b), failed to demonstrate involvement of endogenous,
endothelial-derived NO as trigger of PC in rat hearts. This discrepancy may be due to
several minor, but possibly important differences in (i) protocol: 3 x 2 min coronary
occlusion (Lu et al. 1995), 1 x 3 min coronary occlusion (Sun et al. 1997), 4 x 5 min
global ischaemia (Weselcouch et al. 1995) and 1 x 5 min global ischaemia (Nakano et
al. 2000b) vs. 3 x 5 min global ischaemia in the present study (ii) perfusion model:
anesthetized rats (Lu et al. 1995, Sun et al. 1997) and retrogradely perfused rat or
rabbit hearts fitted with an intraventricular balloon (Weselcouch et al. 1995, Nakano et
al. 2000b) vs. our working rat hearts (iii) concentration of NOS inhibitors administered:
10mg/kg NG-monomethyl-L-arginine (L-NMMA) or L-NAME (Lu et al. 1995), 10-
100mg/kg L-NAME or 1-50mg/kg methylene blue (Sun et al. 1997), 30 ~M L-NAME
(Weselcouch et al. 1995) 100 ~M L-NAME (Nakano et al. 2000b) vs. 50 ~M L-NAME in
our study (iv) endpoints: arrhythmias (Lu et al. 1995, Sun et al. 1997), contractile
function or enzyme release (Weselcouch et al. 1995) and infarct size (Nakano et al.
2000b) vs. functional recovery of the working rat heart in the present study.
Although we do not have an explanation as yet for the above discrepancies, it is of
significance that, in our hands, inhibitors such as L-NAME or L-NA were able to abolish
ischaemie PC induced by a multi-cycle protocol (3 x 5min), which was shown to elicit
more effective protection than one or two cycles (Sandhu et a/., 1997).
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5.3.1.3 Non-PC and inhibitors:
Inhibition of NOS activation by L-NAME had no effect on the functional recovery of non-
preconditioned (non-PC) hearts, regardless of the protocol used (Fig. 5.17), suggesting
that inhibition of NO generation during sustained ischaemia did not protect against cell
damage in our model. Likewise, Weselcouch et al. (1995) and Nakano et al. (2000b)
showed that NOS inhibition (L-NAME) alone had no effect on the severity of ischaemia
in non-PC rat and rabbit hearts, respectively. In addition, we also demonstrated that
guanylyl cyclase inhibition by 000 did not improve functional recovery in non-
preconditioned hearts, when administered for 3 x 5 or 4 x 5 min. In fact, when
administered in this manner, 000 significantly impaired functional recovery in non-
preconditioned hearts, when compared to functional recovery observed in the protocol
with a shorter (5 min) total exposure to 000. As stated previously (5.3.1.1) it would
seem that repeated administration of the drug could have a detrimental effect (Fig.
5.16).
These results are in contrast to other studies where NOS inhibition protected against
ischaemia-reperfusion (Woolfson et ai., 1995, Depré et ai., 1995, Naseem et ai., 1995,
Csonka et al. 1999). This discrepancy could be due to differences in species,
experimental protocol and end-points: coronary artery ligation of isolated rabbit hearts
with infarct size as end-point (Woolfson et ai., 1995), low-flow ischaemia of isolated
rabbit hearts with functional recovery (left ventricular developed pressure) (Depré et ai.,
1995) or global ischaemia of retrogradely perfused rat hearts with functional recovery
(arrhythmias) (Naseem et ai., 1995) compared to global ischaemia of isolated working
rat heart with functional recovery (aortic flow) in our study. Although Csonka et al.
(1999) also utilized global ischaemia in isolated working rat hearts with functional
recovery (aortic flow), they induced a 30 min ischaemie period vs. 25 min in our model.
The time of administration of NOS inhibitor may also be important, since L-NAME was
administered continuously during 45 min of coronary artery ligation (Woolfson et ai.,
1995), or L-NMMA was added 15 min before low-flow ischaemia (Depré et ai., 1995), or
LNA was infused for either 30 min (Naseem et aI., 1995) or 20 min before no-flow
ischaemia (Csonka et al. 1999). However, in our study L-NAME was administered for 5
min, or for 3 - 4 periods of 5 min alternating with drug-free perfusion and also for 15 min
before onset of global ischaemia.
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A recent study from our laboratory (unpublished results) showed that the perfusion
mode (retrograde vs. working), grade of ischaemia (global vs. regional) and endpoint
(functional recovery vs. infarct size) could all affect the outcome of the results in PC.
Taking all these variables into account may help solve the discrepancies that so often
hampered the experimental work on PC.
5.3.2 Mimicking of PC by using NO donors as triggers
5.3.2.1 PC protocol
Elevation of cAMP per se acts as trigger during ischaemie PC (as observed in chapter
4). Therefore, to distinguish between the contribution of cAMP and cGMP as triggers, it
was a prerequisite to use a NO donor that would not increase tissue cAMP levels before
the onset of sustained ischaemia. Both SNAP and SNP caused dose-dependent
increases in cGMP, while it had no significant effect on tissue cAMP at 50 J.lM(Figs 5.4.
and 5.5). However, at 10 J.lM,SNAP caused slight but not significant increases in
cAMP, except when administered for 1 x 5 min, followed by reperfusion. Low
concentrations of SNAP (1 J.lM)have also been shown to elevate cAMP content of
isolated adult myocytes and to increase contractility; while at 100 J.lMthe drug had no
effect on cAMP (Vila-Petroff et ai., 1999). These researchers attributed the increase in
cAMP, induced by low levels of NO, to a novel cGMP-independent activation of adenylyl
cyclase. In view of the above, it is possible but unlikely that generation of NO (as
suggested by the cyclic increases in cGMP) during a multi-episode PC protocol in
isolated rat hearts, contribute to the characteristic ischaemia-induced increases in
cAMP during the PC protocol in the present study. Furthermore, if NO donors
contribute to increases in cAMP, then repeated NO donor treatment would result in
desensitization of the p-adrenergic receptor as observed after repeated increases in
cAMP by ischaemie-PC or isoproterenol-PC (Fig. 4.8). However repetitive SNP
administration does not desensitize the heart to additional p-adrenergic receptor
stimulation (Fig. 5.7).
5.3.2.2 Ischaemia-Reperfusion
The improvement in functional recovery induced by NO donors was not dose-dependent
in the range of tissue cGMP levels observed: elevation of cGMP to 52.44 ± 7.13 (1 x 5
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min 50 j..lMSNAP) or 18.96 ± 3.67 (1 x 5 min 100 j..lMSNP) pmoles/g wet weight (Fig.
5.4) elicited the same degree of protection during reperfusion (Fig. 5.19, Table 5.3).
Since 20.22 ± 0.91 pmoles/g wet weight was the highest level to which cGMP increased
during the ischaemic PC protocol (PC2-, Table 3.1) it seems as if maximal protection is
achieved with cGMP levels in that range.
Failure of L-arginine (10 mM) to elicit protection (Fig. 5.19) was surprising in view of
previous findings that this substrate protects against ischaemia-reperfusion injury
(Engelman et aI., 1995a, Mizuno et aI., 1998). A possible explanation may be the
failure of intermittent administration of L-arginine to increase cGMP in the present study
(Table 5.2). On the other hand, it has also been shown that intracoronary
administration of L-arginine aggravates myocardial stunning through production of
peroxynitrite in dogs (Mori et aI., 1998). However, although the possibility exists that
NO donors may contribute to improved function by reduction of stunning, as has been
shown by others in large animals (Engelman et aI., 1995b, Ferdinandy et aI., 1996), this
remains to be elucidated in our model.
As far as we know, this is the first direct demonstration that exogenous NO improves
functional recovery during reperfusion in working rat hearts, by repeated transient
administration and washout of NO donors before the onset of sustained ischaemia. (Fig.
5.19, Table 5.6). These results are consistent with the findings that exogenous NO
donors mimic the effect of early PC on (i) reperfusion arrhythmias in rat hearts (Bilinska
et aI., 1996), (ii) infarct size in rabbit hearts (Nakano et al., 2000b), as well as on (iii) cell
viability and enzyme release in cultured neonatal rat ventricular myocytes (Rakhit et al.,
2000).
Few studies have implicated a role for NO in early PC, and these largely involve animal
models of protection against pacing (Vegh et al., 1992) and reperfusion-induced
arrhythmias (Bilinska et aI., 1996). The latter study showed that NO donors (glyceryl
trinitrate, GTN and 3-morpholino-sydnonimine-hydrochloride, SIN-1), administered for 5
min and washed out for another 5min prior to ischaemia (10 min regional ischaemia),
abolished reperfusion induced ventricular tachycardia in Langendortt perfused rat
hearts. Recently, Nakano et al. (2000b) demonstrated that rabbit hearts treated with a
NO donor, S-nitroso-N-acetylpenicillamine (SNAP, 2 j..lM),for 5 min followed by a 10
min drug-free interval prior to 30 min regional ischaemia, reduced infarct size during
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reperfusion. Furthermore, the study of Rakhit et al. (2000) in a simulated ischaemia
model of early PC in rat neonatal cardiocytes suggested that the NO donor, SNAP,
given for 90 min prior to lethal hypoxia (6 h) significantly protects against ischaemie
injury. They also indicated that the NOS inhibitor, LNMMA, blocked the protective effect
of PC. Hence, NO is implicated as a trigger in this model of early PC via activation of a
constitutive NOS (eNOS) isoform.
Furthermore, Bell et al. (2001) recently used eNOS knockout mice to determine whether
it is pivotal to early PC. They concluded that eNOS is not essential for robust (four
cycles of 5 min ischaemia/reperfusion) PC, but may contribute to early PC by lowering
the ischaemie threshold for protection. In addition they also demonstrated that
triggering with NO (SNAP, 2 llM) per se could be cardioprotective.
5.3.2.3 Contractile Reserve
In our studies there was no difference in the protection induced by either ischaemia or
NO donors (Fig. 5.19, Table 5.6). Interestingly, the contractile reserve of hearts
preconditioned with SNP or SNAP was significantly higher than that of ischaemie
preconditioned hearts: for example, infusion of adrenaline (10-6 M) at the end of
reperfusion, caused a -3 fold higher percentage stimulation of cardiac output and Wt
compared to preconditioned hearts (Table 5.7). This indicates that the superior
protection induced by NO was unmasked by adrenaline, and that in fact, it offered a
major advantage above PC with ischaemia. Therefore, these data suggest that NO-
induced PC may be a useful clinical manipulation, and this possibility should be further
investigated. It should, however, be kept in mind that the superior contractile reserve of
NO donor treated hearts might be related to some of the other many actions of NO.
Thus, whether the improved contractile reserve is due to prior preconditioning, or
another mechanism, remains to be established.
5.3.3 How does NO-cGMPpathway trigger protection?
Establishing the relative importance of a trigger is difficult, since pharmacological
mimicking of a trigger often elicits maximal protection, similar to that observed with
ischaemie PC. Also in the present study where cyclic elevations in cGMP and cAMP
occur simultaneously during the PC protocol (Fig. 3.2, Table 3.1), elevation in both
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nucleotides is not a prerequisite for subsequent protection against ischaemie damage:
elevation in cAMP per se by p-adrenergic stimulation (Fig. 4.6) or in cGMP per se by
NO donors (Fig. 5.4) could induce protection similar to that induced by ischaemie PC
(Figs. 4.23, 4.24 and 5.19). On the other hand, prevention of these cyclic increases in
cAMP (Fig. 4.4) or cGMP (Table 5.1, Fig. 5.2), only partially suppressed PC induced
protection (Figs. 4.21,5.16 and 5.17), confirming involvement of more than one trigger.
5.3.3.1 "Cross-talk"
Considerable "cross-talk" may occur between the signal transduction pathways of the
released triggers during an ischaemie PC protocol. For example, NO (and thus cGMP)
attenuates p-receptor mediated responses (Ebihara et ai., 1996), whereas inhibition of
NOS activity could enhance the p-response to isoproterenol in myocytes (Balligand et
aI., 1993). Furthermore, NO-induced elevated cGMP can act by stimulating a cGMP
sensitive phosphodiesterase with a resultant reduction in levels of cAMP (Parratt 1995).
Therefore, in the present study, the very significant increases in cGMP during the PC
protocol (PC2- and PC3-: 140 and 99%, respectively, refer to 3.2.1.2.1), suggests an
important role for NO and could possibly account for the significantly smaller increases
in cAMP (PC2- and PC3-: 16 and 17%, respectively) occurring simultaneously.
5.3.3.2 Reactive oxygen species (ROS)
Other possible mechanisms of action of NO in the PC process have recently been
reviewed by Rakhit and coworkers (1999). NO can for example act as a free radical
donor. NO combines with superoxide to generate peroxynitrite which, in turn,
decomposes to yield hydroxyl radicals and other reactive oxygen species (ROS)
(Beckman et aI., 1990). These NO-derived radicals are thought to aggravate injury
under certain circumstances. However, free radicals can also trigger PC since
administration of antioxidants during the brief triggering ischaemia has been found to
prevent both early and late PC (Sun et ai., 1996). Furthermore, a recent study by
Csonka et al. (2001) demonstrated that during a PC protocol (three intermittent periods
of global ischaemia) peroxynitrite formation by the first period of ischaemia/reperfusion
was gradually attenuated by the subsequent ischaemia/reperfusion periods, confirming
that a detrimental component of NO can paradoxically trigger subsequent protection.
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Recent studies, using appropriate blockers or scavengers, suggested that NO may use
bath cGMP and ROS as triggers during NO-induced PC: Rakhit et al. (2000) indicated
that SNAP-triggered protection was completely abolished by 000 in cultured rat
ventricular myocytes, thus the NO-induced trigger is cGMP dependent. On the other
hand, Nakano et al. (2000) has reported that the beneficial effect of exogenous NO
production during SNAP pretreatment was blocked by a free radical scavenger, N-(2-
mercaptopropionyl)-glycine or MPG, in isolated rabbit hearts.
In turn, several studies have demonstrated activation of PKC by ROS (Baines et al.,
1997, Konishi et al., 1997). It has recently been shown (Ping et al., 1999c) that
activation of PKC during a 6 x 4 min PC protocol is NO dependent and that exogenous
NO donors can translocate PKC E and 'Il in the absence of ischaemia. In addition,
Nakano et al. (2000) also reported that SNAP's protection could be blocked by
chelerythrine, indicating that NO-triggered protection may be mediated by a PKC-
dependent pathway.
5.3.3.3 p38 MAPK:
Protein tyrosine kinases are reported to be downstream of PKC for early and late
ischaemie PC (Baines et al., 1998, Ping et al., 1999a,b). During the late phase of PC it
was shown that protein tyrosine kinase signalling is essential for the increase of
inducible NOS activity, indicating that iNOS is involved as a downstream element of
protein tyrosine kinase (Dawn et al., 1999). In addition, several studies have examined
the potential role of the stress kinase, p38 MAPK as a component of the pathway of PC
distal of PKC (Maulik et al., 1996, Weinbrenner et al., 1997). However, to our
knowledge, the relationship between NO and p38 MAPK in early PC has not been
investigated previously and there are also no data concerning the downstream effects of
cGMP in the context of early PC.
In the present study, L-NAME (NOS inhibitor) could significantly attenuate p38 MAPK
activation induced by 5 min ischaemia (PC1-), however this p38 MAPK activation was
insensitive to 000 (GC inhibitor) (Fig. 5.8). These results indicate that p38 MAPK are
activated by 5 min ischaemia in a L-arginine-NO dependent way, but not by the rise in
cGMP which occurs simultaneously.
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Furthermore, our results indicate that 5 min administration of both NO donors, SNAP
and SNP, significantly activated p38 MAPK, however not to the same extent as that
induced by 5 min ischaemia (Fig. 5.9). Recently Kim et al. (2000) investigated the role
of SNP in the regulation of the MAPKs in isolated adult rat cardiomyocytes and they
also found that SNP maximally activated p38 MAPK, as well as its substrate
MAPKAPK2, in 5 - 10 min. In addition, they blocked the activation of MAPKAPK2 by
SNP with 000 (GC inhibitor), indicating that p38 MAPK and MAPKAPK2 are activated
by SNP in a cGMP-dependent way (which differs from ischaemia-induced p38 MAPK
activation, Fig. 5.8). Furthermore, a study by Browning et al. (2000) demonstrated that
exogenously supplied NO leads to activation of p38 MAPK that requires activation of
cGMP-dependent protein kinase (PKG) in 293T fibroblasts.
The above mentioned studies indicate that triggering with NO donors induces p38
MAPK activation. However whether p38 MAPK activation acts as a trigger in NO-
induced PC has not yet been studied - what is required is to study a NO donor in
combination with a p38 MAPK inhibitor, like SB203580.
The physiological importance of p38 MAPK induced by brief surges of NO also remains
to be investigated, but its downstream substrate, MAPKAPK2, can phosphorylate
various transcription factors, i.e. HSP27 (Tan et aI., 1996). The phosphorylated HSP27
appears to stimulate the polymerization of actin and this might facilitate recovery of the
actin microfilament networks, which are disrupted during cellular stresses like
ischaemia.
5.3.4 How does the NO-cGMP pathway mediate protection during
sustained ischaemia?
As observed in chapter 3, PC significantly attenuates the increase in tissue cAMP and
stimulates an increase in cGMP in response to sustained ischaemia (Fig. 3.13). It is not
yet known whether these changes are merely the consequence of or whether they
contribute to the protection induced by ischaemie PC.
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5.3.4.1 Calcium (Ca2+)
It is possible that the NO-cGMP pathway could be protective: elevated cGMP during
sustained ischaemia may act by reducing the influx of Ca2+ through the L-type Ca2+
channels (Sperelakis, 1994) via protein kinase G (Sumii and Sperelakis 1995, Klein et
aI., 2000), therefore limiting myocyte contractility (Brady et al., 1992) that could serve to
reduce oxygen consumption and energy demand. Similarly, Node et al. (1996)
indicated that increased release of NO during ischaemia reduces myocardial
contractility and improves metabolic dysfunction. In addition, Rakhit et al. (2001)
recently indicated that pre-treatment with a NO donor (SNAP, 1mM for 90 min followed
by 10 to 30 min washout) protects cardiomyocytes from ischaemia-reperfusion injury.
They demonstrated a modest, sustained mitochondrial depolarization and a reduction in
mitochondrial Ca2+ uptake that possibly reduces Ca2+ overload, thus providing a likely
mechanism for NO-induced protection.
5.3.4.2 Phosphodiesterase (POE):
Elevated cGMP during sustained ischaemia may be due to stimulation of cGMP
sensitive phosphodiesterase in PC hearts (Fig. 3.14) with resultant lowering of cAMP. It
is possible that these two nucleotides act in synergism during sustained ischaemia: in
view of their opposing effects on the Ca2+ slow channel, the simultaneous lowering of
tissue cAMP and elevation in cGMP may reduce Ca2+ influx (Sperelakis, 1994) during
ischaemia as well as during reperfusion.
In addition to the above, there is substantial pharmacological evidence that the guanylyl
cyclase-cGMP-POE system contributes to cardioprotection. For example, Ljusegren
and Axelsson (1993) described that an increase in myocardial cGMP by SNP, atrial
natriuretic peptide or zaprinast (an inhibitor or cGMP-specific POEy) caused a reduction
of lactate accumulation in isolated hypoxic rat ventricular myocardium.
5.3.4.3 p38 MAPK:
In the previous chapters our results indicate that p38 MAPK plays a role as mediator of
protection in ischaemia (chapter 3) and p-adrenergic (chapter 4) preconditioned hearts.
The improved functional recovery of these hearts during reperfusion was associated
Stellenbosch University http://scholar.sun.ac.za
157
with a decrease in activation of p38 MAPK during the sustained period of ischaemia.
The mechanism by which attenuated p38 MAPK activity could protect was suggested by
Saurin et al. (2000), who have shown that PC protects by suppressing the activation of
p38-alpha isoform, which is an activator of apoptosis. Consistent with these results, is
our observation that the cardioprotective effect of both NO donors (SNAP and SNP)
(Fig. 5.19) may be due to their ability to elicit the same attenuation in p38 MAPK as PC
at the end of sustained ischaemia (Fig. 5.14). This indicates that prior triggering with
NO donors may affect the p38 MAPK activity during sustained ischaemia. Our findings
concur with a recent study by Rakhit et al. (2001), which indicated that SNAP
pretreatment delayed peak activation of p38a MAPK during ischaemia-reoxygenation in
neonatal rat cardiomyocytes. Thus the delay in peak p38 MAPK activation may
contribute to, rather than be the effect of, NO-induced (SNAP) cardioprotection.
Furthermore, administration of GC- or NOS- inhibitors, 000 or L-NAME, respectively,
during the ischaemic PC protocol, significantly attenuated functional recovery conferred
by PC to the same extent as non-PC during reperfusion (Figs. 5.16 and 5.17). However
000 did not affect the PC-induced attenuation of p38 MAPK activity, while L-NAME
partially reversed this effect (Fig. 5.13A, B). This confirms our data on the triggering
effect of NO during the PC protocol: L-NAME (NOS inhibitor) could significantly
attenuate p38 MAPK activation induced by 5 min ischaemia (PC1-), however this p38
MAPK activation was insensitive to 000 (GC inhibitor) (Fig. 5.8).
The results obtained suggest that early ischaemic PC and NO donors may trigger p38
MAPK via a pathway independent of cGMP, which could result in the attenuation of this
stress kinase during sustained ischaemia and subsequent cardioprotection. As
mentioned before, NO derived oxygen free radicals (i.e. peroxynitrite) may trigger the
pathway leading to PC protection (Rakhit et ai., 1999). This free radical signalling
involves p38 MAPK (Das et ai., 1999b). The latter might be upstream of the nuclear
factor NFkB, which could be the link between PC and the adaptive protection mediated
by expression of antioxidant genes during PC (Schieven et ai., 1993, Maulik et ai.,
1998).
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5.3.4.4 ATP-sensitive potassium (KATP)-channels
Although further downstream events remain to be elucidated, it is suggested that PKC
and the putative end-effector, the mitochondrial KATP channel are linked (Sato et aI.,
1998). These channels may be involved in the end effect of both early and late
ischaemie PC (reviewed by Sato and Marban, 2000). For example, Gross and
Auchampach (1992) first demonstrated the involvement of the KATP channels in
ischaemie PC in the canine model and demonstrated that glibenclamide, administered
either before of after PC could abolish cardioprotection. These data imply that the
KATP channels may set the heart into a preconditioned state but clearly demonstrate
that the KATP channel is an end effector of PC. Additionally, in intact rabbit hearts,
Ockaili et al. (1999) found that pretreatment with diazoxide 30 min or 24 hours before 30
min of ischaemia produced a reduction in infarct size. This was blocked by 5-
hydroxydecanoate (5-HD) if administered after diazoxide in both the early and late
phases of cardioprotection.
However, recent data from the laboratory of Downey indicated that mitochondrial KATP
channels might act as a trigger rather than an end-effector of the protection of PC (Pain
et el., 1999). One possible hypothesis, which might explain the trigger action of
mitochondrial KATP channels, involves mitochondrial generation of free radicals (Carroll
et aI., 2001), which then stimulate downstream kinases. This theory is attractive since
two of the kinases, which are though to be involved in PC protection, PKC and p38
MAPK are known to be activated by free radicals (Downey and Cohen, 2000).
Furthermore, Wang and Ashraf (1999) have reported that diazoxide's protection in rat
heart can be blocked by a PKC antagonist, a result which would put KATP channels far
upstream. Thus, it is possible that a different ion channel or an unidentified protein may
still be the elusive end-effector.
Recent studies revealed that NO directly activates the mitochondrial KATP channels but
not sarcolemmal KATP channels (MacKay and Mochly-Rosen, 1999, Sasaki et aI.,
2000), while NO also potentiates the ability of KATP channel openers (i.e. diazoxide) to
activate the potassium (K+) current in rabbit cardiomyocytes (Sasaki et aI., 2000). In
addition, recently Han et al. (2001) provided the first direct evidence that KATP
channels can be opened through PKG-dependent phosphorylation in rabbit ventricular
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myocytes. Therefore, these data suggest that NO-induced protection may be mediate
via direct opening of the KATP channels.
It appears that NO is involved as a trigger for protection in both VOP-induced or no-flow
ischaemia-induced classic PC (Csonka et aI., 1999). However, the way they mediate
their cardioprotective mechanism may be different in terms of the activation of the
KATP-channel: glibenclamide (blocker of the KATP-channel) inhibited VOP-induced
protection, but did not affect no-flow ischaemia-induced PC (Ferdinandy et aI., 1995b).
In addition, in a simulated ischaemia model of early PC (rat neonatal cardiocytes),
SNAP-triggered protection (accompanied by increased cGMP levels) was completely
abolished by ODQ, but not by chelerythrine or glibenclamide plus 5-HD (a KATP-
channel blocker) (Rakhit et aI., 2000). Therefore it was proposed that the mechanism of
cardioprotection in early PC is cGMP dependent but independent of protein kinase C or
KATP-channels. This differs from the proposed mechanism of NO-induced
cardioprotection in late PC (Wang Y et aI., 2001).
5.4 SUMMARY
The results obtained suggest that NO and thus the generation of cGMP act as a trigger
in classic PC. Cyclic elevation of cGMP by NO donors effectively protects against
ischaemie damage, whereas inhibition of NOS or guanylyl cyclase partially abolishes
the beneficial effects of PC.
Furthermore, our results suggest that NO mediated attenuation of the activation of p38
MAPK during sustained ischaemia plays a role in the mechanism of protection.
However, conclusive interpretation of the relevance of p38 MAPK activation in
cardioprotection cannot be made at this point in time. Amongst others, use of
appropriate agonists or inhibitors as well as identification of the isoforms of p38 MAPK
involved, are required.
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CHAPTER 6
Evaluation of the role of p3S MAPK
6.1 Introduction
As mentioned before in chapter 3, the signal transduction cascade of ischaemic PC can
be divided into triggers and mediators. Blockade of a trigger's action during an
ischaemie PC protocol will abolish its cardioprotective effects. In addition, an
intervening washout period between the PC protocol and the onset of sustained
ischaemia may be essential in order to determine an initiator of PC. Mediators are
important during the sustained ischaemia, and blockade of a mediator's action during
this phase will abolish protection. Careful manipulation of the protocol is therefore
necessary to distinguish between a trigger and mediator effect of a particular signalling
pathway.
6.1.1 p38 MAPK activation: trigger or mediator?
Two potential roles for p38 MAPK have been proposed. (i) First, there is increasing
evidence that even brief, non-lethal episodes of myocardial ischaemia (i.e. ischaemic
PC) elicit a significant increase in the activity of p38 MAPK (Maulik et aI., 1998d, Vue et
aI., 2000, Sato et aI., 2000) and further, that this activation of p38 MAPK during the PC
stimulus may participate in triggering the benefits achieved with PC (Maulik et aI.,
1998d, Sato et aI., 2000). However, several studies have reported that activation of p38
MAPK during ischaemia is transient and does not correlate with the PC effect (Ping et
aI., 1999a, Behrends et el., 2000), thereby questioning the significance of p38 MAPK as
a trigger in PC. (ii) A second hypothesis is that p38 MAPK may mediate
cardioprotection, with evidence of increased activation of p38 MAPK signalling during
sustained ischaemia in preconditioned hearts, as well as in myocytes (Weinbrenner et
aI., 1997, Armstrong et el., 1999, Nakano et aI., 2000). However, activation of p38
MAPK during sustained ischaemia-reprefusion has, in several studies, been associated
with myocyte necrosis/apoptosis which makes its contribution as mediator unlikely
(Bogoyevitch et aI., 1996, Ma et aI., 1999, Mackay et aI., 1999, Barancik et al., 2000).
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Investigation into the role of p38 MAPK in PC was approached in most cases by
evaluation of (i) the effects of ischaemia on the activation of the kinase and (ii)
pharmacological inhibition of p38 MAPK and assessing the consequences thereof on
cardioprotection. Unfortunately, in most studies the inhibitor was added immediately
before the onset of sustained ischaemia, a protocol that allows for evaluation of its role
as mediator during sustained ischaemia only.
Furthermore, the selectivity of the inhibitor of p38 MAPK is questionable (Ping et a/.,
2000) (88203580, the most commonly used, also inhibits JNK) and no suitable activator
of p38 MAPK exists. Therefore, since p-adrenergic stimulation also stimulates p38
MAPK activation (Zheng et a/., 2000, Communal et a/., 2000), it could be a useful tool to
evaluate whether this particular stress kinase acts as trigger or mediator in ischaemie or
p-adrenergic PC.
6.1.2 The aim
In view of the above, our subsequent aim was to determine the effects of inhibition of
ischaemia or p-adrenergic-induced p38 MAPK activation on functional recovery during
reperfusion after global ischaemia of isolated perfused rat hearts. The results obtained
in this study may help clarify whether p38 MAPK acts as a trigger and/or mediator in the
PC process, as well as whether its activation during sustained ischaemia is beneficial or
not.
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6.2 Experimental Protocols and Results
6.2.1 Inhibition of p38 MAPK during global ischaemia in the perfused rat
heart
6.2.1.1 Experimental protocol
Evaluation of functional recovery
Non-preconditioned hearts
Hearts were stabilized for 60 min (15 min retrograde, 15 min working mode, 30 min
retrograde), followed by 25 min sustained global ischaemia and 30 min reperfusion
(10 min retrograde, 20 min working mode) (Fig. 6.1A).
Non-preconditioned hearts plus SB 203580: p38 MAPK as mediator or trigger?
(i) Mediator: SB 203580 administered immediately before sustained ischaemia (Fig.
6.1B): hearts were stabilized for 50 min (15 min retrograde, 15 min working, 20 min
retrograde) followed by administration of SB 203580 (1 IlM) for 10 min. Hearts were
then subjected to 25 min global ischaemia and 30 min reperfusion (10 min retrograde,
20 minworking heart).
(ii) Trigger: SB 203580 administered 3 x 5 min (Fig. 6.1C): hearts were stabilized for
30 min (15 min retrograde, 15 min working), followed by SB 203580 (1 IlM, 3 x 5 min),
alternated with 5 min drug-free reperfusion. Hearts were then subjected to sustained
ischaemiaand reperfusion as described above.
Ischaemie preconditioned hearts
Heartswere stabilized for 30 min (15 min retrograde, 15 min working) followed by either
a multi-cycle ischaemie PC protocol (3 x 5 min global ischaemia, alternated with 5 min
of reperfusion) (Fig. 6.1D) or a single episode of PC (1 x 5 min global ischaemia and 5
min of reperfusion) (Fig. 6.1F). Hearts were then subjected to 25 min sustained global
ischaemiaand 30 min reperfusion as described above.
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Fig 6.1 Effect of SB 203580, an inhibitor of p38 MAPK activation, pretreatment on non-preconditioned, ischaemic-preconditioned and
isoproterenol perfused rat hearts: Experimental protocol. See text for details on different protocols, Arrows indicate time(after 30 min
reperfusion) of determination of mechanical function, n = 4 to 6 hearts per series,
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Ischaemie preconditioned hearts plus SB 203580: p38 MAPK as trigger?
Multi-cycle ischaemic-PC hearts plus SB 203580 (Fig. 6.1 E): hearts were perfused
retrogradely for 15 min, followed by 10 min perfusion in the working mode. SB 203580
(111M) was administered for 5 min before and after the first PC episode (PC1-) and also
during reperfusion after the second PC episode (PC2-). After the third PC episode
(PC3-) hearts were perfused for 10 min to ensure washout of the drug.
Single episode ischaemic-PC hearts plus SB 203580 (Fig. 6.1G): hearts were perfused
retrogradely for 15 min, followed by 15 min in the working mode and 10 min
retrogradely. SB 203580 was then administered for 5 min, followed by 5 min global
ischaemia and 10 min washout. All hearts were then subjected to ischaemia-
reperfusion as described above.
Isoproterenol hearts
Hearts were stabilized for 50 min (15 min retrograde, 15 min working, 20 min
retrograde) followed by 5 min administration of 10-7 M isoproterenol and 5 min drug-free
perfusion (Fig. 6.1 H). All hearts were then subjected to 25 min sustained global
ischaemia and 30 min reperfusion as described above.
Isoproterenol hearts plus SB 203580: p38 MAPK as trigger?
Hearts were stabilized for 45 min (15 min retrograde, 15 min working, 15 min
retrograde), followed by administration of SB 203580 (111M) for 10 min (Fig. 6.11).
During the last 5 min of SB 203580 administration, isoproterenol (10-7 M) was given
simultaneously, followed by 5 min drug-free perfusion. Hearts were then subjected to
sustained ischaemia and reperfusion as described above.
6.2.1.2 Results
To determine the efficacy of the p38 MAPK inhibitor, SB 203580, at a concentration of 1
11Min global ischaemia or during p-adrenergic treatment of perfused rat hearts, it was
administered either (i) for 5 min before a brief 5 min global ischaemie episode or (ii) 5
min before and during isoproterenol-treatment (5 min). The results showed that while
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SB 203580 had no effect on the p38 MAPK activity of control perfused hearts, it
completely abolished the activation induced by either global ischaemia (Fig. 6.2) or
isoproterenol (Fig. 6.3). Therefore SB 203580 at a concentration of 1 j.!M was used in
all experiments.
Non-preconditioned hearts plus SB 203580: p38 MAPK as mediator or trigger?
The effect of SB 203580 on the functional recovery of non-preconditioned hearts was
dependent on the protocol used (Fig. 6.1 B and C). When administered for 10 min
immediately before the onset of sustained ischaemia (without washout), the effect on
functional recovery during reperfusion after sustained ischaemia were similar to those of
ischaemie-PC or isoproterenol hearts and significantly higher than those of untreated
non-preconditioned hearts (Fig. 6.4, protocol i and Table 6.1). These findings indicate
that p38 MAPK may act as a mediator. However, when administered for 3 x 5 min and
washed out before the onset of sustained ischaemia (Fig. 6.4, protocol ii and Table 6.1),
no improvement occurred and values similar to those of untreated non-preconditioned
hearts were obtained, indicating that no triggering effect occurred and excluding the
possibility that the drug was not washed out prior to sustained ischaemia.
Preconditioned and isoproterenol hearts plus SB 203580: p38 MAPK as trigger?
Bracketing the multi-cycle (3 x 5 min) ischaemic-PC protocol with SB 203580, did not
abolish PC, but in fact the aortic output of these hearts was significantly higher than
those of untreated ischaemic-preconditioned hearts (Fig. 6.4). However, the increases
in cardiac output and total work performance were not significant (Table 6.1). Therefore
p38 MAPK does not act as a trigger in a multi-cycle (3 x 5 min) ischaemic-PC protocol.
On the other hand, bracketing of either the single episode (1 x 5 min) ischaemic-PC or
the 5 min isoproterenol protocol with SB 203580, followed by 10 min washout, caused a
significant decrease in functional recovery during reperfusion, when compared with
either the single episode ischaemic-PC or the isoproterenol protocol alone, respectively
(Fig. 6.4 and Table 6.1). Therefore p38 MAPK may act as a trigger during these
protocols.
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SB 203580 - + + -
5 min Isch. - +- -
- - - -
- + +
+ + +
Fig 6.2 Effect of SB 203580 (111M) on p38 MAPK activation: The p38 MAPK inhibitor SB 203580 prevents the dual activation of
p38 MAPK induced by brief global ischaemia (5 min) in the perfused rat heart.
+
+
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Control + - - - -
SB 203580 - - - + +
5 min Iso. - + + + +
Fig 6.3 Effect of SB 203580 (111M) on p38 MAPK activation: The p38 MAPK inhibitor SB 203580 prevents the dual activation of
p38 MAPK induced by isoproterenol (5 min) in the perfused rat heart.
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t p < 0.05 vs lso without SB
Fig 6.4 Functional recovery during reperfusion after 25 min global ischaemia of perfused rat hearts: Effect of inhibition of p38
MAPK with SB203580 on non-preconditioned, ischaemic-preconditioned and isoproterenol hearts.
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Table 6.1
Mechanical function after arrest during 30 min of reperfusion: Effect of 88203580,
an inhibitor of p38 MAPK, on non-preconditioned (Non-PC), ischaemic-
preconditioned (PC) and isoproterenol (Iso) hearts.
Non-Preconditioned:
Without SB (7)
With SB(i) (8)
With ss'" (8)
Coronary flow Cardiacoutput Peaksystolic HeartRate Total work
(ml/min) (ml/min) Pressure (beats/min) (mV)
(mmHg)
8.0±1.4
12.0±O.7
11.4±1.1
Preconditioned (3 x 5min):
Without SB (9)
With SB (8)
11.1±O.6
11.4±O.7
Preconditioned (1 x 5 min):
Without SB (5)
With SB (8)
Isoproterenol (10.7M):
Without SB (6)
With SB (6)
12.5±O.5
11.5±O.3
10.1±O.9
10.8±1.0
11.9±2.5 *
31.3±2.8 #
14.7±1.6 *
#27.7±2.1
#37.4±O.7
23.9±1.3 #
&18.9±O.3
29.7±1.5 #
t15.7±1.6
80.0±2.0
88.6±1.3
84.9±3.2
86.0±1.5
93.0±1.4 #
91.0±1.1
86.0±O.8
94.2±4.3 #
85.8±O.8 t
211±15
262±20 #
200±20
250±13 #
257±16 #
228±6
206±15 s
202±17
202±11
2.6±0.4 *
6.3±O.7 #
2.8±0.4 *
5.5±O.5 #
7.9±O.2 #
5.1±0.4 #
3.7±O.3 s
5.5±0.4 #
3.0±O.2 t
Results expressed as the mean values ± SE obtained during 30 min reperfusion after 25
min sustained ischaemie arrest. Numbers in parentheses indicate number of hearts.
Hearts were treated with S8 203580 before sustained ischaemia as shown in Fig. 6.1. For
example; (i) Non-PC with 10 min S8 before sustained ischaemia and (ii) Non-PC with 3 x
5 min SB followed by 10 min washout before sustained ischaemia.
# P < 0.05 vs Non-PC without SB
* P < 0.05 vs PC (3x5min) without SB
8 P < 0.05 vs PC (1x5min) without SB
t p < 0.05 vs lso without SB
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6.3 Discussion on role of p3SMAPK
6.3.1 p38 MAPKactivation during the PC protocol: a trigger for eliciting
protection?
Since repeated but transient p38 MAPK activation could be observed during a multi-
cycle (3 x 5 min) ischaemie PC protocol (Fig. 3.12), the question arises whether this
phenomenon acts as a trigger in the PC process or whether this is merely an
epiphenomenon of the multiple changes occurring in the myocardium during a multi-
cycle ischaemie PC protocol. Some of the results obtained in the present study suggest
that p38 MAPK activation may act as a trigger: experimental activation of the kinase
with isoproterenol (Fig. 4.14) or transient ischaemia (as in ischaemie PC, PC1-, Fig.
4.13), elicits protection against subsequent sustained ischaemia (Fig. 4.23). Although
these findings do not prove cause and effect, the fact that p-adrenergic blockade with
alprenolol inhibited p38 MAPK activation during the ischaemie PC protocol (Fig. 4.13),
completely abolishes functional recovery (Fig. 4.21), suggest a triggering action.
Further evidence for a trigger role of this kinase, is the observation that inhibition of
either a single episode (1 x 5min) ischaemie PC- or isoproterenol-induced p38 MAPK
activation by the inhibitor SB 203580, completely abolished cardioprotection (Fig. 6.4
and Table 6.1). Sato et al. (2000), also using a working rat heart model, reported that
activation of both JNK1 and p38 MAPK was obligatory as triggers for PC: SB 203580,
when administered before a 4 x 5min ischaemic-PC protocol and washed out (10 min)
before sustained ischaemia, completely abolished cardioprotection. In addition,
Nagarkatti et aI, (1998), who also washed away the inhibitor after PC (viz. brief duration
of ischaemia) could also abolish the protective effect of PC in a rat myoblast cell line
(see chapter 1, Table 1.1).
Despite the above, several observations argue against a role for p38 MAPK activation
as trigger. For example, activation of p38 MAPK during a multi-cycle ischaemie-PC
protocol is transient (Fig. 3.12, Ping et aI., 1999a, Schneider et aI., 2001), compared to
the persistent activation of p46/p54 JNK (Ping et aI., 1999a) and p44/p42 MAPK (Ping
et aI., 1999b). Although transient activation of p38 MAPK does not exclude a role as
trigger, other observations also argue against activation of this kinase as the only trigger
in a multi-cycle PC protocol: bracketing of the multi-cycle ischaemie-PC protocol with
SB 203580 did not abolish cardioprotection in isolated working rat hearts (Fig. 6.1E and
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Fig. 6.4). Contrary to expectations, this intervention caused a significant increase
in aortic output during reperfusion (Fig. 6.4), suggesting that p38 MAPK activation
during the ischaemic PC protocol may indeed be harmful. Schneider ef al. (2001) also
showed that p38 MAPK inhibition by SB 202190 (a related compound to SB 203580)
during a multi-cycle PC protocol did not block the PC-induced improvement in post-
ischaemie contractile function and reduction in necrosis in an isolated perfused rat heart
model. A similar failure of SB 203580 to abolish protection was observed with a 2 x 5
min PC protocol in rat hearts (Mocanu ef ai., 2000). In addition, SB 203580 also could
not block PC protection in different models, for example in neonatal rat cardiomyocytes
(Mockridge et aI., 2000) or in an in vivo pig model (Barancik ef ai., 2000).
Contrary to the above mentioned observations that SB 203580 does not block the
cardioprotection elicited by a multi-cycle PC protocol, the inhibitor causes a significant
attenuation of protection when a single cycle ischaemie PC protocol was used (Fig 6.4
and Table 6.1). This observation is in agreement with the findings of Sandhu ef al.
(1997) that PC induced by a one-cycle was more susceptible to blockade by inhibitors
than that induced by a multi-cycle protocol. It has been suggested that several receptor
systems contribute to triggering multi-cycle ischaemic-PC and one particular inhibitor
often fails to inhibit protection (Sandhu ef ai., 1997, Cohen ef aI., 2000). This concept
was also demonstrated by Sakamoto ef al. (2000) and Fryer ef al. (2001): they could
block a single cycle protocol with SB 203580, while Schneider ef al. (2001), using SB
202190 failed to block a 4 x 5 min protocol in working hearts.
Apart from a few studies with anisomycin (Weinbrenner ef ai., 1997, Sato ef ai., 2000),
the role of p38 MAPK activation acting as a trigger during a PC protocol has not been
assessed with other activators of this kinase. Furthermore, anisomycin, an inhibitor of
protein synthesis, is also a powerful stimulant of JNK (Barancik ef ai., 1999, Schneider
ef ai., 2001) and is therefore unsuitable for use in studies aimed at elucidating the role
of p38 MAPK per se. In view of the above, isoproterenol mediated protection is
probably dependent on p38 MAPK activation before the onset of ischaemia (i.e. as
trigger) and may be a useful tool to clarify the triggering role of this kinase. Further
evidence for p38 MAPK activation as a contributing trigger for cardioprotection is the
observation that SB 203580 inhibition of isoproterenol-induced p38 MAPK activation
completely blocked functional recovery during reperfusion (Fig 6.4 and Table 6.1).
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In addition, recent findings in our laboratory (Hartley, MSc Thesis) indicated that
p38 MAPK activation act as a trigger: anisomycin (5 IlM) administration for 10 min, then
washed out for 10 min prior to sustained ischaemia, resulted in significant protection
against necrosis (decreased infarct size) and reduced apoptosis. These findings were
also accompanied by attenuation of p38 MAPK activation during sustained ischaemia.
Furthermore, the elucidation of the role of p38 MAPK would necessitate the use of
anisomycin in the presence of an agent such as SP 600125, an inhibitor of JNK (work in
progress).
6.3.2 p38 MAPK activation during ischaemia and reperfusion: a mediator
of protection?
Numerous studies have suggested a role for p38 MAPK activation as a mediator of
protection against ischaemia: (i) pharmacological activation of p38 MAPK by
administration of anisomycin before the onset of sustained ischaemia (without washout),
elicited cardioprotection in isolated rabbit cardiomyocytes (Weinbrenner et ai., 1997),
perfused rat hearts (Nakano et ai., 2000a) and pig hearts (Barancik et ai., 1999), while
(ii) inhibition of p38 MAPK prior to sustained ischaemia only, completely abolished PC-
induced protection (Nakano et ai., 2000a, Barancik et ai., 1999, Mocanu et ai., 2000,
Nakano et ai., 2000c) again indicating a mediator role. However, though there is
reasonable consensus that p38 MAPK acts as mediator, considerable controversy
exists whether this occurs via increased or attenuated activation of this kinase.
In chapter 3 we showed that apart from the transient activation of p38 MAPK during the
ischaemic PC protocol, p38 MAPK activation was significantly less in preconditioned
than in non-preconditioned hearts during both sustained ischaemia (Fig. 3.16) and
reperfusion (Fig. 3.21). This observation correlates with the reduction in cAMP
accumulation occurring during sustained ischaemia in preconditioned hearts (Fig. 3.13)
and could indicate that cAMP generation during sustained ischaemia (as in transient
ischaemia) is one of the factors activating p38 MAPK. Since the marked attenuation in
p38 MAPK activation in preconditioned hearts was associated with improved functional
recovery, it was suggested that inhibition of the kinase might be an essential element in
PC-induced cardioprotection.
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This suggestion is supported by the findings obtained in chapter 4: the pattern of
p38 MAPK activation (as indicated by its dual phosphorylation and kinase activity)
during sustained ischaemia and reperfusion in hearts failing to recover functionally upon
reperfusion after ischaemia, as in non-preconditioned hearts and alprenolol-treated
preconditioned hearts, was similar (Fig. 4.27). Conversely, activation of p38 MAPK
during both sustained ischaemia and reperfusion was significantly lower in ischaemie-
(Figs. 3.16 and 3.21) and isoproterenol- preconditioned hearts (Fig. 4.26), associated
with functional recovery during reperfusion. Interestingly, despite the possible
differences in signalling during sustained ischaemia occurring in ischaemie and p-
adrenergic preconditioned hearts, the pattern of p38 MAPK activation during both
sustained ischaemia and reperfusion is similar in the two groups.
In addition to the above, considerable evidence exists suggesting that inhibition of p38
MAPK during sustained ischaemia may indeed be cardioprotective. For example, we
have shown that administration of SB 203580 immediately before the onset of sustained
ischaemia to non-preconditioned hearts (Fig. 6.4, protocol i) elicited cardioprotection
similar to that seen in ischaemie or p-adrenergic preconditioned hearts (Fig. 6.4). In
addition, not only does inhibition of p38 MAPK by SB 203580, protect myocytes against
ischaemia (MacKay et al., 1999), reduce apoptosis (Nagarkatti and Sha'afi, 1998) and
limit infarct size (Sanada et al. 2001), but significantly less activation of p38 MAPK
during ischaemia has been reported in preconditioned rat myoblast cells (Nagarkatti and
Sha'afi 1998) and perfused hearts (Sato et a/., 2000). Schneider and coworkers (2001)
also showed that another inhibitor of p38 MAPK, SB 202190, administered immediately
before ischaemia, significantly improved functional recovery of the isolated perfused rat
heart and reduced necrosis. Their data also indicated that although inhibition of p38
MAPK and PC are protective, their protection is not additive, which may suggest that
PC and SB 202190 enhance protection via similar mechanisms. The latter finding is in
contrast to our results, which showed additive protection (Fig. 6.4). Minor differences in
the perfusion protocol and inhibitor used (SB 203580 vs. SB 202190) may account for
this.
Perhaps the most convincing evidence thus far for the suggestion that attenuation of
p38 MAPK activation during ischaemia is indeed protective comes from a recent study
on cultured neonatal myocytes: not only did SB 203580 reduce ischaemie injury, but
prior PC of these cells prevented p38a MAPK activation during ischaemia. Moreover,
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cells expressing a dominant negative p38a, which prevented p38 activation, were
resistant to lethal ischaemia (Saurin et ai., 2000). Selective activation of p38a over
p38p during ischaemia was shown to occur in these cells, therefore inhibition of the a-
isoform by SB 202190 was suggested to be involved in cardioprotection. Previous
studies in neonatal cardiac myocytes supported a role for the a-isoform in mediating
apoptotic cell death (Wang et ai., 1998). However, in the present study no attempt was
made to distinguish between the different isoforms of p38 MAPK, as the inhibitors
currently available commercially do not allow distinction between isoforms.
Despite the above convincing evidence that attenuation of p38 MAPK activation during
sustained ischaemia is beneficial, several other workers reported the contrary.
Cardioprotection, associated with increased activation of p38 MAPK during sustained
ischaemia, has been reported in rabbit cardiomyocytes (Armstrong et ai., 1999),
isolated rabbit (Weinbrenner et al., 1997, Nakano et al., 2000a) as well as rat hearts
(Liu et ai., 1998, Maulik et ai., 2000, Mocanu et ai., 2000) and linked to activation of its
downstream signalling substrate MAPKAPK2 (Nakano et ai., 2000a, Maulik et ai.,
2000). In addition, a recent study from Pain et al. (2000) showed that, like PC,
diazoxide-induced (opening of the KAlP channels) reduction in infarct size was
characterized by increased p38 MAPK activation during sustained ischaemia. However,
an explanation for the variability in results is not yet available and remains a matter of
serious concern. Possible reasons for these discrepancies have recently been
reviewed by Michel et al. (2001): differences in species (rat, rabbit, dog, pig, human)
and model systems may be important. Most of the studies showing increased activation
of p38 MAPK in cardioprotection, have been done in rabbits (Weinbrenner et aI., 1997,
Armstrong et aI., 1999, Nakano et al., 2000a). Furthermore, the rat model has been
shown to be a complex model in PC, since contradictory results with regard to p38
MAPK activation in preconditioned rat hearts have also been reported: our study as
well as work by Saurin et al. (2000) vs. the studies by Liu et al. (1998), Maulik et al.
(2000) and Mocanu et al. (2000).
6.3.3 p3SMAPK inhibition: good or bad?
Activation of p38 MAPK during sustained ischaemia in non-preconditioned hearts has
been demonstrated in several studies (Bogoyevitch et ai., 1996, Yin et ai., 1997,
MacKay et ai., 1999, Ma et ai., 1999) and according to these studies this could be
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harmful to the ischaemie myocardium. Studies using SB 203580, support this
viewpoint: protection against ischaemie damage by SB 203580 has been shown in rat
neonatal cells (MacKay et aI., 1999) and rat myoblast cell lines (Nagarkatti and Sha'afi,
1998), while it inhibits apoptosis in perfused rabbit hearts (Ma et aI., 1999) and limits
necrosis in the in vivo pig model (Barancik et aI., 2000). Recently, Gysembergh et al.
(2001) also indicated that SB 203580, which caused attenuation of p38 MAPK activity
early (5 min) during sustained coronary occlusion of rabbit hearts, is cardioprotective.
Although the dose of SB 203580 they employed (8 JlM) was similar to the 5-10 )JM
concentration used in most previous studies, recent evidence suggests that
concentrations of SB in the 10 )JM range may also inhibit other kinases, including JNKs
(Sugden et el., 1998, Clerk et aI., 1998b). Therefore using 1 )JM SB 203580 in the
present study, may selectively inhibit p38 MAPK and thereby exclude the possibility that
inhibition of other kinases may have participated in the cardioprotection we observed.
Vue et aI., 2000 used a selective inhibitor of p38 MAPK, SB242719, which had no effect
on JNK or ERK in ischaemia-triggered myocytes and indicated that the protective effect
of this compound was exclusively due to inhibition of p38 MAPK.
However, elucidating the exact role of p38 MAPK in cardioprotection is complicated by
the identification of at least six isoforms of the enzyme (Sugden et aI., 1998). These
isoforms may have distinct roles, with p38a activation mediating apoptotic death in
several cell types (Zia et aI., 1995, Kawasaki et aI., 1997, Kummer et aI., 1997), as well
as in cardiomyocytes (MacKay and Mochly-Rosen 1999, Ma et aI., 1999, Saurin et aI.,
2000, Sato et aI., 2000,) and p3813potentially contributing to cell survival (Wang et aI.,
1998, Saurin et aI., 2000), while the presence and importance of p38y and 0 in the
myocardium remain to be determined. An additional confounding factor is that SB
203580 is a potent inhibitor of bath p38a and p3813 MAPKs (Ping et aI., 2000).
Therefore development of isoform-specific pharmacological inhibitors, selective
monoclonal antibodies for all members of the p38 MAPK family or transgenic animals in
which individual isoforms are manipulated, is essential.
A recent study by Martin et al. (2001), confirmed that SB 203580-mediated protection in
adult rat cardiac myocytes depends on the inhibition of p38a MAPK. In myocytes
expressing wild-type p38a MAPK, SB 203580 present during simulated ischaemia
reduced injury, while SB 203580 did not protect cells expressing the SB 203580-
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resistant form of p38a MAPK. Therefore based on the evidence provided by
Saurin et al. (2000) and Martin et al. (2001), it is possible that in ischaemie and p-
adrenergic PC activation of p38a MAPK is prevented during sustained ischaemia while
only the protective P-isoform is expressed.
6.3.4 Mechanism of p38 MAPK in PC protection:
The relationship between p38 MAPK activation and its consequent underlying cellular
mechanisms of cardioprotection by ischaemic PC is not yet clear. Furthermore, the end-
effector of PC also needs to be elucidated. There are a number of candidates for the
downstream effectors of p38 MAPK, which may also be the final effectors of
cardioprotection. Although these effectors were not investigated in this study, we would
like to speculate that they may indeed be involved in the cardioprotection of PC.
6.3.4.1 Free radicals and NFkB:
Our results indicated that during p-adrenergic preconditioning, cAMP induced transient
p38 MAPK activation. This could have been mediated by cAMP-induced reduction of
mitochondrial complex 1 activity (Scacco et ai., 2000) and generation of free radicals
(Givertz et ai., 2001). Furthermore, Maulik et al. (1998a) proposed that during ischaemic
adaptation (PC protocol) oxidative stress is developed by free radicals that function as
second messengers resulting in the activation of p38 MAPK and MAPKAPK2 that could
lead to the activation of NFkB (Maulik et ai., 1998a). The latter in turn may be involved in
the induction of expression of antioxidant genes (Schieven et ai., 1993).
6.3.4.2 Heat-shock protein (HSP) 27:
Changes in localization of HSP27 may play a role in the mechanism of PC:
redistribution of HSP27 from the cytosolic to the cytoskeletal fraction occurs after PC
with 4 cycles of 5 min hypoxia-reoxygenation of rat myoblast cell line H9C2 (Sakamoto
et ai., 1998). In addition, Sanada et al. (2001) concluded that phosphorylation and
translocation of HSP27 occurs after ischaemic PC through the transient activation of
p38 MAPK and protects myocardium from subsequent sustained ischaemie injuries.
Phosphorylation of HSP27 is instrumental in polymerization and prevention of
fragmentation of actin (Huot et ai., 1996, Bluhm et ai., 1998, Yoshida et ai., 1999),
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thereby counteracting the disruptive effects of ischaemia on actin microfilaments
(Das et aI., 1999).
6.3.4.3 cAMP response element-binding protein (CREB):
CREB could be activated by phosphorylation in response to a number of signalling
pathways, including cAMP, calcium, stress and mitogenic stimuli (reviewed by Mayr and
Montminy, 2001), as well as by transient global ischaemia (Williams and Ford 2001).
Specifically, two downstream kinases of p38 MAPK, namely MAPKAPK-2 and MSK-1,
may mediate activation of CREB (Tan et aI., 1996, Deak et aI., 1998). Activation of
CREB induces the expression of the anti-apoptotic factor bcl-2, mediating cell survival
of cardiomyocytes (Mehrhof et aI., 2001). Therefore the activation of CREB by cAMP,
as well as p38 MAPK, during the ischaemie PC protocol could elicit a pro-survival
response.
6.3.4.4 Stress-responsive genes (ATF-2, MEF-2, c-Jun):
ATF-2, unlike the related CREB, is not activated by increased cAMP, but by stimuli that
activate SAPKs. Both JNK and p38 MAPK regulate ATF-2 and its function appears to
be similar to that of c-Jun (Gupta et aI., 1995). Furthermore, p38 MAPK also
phosphorylates the transcription factor MEF-2, which leads to the increase in c-jun
transcription, thus linking p38 MAPK and JNK pathways (Han et aI., 1997). In addition,
a significant increase in apoptotic cell death, was evident in the rat heart following
ischaemia-reperfusion and correlated with the pattern of JNK and p38 MAPK activation,
as well as expression of two stress-responsive genes, c-Jun and ATF3 (Yin et aI.,
1997). Therefore, attenuation of p38 MAPK during sustained ischaemia by PC could
result in a decreased expression of the stress-responsive genes and diminished cell
death.
6.3.4.5 Phosphatases:
Protein phosphatase regulation also plays a role in regulating intracellular signalling
pathways. According to Bogoyevitch (2000) it remains possible that phosphatase
inhibition during ischaemia will facilitate higher levels and/or prolonged phosphorylation
of proteins that provide protection. However, the deleterious effects of sustained p38
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MAPK activation in ischaemia are emphasized by evidence that inactivation of a
tyrosine phosphatase during ischaemia results in prolonged p38 MAPK activation that
causes cell death (MacKay et ai., 2000). The identification of this phosphatase might
assist in elucidating what cellular mechanism is responsible for the attenuation of the
ischaemia-induced increase in p38 MAPK seen in preconditioned hearts (Gysembergh
et ai., 2001).
6.3.4.6 ATP-sensitive potassium (KA TP) channels:
For the past decade attention has focused on the KATP channel following the initial
discovery by Gross and Auchampach (1992) that KATP channels appeared to be the
elusive end-effector of ischaemie PC's protection. Since then, the involvement of the
mitochondrial rather than the sarcolemmal KATP channel has been demonstrated by
several workers (Garlid et ai., 1997, Liu et ai., 1998). Traditionally, KATP channels
were thought to be located distal to MAPKs; e.g. Baines et al. (1999) reported that the
opening of KATP channels on mitochondria are activated by p38 MAPK and could
mediate cardioprotection. However, recent data indicated that mitochondrial KATP
channels might act as a trigger rather than an end-effector of the protection of PC (Pain
et ai., 1999,Wang and Ashraf (1999).
Besides the fact that there is controversy regarding these channels' location in the
sequence of events leading to cell protection, it is also unknown in which manner the
signalling events occurring in the preconditioned cell lead to opening of these channels
and the exact mechanism of the latter. Garlid (2000) recently concluded that the only
primary effect of K+ flux through mitochondrial KATP channels is to regulate
mitochondrial volume and that reported changes in membrane potential and Ca2+
uptake are epiphenomena of supra-pharmacological drug doses.
Although, activation of a number of surface receptors probably precedes opening of the
KATP channels prior to sustained ischaemia (Baines et ai., 1999), the link (if any)
between these events remains to be established. Furthermore, it is possible that a
different ion channel or an unidentified protein may still be the elusive end-effector.
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6.4 SUMMARY
The results obtained in this study suggest that p38 MAPK plays a putative role in
myocardial protection against ischaemia and that it is not a mere epiphenomenon of
prior PC. Although transient activation of the kinase appears to be the trigger in ~-
adrenergic PC, and may contribute to triggering ischaemie PC, other triggers may also
be involved in a multi-cycle protocol. This study showed that cardioprotection elicited by
either ischaemie or pharmacological PC, is associated with attenuation of p38 MAPK
activation during sustained ischaemia and reperfusion. In view of the fact that a blocker
of p38 MAPK activation, SB 203580, also protects against ischaemie damage, we
propose that activation of p38 MAPK during ischaemia-reperfusion is harmful and
attenuation of activation is required for cardioprotection. Since the changes in p38
MAPK activation both during the PC protocol and during ischaemia follow the pattern
observed in the ~-adrenergic signal transduction pathway, the changes in p38 MAPK
may be downstream to cAMP.
It remains intriguing that activation of the ~-adrenergic signalling pathway and p38
MAPK acts as triggers, whereas attenuation of the same pathway during sustained
ischaemia is required for cardioprotection. The exact cellular mechanism by which
attenuation of the kinase occurs remains to be established.
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CHAPTER 7
Conclusions
In this study, we showed that during a multi-cycle ischaemic preconditioning protocol
triggering agonists, for example catecholamines and nitric oxide, are released which
induced cyclic changes in the cyclic nucleotides, cAMP and cGMP, with concomitant
changes in cAMP- and cGMP- phosphodiesterase activities. The changes in the ~-
adrenergicpathwaywas associated by marked fluctuations in adenylyl cyclase and protein
kinaseA activity, accompanied by a decrease in receptoraffinity (Kd) and responsiveness
despite a gradual upregulationof the ~-adrenergicreceptor population (Bmax). In addition,
transient activation of the stress kinase, p38 MAPK was observed during the PC
protocol. This kinase could set in motion further downstream adaptive processes, such
as activation of HSP27 and mitochondrial ATP-sensitive potassium channel (mito.
KATP-channel), which upon induction of the second period of sustained ischaemia,
could protect the myocardium. The significance of these changes during the PC
protocol and their role as triggers was investigated by using appropriate activators and
inhibitors of cAMP, cGMP and p38 MAPK.
Furthermore, the sustained ischaemie period of PC hearts was characterized by
reduced tissue cAMP levels, an attenuated ~-adrenergic response and elevated cGMP
levels, associated with less POE inhibition and reduced energy utilization, as well as
attenuated activation of p38 MAPK. This was associated with cardioprotection and
confirmed by appropriate manipulations with drugs. In addition pharmacological
inhibition of p38 MAPK during sustained ischaemia also protects against ischaemie
damage. Therefore activation of p38 MAPK during sustained ischaemia is harmful and
attenuation thereof, which may reduce necrosis/apoptosis, is required for
cardioprotection.
Therefore, from the results obtained in this study, an alternative mechanism (Fig 7) is
proposed to the current proposed mechanism of classic ischaemic PC as reviewed by
Downey and colleagues (Pain et ai., 2000, Schulz et ai., 2001, Fig 7): They stated that
ischaemie PC confers protection to the myocardium through a signal-transduction
pathway that could be divided into 2 phases. The first is the trigger phase, which occurs
before the sustained ischaemia, followed by the mediator/effector phase during the
sustained ischaemia. The triggers of PC involve binding to membrane receptors such
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as adenosine (A1), bradykinin (82) and opioid (ê) receptors. Ligand-receptor
binding is though to initiate the intracellular mediator phase by activation of protein
kinase C (PKC). Free radicals also contribute to PKC's activation. The kinase cascade
that follows PKC activation has not been clearly defined, but appears to involve at least
one tyrosine kinase and perhaps p38 MAPK. Finally, it has been assumed that the
mito. KATP-channel may be the final effector of this protection. However, recent
evidence suggests that mito. KATP-channel opening triggers protection through free
radical generation. Once in the preconditioned state, kinases (such as p38 MAPK)
become activated if the heart again becomes ischaemie (during sustained ischaemia),
and these kinases mediate protection by modulating an as-yet-unknown end-effector.
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and the p-adrenergic signal transduction pathway. Circulation 1999; 100: 958 - 966.
Lochner A, Marais E, Genade S, Moolman JA. Nitric oxide: a trigger for classic
preconditioning. Am J Physiol2000; 279: H2752 - H2765.
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